{{#lst:Section editor transclusions|breast}}
''Are you looking for a regimen, but can't find it here? It is possible that we've moved it to the [[Breast_cancer_-_historical|historical regimens page]]. If you still can't find it, please let us know so we can add it!''
*'''Note: this page contains regimens which are not biomarker-specific, although they may have been studied in patients selected by biomarker. The following links will take you to biomarker-specific subpages:''' 
*<big>Regimens for [[Breast_cancer,_ER/PR-positive|'''ER/PR positive breast cancer are here''']]</big>.
*<big>Regimens for [[Breast_cancer,_HER2-positive|'''HER2 positive breast cancer are here''']]</big>.
*<big>Regimens for [[Breast_cancer,_triple_negative|'''Triple negative breast cancer (TNBC) are here''']]</big>.
*<big>Regimens for [[Breast_cancer,_BRCA-mutated|'''BRCA-mutated breast cancer are here''']]</big>.
*<big>Regimens for [[CNS_carcinoma|'''CNS metastases are here''']]</big>.
*''Because docetaxel and paclitaxel are both often abbreviated as "T," we try to always make clear in the regimen name which agent is being used.''
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}

=Guidelines=
==[https://www.asco.org/ ASCO]==
*'''2018:''' Denduluri et al. [http://ascopubs.org/doi/full/10.1200/JCO.2018.78.8604 Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO clinical practice guideline focused update] [https://www.ncbi.nlm.nih.gov/pubmed/29787356 PubMed]
*'''2016:''' Burstein et al. [http://ascopubs.org/doi/full/10.1200/JCO.2015.65.9573 Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression] [https://www.ncbi.nlm.nih.gov/pubmed/26884586 PubMed]
*'''2016:''' Harris et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933134/ Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline]
*'''2015:''' van Poznak et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478102/ Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical practice guideline]
===Older===
*'''2014:''' Partridge et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076042/ Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline]

==ASCO/CCO==
*'''2017:''' [http://ascopubs.org/doi/full/10.1200/JCO.2017.75.4614 Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology–Cancer Care Ontario focused guideline update] [https://www.ncbi.nlm.nih.gov/pubmed/29035643 PubMed]
==[http://www.esmo.org/ ESMO]==
*'''2015:''' Senkus et al. [https://www.esmo.org/Guidelines/Breast-Cancer/Primary-Breast-Cancer Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up]

==ESO/ESMO==
*'''2018:''' Cardoso et al. [https://academic.oup.com/annonc/article/29/8/1634/5055519 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)]
===Older===
*'''2017:''' Cardoso et al. [http://www.thebreastonline.com/article/S0960-9776(16)30183-7/fulltext 3rd ESO-ESMO International consensus guidelines for advanced breast cancer (ABC3)] [https://www.ncbi.nlm.nih.gov/pubmed/27927580 PubMed]
*'''2014:''' Cardoso et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176456/ ESO-ESMO 2nd International consensus guidelines for advanced breast cancer (ABC2)]
*'''2012:''' Cardoso et al. [https://www.thebreastonline.com/article/S0960-9776(12)00062-8/fulltext 1st International consensus guidelines for advanced breast cancer (ABC 1)]

==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf NCCN Guidelines - Breast Cancer]

== St Gallen Breast Guidelines ==
*'''2017:''' Curigliano et al. [https://www.ncbi.nlm.nih.gov/pubmed/28838210 St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017]
===Older===
*'''2015:''' Coates et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511219/ Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015]

=Neoadjuvant chemotherapy=
==AC {{#subobject:647f67|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
AC: '''<u>A</u>'''driamycin (Doxorubicin) & '''<u>C</u>'''yclophosphamide
===Variant #1, 4 cycles {{#subobject:b18877|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1997.15.7.2483 Fisher et al. 1997 (NSABP B-18)]
| style="background-color:#1a9851" |Phase III (E)
|[[#AC_2|Adjuvant AC]]
| style="background-color:#1a9850" |Superior resectability
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2003.12.005 Bear et al. 2003 (NSABP B-27)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#NSABP_B-27|See link]]
|[[Complex_multipart_regimens#NSABP_B-27|See link]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.05.078 von Minckwitz et al. 2005 (GeparDuo)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#GeparDuo|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#GeparDuo|See link]]
|-
|[https://link.springer.com/article/10.1007%2Fs10549-007-9672-y Lee et al. 2007]
| style="background-color:#1a9851" |Phase III (C)
|TX
| style="background-color:#fc8d59" |Seems to have inferior pCR rate
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401076/ Bear et al. 2012 (NSABP B-40)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#NSABP_B-40|See link]]
| style="background-color:#fc8d59" |[[Complex_multipart_regimens#NSABP_B-40|See link]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70411-X/fulltext Robidoux et al. 2013 (NSABP B-41)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259558/ Park et al. 2016 (I-SPY 2)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
''Note: patients in '''NSABP B-41''' and '''I-SPY 2''' were HER2-positive.''
====Preceding treatment====
*NSABP B-40: [[#Docetaxel_monotherapy|T (Taxotere)]] x 4 versus TX x 4 versus TG x 4
*I-SPY 2: [[Breast_cancer,_HER2-positive#Neratinib_.26_Paclitaxel|Neratinib & Paclitaxel]] x 12 wk versus [[Breast_cancer,_HER2-positive#TH_.28Taxol.29|TH]] x 12 wk
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''

====Subsequent treatment====
*NSABP B-18 & B-40: [[Surgery#Breast_cancer_surgery|Surgery]]
*Lee et al. 2007: [[Surgery#Breast_cancer_surgery|Surgery]], then TX x 4
*NSABP B-27: [[#Docetaxel_monotherapy|T (Taxotere)]] x 4, then [[Surgery#Breast_cancer_surgery|surgery]] versus [[Surgery#Breast_cancer_surgery|surgery]] versus [[Surgery#Breast_cancer_surgery|surgery]], then [[#Docetaxel_monotherapy_2|T (Taxotere)]] x 4
*GeparDuo: [[#Docetaxel_monotherapy|T (Taxotere)]] x 4, then [[Surgery#Breast_cancer_surgery|surgery]]
*NSABP B-41: [[Breast_cancer,_HER2-positive#TH_.28Taxol.29|TH]] versus [[Breast_cancer,_HER2-positive#THL_.28Taxol.29|THL]] versus [[Breast_cancer,_HER2-positive#TL_.28Taxol.29|TL]], then [[Surgery#Breast_cancer_surgery|surgery]]
*I-SPY 2: [[Surgery#Breast_cancer_surgery|Surgery]]

===Variant #2, 5 cycles {{#subobject:80c6e6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068051/ Ellis et al. 2011 (SWOG 0012)]
| style="background-color:#1a9851" |Phase III (C)
|Weekly doxorubicin & daily paclitaxel
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 5 cycles'''

====Subsequent treatment====
*[[#Paclitaxel_monotherapy.2C_weekly|Weekly Paclitaxel]] x 12, then [[Surgery#Breast_cancer_surgery|surgery]]

===Variant #3, 6 cycles {{#subobject:d63ca0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/15/5/751/188343 Smith et al. 2004 (TOPIC)]
| style="background-color:#1a9851" |Phase III (C)
|ECisF
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.06.156 Evans et al. 2005]
| style="background-color:#1a9851" |Phase III (C)
|AD
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://academic.oup.com/annonc/article/16/9/1435/180378 Chua et al. 2005 (TOPIC 2)]
| style="background-color:#1a9851" |Phase III (C)
|VE
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 cycles'''

====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]

===References===
# '''NSABP B-18:''' Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997 Jul;15(7):2483-93. [http://ascopubs.org/doi/abs/10.1200/JCO.1997.15.7.2483 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9215816 PubMed]
## '''Update:''' Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998 Aug;16(8):2672-85. [http://ascopubs.org/doi/abs/10.1200/JCO.1998.16.8.2672 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9704717 PubMed]
## '''Update:''' Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst. 2001;(30):96-102. [https://www.ncbi.nlm.nih.gov/pubmed/11773300 PubMed]
## '''Pooled update:''' Taghian A, Jeong JH, Mamounas E, Anderson S, Bryant J, Deutsch M, Wolmark N. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004 Nov 1;22(21):4247-54. Epub 2004 Sep 27. [http://ascopubs.org/doi/full/10.1200/JCO.2004.01.042 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15452182 PubMed]
## '''Pooled update:''' Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008 Feb 10;26(5):778-85. Erratum in: J Clin Oncol. 2008 Jun 1;26(16):2793. [http://ascopubs.org/doi/full/10.1200/JCO.2007.15.0235 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18258986 PubMed]
# '''NSABP B-27:''' Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N; National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003 Nov 15;21(22):4165-74. Epub 2003 Oct 14. [http://ascopubs.org/doi/full/10.1200/JCO.2003.12.005 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14559892 PubMed]
## '''Update:''' Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006 May 1;24(13):2019-27. Epub 2006 Apr 10. [http://ascopubs.org/doi/full/10.1200/JCO.2005.04.1665 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16606972 PubMed]
## '''Pooled update:''' Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008 Feb 10;26(5):778-85. Erratum in: J Clin Oncol. 2008 Jun 1;26(16):2793. [http://ascopubs.org/doi/full/10.1200/JCO.2007.15.0235 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18258986 PubMed]
# '''TOPIC:''' Smith IE, A'Hern RP, Coombes GA, Howell A, Ebbs SR, Hickish TF, O'Brien ME, Mansi JL, Wilson CB, Robinson AC, Murray PA, Price CG, Perren TJ, Laing RW, Bliss JM; TOPIC Trial Group. A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. Ann Oncol. 2004 May;15(5):751-8. [https://academic.oup.com/annonc/article/15/5/751/188343 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15111342 PubMed]
# '''GeparDuo:''' von Minckwitz G, Raab G, Caputo A, Schütte M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Merkle E, Eidtmann H, Lampe D, Jackisch C, du Bois A, Kaufmann M. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 2005 Apr 20;23(12):2676-85. [http://ascopubs.org/doi/full/10.1200/JCO.2005.05.078 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15837982 PubMed]
# Evans TR, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J, Jones AL, Highley M, Leonard RC, Mansi JL. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol. 2005 May 1;23(13):2988-95. [http://ascopubs.org/doi/full/10.1200/JCO.2005.06.156 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15860854 PubMed]
## '''Update:''' Mansi JL, Yellowlees A, Lipscombe J, Earl HM, Cameron DA, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J, Jones AL, Highley M, Leonard RC, Evans TR. Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study. Breast Cancer Res Treat. 2010 Aug;122(3):787-94. Epub 2010 Jun 18. [https://link.springer.com/article/10.1007%2Fs10549-010-0989-6 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20559708 PubMed]
# '''TOPIC 2:''' Chua S, Smith IE, A'Hern RP, Coombes GA, Hickish TF, Robinson AC, Laing RW, O'Brien ME, Ebbs SR, Hong A, Wardley A, Mughal T, Verrill M, Dubois D, Bliss JM; TOPIC Trial Group. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Ann Oncol. 2005 Sep;16(9):1435-41. Epub 2005 Jun 9. [https://academic.oup.com/annonc/article/16/9/1435/180378 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15946977 PubMed]
# Lee KS, Ro J, Nam BH, Lee ES, Kwon Y, Kwon HS, Chung KW, Kang HS, Kim EA, Kim SW, Shin KH, Kim SK. A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. Breast Cancer Res Treat. 2008 Jun;109(3):481-9. Epub 2007 Jul 26. [https://link.springer.com/article/10.1007%2Fs10549-007-9672-y link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17653851 PubMed]
# '''SWOG 0012:''' Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Russell CA, Royce ME, Perez EA, Lew D, Livingston RB. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol. 2011 Mar 10;29(8):1014-21. Epub 2011 Jan 10. [http://ascopubs.org/doi/full/10.1200/JCO.2009.27.6543 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068051/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21220618 PubMed]
# '''NSABP B-40:''' Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012 Jan 26;366(4):310-20. [https://www.nejm.org/doi/full/10.1056/NEJMoa1111097 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401076/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22276821 PubMed]
## '''Update:''' Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol. 2015 Sep;16(9):1037-1048. Epub 2015 Aug 10. Erratum in: Lancet Oncol. 2015 Dec;16(16):e589. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00041-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624323/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26272770 PubMed]
# '''NSABP B-41:''' Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, Brufsky AM, Shibata HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 2013 Nov;14(12):1183-92. Epub 2013 Oct 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70411-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24095300 PubMed]
<!-- Presented in part by Dr. Park at the 104th annual meeting of the American Association for Cancer Research, Washington, DC, April 6–10, 2013. -->
# '''I-SPY 2:''' Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016 Jul 7;375(1):11-22. [https://www.nejm.org/doi/full/10.1056/NEJMoa1513750 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259558/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27406346 PubMed]
# '''ETNA:''' Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, Morales S, Alvarez I, Plazaola A, Zambetti M, Redfern AD, Dittrich C, Dent RA, Magazzù D, De Fato R, Valagussa P, Tusquets I. Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/HER2-negative breast cancer-the Evaluating Treatment with Neoadjuvant Abraxane (ETNA) trial: a randomized phase 3 clinical trial. JAMA Oncol. 2018 Mar 1;4(3):302-308. Epub 2018 Jan 11. [https://jamanetwork.com/journals/jamaoncology/fullarticle/2668528 link to original article]  [https://www.ncbi.nlm.nih.gov/pubmed/29327055 PubMed]

==AC & Bevacizumab {{#subobject:cdf505|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
AC+Bev: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>Bev</u>'''acizumab
===Regimen {{#subobject:8a7869|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401076/ Bear et al. 2012 (NSABP B-40)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#NSABP_B-40|See link]]
|[[Complex_multipart_regimens#NSABP_B-40|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#Docetaxel_.26_Bevacizumab|T+Bev]] x 4 versus TX+Bev x 4 versus TG+Bev x 4
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] as follows:
**Cycles 1 & 2: 15 mg/kg IV once on day 1
**Cycles 3 & 4: none

'''21-day cycle for 4 cycles'''

====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[#Bevacizumab_monotherapy|adjuvant bevacizumab]]

===References===
# Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012 Jan 26;366(4):310-20. [https://www.nejm.org/doi/full/10.1056/NEJMoa1111097 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401076/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22276821 PubMed]
## '''Update:''' Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol. 2015 Sep;16(9):1037-1048. Epub 2015 Aug 10. Erratum in: Lancet Oncol. 2015 Dec;16(16):e589. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00041-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624323/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26272770 PubMed]

==ddAC {{#subobject:dcfdd2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ddAC: '''<u>d</u>'''ose-'''<u>d</u>'''ense '''<u>A</u>'''driamycin (Doxorubicin) and '''<u>C</u>'''yclophosphamide
===Regimen {{#subobject:daff10|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/23/33/8340.long Burstein et al. 2005]
| style="background-color:#91cf61" |Non-randomized
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259558/ Park et al. 2016 (I-SPY 2)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. Patients in '''I-SPY 2''' were HER2-positive.''
====Preceding treatment====
*I-SPY 2: [[Breast_cancer,_HER2-positive#Neratinib_.26_Paclitaxel|Neratinib & Paclitaxel]] x 12 wk versus [[Breast_cancer,_HER2-positive#TH_.28Taxol.29|TH]] x 12 wk
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2, given 24 hours after chemotherapy
*'''Burstein et al. 2005:''' [[Darbepoetin alfa (Aranesp)]] 200 mcg SC once on day 1 for patients with Hb 10 to 12 g/dL; see paper for additional dose adjustments

'''14-day cycle for 4 cycles'''
====Subsequent treatment====
*Burstein et al. 2005: Optional [[#Paclitaxel_monotherapy.2C_dose-dense_.28q2wk.29|dose-dense paclitaxel]], then [[Surgery#Breast_cancer_surgery|surgery]] or [[Surgery#Breast_cancer_surgery|surgery]], then [[#Paclitaxel_monotherapy.2C_dose-dense_.28q2wk.29_2|dose-dense paclitaxel]]; this was not a randomization
*I-SPY 2: [[Surgery#Breast_cancer_surgery|Surgery]]

===References===
# Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20;23(33):8340-7. [http://jco.ascopubs.org/content/23/33/8340.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16293865 PubMed]
<!-- Presented in part by Dr. Park at the 104th annual meeting of the American Association for Cancer Research, Washington, DC, April 6–10, 2013. -->
# Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016 Jul 7;375(1):11-22. [https://www.nejm.org/doi/full/10.1056/NEJMoa1513750 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5259558/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27406346 PubMed]

==DE {{#subobject:d11f5f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DE: '''<u>D</u>'''ocetaxel & '''<u>E</u>'''pirubicin
<br>ED: '''<u>E</u>'''pirubicin & '''<u>D</u>'''ocetaxel
<br>ET: '''<u>E</u>'''pirubicin & '''<u>T</u>'''axotere (Docetaxel)
===Variant #1, 3 cycles {{#subobject:c1953d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.31217 Chen et al. 2017 (CBCRT01)]
| style="background-color:#1a9851" |Phase III (C)
|DEE
| style="background-color:#d73027" |Inferior ORR
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]

===Variant #2, 6 cycles {{#subobject:c2184d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2006.09.1777 Steger et al. 2007 (ABCSG-14)]
| style="background-color:#1a9851" |Phase III (E)
|ED x 3
| style="background-color:#1a9850" |Superior pCR rate
|-
|[https://www.ejso.com/article/S0748-7983(09)00003-1/fulltext Han et al. 2009]
| style="background-color:#1a9851" |Phase III (E)
|ED x 4
| style="background-color:#91cf60" |Seems to have superior pCR rate
|-
|[https://academic.oup.com/annonc/article/25/2/366/191633 Steger et al. 2013 (ABCSG-24)]
| style="background-color:#1a9851" |Phase III (C)
|EDC
| style="background-color:#fc8d59" |Seems to have inferior pCR rate
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]

===References===
# '''ABCSG-14:''' Steger GG, Galid A, Gnant M, Mlineritsch B, Lang A, Tausch C, Rudas M, Greil R, Wenzel C, Singer CF, Haid A, Pöstlberger S, Samonigg H, Luschin-Ebengreuth G, Kwasny W, Klug E, Kubista E, Menzel C, Jakesz R; ABCSG-14. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14. J Clin Oncol. 2007 May 20;25(15):2012-8. [http://ascopubs.org/doi/full/10.1200/JCO.2006.09.1777 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17513805 PubMed]
# Han S, Kim J, Lee J, Chang E, Gwak G, Cho H, Yang KH, Park S, Park K. Comparison of 6 cycles versus 4 cycles of neoadjuvant epirubicin plus docetaxel chemotherapy in stages II and III breast cancer. Eur J Surg Oncol. 2009 Jun;35(6):583-7. Epub 2009 Feb 5. [https://www.ejso.com/article/S0748-7983(09)00003-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19195817 PubMed]
# '''ABCSG-24:''' Steger GG, Greil R, Lang A, Rudas M, Fitzal F, Mlineritsch B, Hartmann BL, Bartsch R, Melbinger E, Hubalek M, Stoeger H, Dubsky P, Ressler S, Petzer AL, Singer CF, Muss C, Jakesz R, Gampenrieder SP, Zielinski CC, Fesl C, Gnant M; Austrian Breast and Colorectal Study Group (ABCSG). Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Ann Oncol. 2014 Feb;25(2):366-71. Epub 2013 Dec 16. [https://academic.oup.com/annonc/article/25/2/366/191633 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24347519 PubMed]
# '''CBCRT01:''' Chen J, Yao Q, Huang M, Wang B, Zhang J, Wang T, Ming Y, Zhou X, Jia Q, Huan Y, Wang J, Wang L. A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first-line therapy for patients with breast cancer (CBCRT01). Int J Cancer. 2018 May 15;142(10):2130-2138. Epub 2017 Dec 23. [https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.31217 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29238974 PubMed]

==Docetaxel monotherapy {{#subobject:1216fd|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
D: '''<u>D</u>'''ocetaxel
<br>T: '''<u>T</u>'''axotere (Docetaxel)
===Variant #1, 75 mg/m<sup>2</sup> x 4 {{#subobject:7377be|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401076/ Bear et al. 2012 (NSABP B-40)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#NSABP_B-40|See link]]
|[[Complex_multipart_regimens#NSABP_B-40|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#AC|AC]] x 4, then [[Surgery#Breast_cancer_surgery|surgery]]

===Variant #2, 100 mg/m<sup>2</sup> x 3 {{#subobject:5b038d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70137-3/fulltext Earl et al. 2015 (ARTemis)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Docetaxel_.26_Bevacizumab|Docetaxel & Bevacizumab]]
| style="background-color:#fc8d59" |Seems to have inferior pCR rate
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[#FEC|FEC]]

===Variant #3, 100 mg/m<sup>2</sup> x 4 {{#subobject:0ff4c4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2003.12.005 Bear et al. 2003 (NSABP B-27)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#NSABP_B-27|See link]]
|[[Complex_multipart_regimens#NSABP_B-27|See link]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.05.078 von Minckwitz et al. 2005 (GeparDuo)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#GeparDuo|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#GeparDuo|See link]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1111065 von Minckwitz et al. 2012 (GeparQuinto)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#GeparQuinto|See link]]
|[[Complex_multipart_regimens#GeparQuinto|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*NSABP B-27 & GeparDuo: [[#AC|AC]] x 4
*GeparQuinto: [[#EC|EC]] x 4
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''

====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]

===References===
# '''NSABP B-27:''' Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N; National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003 Nov 15;21(22):4165-74. Epub 2003 Oct 14. [http://ascopubs.org/doi/full/10.1200/JCO.2003.12.005 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14559892 PubMed]
## '''Update:''' Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006 May 1;24(13):2019-27. Epub 2006 Apr 10. [http://ascopubs.org/doi/full/10.1200/JCO.2005.04.1665 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16606972 PubMed]
## '''Pooled update:''' Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008 Feb 10;26(5):778-85. Erratum in: J Clin Oncol. 2008 Jun 1;26(16):2793. [http://ascopubs.org/doi/full/10.1200/JCO.2007.15.0235 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18258986 PubMed]
# '''GeparDuo:''' von Minckwitz G, Raab G, Caputo A, Schütte M, Hilfrich J, Blohmer JU, Gerber B, Costa SD, Merkle E, Eidtmann H, Lampe D, Jackisch C, du Bois A, Kaufmann M. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 2005 Apr 20;23(12):2676-85. [http://ascopubs.org/doi/full/10.1200/JCO.2005.05.078 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15837982 PubMed]
# '''GeparQuinto:''' von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012 Jan 26;366(4):299-309. [https://www.nejm.org/doi/full/10.1056/NEJMoa1111065 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22276820 PubMed]
# '''NSABP B-40:''' Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012 Jan 26;366(4):310-20. [https://www.nejm.org/doi/full/10.1056/NEJMoa1111097 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401076/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22276821 PubMed]
## '''Update:''' Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol. 2015 Sep;16(9):1037-1048. Epub 2015 Aug 10. Erratum in: Lancet Oncol. 2015 Dec;16(16):e589. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00041-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624323/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26272770 PubMed]
# '''ARTemis:''' Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, Abraham J, Thomas J, Provenzano E, Hughes-Davies L, Gounaris I, McAdam K, Chan S, Ahmad R, Hickish T, Houston S, Rea D, Bartlett J, Caldas C, Cameron DA, Hayward L; ARTemis Investigators. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol. 2015 Jun;16(6):656-66. Epub 2015 May 11. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70137-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25975632 PubMed]

==Docetaxel & Bevacizumab {{#subobject:23b667|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Bev+D: '''<u>Bev</u>'''acizumab & '''<u>D</u>'''ocetaxel
<br>T+Bev: '''<u>T</u>'''axotere (Docetaxel) & '''<u>Bev</u>'''acizumab
===Variant #1, docetaxel 75 mg/m<sup>2</sup> {{#subobject:d65a23|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401076/ Bear et al. 2012 (NSABP B-40)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#NSABP_B-40|See link]]
|[[Complex_multipart_regimens#NSABP_B-40|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#AC_.26_Bevacizumab|AC+Bev]] x 4, then [[Surgery#Breast_cancer_surgery|surgery]]

===Variant #2, docetaxel 100 mg/m<sup>2</sup> {{#subobject:a2a6a4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70137-3/fulltext Earl et al. 2015 (ARTemis)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Docetaxel_monotherapy|Docetaxel]]
| style="background-color:#91cf60" |Seems to have superior pCR rate
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. A total of four bevacizumab doses are given, with the fourth given with the first cycle of FEC.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycle for 3 cycles'''

====Subsequent treatment====
*[[#FEC|FEC]]

===References===
# '''NSABP B-40:''' Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012 Jan 26;366(4):310-20. [https://www.nejm.org/doi/full/10.1056/NEJMoa1111097 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401076/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22276821 PubMed]
## '''Update:''' Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol. 2015 Sep;16(9):1037-1048. Epub 2015 Aug 10. Erratum in: Lancet Oncol. 2015 Dec;16(16):e589. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00041-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624323/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26272770 PubMed]
# '''ARTemis:''' Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, Abraham J, Thomas J, Provenzano E, Hughes-Davies L, Gounaris I, McAdam K, Chan S, Ahmad R, Hickish T, Houston S, Rea D, Bartlett J, Caldas C, Cameron DA, Hayward L; ARTemis Investigators. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol. 2015 Jun;16(6):656-66. Epub 2015 May 11. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70137-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25975632 PubMed]

==EC {{#subobject:3e1e8f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EC: '''<u>E</u>'''pirubicin & '''<u>C</u>'''yclophosphamide
===Regimen {{#subobject:da3717|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/22/9/1999/211410 Untch et al. 2011 (PREPARE)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#PREPARE|See link]]
| style="background-color:#ffffbf" |[[Complex_multipart_regimens#PREPARE|See link]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.23.8303 von Minckwitz et al. 2010 (GeparQuattro)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1111065 von Minckwitz et al. 2012 (GeparQuinto)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#GeparQuinto|See link]]
|[[Complex_multipart_regimens#GeparQuinto|See link]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70554-0/fulltext Earl et al. 2013 (Neo-tAnGo)]
|style="background-color:#1a9851" |Phase III (*)
|[[Complex_multipart_regimens#Neo-tAnGo|See link]]
|[[Complex_multipart_regimens#Neo-tAnGo|See link]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00542-2/abstract Untch et al. 2016 (GeparSepto)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm in this context.''
====Preceding treatment====
*GeparSepto: [[#Paclitaxel.2C_nanoparticle_albumin-bound_monotherapy|nab-Paclitaxel]] x 4 versus [[#Paclitaxel_monotherapy.2C_weekly|weekly Paclitaxel]] x 12
*Neo-tAnGo (taxanes-EC arm): [[#Paclitaxel_monotherapy.2C_dose-dense_.28q2wk.29|ddT]] x 4 versus ddTG x 4
====Chemotherapy====
*[[Epirubicin (Ellence)]] 90 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*GeparQuattro: [[#Docetaxel_monotherapy|T (Taxotere)]] x 4 versus T-X versus TX, then [[Surgery#Breast_cancer_surgery|surgery]]
*GeparQuinto: [[#Docetaxel_monotherapy|Docetaxel]], then [[Surgery#Breast_cancer_surgery|surgery]]
*Neo-tAnGo (EC-taxane arms): [[#Paclitaxel_monotherapy.2C_dose-dense_.28q2wk.29|ddT]] x 4 versus ddTG x 4, then [[Surgery#Breast_cancer_surgery|surgery]]
*GeparSepto: [[Surgery#Breast_cancer_surgery|Surgery]]

===References===
# '''PREPARE:''' Untch M, von Minckwitz G, Konecny GE, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Beckmann MW, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Nekljudova V, Lebeau A, Loibl S, Fasching PA; Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis. Ann Oncol. 2011 Sep;22(9):1999-2006. Epub 2011 Mar 7. [https://academic.oup.com/annonc/article/22/9/1999/211410 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21382868 PubMed]
# '''GeparQuattro:''' von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Untch M. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol. 2010 Apr 20;28(12):2015-23. Epub 2010 Mar 22. [http://ascopubs.org/doi/full/10.1200/JCO.2009.23.8303 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20308671 PubMed]
# '''GeparQuinto:''' von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012 Jan 26;366(4):299-309. [https://www.nejm.org/doi/full/10.1056/NEJMoa1111065 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22276820 PubMed]
# '''Neo-tAnGo:''' Earl HM, Vallier AL, Hiller L, Fenwick N, Young J, Iddawela M, Abraham J, Hughes-Davies L, Gounaris I, McAdam K, Houston S, Hickish T, Skene A, Chan S, Dean S, Ritchie D, Laing R, Harries M, Gallagher C, Wishart G, Dunn J, Provenzano E, Caldas C; Neo-tAnGo Investigators. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial. Lancet Oncol. 2014 Feb;15(2):201-12. Epub 2013 Dec 19. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70554-0/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24360787 PubMed]
# '''GeparSepto:''' Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kümmel S, Hilfrich J, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Darb-Esfahani S, Schmitt WD, Dan Costa S, Gerber B, Engels K, Nekljudova V, Loibl S, von Minckwitz G; German Breast Group (GBG).; Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) Investigators. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol. Epub 2016 Feb 8. 2016 Mar;17(3):345-56. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00542-2/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26869049 PubMed]
## '''Update:''' Furlanetto J, Jackisch C, Untch M, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Wiebringhaus H, Kümmel S, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Costa SD, Gerber B, Nekljudova V, Loibl S, von Minckwitz G. Efficacy and safety of nab-paclitaxel 125 mg/m(2) and nab-paclitaxel 150 mg/m(2) compared to paclitaxel in early high-risk breast cancer: results from the neoadjuvant randomized GeparSepto study (GBG 69). Breast Cancer Res Treat. 2017 Jun;163(3):495-506. Epub 2017 Mar 17. [https://link.springer.com/article/10.1007%2Fs10549-017-4200-1 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28315068 PubMed]
# '''ETNA:''' Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, Morales S, Alvarez I, Plazaola A, Zambetti M, Redfern AD, Dittrich C, Dent RA, Magazzù D, De Fato R, Valagussa P, Tusquets I. Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/HER2-negative breast cancer-the Evaluating Treatment with Neoadjuvant Abraxane (ETNA) trial: a randomized phase 3 clinical trial. JAMA Oncol. 2018 Mar 1;4(3):302-308. Epub 2018 Jan 11. [https://jamanetwork.com/journals/jamaoncology/fullarticle/2668528 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29327055 PubMed]

==DI EC {{#subobject:31c3a1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DI EC: '''<u>D</u>'''ose-'''<u>I</u>'''ntense '''<u>E</u>'''pirubicin & '''<u>C</u>'''yclophosphamide
===Regimen {{#subobject:da1317|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://academic.oup.com/annonc/article/26/8/1692/247927 Gonçalves et al. 2015 (UNICANCER PEGASE 07)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''This regimen required hematopoeitic stem cell support; see paper for details.''
====Chemotherapy====
*[[Epirubicin (Ellence)]] 150 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 4000 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then Docetaxel & 5-FU versus no further treatment

===References===
# '''UNICANCER PEGASE 07:''' Gonçalves A, Pierga JY, Ferrero JM, Mouret-Reynier MA, Bachelot T, Delva R, Fabbro M, Lerebours F, Lotz JP, Linassier C, Dohollou N, Eymard JC, Leduc B, Lemonnier J, Martin AL, Boher JM, Viens P, Roché H. UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. Ann Oncol. 2015 Aug;26(8):1692-7. Epub 2015 May 5. [https://academic.oup.com/annonc/article/26/8/1692/247927 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25943350 PubMed]

==EP {{#subobject:38119e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EP: '''<u>E</u>'''pirubicin & '''<u>P</u>'''aclitaxel
<br>ET: '''<u>E</u>'''pirubicin & '''<u>T</u>'''axol (Paclitaxel)
===Regimen {{#subobject:040ce0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360722/ Frasci et al. 2006]
| style="background-color:#1a9851" |Phase III (C)
|PET
| style="background-color:#fc8d59" |Seems to have inferior pCR rate
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2008.20.3133 Untch et al. 2009]
| style="background-color:#1a9851" |Phase III (C)
|ddE, then ddP
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Epirubicin (Ellence)]] 90 mg/m<sup>2</sup> IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*Frasci et al. 2006: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#CMF|CMF]] x 4 or [[#FEC_2|FEC]] x 4, depending on number of involved lymph nodes
*Untch et al. 2009: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#CMF|CMF]] x 3

===References===
# Frasci G, D'Aiuto G, Comella P, Thomas R, Botti G, Di Bonito M, De Rosa V, Iodice G, Rubulotta MR, Comella G; Southern Italy Cooperative Oncology Group (SICOG). Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a SICOG phase III study. Br J Cancer. 2006 Oct 23;95(8):1005-12. [https://www.nature.com/articles/6603395 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360722/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/17047649 PubMed]
# Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, Harbeck N, Werner C, Lebeau A, Schneeweiss A, Kahlert S, von Koch F, Petry KU, Wallwiener D, Kreienberg R, Albert US, Lück HJ, Hinke A, Jänicke F, Konecny GE. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol. 2009 Jun 20;27(18):2938-45. Epub 2009 Apr 13. [http://ascopubs.org/doi/full/10.1200/JCO.2008.20.3133 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19364964 PubMed]

==FAC {{#subobject:8d91b0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FAC: '''<u>F</u>'''luorouracil, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide
===Variant #1, 600/50/600 {{#subobject:b99a59|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://journals.sagepub.com/doi/abs/10.1177/030089169708300511 Baldini et al. 1997]
| style="background-color:#1a9851" |Phase III (C)
|DES-CAF
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup>/day IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]

===Variant #2, 1000/50/500 {{#subobject:1bb303|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1999.17.11.3412 Buzdar et al. 1999]
| style="background-color:#1a9851" |Phase III (C)
|q3wk Paclitaxel x 4
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.06.232 Green et al. 2005]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*Green et al. 2005: [[#Paclitaxel_monotherapy.2C_weekly|Weekly paclitaxel]] x 12 versus q3wk paclitaxel x 4
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 4
*[[Doxorubicin (Adriamycin)]] 16.7 mg/m<sup>2</sup>/day IV continuous infusion over 72 hours, started on day 1 (total dose per cycle: 50 mg/m<sup>2</sup>)
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*Buzdar et al. 1999: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#FAC_2|FAC]] x 4
*Green et al. 2005: [[Surgery#Breast_cancer_surgery|Surgery]]

===Variant #3, 2000/50/100 {{#subobject:1aa303|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.sciencedirect.com/science/article/pii/0959804994905371 Scholl et al. 1994]
| style="background-color:#1a9851" |Phase III (E)
|[[#FAC_2|Adjuvant FAC]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1, 3, 5, 8
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup>/day IV once per day on days 1 & 8
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 5

'''28-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]

===References===
# '''S6:''' Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, Dorval T, Palangié T, Jouve M, Beuzeboc P, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer. 1994;30A(5):645-52. [https://www.sciencedirect.com/science/article/pii/0959804994905371 link to SD article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8080680 PubMed]
# Baldini E, Gardin G, Giannessi P, Brema F, Camorriano A, Carnino F, Naso C, Pastorino G, Pronzato P, Rosso R, Rubagotti A, Torretta G, Conte PF; North-West Oncology Group (GONO) Study, Italy. A randomized trial of chemotherapy with or without estrogenic recruitment in locally advanced breast cancer. Tumori. 1997 Sep-Oct;83(5):829-33. [https://journals.sagepub.com/doi/abs/10.1177/030089169708300511 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9428917 PubMed]
# Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, Smith TL, Asmar L, Frye D, Manuel N, Kau SW, McNeese M, Strom E, Hunt K, Ames F, Hortobagyi GN. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999 Nov;17(11):3412-7. [http://ascopubs.org/doi/full/10.1200/JCO.1999.17.11.3412 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10550135 PubMed]
# Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005 Sep 1;23(25):5983-92. Epub 2005 Aug 8. [http://ascopubs.org/doi/full/10.1200/JCO.2005.06.232 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16087943 PubMed]

==FEC {{#subobject:ec48df|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FEC: '''<u>F</u>'''luorouracil, '''<u>E</u>'''pirubicin, '''<u>C</u>'''yclophosphamide
===Variant #1, 500/75/500 ("FEC-75") {{#subobject:9e61ad|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176878/ Buzdar et al. 2013 (ACOSOG Z1041)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#ACOSOG_Z1041|See link]]
|[[Complex_multipart_regimens#ACOSOG_Z1041|See link]]
|-
|}
''Note that patients in this trial had HER2-positive breast cancer. This is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Breast_cancer,_HER2-positive#TH_.28Taxol.29|TH (Taxol)]] x 12 wk, then [[Surgery#Breast_cancer_surgery|surgery]]

===Variant #2, 500/100/500 x 3 {{#subobject:a74d5d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70137-3/fulltext Earl et al. 2015 (ARTemis)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note that for the patients randomized to the bevacizumab arm, a fourth dose was given with the first cycle of FEC. This is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#Docetaxel_.26_Bevacizumab|Docetaxel & Bevacizumab]] x 3 versus [[#Docetaxel_monotherapy|Docetaxel]] x 3
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 100 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]

===Variant #3, 500/100/500 x 4 {{#subobject:05f290|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.36.2079 Kelly et al. 2012]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''This is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#Paclitaxel_monotherapy.2C_weekly|Weekly paclitaxel]] x 12 versus XT
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 100 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]

===Variant #4, 500/100/600 x 3 {{#subobject:7ddba5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/24/9/2278.long Schneeweiss et al. 2013 (TRYPHAENA)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[Complex_multipart_regimens#TRYPHAENA|See link]]
|style="background-color:#d3d3d3"|Not reported
|-
|}
''Note: patients enrolled in this trial had HER2+ disease. This is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 100 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Breast_cancer,_HER2-positive#THP_.28Taxotere.29|THP]] x 3, then [[Surgery#Breast_cancer_surgery|surgery]]

===Variant #5, 600/60/600 x 3 {{#subobject:792fef|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/14/2/227/153994 Baldini et al. 2003]
| style="background-color:#1a9851" |Phase III (C)
|ddFEC
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then CEF/CMF x 3

===Variant #6, 600/60/600 x 4 {{#subobject:547837|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2001.19.22.4224 van der Hage et al. 2001 (EORTC 10902)]
| style="background-color:#1a9851" |Phase III (E)
|[[#FEC_2|Adjuvant FEC]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]

===Variant #7, 1000/75/500 x 4 {{#subobject:1350d9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/16/3676.long Buzdar et al. 2005]
|style="background-color:#1a9851"|Randomized (C)
|[[Complex_multipart_regimens#Buzdar_et_al._2005|See link]]
| style="background-color:#fc8d59" |[[Complex_multipart_regimens#Buzdar_et_al._2005|See link]]
|-
|}
''Note that patients in this trial had HER2-positive breast cancer. This is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*CI paclitaxel x 4
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 4
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]

===Variant #8, 1000/120/1050 x 6 {{#subobject:c3c026|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2003.05.135 Therasse et al. 2003 (EORTC 10921)]
|style="background-color:#1a9851"|Phase III (C)
|ddEC
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Cyclophosphamide (Cytoxan)]] 75 mg/m<sup>2</sup> PO once per day on days 1 to 14

'''28-day cycle for 6 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
===References===
# '''EORTC 10902:''' van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001 Nov 15;19(22):4224-37. [http://ascopubs.org/doi/full/10.1200/JCO.2001.19.22.4224 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11709566 PubMed] 
## '''Update:''' van Nes JG, Putter H, Julien JP, Tubiana-Hulin M, van de Vijver M, Bogaerts J, de Vos M, van de Velde CJ; Cooperating Investigators of the EORTC. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. Breast Cancer Res Treat. 2009 May;115(1):101-13. Epub 2008 May 18. [https://link.springer.com/article/10.1007%2Fs10549-008-0050-1 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18484198 PubMed]
# Baldini E, Gardin G, Giannessi PG, Evangelista G, Roncella M, Prochilo T, Collecchi P, Rosso R, Lionetto R, Bruzzi P, Mosca F, Conte PF. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann Oncol. 2003 Feb;14(2):227-32. [https://academic.oup.com/annonc/article/14/2/227/153994 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12562649 PubMed]
# '''EORTC 10921:''' Therasse P, Mauriac L, Welnicka-Jaskiewicz M, Bruning P, Cufer T, Bonnefoi H, Tomiak E, Pritchard KI, Hamilton A, Piccart MJ; EORTC. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol. 2003 Mar 1;21(5):843-50. [http://ascopubs.org/doi/full/10.1200/JCO.2003.05.135 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12610183 PubMed]
# Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 1;23(16):3676-85. Epub 2005 Feb 28. [http://jco.ascopubs.org/content/23/16/3676.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15738535 PubMed]
## '''Update:''' Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007 Jan 1;13(1):228-33. [http://clincancerres.aacrjournals.org/content/13/1/228.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17200359 PubMed]
<!-- Presented at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30-June 3, 2008. -->
# Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012 Mar 20;30(9):930-5. Epub 2012 Feb 13. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.2079 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22331946 PubMed]
# '''TRYPHAENA:''' Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cortés J. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013 Sep;24(9):2278-84. Epub 2013 May 22. [http://annonc.oxfordjournals.org/content/24/9/2278.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23704196 PubMed]
# '''ACOSOG Z1041:''' Buzdar AU, Suman VJ, Meric-Bernstam F, Leitch AM, Ellis MJ, Boughey JC, Unzeitig G, Royce M, McCall LM, Ewer MS, Hunt KK; American College of Surgeons Oncology Group investigators. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol. 2013 Dec;14(13):1317-25. Epub 2013 Nov 13. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70502-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4176878/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24239210 PubMed]
# '''ARTemis:''' Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, Abraham J, Thomas J, Provenzano E, Hughes-Davies L, Gounaris I, McAdam K, Chan S, Ahmad R, Hickish T, Houston S, Rea D, Bartlett J, Caldas C, Cameron DA, Hayward L; ARTemis Investigators. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol. 2015 Jun;16(6):656-66. Epub 2015 May 11. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70137-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25975632 PubMed]
# '''ETNA:''' Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, Morales S, Alvarez I, Plazaola A, Zambetti M, Redfern AD, Dittrich C, Dent RA, Magazzù D, De Fato R, Valagussa P, Tusquets I. Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/HER2-negative breast cancer-the Evaluating Treatment with Neoadjuvant Abraxane (ETNA) trial: a randomized phase 3 clinical trial. JAMA Oncol. 2018 Mar 1;4(3):302-308. Epub 2018 Jan 11. [https://jamanetwork.com/journals/jamaoncology/fullarticle/2668528 link to original article]  [https://www.ncbi.nlm.nih.gov/pubmed/29327055 PubMed]

==Paclitaxel monotherapy, weekly {{#subobject:f579fb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
T: '''<u>T</u>'''axol (Paclitaxel)
===Variant #1, 80 mg/m<sup>2</sup> weekly {{#subobject:c345c9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.06.232 Green et al. 2005]
| style="background-color:#1a9851" |Phase III (E)
|q3wk paclitaxel
| style="background-color:#91cf60" |Seems to have superior pCR rate
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068051/ Ellis et al. 2011 (SWOG 0012)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.36.2079 Kelly et al. 2012]
| style="background-color:#1a9851" |Phase III (C)
|XT
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00542-2/fulltext Untch et al. 2016 (GeparSepto)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Paclitaxel.2C_nanoparticle_albumin-bound_monotherapy|nab-Paclitaxel]]
| style="background-color:#d73027" |Inferior pCR rate
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*SWOG 0012: [[#AC|AC]] x 5 versus weekly doxorubicin & daily cyclophosphamide
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per week

'''12-week course'''
====Subsequent treatment====
*Green et al. 2005: [[#FAC|FAC]] x 4, then [[Surgery#Breast_cancer_surgery|surgery]]
*SWOG 0012: [[Surgery#Breast_cancer_surgery|Surgery]]
*Kelly et al 2012: [[#FEC|FEC]] x 4, then [[Surgery#Breast_cancer_surgery|surgery]]
*GeparSepto: [[#EC|EC]] x 4, then [[Surgery#Breast_cancer_surgery|surgery]]

===Variant #2, 90 mg/m<sup>2</sup>, 3 out of 4 weeks {{#subobject:759920|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://jamanetwork.com/journals/jamaoncology/fullarticle/2668528 Gianni et al. 2018 (ETNA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Paclitaxel.2C_nanoparticle_albumin-bound_monotherapy|nab-Paclitaxel]]
|style="background-color:#ffffbf"|Seems not superior
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 90 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''4-week cycle for 4 cycles'''
====Subsequent treatment====
*[[#AC|AC]] or [[#EC|EC]] or [[#FEC|FEC]], then [[Surgery#Breast_cancer_surgery|surgery]]

===References===
# Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005 Sep 1;23(25):5983-92. Epub 2005 Aug 8. [http://ascopubs.org/doi/full/10.1200/JCO.2005.06.232 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16087943 PubMed]
# '''SWOG 0012:''' Ellis GK, Barlow WE, Gralow JR, Hortobagyi GN, Russell CA, Royce ME, Perez EA, Lew D, Livingston RB. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol. 2011 Mar 10;29(8):1014-21. Epub 2011 Jan 10. [http://ascopubs.org/doi/full/10.1200/JCO.2009.27.6543 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068051/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21220618 PubMed]
<!-- Presented at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30-June 3, 2008. -->
# Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012 Mar 20;30(9):930-5. Epub 2012 Feb 13. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.2079 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22331946 PubMed]
# '''GeparSepto:''' Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kümmel S, Hilfrich J, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Darb-Esfahani S, Schmitt WD, Dan Costa S, Gerber B, Engels K, Nekljudova V, Loibl S, von Minckwitz G; German Breast Group (GBG).; Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) Investigators. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol. Epub 2016 Feb 8. 2016 Mar;17(3):345-56. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00542-2/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26869049 PubMed]
## '''Update:''' Furlanetto J, Jackisch C, Untch M, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Wiebringhaus H, Kümmel S, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Costa SD, Gerber B, Nekljudova V, Loibl S, von Minckwitz G. Efficacy and safety of nab-paclitaxel 125 mg/m(2) and nab-paclitaxel 150 mg/m(2) compared to paclitaxel in early high-risk breast cancer: results from the neoadjuvant randomized GeparSepto study (GBG 69). Breast Cancer Res Treat. 2017 Jun;163(3):495-506. Epub 2017 Mar 17. [https://link.springer.com/article/10.1007%2Fs10549-017-4200-1 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28315068 PubMed]
# '''ETNA:''' Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, Morales S, Alvarez I, Plazaola A, Zambetti M, Redfern AD, Dittrich C, Dent RA, Magazzù D, De Fato R, Valagussa P, Tusquets I. Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/HER2-negative breast cancer-the Evaluating Treatment with Neoadjuvant Abraxane (ETNA) trial: a randomized phase 3 clinical trial. JAMA Oncol. 2018 Mar 1;4(3):302-308. Epub 2018 Jan 11. [https://jamanetwork.com/journals/jamaoncology/fullarticle/2668528 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29327055 PubMed]

==Paclitaxel monotherapy, dose-dense (q2wk) {{#subobject:fa1c6b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ddT: '''<u>d</u>'''ose-'''<u>d</u>'''ense '''<u>T</u>'''axol (Paclitaxel)
===Regimen {{#subobject:b5be66|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/33/8340.long Burstein et al. 2005]
| style="background-color:#91cf61" |Non-randomized
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70554-0/fulltext Earl et al. 2013 (Neo-tAnGo)]
|style="background-color:#1a9851" |Phase III (*)
|[[Complex_multipart_regimens#Neo-tAnGo|See link]]
|[[Complex_multipart_regimens#Neo-tAnGo|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*Burstein et al. 2005: [[#ddAC|ddAC]] x 4
*Neo-tAnGo (EC-ddT arm): [[#EC|EC]] x 4
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1
====Supportive medications====
*Burstein et al. 2005: [[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2
*Neo-tAnGo: primary propyhylaxis not provided

'''14-day cycle for 4 cycles'''
====Subsequent treatment====
*Burstein et al. 2005 and Neo-tAnGo (EC-ddT arm): [[Surgery#Breast_cancer_surgery|Surgery]]
*Neo-tAnGo (ddT-EC arm): [[#EC|EC]] x 4, then [[Surgery#Breast_cancer_surgery|surgery]]

===References===
# Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20;23(33):8340-7. [http://jco.ascopubs.org/content/23/33/8340.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16293865 PubMed]
# '''Neo-tAnGo:''' Earl HM, Vallier AL, Hiller L, Fenwick N, Young J, Iddawela M, Abraham J, Hughes-Davies L, Gounaris I, McAdam K, Houston S, Hickish T, Skene A, Chan S, Dean S, Ritchie D, Laing R, Harries M, Gallagher C, Wishart G, Dunn J, Provenzano E, Caldas C; Neo-tAnGo Investigators. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial. Lancet Oncol. 2014 Feb;15(2):201-12. Epub 2013 Dec 19. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70554-0/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24360787 PubMed]

==Paclitaxel, nanoparticle albumin-bound monotherapy {{#subobject:8f6227|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:fe2978|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00542-2/abstract Untch et al. 2016 (GeparSepto)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel_monotherapy.2C_weekly|Weekly Paclitaxel]]
| style="background-color:#1a9850" |Superior pCR rate
|-
|}
''Note: this is the dose after study amendment due to increased treatment discontinuation and sensory neuropathy. This is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Chemotherapy====
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 125 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''21-day cycle for 4 cycles'''

====Subsequent treatment====
*[[#EC|EC]] x 4, then [[Surgery#Breast_cancer_surgery|surgery]]

===References===
# '''GeparSepto:''' Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kümmel S, Hilfrich J, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Darb-Esfahani S, Schmitt WD, Dan Costa S, Gerber B, Engels K, Nekljudova V, Loibl S, von Minckwitz G; German Breast Group (GBG).; Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) Investigators. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol. Epub 2016 Feb 8. 2016 Mar;17(3):345-56. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00542-2/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26869049 PubMed]
## '''Update:''' Furlanetto J, Jackisch C, Untch M, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Wiebringhaus H, Kümmel S, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Costa SD, Gerber B, Nekljudova V, Loibl S, von Minckwitz G. Efficacy and safety of nab-paclitaxel 125 mg/m(2) and nab-paclitaxel 150 mg/m(2) compared to paclitaxel in early high-risk breast cancer: results from the neoadjuvant randomized GeparSepto study (GBG 69). Breast Cancer Res Treat. 2017 Jun;163(3):495-506. Epub 2017 Mar 17. [https://link.springer.com/article/10.1007%2Fs10549-017-4200-1 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28315068 PubMed]
# '''ETNA:''' Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, Morales S, Alvarez I, Plazaola A, Zambetti M, Redfern AD, Dittrich C, Dent RA, Magazzù D, De Fato R, Valagussa P, Tusquets I. Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/HER2-negative breast cancer-the Evaluating Treatment with Neoadjuvant Abraxane (ETNA) trial: a randomized phase 3 clinical trial. JAMA Oncol. 2018 Mar 1;4(3):302-308. Epub 2018 Jan 11. [https://jamanetwork.com/journals/jamaoncology/fullarticle/2668528 link to original article]  [https://www.ncbi.nlm.nih.gov/pubmed/29327055 PubMed]

==TAC (Taxotere) {{#subobject:413b30|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TAC: '''<u>T</u>'''axotere (Docetaxel), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide
<br>ATC: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>T</u>'''axotere (Docetaxel), '''<u>C</u>'''yclophosphamide
===Regimen {{#subobject:8dbe27|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/jnci/article/100/8/542/931241 von Minckwitz et al. 2008 (GeparTrio)]
| style="background-color:#1a9851" |Phase III (E)
|TAC x 2, then NX x 4
| style="background-color:#eeee01" |Non-inferior sonographic response
|-
|[https://www.ejcancer.com/article/S0959-8049(13)00487-5/fulltext Vriens et al. 2013 (INTENS)]
| style="background-color:#1a9851" |Phase III (E)
|[[#AC|AC]], then [[#Docetaxel_monotherapy|T]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 cycles'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
===References===
# '''GeparTrio:''' von Minckwitz G, Kümmel S, Vogel P, Hanusch C, Eidtmann H, Hilfrich J, Gerber B, Huober J, Costa SD, Jackisch C, Loibl S, Mehta K, Kaufmann M; German Breast Group. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008 Apr 16;100(8):542-51. Epub 2008 Apr 8. [https://academic.oup.com/jnci/article/100/8/542/931241 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18398097 PubMed]
# '''INTENS:''' Vriens BE, Aarts MJ, de Vries B, van Gastel SM, Wals J, Smilde TJ, van Warmerdam LJ, de Boer M, van Spronsen DJ, Borm GF, Tjan-Heijnen VC; Breast Cancer Trialists' Group of the Netherlands (BOOG). Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer. Eur J Cancer. 2013 Oct;49(15):3102-10. Epub 2013 Jul 10. [https://www.ejcancer.com/article/S0959-8049(13)00487-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23850450 PubMed]
## '''Update:''' Vriens BEPJ, Vriens IJH, Aarts MJB, van Gastel SM, van den Berkmortel FWPJ, Smilde TJ, van Warmerdam LJC, van Spronsen DJ, Peer PGM, de Boer M, Tjan-Heijnen VCG; Breast Cancer Trialists’ Group of the Netherlands (BOOG). Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer. Breast Cancer Res Treat. 2017 Oct;165(3):593-600. Epub 2017 Jul 3. [https://link.springer.com/article/10.1007%2Fs10549-017-4364-8 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602024/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28674765 PubMed]

=Neoadjuvant response criteria=

==Clinical response rate (cRR)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
''Although fairly dated, some trials such as [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107749/ ACOSOG Z1031] make use of the WHO criteria for response to neoadjuvant therapy. Included here primarily for historical purposes.''
===References===
# Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207-14. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19810101)47:1%3C207::AID-CNCR2820470134%3E3.0.CO;2-6/abstract link to original article]  [https://www.ncbi.nlm.nih.gov/pubmed/7459811 PubMed]

==Miller-Payne scoring system==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
*Grade 1: No change or some changes to individual malignant cells, but no reduction in overall cellularity
*Grade 2: Minor loss of tumor cells (up to 30%), but overall cellularity still high 
*Grade 3: An estimated 30 to 90% reduction in the number of tumor cells
*Grade 4: Marked disappearance of tumor cells such that only small clusters or widely dispersed individual cells remain (loss of greater than 90% of tumor cells) 
*Grade 5: No invasive cancer cells identifiable in sections from the site of the tumor (carcinoma ''in situ'' may be present) 
===References===
# Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003 Oct;12(5):320-7. [http://www.thebreastonline.com/article/S0960-9776(03)00106-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14659147 PubMed]

==Residual cancer burden (RCB)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
*The RCB is calculated as follows: RCB = 1.4 (''f<sub>inv</sub>*d<sub>prim</sub>'')<sup>0.17</sup> + [4(1 - 0.75<sup>''LN''</sup>)''d<sub>met</sub>'']<sup>0.17</sup>
**where ''d<sub>prim</sub>'' is derived from the bidimensional diameters of the primary tumor bed in the resected specimen, ''f<sub>inv</sub>'' is the proportion of the primary tumor bed that contains invasive carcinoma, ''LN'' is the number of axillary lymph nodes containing metastatic carcinoma, and ''d<sub>met</sub>'' is the diameter of the largest metastasis in an axillary lymph node.
**The cut-off points are 1.36 and 3.28.
===References===
# Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007 Oct 1;25(28):4414-22. Epub 2007 Sep 4. [http://ascopubs.org/doi/full/10.1200/JCO.2007.10.6823 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17785706 PubMed]

==Residual disease in breast and nodes (RDBN)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
*Level 1: pCR in breast and nodes with or without ''in situ'' carcinoma
*Levels 2 to 4: Residual disease, calculated as 0.2 (residual breast tumor size in cm) + index of involved nodes (0 for no positive nodes, 1 for 1 to 4 positive nodes, 2 for 5 to 7 positive nodes, and 3 for 8 positive nodes) + the Scarff–Bloom–Richardson grade (1, 2, or 3). The cut-off points are 3 and 4.3.
===References===
# Chollet P, Abrial C, Durando X, Thivat E, Tacca O, Mouret-Reynier MA, Leheurteur M, Kwiatkowski F, Dauplat J, Penault-Llorca F. A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN). Cancer J. 2008 Mar-Apr;14(2):128-32. [https://insights.ovid.com/pubmed?pmid=18391619 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18391619 PubMed]

==Sataloff's classification==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
*Breast: 
**T-A: Total or nearly total therapeutic effect 
**T-B: Greater than 50% therapeutic effect
**T-C: Less than 50% therapeutic effect 
**T-D: No therapeutic effect
*Lymph node:
**N-A: Therapeutic effect but no metastasis
**N-B: No metastasis, no therapeutic effect
**N-C: Therapeutic effect but metastasis
**N-D: Metastasis, no therapeutic effect
===References===
# Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995 Mar;180(3):297-306. [https://www.ncbi.nlm.nih.gov/pubmed/7874340 PubMed]

==Tumor response ratio==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Calculated as follows: Residual breast disease observed upon pathologic examination divided by the size of the tumor on the pre-neoadjuvant therapy image.
*TRR = 0: pathologic complete response (pCR)
*TRR greater than 0 up to 0.4: strong partial response
*TRR greater than 0.4 up to 1.0: weak partial response (WPR)
*TRR greater than 1.0: tumor growth
===References===
# Miller M, Ottesen RA, Niland JC, Kruper L, Chen SL, Vito C. Tumor response ratio predicts overall survival in breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2014 Oct;21(10):3317-23. Epub 2014 Jul 25. [https://link.springer.com/article/10.1245%2Fs10434-014-3922-0 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25059788 PubMed]

==ypTNM staging==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
This system is proprietary to the AJCC. Please [https://cancerstaging.org/Pages/default.aspx visit their site] or consult the AJCC Manual for further details.

=Adjuvant chemotherapy=

==AC {{#subobject:77b0fd|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
AC: '''<u>A</u>'''driamycin (Doxorubicin) and '''<u>C</u>'''yclophosphamide
<br>CA: '''<u>C</u>'''yclophosphamide and '''<u>A</u>'''driamycin (Doxorubicin)
===Variant #1, 54/1200 x 6 {{#subobject:8f5df7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2006.07.0847 Linden et al. 2007 (INT-0137)]
| style="background-color:#1a9851" |Phase III (C)
|A, then C
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 54 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 1200 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 cycles'''

===Variant #2, 60/600 x 4 {{#subobject:ac3513|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1997.15.5.1858 Fisher et al. 1997 (NSABP B-22)]
| style="background-color:#1a9851" |Phase III (C)
|1. Intensified AC<br> 2. Intensified & Increased AC
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1997.15.7.2483 Fisher et al. 1997 (NSABP B-18)]
| style="background-color:#1a9851" |Phase III (C)
|[[#AC|Neoadjuvant AC]]
| style="background-color:#d73027" |Inferior resectability
|-
|[http://jco.ascopubs.org/content/19/4/931.full Fisher et al. 2001 (NSABP B-23)]
| style="background-color:#1a9851" |Phase III (E)
|[[#CMF|CMF]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://academic.oup.com/annonc/article/12/7/1011/150435 Içli et al. 2001]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://jco.ascopubs.org/content/21/6/976.long Henderson et al. 2003 (INT 0148/CALGB 9344)]
| style="background-color:#1a9851" |Phase III (C)
|1. High-dose AC<br> 2. Very-high-dose AC
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://jco.ascopubs.org/content/21/8/1431.long Citron et al. 2003 (CALGB 9741)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#CALGB_9741|See link]]
|[[Complex_multipart_regimens#CALGB_9741|See link]]
|-
|[https://www.clinical-breast-cancer.com/article/S1526-8209(11)70948-X/pdf Van Pelt et al. 2003]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://jco.ascopubs.org/content/23/16/3686.long Mamounas et al. 2005 (NSABP B-28)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://jamanetwork.com/journals/jama/fullarticle/200883 Brain et al. 2005 (RAPP-01)]
| style="background-color:#1a9851" |Phase III (C)
|AT (Taxotere)
| style="background-color:#d3d3d3" |Not reported
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa052122 Romond et al. 2005 (NSABP B-31)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa052122 Romond et al. 2005 (NCCTG N9831)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.03.0783 Colleoni et al. 2006 (IBCSG 13-93)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://jco.ascopubs.org/content/24/34/5381.full Jones et al. 2006 (US Oncology Trial 9735)]
| style="background-color:#1a9851" |Phase III (C)
|[[#DC|TC]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://academic.oup.com/jnci/article/100/2/121/1130035 Francis et al. 2008 (BIG 02-98)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#BIG_02-98|See link]]
| style="background-color:#ffffbf" |[[Complex_multipart_regimens#BIG_02-98|See link]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743943/ Sparano et al. 2008 (ECOG E1199)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654376/ Goldstein et al. 2008 (ECOG E2197)]
| style="background-color:#1a9851" |Phase III (C)
|AT (Taxotere)
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082436/ Muss et al. 2009 (CALGB 49907)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Capecitabine_monotherapy|Capecitabine]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799234/ Burnell et al. 2009 (NCIC CTG MA.21)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#NCIC_CTG_MA.21|See link]]
| style="background-color:#d73027" |[[Complex_multipart_regimens#NCIC_CTG_MA.21|See link]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.24.1000 Loesch et al. 2010]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#Loesch_et_al._2010|See link]]
| style="background-color:#ffffbf" |[[Complex_multipart_regimens#Loesch_et_al._2010|See link]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935316/ Swain et al. 2010 (NSABP B-30)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#NSABP_B-30|See link]]
| style="background-color:#91cf60" |[[Complex_multipart_regimens#NSABP_B-30|See link]]
|-
|[http://jco.ascopubs.org/content/29/29/3877.long Eiermann et al. 2011 (BCIRG-005)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#BCIRG-005|See link]]
| style="background-color:#ffffbf" |[[Complex_multipart_regimens#BCIRG-005|See link]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268553/ Slamon et al. 2011 (BCIRG 006)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#BCIRG_006|See link]]
|[[Complex_multipart_regimens#BCIRG_006|See link]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.30421/abstract Watanabe et al. 2017 (NSAS BC-02)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#NSAS_BC-02|See link]]
| style="background-color:#ffffbf" |[[Complex_multipart_regimens#NSAS_BC-02|See link]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2018.79.2028 Miller et al. 2018 (ECOG E5103)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#ECOG_E5103|See link]]
| style="background-color:#ffffbf" |[[Complex_multipart_regimens#ECOG_E5103|See link]]
|-
|}
''Patients in Van Pelt et al. 2003, NSABP B-31, NCCTG N9831, and BCIRG 006 were HER2-positive.''
====Preceding treatment====
*Most protocols: [[Surgery#Breast_cancer_surgery|Surgery]]
*Van Pelt et al. 2003: [[Breast_cancer,_HER2-positive#TH_.28Taxotere.29|Neoadjuvant TH]], then [[Surgery#Breast_cancer_surgery|surgery]]
*INT 0148/CALGB 9344: [[Surgery#Breast_cancer_surgery|Surgery]], within 84 days
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''

====Subsequent treatment====
*NSABP B-23: [[Breast_cancer,_ER/PR-positive#Tamoxifen_monotherapy|Tamoxifen]] x 5 y versus [[Breast_cancer,_ER/PR-positive#Placebo|placebo]]
*Içli et al. 2001: EP x 2 versus no further treatment
*Van Pelt et al. 2003: [[Breast_cancer,_HER2-positive#Trastuzumab_monotherapy_2|H]] x 12 mo
*INT 0148/CALGB 9344 and NSABP B-28: [[Breast_cancer_-_historical#Paclitaxel_monotherapy.2C_q3wk|q3wk T (Taxol)]] x 4 versus [[Breast_cancer_-_historical#Observation|no further therapy]]
*CALGB 9741, NCIC CTG MA.21, Loesch et al. 2010: [[Breast_cancer_-_historical#Paclitaxel_monotherapy.2C_q3wk|q3wk T (Taxol)]] x 4
*NSABP B-31: [[#Paclitaxel_monotherapy.2C_weekly_2|weekly T (Taxol)]] x 12 versus [[Breast_cancer,_HER2-positive#TH_.28Taxol.29_2|TH (Taxol)]] x 12 mo
*IBCSG 13-93: [[#CMF|CMF]] x 3, then [[Breast_cancer,_ER/PR-positive#Tamoxifen_monotherapy|Tamoxifen]] x 5 y versus [[Breast_cancer,_ER/PR-positive#Observation|no further treatment]]
*NCCTG N9831: [[#Paclitaxel_monotherapy.2C_weekly_2|weekly T (Taxol)]] x 12 versus sequential [[#Paclitaxel_monotherapy.2C_weekly_2|weekly T (Taxol)]] x 12, then [[Breast_cancer,_HER2-positive#Trastuzumab_monotherapy|H]] x 12 mo versus concurrent [[Breast_cancer,_HER2-positive#TH_.28Taxol.29_2|TH (Taxol)]] x 12 mo
*BIG 02-98: [[#CMF|CMF]] x 3
*ECOG E1199: [[#Docetaxel_monotherapy_2|q3wk T (Taxotere)]] x 4 versus [[#Docetaxel_monotherapy_2|weekly T (Taxotere)]] x 12 versus [[Breast_cancer_-_historical#Paclitaxel_monotherapy.2C_q3wk|q3wk T (Taxol)]] x 4 versus [[#Paclitaxel_monotherapy.2C_weekly_2|weekly T (Taxol)]] x 12
*NSABP B-30 & BCIRG-005: [[#Docetaxel_monotherapy_2|q3wk T (Taxotere)]] x 4
*BCIRG 006: [[#Docetaxel_monotherapy_2|q3wk T (Taxotere)]] x 4 versus [[Breast_cancer,_HER2-positive#TH_.28Taxotere.29_2|TH (Taxotere)]] x 12 mo
*NSAS BC-02: [[#Docetaxel_monotherapy_2|q3wk T (Taxotere)]] x 4 versus [[Breast_cancer_-_historical#Paclitaxel_monotherapy.2C_q3wk|T (Taxol) q3wk]] x 4
*ECOG E5103: [[#Paclitaxel_monotherapy.2C_weekly_2|weekly T (Taxol)]] x 12

===Variant #3, 80/600 x 4 {{#subobject:42ada7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2006.08.9383 Moore et al. 2007 (SWOG S9623)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 80 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''

===Variant #4, with range {{#subobject:67eda7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ von Minckwitz et al. 2017 (APHINITY)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Patients in APHINITY had HER2-positive breast cancer. Note that ranges for AC are given in the protocol, replicated here. This is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 to 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Breast_cancer,_HER2-positive#TH_.28Taxol.29_2|TH (Taxol)]] versus [[Breast_cancer,_HER2-positive#THP_.28Taxol.29_2|THP (Taxol)]] or [[Breast_cancer,_HER2-positive#TH_.28Taxotere.29_2|TH (Taxotere)]] versus [[Breast_cancer,_HER2-positive#THP_.28Taxotere.29_2|THP (Taxotere)]]
===References===
# '''NSABP B-22:''' Fisher B, Anderson S, Wickerham DL, DeCillis A, Dimitrov N, Mamounas E, Wolmark N, Pugh R, Atkins JN, Meyers FJ, Abramson N, Wolter J, Bornstein RS, Levy L, Romond EH, Caggiano V, Grimaldi M, Jochimsen P, Deckers P. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol. 1997 May;15(5):1858-69. [http://ascopubs.org/doi/abs/10.1200/JCO.1997.15.5.1858 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9164196 PubMed]
## '''Pooled update:''' Taghian A, Jeong JH, Mamounas E, Anderson S, Bryant J, Deutsch M, Wolmark N. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004 Nov 1;22(21):4247-54. Epub 2004 Sep 27. [http://ascopubs.org/doi/full/10.1200/JCO.2004.01.042 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15452182 PubMed]
# '''NSABP B-18:''' Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997 Jul;15(7):2483-93. [http://ascopubs.org/doi/abs/10.1200/JCO.1997.15.7.2483 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9215816 PubMed]
## '''Update:''' Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998 Aug;16(8):2672-85. [http://ascopubs.org/doi/abs/10.1200/JCO.1998.16.8.2672 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9704717 PubMed]
## '''Update:''' Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst. 2001;(30):96-102. [https://www.ncbi.nlm.nih.gov/pubmed/11773300 PubMed]
## '''Pooled update:''' Taghian A, Jeong JH, Mamounas E, Anderson S, Bryant J, Deutsch M, Wolmark N. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004 Nov 1;22(21):4247-54. Epub 2004 Sep 27. [http://ascopubs.org/doi/full/10.1200/JCO.2004.01.042 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15452182 PubMed]
## '''Pooled update:''' Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008 Feb 10;26(5):778-85. Erratum in: J Clin Oncol. 2008 Jun 1;26(16):2793. [http://ascopubs.org/doi/full/10.1200/JCO.2007.15.0235 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18258986 PubMed]
# '''NSABP B-23:''' Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, Dimitrov NV, Atkins JN, Abramson N, Merajver S, Romond EH, Kardinal CG, Shibata HR, Margolese RG, Farrar WB. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 2001 Feb 15;19(4):931-42. [http://jco.ascopubs.org/content/19/4/931.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11181655 PubMed]
# Içli F, Akbulut H, Dinçol D, Onur H, Demirkazik A, Cam R, Cay F, Demirci S, Uner A, Erekul S. A randomized trial of four cycles of adjuvant AC (adriamycin + cyclophosphamide) +/- two cycles of EP (etoposide + cisplatin) in node positive patients with breast cancer. Ann Oncol. 2001 Jul;12(7):1011-3. [https://academic.oup.com/annonc/article/12/7/1011/150435 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11521785 PubMed]
# '''INT 0148/CALGB 9344:''' Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15;21(6):976-83. [http://jco.ascopubs.org/content/21/6/976.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12637460 PubMed]
# '''CALGB 9741:''' Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15;21(8):1431-9. Epub 2003 Feb 13. [http://jco.ascopubs.org/content/21/8/1431.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12668651 PubMed]
# Van Pelt AE, Mohsin S, Elledge RM, Hilsenbeck SG, Gutierrez MC, Lucci A Jr, Kalidas M, Granchi T, Scott BG, Allred DC, Chang JC. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer. 2003 Dec;4(5):348-53. [https://www.clinical-breast-cancer.com/article/S1526-8209(11)70948-X/pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14715110 PubMed]
<!-- Presented in abstract form at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3, 2003; interim results were presented at the 2000 NIH Consensus Development Conference, Bethesda, MD, November 1-3, 2000. -->
# '''NSABP B-28:''' Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005 Jun 1;23(16):3686-96. Epub 2005 May 16. [http://jco.ascopubs.org/content/23/16/3686.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15897552 PubMed]
# '''RAPP-01:''' Brain EG, Bachelot T, Serin D, Kirscher S, Graic Y, Eymard JC, Extra JM, Combe M, Fourme E, Noguès C, Rouëssé J; RAPP-01 Trial Investigators. Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. JAMA. 2005 May 18;293(19):2367-71. [https://jamanetwork.com/journals/jama/fullarticle/200883 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15900007 PubMed]
<!-- no pre-pub disclosed -->
# '''NSABP B-31/NCCTG N9831:''' Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1673-84. [https://www.nejm.org/doi/full/10.1056/NEJMoa052122 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16236738 PubMed]
## '''Update:''' Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011 Sep 1;29(25):3366-73. Epub 2011 Jul 18. [http://ascopubs.org/doi/full/10.1200/JCO.2011.35.0868 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164242/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21768458 PubMed]
## '''Update:''' Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011 Dec 1;29(34):4491-7. Epub 2011 Oct 31. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.7045 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236650/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22042958 PubMed]
## '''Update:''' Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014 Nov 20;32(33):3744-52. [http://ascopubs.org/doi/full/10.1200/JCO.2014.55.5730 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226805/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25332249 PubMed]
## '''Update and HRQoL analysis:''' Ganz PA, Romond EH, Cecchini RS, Rastogi P, Geyer CE Jr, Swain SM, Jeong JH, Fehrenbacher L, Gross HM, Brufsky AM, Flynn PJ, Wahl TA, Seay TE, Wade JL 3rd, Biggs DD, Atkins JN, Polikoff J, Zapas JL, Mamounas EP, Wolmark N. Long-term follow-up of cardiac function and quality of life for patients in NSABP protocol B-31/NRG Oncology: a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2. J Clin Oncol. 2017 Dec 10;35(35):3942-3948. Epub 2017 Oct 26. [http://ascopubs.org/doi/full/10.1200/JCO.2017.74.1165 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721228/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29072977 PubMed]
# '''IBCSG 13-93:''' Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD; International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol. 2006 Mar 20;24(9):1332-41. Epub 2006 Feb 27. [http://ascopubs.org/doi/full/10.1200/JCO.2005.03.0783 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16505417 PubMed]
# '''US Oncology Trial 9735:''' Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006 Dec 1;24(34):5381-7. Erratum in: J Clin Oncol. 2007 May 1;25(13):1819. [http://jco.ascopubs.org/content/24/34/5381.full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17135639 PubMed]
## '''Update:''' Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology research trial 9735. J Clin Oncol. 2009 Mar 10;27(8):1177-83. Epub 2009 Feb 9. [http://jco.ascopubs.org/content/27/8/1177.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19204201 PubMed]
# '''INT-0137:''' Linden HM, Haskell CM, Green SJ, Osborne CK, Sledge GW Jr, Shapiro CL, Ingle JN, Lew D, Hutchins LF, Livingston RB, Martino S. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313). J Clin Oncol. 2007 Feb 20;25(6):656-61. [http://ascopubs.org/doi/full/10.1200/JCO.2006.07.0847 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17308269 PubMed]
# '''SWOG S9623:''' Moore HC, Green SJ, Gralow JR, Bearman SI, Lew D, Barlow WE, Hudis C, Wolff AC, Ingle JN, Chew HK, Elias AD, Livingston RB, Martino S; Southwest Oncology Group/Intergroup Study 9623. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. J Clin Oncol. 2007 May 1;25(13):1677-82. Epub 2007 Apr 2. [http://ascopubs.org/doi/full/10.1200/JCO.2006.08.9383 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17404368 PubMed]
# '''BIG 02-98:''' Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, Nordenskjöld B, Lang I, Jakesz R, Vorobiof D, Gutiérrez J, van Hazel G, Dolci S, Jamin S, Bendahmane B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Piccart-Gebhart M; BIG 02-98 Collaborative Group. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst. 2008 Jan 16;100(2):121-33. Epub 2008 Jan 8. Erratum in: J Natl Cancer Inst. 2008 Nov 19;100(22):1655. [https://academic.oup.com/jnci/article/100/2/121/1130035 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18182617 PubMed]
## '''Update:''' Oakman C, Francis PA, Crown J, Quinaux E, Buyse M, De Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Jakesz R, Thürlimann B, Gutiérrez J, Harvey V, Punzalan L, Dell'orto P, Larsimont D, Steinberg I, Gelber RD, Piccart-Gebhart M, Viale G, Di Leo A. Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial. Ann Oncol. 2013 May;24(5):1203-11. Epub 2013 Jan 4. [https://academic.oup.com/annonc/article/24/5/1203/215838 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23293111 PubMed]
## '''Update:''' Sonnenblick A, Francis PA, Azim HA Jr, de Azambuja E, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart M, Crown J. Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. Eur J Cancer. 2015 Aug;51(12):1481-9. Epub 2015 Jun 11. [https://www.ejcancer.com/article/S0959-8049(15)00285-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26074397 PubMed]
<!-- Presented in part at the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8–11, 2007, and the American Society of Clinical Oncology meeting, Chicago, June 1–4, 2005. -->
# '''ECOG E1199:''' Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008 Apr 17;358(16):1663-71. [https://www.nejm.org/doi/full/10.1056/NEJMoa0707056 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743943/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18420499 PubMed]
## '''Update:''' Sparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer. J Clin Oncol. 2015 Jul 20;33(21):2353-60. Epub 2015 Jun 15. [http://jco.ascopubs.org/content/33/21/2353.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500829/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26077235 PubMed]
# '''ECOG E2197:''' Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol. 2008 Sep 1;26(25):4092-9. Epub 2008 Aug 4. [http://ascopubs.org/doi/full/10.1200/JCO.2008.16.7841 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654376/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18678836 PubMed]
# Loesch D, Greco FA, Senzer NN, Burris HA, Hainsworth JD, Jones S, Vukelja SJ, Sandbach J, Holmes F, Sedlacek S, Pippen J, Lindquist D, McIntyre K, Blum JL, Modiano MR, Boehm KA, Zhan F, Asmar L, Robert N. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. J Clin Oncol. 2010 Jun 20;28(18):2958-65. Epub 2010 May 17. [http://ascopubs.org/doi/full/10.1200/JCO.2009.24.1000 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20479419 PubMed]
# '''NSABP B-30:''' Swain SM, Jeong JH, Geyer CE Jr, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land SR, Ganz PA, Wolmark N. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010 Jun 3;362(22):2053-65. [https://www.nejm.org/doi/10.1056/NEJMoa0909638 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935316/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20519679 PubMed]
# '''CALGB 49907:''' Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP; CALGB Investigators. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 May 14;360(20):2055-65. Erratum in: N Engl J Med. 2009 Oct 22;361(17):1714. Magrinat, Gutav [corrected to Magrinat, Gustav]. [https://www.nejm.org/doi/10.1056/NEJMoa0810266 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082436/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19439741 PubMed]
# '''NCIC CTG MA.21:''' Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien P, Shepherd LE. Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol. 2010 Jan 1;28(1):77-82. Epub 2009 Nov 9. [http://ascopubs.org/doi/full/10.1200/JCO.2009.22.1077 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799234/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19901117 PubMed]
# '''BCIRG-005:''' Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martín M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press M, Sauter G, Lindsay MA, Riva A, Buyse M, Drevot P, Taupin H, Mackey JR. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol. 2011 Oct 10;29(29):3877-84. Epub 2011 Sep 12. [http://jco.ascopubs.org/content/29/29/3877.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21911726 PubMed]
## '''Update:''' Mackey JR, Pieńkowski T, Crown J, Sadeghi S, Martín M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press MF, Sauter G, Lindsay M, Houé V, Buyse M, Drevot P, Hitier S, Bensfia S, Eiermann W; Translational Research In Oncology (TRIO)/ Breast Cancer International Research Group (BCIRG)-005 investigators. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. Ann Oncol. 2016 Jun;27(6):1041-7. Epub 2016 Mar 2. [https://academic.oup.com/annonc/article/27/6/1041/2240122 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26940688 PubMed]
<!-- no pre-pub disclosed -->
# '''BCIRG 006:''' Slamon D, Eiermann W, Robert N, Pienkowski T, Martín M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6;365(14):1273-83. [https://www.nejm.org/doi/full/10.1056/NEJMoa0910383 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268553/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21991949 PubMed]
# '''NSAS BC-02:''' Watanabe T, Kuranami M, Inoue K, Masuda N, Aogi K, Ohno S, Iwata H, Mukai H, Uemura Y, Ohashi Y. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study. Cancer. 2017 Mar 1;123(5):759-768. Epub 2017 Jan 12. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.30421/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28081304 PubMed]
# '''APHINITY:''' von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. Epub 2017 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1703643 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1703643/suppl_file/nejmoa1703643_protocol.pdf link to supplementary protocol] '''contains verified protocol in supplementary protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28581356 PubMed]
# '''ECOG E5103:''' Miller KD, O'Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA, Bloom S, Brufsky AM, Tevaarwerk AJ, Sparano JA, Le-Lindqwister NA, Hendricks CB, Northfelt DW, Dang CT, Sledge GW Jr. Double-blind phase III trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node-positive and high-risk lymph node-negative breast cancer (E5103). J Clin Oncol. 2018 Sep 1;36(25):2621-2629. Epub 2018 Jul 24. [http://ascopubs.org/doi/full/10.1200/JCO.2018.79.2028 link to original article] '''refers to ECOG E1199 protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30040523 PubMed]

==AT (Taxol) {{#subobject:0ed69b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
AT: '''<u>A</u>'''driamycin (Doxorubicin) & '''<u>T</u>'''axol (Paclitaxel)
===Regimen {{#subobject:61e706|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2008.19.2567 Gianni et al. 2009 (ECTO)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#ECTO|See link]]
| style="background-color:#91cf60" |[[Complex_multipart_regimens#ECTO|See link]]
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#CMF|CMF]] x 4
===References===
# '''ECTO:''' Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Cussac AL, Bozhok A, Martinez-Agulló A, Greco M, Byakhov M, Lopez JJ, Mansutti M, Valagussa P, Bonadonna G. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol. 2009 May 20;27(15):2474-81. Epub 2009 Mar 30. [http://ascopubs.org/doi/full/10.1200/JCO.2008.19.2567 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19332727 PubMed]

==Bevacizumab monotherapy {{#subobject:c254bd|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:6c056e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401076/ Bear et al. 2012 (NSABP B-40)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#NSABP_B-40|See link]]
|[[Complex_multipart_regimens#NSABP_B-40|See link]]
|-
|}
====Preceding treatment====
*[[#AC_.26_Bevacizumab|Neoadjuvant AC+Bev]] x 4, then [[Surgery#Breast_cancer_surgery|surgery]]
====Chemotherapy====
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycle for 10 cycles'''
===References===
# Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012 Jan 26;366(4):310-20. [https://www.nejm.org/doi/full/10.1056/NEJMoa1111097 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401076/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22276821 PubMed]
## '''Update:''' Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol. 2015 Sep;16(9):1037-1048. Epub 2015 Aug 10. Erratum in: Lancet Oncol. 2015 Dec;16(16):e589. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00041-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624323/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26272770 PubMed]

==Capecitabine monotherapy {{#subobject:e058c1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 4 cycles {{#subobject:36e4ba|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2015.61.9510 Martín et al. 2015 (GEICAM/2003-10)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#GEICAM.2F2003-10|See link]]
|[[Complex_multipart_regimens#GEICAM.2F2003-10|See link]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489700/ Cameron et al. 2017 (TACT2)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#TACT2|See link]]
|[[Complex_multipart_regimens#TACT2|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*GEICAM/2003-10: ET x 4
*TACT2: ddE x 4 versus [[#Epirubicin_monotherapy|Epirubicin]] x 4
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1250 mg/m<sup>2</sup> PO twice per day on days 1 to 14

'''21-day cycle for 4 cycles'''

===Variant #2, 6 to 8 cycles {{#subobject:9cc782|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082436/ Muss et al. 2009 (CALGB 49907)]
| style="background-color:#1a9851" |Phase III (E)
|Physician's choice of:<br> 1. [[#AC_2|AC]] x 4<br> 2. [[#CMF|CMF]] x 6
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1612645 Masuda et al. 2017 (CREATE-X)]
| style="background-color:#1a9851" |Phase III (E)
|Standard therapy
| style="background-color:#1a9850" |Superior OS
|-
|}
''Note: patients in CALGB 49907 received a maximum of 6 cycles. All patients in CREATE-X had residual disease at time of surgical resection. Concomitant endocrine therapy was allowed.''
====Preceding treatment====
*CALGB 49907: [[Surgery#Breast_cancer_surgery|Surgery]]
*CREATE-X: Neoadjuvant chemotherapy containing anthracycline, taxane, or both, then [[Surgery#Breast_cancer_surgery|surgery]]
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1250 mg/m<sup>2</sup> PO twice per day on days 1 to 14

'''21-day cycle for 6 to 8 cycles'''

===References===
# '''CALGB 49907:''' Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP; CALGB Investigators. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 May 14;360(20):2055-65. Erratum in: N Engl J Med. 2009 Oct 22;361(17):1714. Magrinat, Gutav [corrected to Magrinat, Gustav]. [https://www.nejm.org/doi/10.1056/NEJMoa0810266 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082436/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19439741 PubMed]
# '''GEICAM/2003-10:''' Martín M, Ruiz Simón A, Ruiz Borrego M, Ribelles N, Rodríguez-Lescure A, Muñoz-Mateu M, González S, Margelí Vila M, Barnadas A, Ramos M, Del Barco Berron S, Jara C, Calvo L, Martínez-Jáñez N, Mendiola Fernández C, Rodríguez CA, Martínez de Dueñas E, Andrés R, Plazaola A, de la Haba-Rodríguez J, López-Vega JM, Adrover E, Ballesteros AI, Santaballa A, Sánchez-Rovira P, Baena-Cañada JM, Casas M, del Carmen Cámara M, Carrasco EM, Lluch A. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. J Clin Oncol. 2015 Nov 10;33(32):3788-95. Epub 2015 Sep 28. [http://ascopubs.org/doi/full/10.1200/JCO.2015.61.9510 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26416999 PubMed]
# '''CREATE-X:''' Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017 Jun 1;376(22):2147-2159. [https://www.nejm.org/doi/full/10.1056/NEJMoa1612645 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28564564 PubMed]
# '''TACT2:''' Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, Agrawal R, Banerji J, Bertelli G, Bloomfield D, Brunt AM, Earl H, Ellis P, Gaunt C, Gillman A, Hearfield N, Laing R, Murray N, Couper N, Stein RC, Verrill M, Wardley A, Barrett-Lee P, Bliss JM; TACT2 Investigators. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2017 Jul;18(7):929-945. Epub 2017 Jun 7. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30404-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489700/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28600210 PubMed]

==CMF {{#subobject:fb4c46|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CMF: '''<u>C</u>'''yclophosphamide, '''<u>M</u>'''ethotrexate, '''<u>F</u>'''luorouracil
===Variant #1, 600/40/600 x 8 {{#subobject:93cae2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1991.9.12.2134 Buzzoni et al. 1991 (Milan trial)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#Buzzoni_et_al._1991|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#Buzzoni_et_al._1991|See link]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199710023371401 Overgaard et al. 1997 (DBCG 82b)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#DBCG_82b|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#DBCG_82b|See link]]
|-
|}
''Note: in DBCG 82b, radiotherapy was given between cycles 1 & 2
====Preceding treatment====
*Milan trial: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#Doxorubicin_monotherapy|A]] x 4
*DBCG 82b: [[Surgery#Mastectomy|Mastectomy]]
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Methotrexate (MTX)]] 40 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for 8 cycles'''

===Variant #2, 600/50/600 x 8 {{#subobject:93cae2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/jnci/article/96/14/1076/2520847 Leonard et al. 2004]
| style="background-color:#1a9851" |Phase III (C)
|Cyclophosphamide & Thiotepa with auto HSCT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[#Doxorubicin_monotherapy|A]] x 4
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Methotrexate (MTX)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for 8 cycles'''

===Variant #3, 700/30/700 x 24 {{#subobject:8ba32c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.1.33 Clahsen et al. 1995]
| style="background-color:#1a9851" |Phase III (E)
|[[Breast_cancer_-_historical#Observation|Observation]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 50 mg/m<sup>2</sup> PO once per day on days 1 to 14
*[[Methotrexate (MTX)]] 15 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Fluorouracil (5-FU)]] 350 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''Monthly cycle for 24 cycles (2 years)'''

===Variant #4, 750/50/600 x 4 {{#subobject:98f74e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa052084 Poole et al. 2006 (BR9601)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#BR9601|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#BR9601|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#Epirubicin_monotherapy_2|E]] x 4
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Methotrexate (MTX)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''

===Variant #5, 750/50/600 x 8 {{#subobject:7a96ee|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.sciencedirect.com/science/article/pii/014067369390812U Stewart et al. 1993]
| style="background-color:#1a9851" |Phase III (C)
|1. [[Breast_cancer_-_historical#CMFP|CMFP]]<br> 2. Oopherectomy<br> 3. Oopherectomy & Prednisolone
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa052084 Poole et al. 2006 (BR9601)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Epirubicin_monotherapy|Epirubicin]], then CMF x 4
| style="background-color:#d73027" |Inferior OS
|-
|}
''Note: after 1984, patients in Stewart et al. 1993 only received 6 cycles.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1
*[[Methotrexate (MTX)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 8 cycles (see note)'''

===Variant #6, 1000/80/1000 x 6 {{#subobject:8abc32|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://link.springer.com/article/10.1007%2Fs12282-009-0132-x Kimura et al. 2009]
| style="background-color:#1a9851" |Phase III (C)
|[[#FEC_2|FEC]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Methotrexate (MTX)]] 40 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycle for 6 cycles'''

===Variant #7, 1000/80/1200 x 3 {{#subobject:a2edc8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.2004.07.026 Zander et al. 2004]
| style="background-color:#1a9851" |Phase III (C)
|Cyclophosphamide, Mitoxantrone, Thiotepa with auto HSCT
| style="background-color:#fee08b" |Might have inferior EFS
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[#EC_2|EC]] x 4
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Methotrexate (MTX)]] 40 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycle for 3 cycles'''

===Variant #8, 1000/80/1200 x 6 {{#subobject:831237|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.05.042 Jonat et al. 2002 (ZEBRA)]
| style="background-color:#1a9851" |Phase III (C)
|Goserelin x 2 y
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://jco.ascopubs.org/content/25/18/2509.long Schmid et al. 2007 (TABLE)]
| style="background-color:#1a9851" |Phase III (C)
|[[Breast_cancer,_ER/PR-positive#Leuprolide_monotherapy|Leuprolide]]
| style="background-color:#d73027" |Inferior OS
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], within 6 weeks
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Methotrexate (MTX)]] 40 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycle for 6 cycles'''

===Variant #9, 1120/60/1000 x 12 {{#subobject:61d518|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=3|[https://link.springer.com/article/10.1007/BF01806239 Brinker et al. 1983 (DBCG 77B)]
|rowspan=3 style="background-color:#1a9851" |Phase III (E)
|1. Cyclophosphamide
| style="background-color:#ffffbf" |Seems not superior
|-
|2. Levamisole
| style="background-color:#d3d3d3" |Not reported
|-
|[[Breast_cancer_-_historical#Observation|3. No chemotherapy]]
| style="background-color:#91cf60" |Seems to have superior OS (*)
|-
|}
''Note: reported efficacy is based on the 2010 update.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 80 mg/m<sup>2</sup> PO once per day on days 1 to 14
*[[Methotrexate (MTX)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''1-month cycle for 12 cycles'''

===Variant #10, 1120/64/960 x 12 {{#subobject:611b18|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(84)92684-9/fulltext Howell et al. 1984]
|style="background-color:#1a9851" |Phase III (E)
|[[Breast_cancer_-_historical#Observation|Observation]]
| style="background-color:#91cf60" |Seems to have superior RFS
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 80 mg/m<sup>2</sup> PO once per day on days 1 to 14
*[[Methotrexate (MTX)]] 32 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Fluorouracil (5-FU)]] 4800 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycle for 12 cycles'''

===Variant #11, 1200/80/1200 x 4 {{#subobject:37c8be|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa052084 Poole et al. 2006 (NEAT)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#BR9601|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#BR9601|See link]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2008.19.2567 Gianni et al. 2009 (ECTO)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#ECTO|See link]]
| style="background-color:#ffffbf" |[[Complex_multipart_regimens#ECTO|See link]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687939/ Ellis et al. 2009 (TACT)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[Complex_multipart_regimens#TACT|See link]]
|style="background-color:#ffffbf"|[[Complex_multipart_regimens#TACT|See link]]
|-
|[https://academic.oup.com/annonc/article/26/4/675/203802 Perrone et al. 2014 (ELDA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Docetaxel_monotherapy_2|Docetaxel]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489700/ Cameron et al. 2017 (TACT2)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#TACT2|See link]]
|[[Complex_multipart_regimens#TACT2|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. In ELDA, this protocol was for ER/PR+ patients.''
====Preceding treatment====
*NEAT, TACT, TACT2: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#Epirubicin_monotherapy_2|E]] x 4
*ECTO: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#Doxorubicin_monotherapy|A]] x 4 versus [[#AT_.28Taxol.29|AT (Taxol)]] x 4
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Methotrexate (MTX)]] 40 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycle for 4 cycles'''

===Variant #12, 1200/80/1200 x 6 {{#subobject:958ae2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1996.14.1.35 Coombes et al. 1996]
| style="background-color:#1a9851" |Phase III (C)
|[[#FEC_2|FEC]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199710023371402 Ragaz et al. 1997]
| style="background-color:#1a9851" |Phase III (C)
|CMF & RT
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa052084 Poole et al. 2006 (NEAT)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Epirubicin_monotherapy|Epirubicin]], then CMF x 4
| style="background-color:#d73027" |Inferior OS
|-
|[https://link.springer.com/article/10.1007%2Fs10549-007-9844-9 Taucher et al. 2007 (ABCSG-07)]
| style="background-color:#1a9851" |Phase III (C)
|Neoadjuvant CMF
| style="background-color:#91cf60" |Seems to have superior RFS
|-
|[https://academic.oup.com/annonc/article/26/4/675/203802 Perrone et al. 2014 (ELDA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Docetaxel_monotherapy_2|Docetaxel]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: In ELDA, this protocol was for ER/PR- patients.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Methotrexate (MTX)]] 40 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycle for 6 cycles'''

===Variant #13, 1400/80/1000 x 6 {{#subobject:d1abf4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2008.18.3939 Watanabe et al. 2009 (NSAS BC-01)]
| style="background-color:#1a9851" |Phase III (C)
|UFT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 14
*[[Methotrexate (MTX)]] 40 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycle for 6 cycles'''

===Variant #14, 1400/80/1200 x 3 {{#subobject:16ad91|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan = 2|[http://ascopubs.org/doi/abs/10.1200/JCO.1996.14.6.1885 Castiglione-Gertsch et al. 1996 (IBCSG VI)]
|rowspan = 2 style="background-color:#1a9851" |Phase III (E)
|1. CMF x 6
| style="background-color:#fc8d59" |Seems to have inferior DFS
|-
|2. CMF x 3, with re-introduction<br> 3. CMF x 6, with re-introduction
| style="background-color:#fee08b" |Might have inferior DFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.03.0783 Colleoni et al. 2006 (IBCSG 13-93)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
====Preceding treatment====
*IBCSG VI: [[Surgery#Breast_cancer_surgery|Surgery]]
*IBCSG 13-93: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#AC_2|AC]] x 4 or [[#EC_2|EC]] x 4
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 14
*[[Methotrexate (MTX)]] 40 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycle for 3 cycles'''
====Subsequent treatment====
*IBCSG VI: [[Breast_cancer,_ER/PR-positive#Tamoxifen_monotherapy|Tamoxifen]] x 5 y versus [[Breast_cancer,_ER/PR-positive#Observation|no further treatment]]

===Variant #15, 1400/80/1200 x 4 {{#subobject:114f05|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa052084 Poole et al. 2006 (NEAT)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#BR9601|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#BR9601|See link]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489700/ Cameron et al. 2017 (TACT2)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#TACT2|See link]]
|[[Complex_multipart_regimens#TACT2|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#Epirubicin_monotherapy_2|E]] x 4
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 14
*[[Methotrexate (MTX)]] 40 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycle for 4 cycles'''

===Variant #16, 1400/80/1200 x 6 {{#subobject:dcd1f4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/394864 Tancini et al. 1979]
| style="background-color:#1a9851" |Phase III (E)
|CMF x 12
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1996.14.1.35 Coombes et al. 1996]
| style="background-color:#1a9851" |Phase III (C)
|[[#FEC_2|FEC]]
| style="background-color:#ffffbf" |Seems not superior
|-
|rowspan = 2|[http://ascopubs.org/doi/abs/10.1200/JCO.1996.14.6.1885 Castiglione-Gertsch et al. 1996 (IBCSG VI)]
|rowspan = 2 style="background-color:#1a9851" |Phase III (C)
|1. CMF x 3
| style="background-color:#91cf60" |Seems to have superior DFS
|-
|2. CMF x 3, with re-introduction<br> 3. CMF x 6, with re-introduction
| style="background-color:#fee08b" |Might have inferior DFS
|-
|[http://jco.ascopubs.org/content/16/8/2651.long Levine et al. 1998 (NCIC CTG MA.5)]
| style="background-color:#1a9851" |Phase III (C)
|[[#FEC_2|CEF]]
| style="background-color:#d73027" |Inferior RFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.17.3125 Amadori et al. 2000]
| style="background-color:#1a9851" |Phase III (E)
|[[Breast_cancer_-_historical#Observation|Observation]]
| style="background-color:#91cf60" |Seems to have superior DFS
|-
|[http://jco.ascopubs.org/content/19/4/931.full Fisher et al. 2001 (NSABP B-23)]
| style="background-color:#1a9851" |Phase III (C)
|[[#AC|AC]]
| style="background-color:#ffffbf" |Seems not superior
|-
| rowspan="2" |[http://jco.ascopubs.org/content/19/12/3103.long Piccart et al. 2001 (Belgian trial)]
| rowspan="2" style="background-color:#1a9851" |Phase III (C)
|1. [[#EC_2|Full-dose EC]]
| style="background-color:#ffffbf" |Seems not superior
|-
|2. [[#EC_2|Moderate-dose EC]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.05.042 Jonat et al. 2002 (ZEBRA)]
| style="background-color:#1a9851" |Phase III (C)
|Goserelin x 2 y
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://jco.ascopubs.org/content/23/33/8313.long Hutchins et al. 2005 (INT-0102)]
| style="background-color:#1a9851" |Phase III (C)
|[[#FAC_2|CAF]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa052084 Poole et al. 2006 (NEAT)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Epirubicin_monotherapy|Epirubicin]], then CMF x 4
| style="background-color:#d73027" |Inferior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082436/ Muss et al. 2009 (CALGB 49907)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Capecitabine_monotherapy|Capecitabine]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 14
*[[Methotrexate (MTX)]] 40 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycle for 6 cycles'''

====Subsequent treatment====
*NSABP B-23 and INT-0102: [[Breast_cancer,_ER/PR-positive#Tamoxifen_monotherapy|tamoxifen]] x 5 years versus [[Breast_cancer,_ER/PR-positive#Placebo|placebo]]

===Variant #17, 1400/80/1200 x 12 {{#subobject:8a712c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM197602192940801 Bonadonna et al. 1976]
| style="background-color:#1a9851" |Phase III (E)
|[[Breast_cancer_-_historical#Observation|Observation]]
| style="background-color:#1a9850" |Superior RFS
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/394864 Tancini et al. 1979]
| style="background-color:#1a9851" |Phase III (C)
|CMF x 6
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1996.14.4.1136 Misset et al. 1996 (OncoFrance)]
| style="background-color:#1a9851" |Phase III (C)
|AVCF
| style="background-color:#d73027" |Inferior OS
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 14
*[[Methotrexate (MTX)]] 40 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycle for 12 cycles'''

===References===
# Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976 Feb 19;294(8):405-10. [https://www.nejm.org/doi/full/10.1056/NEJM197602192940801 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1246307 PubMed]
## '''Update:''' Bonadonna G, Rossi A, Valagussa P, Banfi A, Veronesi U. The CMF program for operable breast cancer with positive axillary nodes: updated analysis on the disease-free interval, site of relapse and drug tolerance. Cancer. 1977 Jun;39(6 Suppl):2904-15. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197706)39:6%3C2904::AID-CNCR2820390677%3E3.0.CO;2-8/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/326384 PubMed]
## '''Update:''' Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambilla C, Zambetti M, Veronesi U. Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat. 1985;5(2):95-115. [https://www.ncbi.nlm.nih.gov/pubmed/3839424 PubMed]
## '''Update:''' Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995 Apr 6;332(14):901-6. [https://www.nejm.org/doi/ref/10.1056/NEJM199504063321401 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7877646 PubMed]
# Tancini G, Bajetta E, Marchini S, Valagussa P, Bonadonna G, Veronesi U. Preliminary 3-year results of 12 versus 6 cycles of surgical adjuvant CMF in premenopausal breast cancer. Cancer Clin Trials. 1979 Winter;2(4):285-92. [https://www.ncbi.nlm.nih.gov/pubmed/394864 PubMed]
## '''Update:''' Tancini G, Bonadonna G, Valagussa P, Marchini S, Veronesi U. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol. 1983 Jan;1(1):2-10. [http://ascopubs.org/doi/abs/10.1200/JCO.1983.1.1.2 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/6366125 PubMed]
# '''DBCG 77B:''' Brincker H, Mouridsen HT, Andersen KW. Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer. Breast Cancer Res Treat. 1983;3(1):91-5. [https://link.springer.com/article/10.1007/BF01806239 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/6347278 PubMed]
## '''Update:''' Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Andersson M, Kamby C, Knoop AS; Danish Breast Cancer Cooperative Group. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. Cancer. 2010 May 1;116(9):2081-9. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.24969/full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20186830 PubMed]
# Howell A, Bush H, George WD, Howat JM, Crowther D, Sellwood RA, Rubens RD, Hayward JL, Bulbrook RD, Fentiman IS, Chaudary M. Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer. Lancet. 1984 Aug 11;2(8398):307-11. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(84)92684-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/6146861 PubMed]
# '''Milan trial:''' Buzzoni R, Bonadonna G, Valagussa P, Zambetti M. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol. 1991 Dec;9(12):2134-40. [http://ascopubs.org/doi/abs/10.1200/JCO.1991.9.12.2134 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/1960555 PubMed]
## '''Update:''' Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten-year results. JAMA. 1995 Feb 15;273(7):542-7. [https://jamanetwork.com/journals/jama/fullarticle/387001 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7837388 PubMed]
# Stewart HJ, Forrest APM, Hawkins RA, Prescott RJ, Smith DC, Everington D, Richards MA, George WD; Scottish Cancer Trials Breast Group and ICRF Breast Unit Guy's Hospital London. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet. 1993 May 22;341(8856):1293-8. [https://www.sciencedirect.com/science/article/pii/014067369390812U link to SD article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8098446 PubMed]
# Clahsen PC, van de Velde CJ, Welvaart K, van Driel OJ, Sylvester RJ; Cooperating Investigators. Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: a joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party Study. J Clin Oncol. 1995 Jan;13(1):33-41. [http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.1.33 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7799039 PubMed]
# Coombes RC, Bliss JM, Wils J, Morvan F, Espié M, Amadori D, Gambrosier P, Richards M, Aapro M, Villar-Grimalt A, McArdle C, Pérez-López FR, Vassilopoulos P, Ferreira EP, Chilvers CE, Coombes G, Woods EM, Marty M; The International Collaborative Cancer Group. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. J Clin Oncol. 1996 Jan;14(1):35-45. [http://ascopubs.org/doi/full/10.1200/JCO.1996.14.1.35 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8558217 PubMed]
# '''OncoFrance:''' Misset JL, di Palma M, Delgado M, Plagne R, Chollet P, Fumoleau P, Le Mevel B, Belpomme D, Guerrin J, Fargeot P, Metz R, Ithzaki M, Hill C, Mathé G. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. J Clin Oncol. 1996 Apr;14(4):1136-45. [http://ascopubs.org/doi/abs/10.1200/JCO.1996.14.4.1136 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8648368 PubMed]
# '''IBCSG VI:''' Castiglione-Gertsch M, Goldhirsch A; International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol. 1996 Jun;14(6):1885-94. [http://ascopubs.org/doi/abs/10.1200/JCO.1996.14.6.1885 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8656257 PubMed]
## '''Pooled QoL analysis:''' Hürny C, Bernhard J, Coates AS, Castiglione-Gertsch M, Peterson HF, Gelber RD, Forbes JF, Rudenstam CM, Simoncini E, Crivellari D, Goldhirsch A, Senn HJ; International Breast Cancer Study Group. Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. Lancet. 1996 May 11;347(9011):1279-84. Erratum in: Lancet 1997 Jul 26;350(9073):298. [https://www.thelancet.com/journals/lancet/article/PIIS0140673696909368/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8622502 PubMed]
# '''DBCG 82b:''' Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadeberg CC, Mouridsen HT, Jensen MB, Zedeler K. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy: Danish Breast Cancer Cooperative Group 82b trial. N Engl J Med. 1997 Oct 2;337(14):949-55. [https://www.nejm.org/doi/full/10.1056/NEJM199710023371401 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9395428 PubMed]
# Ragaz J, Jackson SM, Le N, Plenderleith IH, Spinelli JJ, Basco VE, Wilson KS, Knowling MA, Coppin CM, Paradis M, Coldman AJ, Olivotto IA. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med. 1997 Oct 2;337(14):956-62. [https://www.nejm.org/doi/full/10.1056/NEJM199710023371402 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9309100 PubMed]
# '''Review:''' Goldhirsch A, Colleoni M, Coates AS, Castiglione-Gertsch M, Gelber RD. Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG). Ann Oncol. 1998 May;9(5):489-93. [http://annonc.oxfordjournals.org/content/9/5/489.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9653488 PubMed]
# '''NCIC CTG MA.5:''' Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D; National Cancer Institute of Canada Clinical Trials Group. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol. 1998 Aug;16(8):2651-8. [http://jco.ascopubs.org/content/16/8/2651.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9704715 PubMed]
## '''Update:''' Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N; National Cancer Institute of Canada Clinical Trials Group. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol. 2005 Aug 1;23(22):5166-70. [http://ascopubs.org/doi/full/10.1200/JCO.2005.09.423 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16051958 PubMed]
## '''Subgroup analysis:''' Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN; National Cancer Institute of Canada Clinical Trials Group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006 May 18;354(20):2103-11. [https://www.nejm.org/doi/10.1056/NEJMoa054504 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16707747 PubMed]
# Amadori D, Nanni O, Marangolo M, Pacini P, Ravaioli A, Rossi A, Gambi A, Catalano G, Perroni D, Scarpi E, Giunchi DC, Tienghi A, Becciolini A, Volpi A. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study. J Clin Oncol. 2000 Sep;18(17):3125-34. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.17.3125 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10963641 PubMed]
## '''Update:''' Amadori D, Nanni O, Volpi A, Casadei Giunchi D, Marangolo M, Livi L, Ravaioli A, Rossi AP, Gambi A, Luzi Fedeli S, Perroni D, Scarpi E, Becciolini A, Silvestrini R. Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis. Breast Cancer Res Treat. 2008 Mar;108(2):259-64. Epub 2007 May 26. [https://link.springer.com/article/10.1007%2Fs10549-007-9593-9 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17530429 PubMed]
# '''NSABP B-23:''' Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, Dimitrov NV, Atkins JN, Abramson N, Merajver S, Romond EH, Kardinal CG, Shibata HR, Margolese RG, Farrar WB. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 2001 Feb 15;19(4):931-42. [http://jco.ascopubs.org/content/19/4/931.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11181655 PubMed]
# '''Belgian trial:''' Piccart MJ, Di Leo A, Beauduin M, Vindevoghel A, Michel J, Focan C, Tagnon A, Ries F, Gobert P, Finet C, Closon-Dejardin MT, Dufrane JP, Kerger J, Liebens F, Beauvois S, Bartholomeus S, Dolci S, Lobelle JP, Paesmans M, Nogaret JM. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol. 2001 Jun 15;19(12):3103-10. [http://jco.ascopubs.org/content/19/12/3103.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11408507 PubMed]
## '''Update:''' de Azambuja E, Paesmans M, Beauduin M, Vindevoghel A, Cornez N, Finet C, Ries F, Closon-Dejardin MT, Kerger J, Gobert P, Focan C, Tagnon A, Dolci S, Nogaret JM, di Leo A, Piccart-Gebhart MJ. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study. J Clin Oncol. 2009 Feb 10;27(5):720-5. Epub 2008 Dec 22. [http://ascopubs.org/doi/full/10.1200/JCO.2008.17.2155 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19103732 PubMed]
# '''ZEBRA:''' Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B; Zoladex Early Breast Cancer Research Association Study. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol. 2002 Dec 15;20(24):4628-35. [http://ascopubs.org/doi/full/10.1200/JCO.2002.05.042 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12488406 PubMed]
# Zander AR, Kröger N, Schmoor C, Krüger W, Möbus V, Frickhofen N, Metzner B, Schultze W, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Trümper L, Kreienberg R, Carstensen M, Schmidt EH, Jänicke F, Schumacher M, Jonat W. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol. 2004 Jun 15;22(12):2273-83. Epub 2004 Apr 26. [http://ascopubs.org/doi/10.1200/JCO.2004.07.026 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15111618 PubMed]
# Leonard RC, Lind M, Twelves C, Coleman R, van Belle S, Wilson C, Ledermann J, Kennedy I, Barrett-Lee P, Perren T, Verrill M, Cameron D, Foster E, Yellowlees A, Crown J; Anglo-Celtic Cooperative Oncology Group. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst. 2004 Jul 21;96(14):1076-83. [https://academic.oup.com/jnci/article/96/14/1076/2520847 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15265969 PubMed]
# '''INT-0102:''' Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE, Osborne CK. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol. 2005 Nov 20;23(33):8313-21. [http://jco.ascopubs.org/content/23/33/8313.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16293862 PubMed]
# '''IBCSG 13-93:''' Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD; International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol. 2006 Mar 20;24(9):1332-41. Epub 2006 Feb 27. [http://ascopubs.org/doi/full/10.1200/JCO.2005.03.0783 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16505417 PubMed]
<!-- no pre-pub disclosed -->
# '''NEAT/BR9601:''' Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, Spooner DA, Agrawal RK, Fernando IN, Brunt AM, O'Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, Harvey P, McAdam K, Foster L, Leonard RC, Twelves CJ; NEAT Investigators and the SCTBG. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006 Nov 2;355(18):1851-62. [https://www.nejm.org/doi/full/10.1056/NEJMoa052084 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17079759 PubMed]
## '''Update:''' Earl HM, Hiller L, Dunn JA, Vallier AL, Bowden SJ, Jordan SD, Blows F, Munro A, Bathers S, Grieve R, Spooner DA, Agrawal R, Fernando I, Brunt AM, O'Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, McAdam K, Foster L, Leonard RC, Twelves CJ, Cameron D, Bartlett JM, Pharoah P, Provenzano E, Caldas C, Poole CJ; NEAT Investigators and the SCTBG. Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. Br J Cancer. 2012 Oct 9;107(8):1257-67. Epub 2012 Sep 11. [https://www.nature.com/articles/bjc2012370 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494422/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23047592 PubMed]
# '''DBCG 89D:''' Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Cold S, Edlund P, Ewertz M, Jensen BB, Kamby C, Nordenskjold B, Bergh J. Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Eur J Cancer. 2007 Mar;43(5):877-84. Epub 2007 Feb 16. [https://www.ejcancer.com/article/S0959-8049(07)00014-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17306974 PubMed]
<!-- Presented in part at the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 18-21, 2002; the San Antonio Breast Cancer Symposium, San Antonio, TX, December 3-6, 2003; the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004; and the San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2004. -->
# '''TABLE:''' Schmid P, Untch M, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Lehmann U, Maubach L, Meurer J, Wallwiener D, Possinger K. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. J Clin Oncol. 2007 Jun 20;25(18):2509-15. [http://jco.ascopubs.org/content/25/18/2509.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17577027 PubMed]
# '''ABCSG-07:''' Taucher S, Steger GG, Jakesz R, Tausch C, Wette V, Schippinger W, Kwasny W, Reiner G, Greil R, Dubsky P, Poestlberger S, Tschmelitsch J, Samonigg H, Gnant M; Austrian Breast and Colorectal Cancer Study Group-07. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07). Breast Cancer Res Treat. 2008 Nov;112(2):309-16. Epub 2007 Dec 14. [https://link.springer.com/article/10.1007%2Fs10549-007-9844-9 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18080748 PubMed]
# '''NSAS BC-01:''' Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, Kohno N, Nakagami K, Iwata H, Shimozuma K, Sonoo H, Tsuda H, Sakamoto G, Ohashi Y. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 trial. J Clin Oncol. 2009 Mar 20;27(9):1368-74. Epub 2009 Feb 9. [http://ascopubs.org/doi/full/10.1200/JCO.2008.18.3939 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19204202 PubMed]
# '''ECTO:''' Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Cussac AL, Bozhok A, Martinez-Agulló A, Greco M, Byakhov M, Lopez JJ, Mansutti M, Valagussa P, Bonadonna G. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol. 2009 May 20;27(15):2474-81. Epub 2009 Mar 30. [http://ascopubs.org/doi/full/10.1200/JCO.2008.19.2567 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19332727 PubMed]
# '''TACT:''' Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C, Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JM, Ellis I, Peckitt C, Hall E, Bliss JM; TACT Trial Management Group; TACT Trialists. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet. 2009 May 16;373(9676):1681-92. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60740-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687939/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19447249 PubMed]
# '''CALGB 49907:''' Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, Partridge AH, Dressler LG, Cohen HJ, Becker HP, Kartcheske PA, Wheeler JD, Perez EA, Wolff AC, Gralow JR, Burstein HJ, Mahmood AA, Magrinat G, Parker BA, Hart RD, Grenier D, Norton L, Hudis CA, Winer EP; CALGB Investigators. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 May 14;360(20):2055-65. Erratum in: N Engl J Med. 2009 Oct 22;361(17):1714. Magrinat, Gutav [corrected to Magrinat, Gustav]. [https://www.nejm.org/doi/10.1056/NEJMoa0810266 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082436/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19439741 PubMed]
# Kimura M, Tominaga T, Takatsuka Y, Toi M, Abe R, Koyama H, Takashima S, Nomura Y, Miura S, Kimijima I, Tashiro H, Ohashi Y; Adjuvant CEF Research Group for Breast Cancer. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan. Breast Cancer. 2010 Jul;17(3):190-8. Epub 2009 Jul 3. [https://link.springer.com/article/10.1007%2Fs12282-009-0132-x link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19575284 PubMed]
# '''ELDA:''' Perrone F, Nuzzo F, Di Rella F, Gravina A, Iodice G, Labonia V, Landi G, Pacilio C, Rossi E, De Laurentiis M, D'Aiuto M, Botti G, Forestieri V, Lauria R, De Placido S, Tinessa V, Daniele B, Gori S, Colantuoni G, Barni S, Riccardi F, De Maio E, Montanino A, Morabito A, Daniele G, Di Maio M, Piccirillo MC, Signoriello S, Gallo C, de Matteis A. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial. Ann Oncol. 2015 Apr;26(4):675-82. Epub 2014 Dec 8. [https://academic.oup.com/annonc/article/26/4/675/203802 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25488686 PubMed]
# '''TACT2:''' Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, Agrawal R, Banerji J, Bertelli G, Bloomfield D, Brunt AM, Earl H, Ellis P, Gaunt C, Gillman A, Hearfield N, Laing R, Murray N, Couper N, Stein RC, Verrill M, Wardley A, Barrett-Lee P, Bliss JM; TACT2 Investigators. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2017 Jul;18(7):929-945. Epub 2017 Jun 7. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30404-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489700/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28600210 PubMed]

==CMFT {{#subobject:acff18|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CMFT: '''<u>C</u>'''yclophosphamide, '''<u>M</u>'''ethotrexate, '''<u>F</u>'''luorouracil, '''<u>T</u>'''amoxifen
===Regimen {{#subobject:9f63d1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)09201-0/fulltext Overgaard et al. 1999 (DBCG 82C)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|[[Breast_cancer,_ER/PR-positive#Tamoxifen_monotherapy|1. Tamoxifen]]
| style="background-color:#1a9850" |Superior DFS (*)
|-
|2. Tamoxifen & RT
| style="background-color:#d3d3d3" |Not reported
|-
|}
''Note: efficacy for this arm versus tamoxifen monotherapy is based on the 2013 update.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Methotrexate (MTX)]] 40 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Tamoxifen (Nolvadex)]] 30 mg PO once per day

'''28-day cycle for 9 cycles (tamoxifen continued for one year total)'''

===References===
# '''DBCG 82C:''' Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, Kamby C, Kjaer M, Gadeberg CC, Rasmussen BB, Blichert-Toft M, Mouridsen HT. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999 May 15;353(9165):1641-8. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)09201-0/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10335782 PubMed]
## '''Update:''' Ejlertsen B, Jensen MB, Elversang J, Rasmussen BB, Andersson M, Andersen J, Nielsen DL, Cold S, Mouridsen HT. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer. Eur J Cancer. 2013 Sep;49(14):2986-94. Epub 2013 Jun 8. [https://www.ejcancer.com/article/S0959-8049(13)00383-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23756360 PubMed]

==DC/TC {{#subobject:faf430|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DC: '''<u>D</u>'''ocetaxel & '''<u>C</u>'''yclophosphamide
<br>TC: '''<u>T</u>'''axotere (Docetaxel) & '''<u>C</u>'''yclophosphamide
===Variant #1, 4 cycles {{#subobject:e9499f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/24/34/5381.full Jones et al. 2006 (US Oncology Trial 9735)]
| style="background-color:#1a9851" |Phase III (E)
|[[#AC_2|AC]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549453/ Blum et al. 2017 (USOR 06-090; NSABP-46-I/USOR 07132; NSABP B-49)]
| style="background-color:#1a9851" |Phase III (C)
|[[#TAC_.28Taxotere.29_2|TAC]]
| style="background-color:#fc8d59" |Seems to have inferior IDFS
|-
|}
''Note: Blum et al. 2017 is a pooled analysis of three RCTs, some of which had arms other than TAC and TC. Refer to the paper for further details.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*All cycles given with [[Filgrastim (Neupogen)]] support

'''21-day cycle for 4 cycles'''

===Variant #2, 6 cycles {{#subobject:d321b7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/27/10/1873/2389052 Mavroudis et al. 2016 (HORG CT/07.17)]
| style="background-color:#1a9851" |Phase III (E)
|[[#ddFEC|ddFEC]], then [[#ddT_.28Taxotere.29|D]]
| style="background-color:#ffffbf" |Inconclusive whether non-inferior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.72.3494 Ejlertsen et al. 2017 (DBCG 07-READ)]
| style="background-color:#1a9851" |Phase III (E)
|[[#EC_2|EC]], then [[#Docetaxel_monotherapy_2|D]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Patients in DBCG 07-READ were TOP2A normal as determined by FISH.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 cycles'''

===References===
# '''US Oncology Trial 9735:''' Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006 Dec 1;24(34):5381-7. Erratum in: J Clin Oncol. 2007 May 1;25(13):1819. [http://jco.ascopubs.org/content/24/34/5381.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17135639 PubMed]
## '''Update:''' Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol. 2009 Mar 10;27(8):1177-83. Epub 2009 Feb 9. [http://jco.ascopubs.org/content/27/8/1177.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19204201 PubMed]
# '''HORG CT/07.17:''' Mavroudis D, Matikas A, Malamos N, Papakotoulas P, Kakolyris S, Boukovinas I, Athanasiadis A, Kentepozidis N, Ziras N, Katsaounis P, Saloustros E, Georgoulias V; Breast Cancer Investigators of the Hellenic Oncology Research Group (HORG). Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol. 2016 Oct;27(10):1873-8. Epub 2016 Aug 8. [https://academic.oup.com/annonc/article/27/10/1873/2389052 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27502729 PubMed]
# '''USOR 06-090; NSABP-46-I/USOR 07132; NSABP B-49:''' Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, Robert NJ, Hopkins JO, O'Shaughnessy JA, Dang CT, Gómez HL, Fehrenbacher L, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Jeong JH, Colangelo LH, Swain SM, Mamounas EP, Jones SE, Wolmark N. Anthracyclines in early breast cancer: The ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017 Aug 10;35(23):2647-2655. Epub 2017 Apr 11. [http://ascopubs.org/doi/full/10.1200/JCO.2016.71.4147 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549453/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28398846 PubMed]
# '''DBCG 07-READ:''' Ejlertsen B, Tuxen MK, Jakobsen EH, Jensen MB, Knoop AS, Højris I, Ewertz M, Balslev E, Danø H, Vestlev PM, Kenholm J, Nielsen DL, Bechmann T, Andersson M, Cold S, Nielsen HM, Maae E, Carlsen D, Mouridsen HT. Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2A-normal breast cancer: DBCG 07-READ, an open-label, phase III, randomized trial. J Clin Oncol. 2017 Aug 10;35(23):2639-2646. Epub 2017 Jun 29. [http://ascopubs.org/doi/full/10.1200/JCO.2017.72.3494 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28661759 PubMed]

==ddA {{#subobject:c9fa7d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ddA: '''<u>d</u>'''ose-'''<u>d</u>'''ense '''<u>A</u>'''driamycin (Doxorubicin)
===Regimen {{#subobject:90fd28|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/21/8/1431.long Citron et al. 2003 (CALGB 9741)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#CALGB_9741|See link]]
|[[Complex_multipart_regimens#CALGB_9741|See link]]
|-
|[http://www.karger.com/Article/Abstract/86987 Kahan et al. 2005]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Filgrastim (Neupogen)]]

'''14-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Paclitaxel monotherapy.2C_dose-dense_.28q2wk.29_2|ddT]]

===References===
# Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15;21(8):1431-9. Epub 2003 Feb 13. [http://jco.ascopubs.org/content/21/8/1431.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12668651 PubMed]
# Kahan Z, Uhercsak G, Hajnal-Papp R, Boda K, Thurzo L. Dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy is well tolerated and safe in high-risk early breast cancer. Oncology. 2005;68(4-6):446-53. Epub 2005 Jul 13. [http://www.karger.com/Article/Abstract/86987 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16020975 PubMed]
## '''Update:''' Kelemen G, Uhercsák G, Ormándi K, Eller J, Thurzó L, Kahán Z. Long-term efficiency and toxicity of adjuvant dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy in high-risk breast cancer. Oncology. 2010;78(3-4):271-3. Epub 2010 Jun 7. [http://content.karger.com/produktedb/produkte.asp?DOI=000315734&typ=pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20523088 PubMed]

==ddAC {{#subobject:b52056|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ddAC: '''<u>d</u>'''ose-'''<u>d</u>'''ense '''<u>A</u>'''driamycin (Doxorubicin) and '''<u>C</u>'''yclophosphamide
===Variant #1, 4 cycles {{#subobject:cdafd0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/21/8/1431.long Citron et al. 2003 (CALGB 9741)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#CALGB_9741|See link]]
|[[Complex_multipart_regimens#CALGB_9741|See link]]
|-
|[http://jco.ascopubs.org/content/23/33/8340.long Burstein et al. 2005]
| style="background-color:#91cf61" |Non-randomized
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://jco.ascopubs.org/content/26/8/1216.long Dang et al. 2008]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
| rowspan="3" |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494835/ Shulman et al. 2012 (CALGB 40101)]
| rowspan="3" style="background-color:#1a9851" |Phase III (E)
|1. ddAC x 6
| style="background-color:#ffffbf" |Seems not superior
|-
|[[#Paclitaxel_monotherapy.2C_dose-dense_.28q2wk.29_2|2. ddT x 4]]
| style="background-color:#ffffbf" |Seems not superior
|-
|3. ddT x 6
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757290/ Swain et al. 2013 (NSABP B-38)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#NSABP_B-38|See link]]
|[[Complex_multipart_regimens#NSABP_B-38|See link]]
|-
|}
''Note: '''CALGB 40101''' originally specified 21-day cycles but was amended to 14-day cycles after results of '''CALGB 9741''' were available. Patients in '''Dang et al. 2008''' had HER2-positive breast cancer.'' 
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*(varies depending on reference):
*'''CALGB 9741:''' 
**[[Filgrastim (Neupogen)]] 5 mcg/kg (rounded to either 300 or 480 mcg) SC once per day on days 3 to 10
***Note: Citron et al. 2003 says the schedule was "filgrastim days 3 to 10 of each cycle (a total of seven doses)," so it is unclear whether 7 or 8 doses was actually used).
*'''Burstein et al. 2005''' and '''Dang et al. 2008:''' 
**[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2, given 24 hours after chemotherapy
*'''Burstein et al. 2005:'''
**[[Darbepoetin alfa (Aranesp)]] 200 mcg SC once on day 1 for patients with Hb 10 to 12 g/dL; see Burstein et al. 2005 for additional dose adjustments
*'''CALGB 40101:''' one of the following:
**[[Filgrastim (Neupogen)]] 5 mcg/kg (rounded to 300 mcg or 480 mcg, whichever is closer) SC on days 3 to 10; may be discontinued before day 10 if ANC has recovered to an "acceptable range, as determined by the treating physician" 
**[[Sargramostim (Leukine)]] 250 to 500 mcg/m<sup>2</sup> SC on days 3 to 10; may be discontinued before day 10 if ANC has recovered to an "acceptable range, as determined by the treating physician" 
**[[Pegfilgrastim (Neulasta)]] 6 mg SC, administered once 24 to 36 hours after chemotherapy

'''14-day cycle for 4 cycles'''

====Subsequent treatment====
*CALGB 9741 and Burstein et al. 2005: [[#Paclitaxel_monotherapy.2C_dose-dense_.28q2wk.29_2|ddT (Taxol)]] x 4
*Dang et al. 2008: [[Breast_cancer,_HER2-positive#ddTH_.28Taxol.29|ddTH (Taxol)]]
*NSABP B-38: [[#Paclitaxel monotherapy.2C_dose-dense_.28q2wk.29_2|ddT (Taxol)]] x 4 versus ddPG x 4

===Variant #2, 4 cycles, with range {{#subobject:b6d1ca|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ von Minckwitz et al. 2017 (APHINITY)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Patients in '''APHINITY''' had HER2-positive breast cancer. Note that ranges for ddAC are given in the protocol, replicated here.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 to 600 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[:Category:Granulocyte_colony-stimulating_factors|G-CSF]] support (drug/dose/schedule not specified)

'''14-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Breast_cancer,_HER2-positive#TH_.28Taxol.29_2|TH (Taxol)]] versus [[Breast_cancer,_HER2-positive#THP_.28Taxol.29_2|THP (Taxol)]] or [[Breast_cancer,_HER2-positive#TH_.28Taxotere.29_2|TH (Taxotere)]] versus [[Breast_cancer,_HER2-positive#THP_.28Taxotere.29_2|THP (Taxotere)]]

===Variant #3, 6 cycles {{#subobject:b6b259|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268253/ Budd et al. 2014 (SWOG S0221)]
| style="background-color:#1a9851" |Phase III (C)
|Continuous AC
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2

'''14-day cycle for 6 cycles'''
====Subsequent treatment====
*[[#Paclitaxel monotherapy.2C_dose-dense_.28q2wk.29_2|Bi-weekly paclitaxel]] versus [[#Paclitaxel_monotherapy.2C_weekly_2|weekly paclitaxel]]
===References===
# '''CALGB 9741:''' Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15;21(8):1431-9. Epub 2003 Feb 13. [http://jco.ascopubs.org/content/21/8/1431.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12668651 PubMed]
# Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20;23(33):8340-7. [http://jco.ascopubs.org/content/23/33/8340.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16293865 PubMed]
# Dang C, Fornier M, Sugarman S, Troso-Sandoval T, Lake D, D'Andrea G, Seidman A, Sklarin N, Dickler M, Currie V, Gilewski T, Moynahan ME, Drullinsky P, Robson M, Wasserheit-Leiblich C, Mills N, Steingart R, Panageas K, Norton L, Hudis C. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. J Clin Oncol. 2008 Mar 10;26(8):1216-22. [http://jco.ascopubs.org/content/26/8/1216.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18323546 PubMed]
# '''CALGB 40101:''' Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol. 2012 Nov 20;30(33):4071-6. Epub 2012 Jul 23. [http://jco.ascopubs.org/content/30/33/4071.long link to original article] '''contains verified protocol''' [http://jco.ascopubs.org/content/suppl/2012/07/23/JCO.2011.40.6405.DC1/Protocol.pdf link to study protocol PDF] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494835/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22826271 PubMed]
## '''Update:''' Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014 Aug 1;32(22):2311-7. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105484/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24934787 PubMed]
# '''NSABP B-38:''' Swain SM, Tang G, Geyer CE Jr, Rastogi P, Atkins JN, Donnellan PP, Fehrenbacher L, Azar CA, Robidoux A, Polikoff JA, Brufsky AM, Biggs DD, Levine EA, Zapas JL, Provencher L, Northfelt DW, Paik S, Costantino JP, Mamounas EP, Wolmark N. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol. 2013 Sep 10;31(26):3197-204. Epub 2013 Aug 12. [http://ascopubs.org/doi/full/10.1200/JCO.2012.48.1275 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757290/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23940225 PubMed]
# '''SWOG S0221:''' Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew DL, Gralow JR, Hortobagyi GN. SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol. 2015 Jan 1;33(1):58-64. Epub 2014 Nov 24. [http://ascopubs.org/doi/full/10.1200/JCO.2014.56.3296 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268253/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25422488 PubMed]
# '''APHINITY:''' von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. Epub 2017 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1703643 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1703643/suppl_file/nejmoa1703643_protocol.pdf link to supplementary protocol] '''contains verified protocol in supplementary protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28581356 PubMed]
# '''ECOG E5103:''' Miller KD, O'Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA, Bloom S, Brufsky AM, Tevaarwerk AJ, Sparano JA, Le-Lindqwister NA, Hendricks CB, Northfelt DW, Dang CT, Sledge GW Jr. Double-blind phase III trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node-positive and high-risk lymph node-negative breast cancer (E5103). J Clin Oncol. 2018 Sep 1;36(25):2621-2629. Epub 2018 Jul 24. [http://ascopubs.org/doi/full/10.1200/JCO.2018.79.2028 link to original article] '''refers to ECOG E1199 protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30040523 PubMed]

==ddC {{#subobject:2ba5c2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ddC: '''<u>d</u>'''ose-'''<u>d</u>'''ense '''<u>C</u>'''yclophosphamide
===Variant #1, 600 mg/m<sup>2</sup> {{#subobject:6f231e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/21/8/1431.long Citron et al. 2003 (CALGB 9741)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#CALGB_9741|See link]]
|[[Complex_multipart_regimens#CALGB_9741|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#Paclitaxel monotherapy.2C_dose-dense_.28q2wk.29_2|ddT]] x 4
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Filgrastim (Neupogen)]] 5 mcg/kg (rounded to either 300 or 480 mcg) SC once per day on days 3 to 10
**Note: Citron et al. 2003 says the schedule was "filgrastim days 3 to 10 of each cycle (a total of seven doses)," so it is unclear whether 7 or 8 doses was actually used).

'''14-day cycle for 4 cycles'''

===Variant #2, 800 mg/m<sup>2</sup> {{#subobject:822b10|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.karger.com/Article/Abstract/86987 Kahan et al. 2005]
| style="background-color:#91cf61" |Phase II
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#Paclitaxel monotherapy.2C_dose-dense_.28q2wk.29_2|ddT]] x 4
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 800 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Filgrastim (Neupogen)]]

'''14-day cycle for 4 cycles'''

===References===
# Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15;21(8):1431-9. Epub 2003 Feb 13. [http://jco.ascopubs.org/content/21/8/1431.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12668651 PubMed]
# Kahan Z, Uhercsak G, Hajnal-Papp R, Boda K, Thurzo L. Dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy is well tolerated and safe in high-risk early breast cancer. Oncology. 2005;68(4-6):446-53. Epub 2005 Jul 13. [http://www.karger.com/Article/Abstract/86987 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16020975 PubMed]
## '''Update:''' Kelemen G, Uhercsák G, Ormándi K, Eller J, Thurzó L, Kahán Z. Long-term efficiency and toxicity of adjuvant dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy in high-risk breast cancer. Oncology. 2010;78(3-4):271-3. Epub 2010 Jun 7. [http://content.karger.com/produktedb/produkte.asp?DOI=000315734&typ=pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20523088 PubMed]

==ddEC {{#subobject:824585|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ddEC: '''<u>d</u>'''ose-'''<u>d</u>'''ense '''<u>E</u>'''pirubicin and '''<u>C</u>'''yclophosphamide
===Variant #1, 90/600 {{#subobject:aa6006|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67784-7/fulltext Nitz et al. 2005 (MA-01)]
|style="background-color:#1a9851" |Phase III (C)
|EC, then ECT with auto HSCT
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62048-1/fulltext Del Mastro et al. 2015 (GIM2)]
|style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#GIM2|See link]]
|[[Complex_multipart_regimens#GIM2|See link]]
|-
|}
''Note: a mid-protocol amendment of GIM2 suggested giving the pegilgrastim at least 72 h after chemotherapy.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Epirubicin (Ellence)]] 90 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
====Supportive medications====
*MA-01: [[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 5 to 12
*GIM2: [[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2

'''14-day cycle for 4 cycles'''
====Subsequent treatment====
*MA-01: ddCMF x 3
*GIM2: [[#Paclitaxel_monotherapy.2C_dose-dense_.28q2wk.29_2|Dose-dense Paclitaxel]]

===Variant #2, 120/830 {{#subobject:bc9489|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799234/ Burnell et al. 2009 (NCIC CTG MA.21)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#NCIC_CTG_MA.21|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#NCIC_CTG_MA.21|See link]]
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Epirubicin (Ellence)]] 120 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 830 mg/m<sup>2</sup> IV once on day 1
====Supportive medications====
*[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 2 to 13
*[[Epoetin alfa (Procrit)]] 40,000 units SC once per week

'''14-day cycle for 6 cycles'''
====Subsequent treatment====
*[[Breast_cancer_-_historical#Paclitaxel_monotherapy.2C_q3wk|T (Taxol)]] x 4

===Variant #3, with range {{#subobject:d9d108|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ von Minckwitz et al. 2017 (APHINITY)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Patients in '''APHINITY''' had HER2-positive breast cancer. Note that ranges for ddEC are given in the protocol, replicated here.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Epirubicin (Ellence)]] 90 to 120 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 to 600 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[:Category:Granulocyte_colony-stimulating_factors|G-CSF]] support (drug/dose/schedule not specified)

'''14-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Breast_cancer,_HER2-positive#TH_.28Taxol.29_2|TH (Taxol)]] versus [[Breast_cancer,_HER2-positive#THP_.28Taxol.29_2|THP (Taxol)]] or [[Breast_cancer,_HER2-positive#TH_.28Taxotere.29_2|TH (Taxotere)]] versus [[Breast_cancer,_HER2-positive#THP_.28Taxotere.29_2|THP (Taxotere)]]

===References===
# '''MA-01:''' Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, Jackisch C, Werner C, Ziske C, Kirchner H, Metzner B, Souchon R, Ruffert U, Schütt G, Pollmanns A, Schmoll HJ, Middecke C, Baltzer J, Schrader I, Wiebringhaus H, Ko Y, Rösel S, Schwenzer T, Wernet P, Hinke A, Bender HG, Frick M; West German Study Group. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet. 2005 Dec 3;366(9501):1935-44. Erratum in: Lancet. 2006 Mar 4;367(9512):730. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67784-7/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16325695 PubMed]
# '''NCIC CTG MA.21:''' Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien P, Shepherd LE. Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol. 2010 Jan 1;28(1):77-82. Epub 2009 Nov 9. [http://ascopubs.org/doi/full/10.1200/JCO.2009.22.1077 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799234/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19901117 PubMed]
# '''GIM2:''' Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet. 2015 May 9;385(9980):1863-72. Epub 2015 Mar 2. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62048-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25740286 PubMed]
# '''APHINITY:''' von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. Epub 2017 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1703643 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1703643/suppl_file/nejmoa1703643_protocol.pdf link to supplementary protocol] '''contains verified protocol in supplementary protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28581356 PubMed]

==ddFEC {{#subobject:45dbc1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ddFEC: '''<u>d</u>'''ose-'''<u>d</u>'''ense '''<u>F</u>'''luorouracil, '''<u>E</u>'''pirubicin, '''<u>C</u>'''yclophosphamide
===Variant #1, 500/75/500 {{#subobject:05e37f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/27/10/1873/2389052 Mavroudis et al. 2016 (HORG CT/07.17)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#HORG_CT.2F07.17|See link]]
|[[Complex_multipart_regimens#HORG_CT.2F07.17|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1 
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[:Category:Granulocyte_colony-stimulating_factors|Filgrastim]] or [[Pegfilgrastim (Neulasta)]] support (drug/dose/schedule not specified)

'''14-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Docetaxel_monotherapy_2|Docetaxel]]

===Variant #2, 600/90/600 {{#subobject:221345|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62048-1/fulltext Del Mastro et al. 2015 (GIM2)]
|style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#GIM2|See link]]
|[[Complex_multipart_regimens#GIM2|See link]]
|-
|}
''Note: a mid-protocol amendment suggested giving the pegilgrastim at least 72 h after chemotherapy. This is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1 
*[[Epirubicin (Ellence)]] 90 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2

'''14-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Paclitaxel_monotherapy.2C_dose-dense_.28q2wk.29_2|Dose-dense Paclitaxel]]

===Variant #3, 700/75/700 {{#subobject:21ab45|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://academic.oup.com/annonc/article/26/7/1333/165655 Mavroudis et al. 2015 (HORG CT/04.23)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note: these patients had HER2+ breast cancer. This is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 700 mg/m<sup>2</sup> IV over 5 to 15 minutes once on day 1 
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV over 5 to 15 minutes once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 700 mg/m<sup>2</sup> IV over 30 to 60 minutes once on day 1

====Supportive medications====
*[[Filgrastim (Neupogen)]] 300 or 480 mcg SC once per day on days 3 to 10

'''14-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Breast_cancer,_HER2-positive#ddTH_.28Taxotere.29|ddTH (Taxotere)]] x 4
===References===
# '''GIM2:''' Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet. 2015 May 9;385(9980):1863-72. Epub 2015 Mar 2. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62048-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25740286 PubMed]
# '''HORG CT/04.23:''' Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, Kentepozidis N, Ziras N, Georgoulias V; Breast Cancer Investigators of Hellenic Oncology Research Group (HORG). Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol. 2015 Jul;26(7):1333-40. Epub 2015 May 1. [https://academic.oup.com/annonc/article/26/7/1333/165655 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25935793 PubMed]
# '''HORG CT/07.17:''' Mavroudis D, Matikas A, Malamos N, Papakotoulas P, Kakolyris S, Boukovinas I, Athanasiadis A, Kentepozidis N, Ziras N, Katsaounis P, Saloustros E, Georgoulias V; Breast Cancer Investigators of the Hellenic Oncology Research Group (HORG). Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol. 2016 Oct;27(10):1873-8. Epub 2016 Aug 8. [https://academic.oup.com/annonc/article/27/10/1873/2389052 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27502729 PubMed]

==ddT (Taxotere) {{#subobject:08ad0f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ddT: '''<u>d</u>'''ose-'''<u>d</u>'''ense '''<u>T</u>'''axotere (Docetaxel)
<br>ddD: '''<u>d</u>'''ose-'''<u>d</u>'''ense '''<u>D</u>'''ocetaxel
===Regimen {{#subobject:a00f8d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://link.springer.com/article/10.1007%2Fs10549-014-3202-5 Saloustros et al. 2014]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel_monotherapy.2C_dose-dense_.28q2wk.29_2|ddT (Taxol)]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://academic.oup.com/annonc/article/27/10/1873/2389052 Mavroudis et al. 2016 (HORG CT/07.17)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#HORG_CT.2F07.17|See link]]
|[[Complex_multipart_regimens#HORG_CT.2F07.17|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#ddFEC|ddFEC]] x 4
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1 

====Supportive medications====
*[[:Category:Granulocyte_colony-stimulating_factors|Filgrastim]] or [[:Category:Granulocyte_colony-stimulating_factors|Pegfilgrastim]] support (drug/dose/schedule not specified)

'''14-day cycle for 4 cycles'''

===References===
# Saloustros E, Malamos N, Boukovinas I, Kakolyris S, Kouroussis C, Athanasiadis A, Ziras N, Kentepozidis N, Makrantonakis P, Polyzos A, Christophyllakis C, Georgoulias V, Mavroudis D. Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Res Treat. 2014 Dec;148(3):591-7. Epub 2014 Nov 16. [https://link.springer.com/article/10.1007%2Fs10549-014-3202-5 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25399229 PubMed]
# '''HORG CT/07.17:''' Mavroudis D, Matikas A, Malamos N, Papakotoulas P, Kakolyris S, Boukovinas I, Athanasiadis A, Kentepozidis N, Ziras N, Katsaounis P, Saloustros E, Georgoulias V; Breast Cancer Investigators of the Hellenic Oncology Research Group (HORG). Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol. 2016 Oct;27(10):1873-8. Epub 2016 Aug 8. [https://academic.oup.com/annonc/article/27/10/1873/2389052 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27502729 PubMed]

==Docetaxel monotherapy {{#subobject:45c144|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
D: '''<u>D</u>'''ocetaxel
<br>T: '''<u>T</u>'''axotere (Docetaxel)
<br>dT: '''<u>d</u>'''oce'''<u>T</u>'''axel
===Variant #1, 35 mg/m<sup>2</sup> weekly x 12 {{#subobject:199d79|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743943/ Sparano et al. 2008 (ECOG E1199)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[Breast_cancer_-_historical#Paclitaxel monotherapy.2C_q3wk|Paclitaxel, q3wk dosing]]
| style="background-color:#ffffbf" |Seems not superior
|-
|2. [[#Paclitaxel_monotherapy.2C_weekly_2|Paclitaxel, weekly dosing]]<br> 3. Docetaxel, q3wk dosing
| style="background-color:#d3d3d3" |Not reported
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#AC_2|AC]] x 4
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 35 mg/m<sup>2</sup> IV over 60 minutes once per week

'''12-week course'''

===Variant #2, 75 mg/m<sup>2</sup> q3wk x 4 {{#subobject:2e0391|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.30421/abstract Watanabe et al. 2017 (NSAS BC-02)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#NSAS_BC-02|See link]]
| style="background-color:#91cf60" |[[Complex_multipart_regimens#NSAS_BC-02|See link]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584474/ Mavroudis et al. 2017]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#Mavroudis_et_al._2017|See link]]
|[[Complex_multipart_regimens#Mavroudis_et_al._2017|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*NSAS BC-02: [[#AC_2|AC]] x 4
*Mavroudis et al. 2017: [[#Epirubicin_monotherapy|E]] x 4
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1

'''21-day cycle for 4 cycles'''

===Variant #3, 80 mg/m<sup>2</sup> q3wk x 3 {{#subobject:254ede|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045-09-70307-9/fulltext Joensuu et al. 2009 (FinXX)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#FinXX|See link]]
|[[Complex_multipart_regimens#FinXX|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 80 mg/m<sup>2</sup> IV over 60 minutes once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[#FEC_2|CEF]] x 3

===Variant #4, 100 mg/m<sup>2</sup> q3wk x 3 {{#subobject:bfeef2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[https://www.nejm.org/doi/full/10.1056/NEJMoa053028 Joensuu et al. 2006 (FinHer)]
| rowspan="2" style="background-color:#1a9851" |Phase III (C)
|1. [[Breast_cancer,_HER2-positive#TH_.28Taxotere.29_2|TH (Taxotere)]]<br> 2. [[Breast_cancer,_HER2-positive#VH|VH]]
| style="background-color:#ffffbf" |Seems not superior
|-
|3. [[#Vinorelbine_monotherapy|Vinorelbine]]
| style="background-color:#1a9850" |Superior DDFS
|-
|[http://jco.ascopubs.org/content/24/36/5664.long Roché et al. 2006 (FNCLCC PACS 01)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#FNCLCC_PACS_01|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#FNCLCC_PACS_01|See link]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.32.7254 Coombes et al. 2011 (DEVA)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#DEVA|See link]]
|[[Complex_multipart_regimens#DEVA|See link]]
|-
|[https://jamanetwork.com/journals/jama/fullarticle/2579866 Foukakis et al. 2016 (PANTHER)]
| style="background-color:#1a9851" |Phase III (C)
|Dose-dense tailored chemotherapy
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.72.3494 Ejlertsen et al. 2017 (DBCG 07-READ)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#DBCG_07-READ|See link]]
|[[Complex_multipart_regimens#DBCG_07-READ|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. Patients in '''FinHer''' without HER2/neu amplification were only randomized to this or the [[#Vinorelbine_monotherapy|vinorelbine arm]]. Patients in '''DBCG 07-READ''' were TOP2A normal as determined by FISH.''
====Preceding treatment====
*FinHer: [[Surgery#Breast_cancer_surgery|Surgery]] with axillary lymph node dissection or sentinel lymph node biopsy, within 12 weeks
*FNCLCC PACS 01 & PANTHER: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#FEC_2|FEC]] x 3
*DEVA: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#Epirubicin_monotherapy|Epirubicin]] x 3
*DBCG 07-READ: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#EC_2|EC]] x 3
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*FinHer: [[#FEC_2|FEC]]

===Variant #5, 100 mg/m<sup>2</sup> q3wk x 4 {{#subobject:199d79|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2003.12.005 Bear et al. 2003 (NSABP B-27)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#NSABP_B-27|See link]]
|[[Complex_multipart_regimens#NSABP_B-27|See link]]
|-
| rowspan="2" |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743943/ Sparano et al. 2008 (ECOG E1199)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[Breast_cancer_-_historical#Paclitaxel_monotherapy.2C_q3wk|Paclitaxel, q3wk dosing]]
| style="background-color:#91cf60" |Seems to have superior DFS
|-
|2. [[#Paclitaxel_monotherapy.2C_weekly_2|Paclitaxel, weekly dosing]]<br> 3. Docetaxel, weekly dosing
| style="background-color:#d3d3d3" |Not reported
|-
|[https://link.springer.com/article/10.1007%2Fs10549-009-0468-0 Polyzos et al. 2009]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#HORG_Polyzos_et_al._2010|See link]]
| style="background-color:#91cf60" |[[Complex_multipart_regimens#HORG_Polyzos_et_al._2010|See link]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687939/ Ellis et al. 2009 (TACT)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[Complex_multipart_regimens#TACT|See link]]
|style="background-color:#ffffbf"|[[Complex_multipart_regimens#TACT|See link]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935316/ Swain et al. 2010 (NSABP B-30)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#NSABP_B-30|See link]]
| style="background-color:#91cf60" |[[Complex_multipart_regimens#NSABP_B-30|See link]]
|-
|[http://jco.ascopubs.org/content/29/29/3877.long Eiermann et al. 2011 (BCIRG-005)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#BCIRG-005|See link]]
|[[Complex_multipart_regimens#BCIRG-005|See link]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268553/ Slamon et al. 2011 (BCIRG 006)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#BCIRG_006|See link]]
|[[Complex_multipart_regimens#BCIRG_006|See link]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2015.61.9510 Martín et al. 2015 (GEICAM/2003-10)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#GEICAM.2F2003-10|See link]]
|[[Complex_multipart_regimens#GEICAM.2F2003-10|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. Patients in '''BCIRG 006''' were HER2-positive.''
====Preceding treatment====
*NSABP B-27: [[#AC|Neoadjuvant AC]] x 4, then [[Surgery#Breast_cancer_surgery|surgery]]
*ECOG E1199, BCIRG-005, and BCIRG 006: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#AC_2|AC]] x 4
*Polyzos et al. 2009: [[Surgery#Breast_cancer_surgery|Surgery]]
*TACT: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#FEC_2|FEC]] x 4
*GEICAM/2003-10: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#EC_2|EC]] x 4
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*Polyzos et al. 2009: [[#EC_2|EC]] x 4
===References===
# '''NSABP B-27:''' Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N; National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003 Nov 15;21(22):4165-74. Epub 2003 Oct 14. [http://ascopubs.org/doi/full/10.1200/JCO.2003.12.005 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14559892 PubMed]
## '''Update:''' Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006 May 1;24(13):2019-27. Epub 2006 Apr 10. [http://ascopubs.org/doi/full/10.1200/JCO.2005.04.1665 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16606972 PubMed]
## '''Pooled update:''' Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008 Feb 10;26(5):778-85. Erratum in: J Clin Oncol. 2008 Jun 1;26(16):2793. [http://ascopubs.org/doi/full/10.1200/JCO.2007.15.0235 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18258986 PubMed]
<!-- no pre-pub disclosed -->
# '''FinHer:''' Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006 Feb 23;354(8):809-20. [https://www.nejm.org/doi/full/10.1056/NEJMoa053028 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16495393 PubMed]
## '''Update:''' Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009 Dec 1;27(34):5685-92. [http://ascopubs.org/doi/full/10.1200/JCO.2008.21.4577 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19884557 PubMed]
<!-- Presented in oral format at the 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2004. -->
# '''FNCLCC PACS 01:''' Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulié P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Genève J, Asselain B. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006 Dec 20;24(36):5664-71. Epub 2006 Nov 20. [http://jco.ascopubs.org/content/24/36/5664.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17116941 PubMed]
## '''Update:''' Coudert B, Asselain B, Campone M, Spielmann M, Machiels JP, Pénault-Llorca F, Serin D, Lévy C, Romieu G, Canon JL, Orfeuvre H, Piot G, Petit T, Jerusalem G, Audhuy B, Veyret C, Beauduin M, Eymard JC, Martin AL, Roché H; UNICANCER Breast Group. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. Oncologist. 2012;17(7):900-9. Epub 2012 May 18. [http://theoncologist.alphamedpress.org/content/17/7/900.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399644/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22610153 PubMed]
<!-- Presented in part at the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8–11, 2007, and the American Society of Clinical Oncology meeting, Chicago, June 1–4, 2005. -->
# '''ECOG E1199:''' Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008 Apr 17;358(16):1663-71. [https://www.nejm.org/doi/full/10.1056/NEJMoa0707056 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743943/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18420499 PubMed]
## '''Update:''' Sparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer. J Clin Oncol. 2015 Jul 20;33(21):2353-60. Epub 2015 Jun 15. [http://jco.ascopubs.org/content/33/21/2353.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500829/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26077235 PubMed]
# '''TACT:''' Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C, Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JM, Ellis I, Peckitt C, Hall E, Bliss JM; TACT Trial Management Group; TACT Trialists. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet. 2009 May 16;373(9676):1681-92. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60740-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687939/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19447249 PubMed]
# Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, Kakolyris S, Syrigos K, Papakotoulas P, Kouroussis C, Karvounis N, Vamvakas L, Christophyllakis C, Athanasiadis A, Varthalitis I, Georgoulias V, Mavroudis D. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Res Treat. 2010 Jan;119(1):95-104. Epub 2009 Jul 28. [https://link.springer.com/article/10.1007%2Fs10549-009-0468-0 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19636702 PubMed]
# '''FinXX:''' Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Asola R, Kokko R, Ahlgren J, Auvinen P, Hemminki A, Paija O, Helle L, Nuortio L, Villman K, Nilsson G, Lahtela SL, Lehtiö K, Pajunen M, Poikonen P, Nyandoto P, Kataja V, Bono P, Leinonen M, Lindman H; FinXX Study Investigators. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncol. 2009 Dec;10(12):1145-51. Epub 2009 Nov 10. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045-09-70307-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19906561 PubMed]
## '''Update:''' Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Paija O, Helle L, Villman K, Nyandoto P, Nilsson G, Pajunen M, Asola R, Poikonen P, Leinonen M, Kataja V, Bono P, Lindman H. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol. 2012 Jan 1;30(1):11-8. Epub 2011 Nov 21. [http://ascopubs.org/doi/full/10.1200/JCO.2011.35.4639 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22105826 PubMed]
# '''NSABP B-30:''' Swain SM, Jeong JH, Geyer CE Jr, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land SR, Ganz PA, Wolmark N. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010 Jun 3;362(22):2053-65. [https://www.nejm.org/doi/10.1056/NEJMoa0909638 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935316/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20519679 PubMed]
<!-- Presented at the 46th Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL. -->
# '''DEVA:''' Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, Marty M, Coleman RE, Tubiana-Mathieu N, den Boer MO, Wardley A, Kilburn LS, Cooper D, Thomas MW, Reise JA, Wilkinson K, Hupperets P. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with  node-positive breast cancer. J Clin Oncol. 2011 Aug 20;29(24):3247-54. Epub 2011 Jul 18. [http://ascopubs.org/doi/full/10.1200/JCO.2010.32.7254 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21768453 PubMed]
<!-- Presented in part at the 28th Annual San Antonio Breast Cancer Symposia, December 8-11, 2005, San Antonio, TX, and at the 31st Annual San Antonio Breast Cancer Symposia, December 10-14, 2008, San Antonio, TX. -->
# '''BCIRG-005:''' Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martín M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press M, Sauter G, Lindsay MA, Riva A, Buyse M, Drevot P, Taupin H, Mackey JR. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol. 2011 Oct 10;29(29):3877-84. Epub 2011 Sep 12. [http://jco.ascopubs.org/content/29/29/3877.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21911726 PubMed]
## '''Update:''' Mackey JR, Pieńkowski T, Crown J, Sadeghi S, Martín M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press MF, Sauter G, Lindsay M, Houé V, Buyse M, Drevot P, Hitier S, Bensfia S, Eiermann W; Translational Research In Oncology (TRIO)/ Breast Cancer International Research Group (BCIRG)-005 investigators. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. Ann Oncol. 2016 Jun;27(6):1041-7. Epub 2016 Mar 2. [https://academic.oup.com/annonc/article/27/6/1041/2240122 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26940688 PubMed]
<!-- no pre-pub disclosed -->
# '''BCIRG 006:''' Slamon D, Eiermann W, Robert N, Pienkowski T, Martín M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 6;365(14):1273-83. [https://www.nejm.org/doi/full/10.1056/NEJMoa0910383 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268553/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21991949 PubMed]
# '''GEICAM/2003-10:''' Martín M, Ruiz Simón A, Ruiz Borrego M, Ribelles N, Rodríguez-Lescure A, Muñoz-Mateu M, González S, Margelí Vila M, Barnadas A, Ramos M, Del Barco Berron S, Jara C, Calvo L, Martínez-Jáñez N, Mendiola Fernández C, Rodríguez CA, Martínez de Dueñas E, Andrés R, Plazaola A, de la Haba-Rodríguez J, López-Vega JM, Adrover E, Ballesteros AI, Santaballa A, Sánchez-Rovira P, Baena-Cañada JM, Casas M, del Carmen Cámara M, Carrasco EM, Lluch A. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. J Clin Oncol. 2015 Nov 10;33(32):3788-95. Epub 2015 Sep 28. [http://ascopubs.org/doi/full/10.1200/JCO.2015.61.9510 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26416999 PubMed]
# '''PANTHER:''' Foukakis T, von Minckwitz G, Bengtsson NO, Brandberg Y, Wallberg B, Fornander T, Mlineritsch B, Schmatloch S, Singer CF, Steger G, Egle D, Karlsson E, Carlsson L, Loibl S, Untch M, Hellström M, Johansson H, Anderson H, Malmström P, Gnant M, Greil R, Möbus V, Bergh J; Swedish Breast Cancer Group (SweBCG); German Breast Group (GBG); Austrian Breast & Colorectal Cancer Study Group (ABCSG). Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer: a randomized clinical trial. JAMA. 2016 Nov 8;316(18):1888-1896. [https://jamanetwork.com/journals/jama/fullarticle/2579866 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27825007 PubMed]
# '''NSAS BC-02:''' Watanabe T, Kuranami M, Inoue K, Masuda N, Aogi K, Ohno S, Iwata H, Mukai H, Uemura Y, Ohashi Y. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study. Cancer. 2017 Mar 1;123(5):759-768. Epub 2017 Jan 12. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.30421/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28081304 PubMed]
# Mavroudis D, Saloustros E, Boukovinas I, Papakotoulas P, Kakolyris S, Ziras N, Christophylakis C, Kentepozidis N, Fountzilas G, Rigas G, Varthalitis I, Kalbakis K, Agelaki S, Hatzidaki D, Georgoulias V. Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group. Br J Cancer. 2017 Jul 11;117(2):164-170. Epub 2017 Jun 22. [https://www.nature.com/bjc/journal/v117/n2/full/bjc2017158a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584474/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28641315 PubMed]
# '''DBCG 07-READ:''' Ejlertsen B, Tuxen MK, Jakobsen EH, Jensen MB, Knoop AS, Højris I, Ewertz M, Balslev E, Danø H, Vestlev PM, Kenholm J, Nielsen DL, Bechmann T, Andersson M, Cold S, Nielsen HM, Maae E, Carlsen D, Mouridsen HT. Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2A-normal breast cancer: DBCG 07-READ, an open-label, phase III, randomized trial. J Clin Oncol. 2017 Aug 10;35(23):2639-2646. Epub 2017 Jun 29. [http://ascopubs.org/doi/full/10.1200/JCO.2017.72.3494 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28661759 PubMed]

==Doxorubicin monotherapy {{#subobject:cc64af|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
A: '''<u>A</u>'''driamycin (Doxorubicin)
===Regimen {{#subobject:a45aaa|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1991.9.12.2134 Buzzoni et al. 1991 (Milan trial)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#Buzzoni_et_al._1991|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#Buzzoni_et_al._1991|See link]]
|-
|[https://academic.oup.com/jnci/article/96/14/1076/2520847 Leonard et al. 2004]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2008.19.2567 Gianni et al. 2009 (ECTO)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#ECTO|See link]]
| style="background-color:#fc8d59" |[[Complex_multipart_regimens#ECTO|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*Milan trial & Leonard et al. 2004: [[#CMF|CMF]] x 8
*ECTO: [[#CMF|CMF]] x 4

===References===
# '''Milan trial:''' Buzzoni R, Bonadonna G, Valagussa P, Zambetti M. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol. 1991 Dec;9(12):2134-40. [http://ascopubs.org/doi/abs/10.1200/JCO.1991.9.12.2134 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/1960555 PubMed]
## '''Update:''' Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes: ten-year results. JAMA. 1995 Feb 15;273(7):542-7. [https://jamanetwork.com/journals/jama/fullarticle/387001 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7837388 PubMed]
# Leonard RC, Lind M, Twelves C, Coleman R, van Belle S, Wilson C, Ledermann J, Kennedy I, Barrett-Lee P, Perren T, Verrill M, Cameron D, Foster E, Yellowlees A, Crown J; Anglo-Celtic Cooperative Oncology Group. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst. 2004 Jul 21;96(14):1076-83. [https://academic.oup.com/jnci/article/96/14/1076/2520847 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15265969 PubMed]
# '''ECTO:''' Gianni L, Baselga J, Eiermann W, Porta VG, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Cussac AL, Bozhok A, Martinez-Agulló A, Greco M, Byakhov M, Lopez JJ, Mansutti M, Valagussa P, Bonadonna G. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol. 2009 May 20;27(15):2474-81. Epub 2009 Mar 30. [http://ascopubs.org/doi/full/10.1200/JCO.2008.19.2567 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19332727 PubMed]

==EC {{#subobject:8d8dbe|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EC: '''<u>E</u>'''pirubicin and '''<u>C</u>'''yclophosphamide
===Variant #1, 60/500 x 8 {{#subobject:50bd25|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[http://jco.ascopubs.org/content/19/12/3103.long Piccart et al. 2001 (Belgian trial)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[#CMF|CMF]]
| style="background-color:#ffffbf" |Seems not superior
|-
|2. High-dose EC
| style="background-color:#fc8d59" |Seems to have inferior EFS
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 8 cycles'''

===Variant #2, 75/600 x 4 {{#subobject:2e39fe|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/15/1/79/143035 Pico et al. 2004 (GEICAM 9401)]
| style="background-color:#1a9851" |Phase III (E)
|ECT (Tamoxifen)
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*Tamoxifen

===Variant #3, 75/700 x 4 {{#subobject:1aad71|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://link.springer.com/article/10.1007%2Fs10549-009-0468-0 Polyzos et al. 2009]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#HORG_Polyzos_et_al._2010|See link]]
| style="background-color:#91cf60" |[[Complex_multipart_regimens#HORG_Polyzos_et_al._2010|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[#Docetaxel_monotherapy_2|T (Taxotere)]] x 4
====Chemotherapy====
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 700 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''

===Variant #4, 90/600 x 3 {{#subobject:8d62d4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.72.3494 Ejlertsen et al. 2017 (DBCG 07-READ)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#DBCG_07-READ|See link]]
| style="background-color:#ffffbf" |[[Complex_multipart_regimens#DBCG_07-READ|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. Patients were TOP2A normal as determined by FISH.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Epirubicin (Ellence)]] 90 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[#Docetaxel_monotherapy_2|Docetaxel]]

===Variant #5, 90/600 x 4 {{#subobject:22ed5f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.2004.07.026 Zander et al. 2004]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.03.0783 Colleoni et al. 2006 (IBCSG 13-93)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361407/ Kümmel et al. 2006]
|style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#K.C3.BCmmel_et_al._2006|See link]]
| style="background-color:#fee08b" |[[Complex_multipart_regimens#K.C3.BCmmel_et_al._2006|See link]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2015.61.9510 Martín et al. 2015 (GEICAM/2003-10)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#GEICAM.2F2003-10|See link]]
| style="background-color:#91cf60" |[[Complex_multipart_regimens#GEICAM.2F2003-10|See link]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62048-1/fulltext Del Mastro et al. 2015 (GIM2)]
|style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#GIM2|See link]]
|[[Complex_multipart_regimens#GIM2|See link]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30319-4/fulltext Earl et al. 2017 (tAnGo)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Epirubicin (Ellence)]] 90 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*Zander et al. 2004: [[#CMF|CMF]] x 3 versus cyclophosphamide, mitoxantrone, thiotepa with auto HSCT
*IBCSG 13-93: [[#CMF|CMF]] x 3, then [[Breast_cancer,_ER/PR-positive#Tamoxifen_monotherapy|Tamoxifen]] x 5 y versus [[Breast_cancer,_ER/PR-positive#Observation|no further treatment]]
*GEICAM/2003-10: [[#Docetaxel_monotherapy_2|Docetaxel]]
*GIM2: [[#Paclitaxel monotherapy.2C_q3wk|Paclitaxel, q3wk dosing]] x 4
*tAnGo: [[#Paclitaxel monotherapy.2C_q3wk|Paclitaxel, q3wk dosing]] x 4 versus TG x 4

===Variant #6, 100/830 x 8 {{#subobject:aead26|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[http://jco.ascopubs.org/content/19/12/3103.long Piccart et al. 2001 (Belgian trial)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[#CMF|CMF]]
| style="background-color:#ffffbf" |Seems not superior
|-
|2. Moderate-dose EC
| style="background-color:#91cf60" |Seems to have superior EFS
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Epirubicin (Ellence)]] 100 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 830 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 8 cycles'''

===Variant #7, 120/600 x 4 (high-dose) {{#subobject:24260d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2003.03.034 Papaldo et al. 2003]
| style="background-color:#1a9851" |Phase III (C)
|EC & Lonidamine
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ von Minckwitz et al. 2017 (APHINITY)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
====Preceding treatment====
*Papaldo et al. 2003: [[Surgery#Breast_cancer_surgery|Surgery]]
*APHINITY: [[Surgery#Breast_cancer_surgery|Surgery]] versus [[Surgery#Breast_cancer_surgery|Surgery]], then [[#Docetaxel_monotherapy_2|D]] x 4
====Chemotherapy====
*[[Epirubicin (Ellence)]] 120 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''

===Variant #8, with range {{#subobject:ef0b86|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ von Minckwitz et al. 2017 (APHINITY)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. Patients in had HER2-positive breast cancer.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Epirubicin (Ellence)]] 90 to 120 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 to 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Breast_cancer,_HER2-positive#TH_.28Taxol.29_2|TH (Taxol)]] versus [[Breast_cancer,_HER2-positive#THP_.28Taxol.29_2|THP (Taxol)]] or [[Breast_cancer,_HER2-positive#TH_.28Taxotere.29_2|TH (Taxotere)]] versus [[Breast_cancer,_HER2-positive#THP_.28Taxotere.29_2|THP (Taxotere)]]

===References===
# '''Belgian trial:''' Piccart MJ, Di Leo A, Beauduin M, Vindevoghel A, Michel J, Focan C, Tagnon A, Ries F, Gobert P, Finet C, Closon-Dejardin MT, Dufrane JP, Kerger J, Liebens F, Beauvois S, Bartholomeus S, Dolci S, Lobelle JP, Paesmans M, Nogaret JM. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol. 2001 Jun 15;19(12):3103-10. [http://jco.ascopubs.org/content/19/12/3103.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11408507 PubMed]
## '''Update:''' de Azambuja E, Paesmans M, Beauduin M, Vindevoghel A, Cornez N, Finet C, Ries F, Closon-Dejardin MT, Kerger J, Gobert P, Focan C, Tagnon A, Dolci S, Nogaret JM, di Leo A, Piccart-Gebhart MJ. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study. J Clin Oncol. 2009 Feb 10;27(5):720-5. Epub 2008 Dec 22. [http://ascopubs.org/doi/full/10.1200/JCO.2008.17.2155 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19103732 PubMed]
# Papaldo P, Lopez M, Cortesi E, Cammilluzzi E, Antimi M, Terzoli E, Lepidini G, Vici P, Barone C, Ferretti G, Di Cosimo S, Nistico C, Carlini P, Conti F, Di Lauro L, Botti C, Vitucci C, Fabi A, Giannarelli D, Marolla P. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J Clin Oncol. 2003 Sep 15;21(18):3462-8. [http://ascopubs.org/doi/full/10.1200/JCO.2003.03.034 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12972521 PubMed]
# '''GEICAM 9401:''' Pico C, Martin M, Jara C, Barnadas A, Pelegri A, Balil A, Camps C, Frau A, Rodriguez-Lescure A, Lopez-Vega JM, De La Haba J, Tres A, Alvarez I, Alba E, Arcusa A, Oltra A, Batista N, Checa T, Perez-Carrion R, Curto J; GEICAM Group. Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients: a GEICAM 9401 study. Ann Oncol. 2004 Jan;15(1):79-87. [https://academic.oup.com/annonc/article/15/1/79/143035 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14679124 PubMed]
# Zander AR, Kröger N, Schmoor C, Krüger W, Möbus V, Frickhofen N, Metzner B, Schultze W, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Trümper L, Kreienberg R, Carstensen M, Schmidt EH, Jänicke F, Schumacher M, Jonat W. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol. 2004 Jun 15;22(12):2273-83. Epub 2004 Apr 26. [http://ascopubs.org/doi/10.1200/JCO.2004.07.026 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15111618 PubMed]
# '''IBCSG 13-93:''' Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD; International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol. 2006 Mar 20;24(9):1332-41. Epub 2006 Feb 27. [http://ascopubs.org/doi/full/10.1200/JCO.2005.03.0783 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16505417 PubMed]
# Kümmel S, Krocker J, Kohls A, Breitbach GP, Morack G, Budner M, Blohmer JU, Elling D. Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer. Br J Cancer. 2006 May 8;94(9):1237-44. [https://www.nature.com/articles/6603085 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361407/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16622463 PubMed]
# Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, Kakolyris S, Syrigos K, Papakotoulas P, Kouroussis C, Karvounis N, Vamvakas L, Christophyllakis C, Athanasiadis A, Varthalitis I, Georgoulias V, Mavroudis D. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Res Treat. 2010 Jan;119(1):95-104. Epub 2009 Jul 28. [https://link.springer.com/article/10.1007%2Fs10549-009-0468-0 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19636702 PubMed]
# '''GOIM 9902:''' Vici P, Brandi M, Giotta F, Foggi P, Schittulli F, Di Lauro L, Gebbia N, Massidda B, Filippelli G, Giannarelli D, Di Benedetto A, Mottolese M, Colucci G, Lopez M. A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Ann Oncol. 2012 May;23(5):1121-9. Epub 2011 Sep 28. [https://academic.oup.com/annonc/article/23/5/1121/193328 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362268/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21965475 PubMed]
# '''GIM2:''' Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet. 2015 May 9;385(9980):1863-72. Epub 2015 Mar 2. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62048-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25740286 PubMed]
# '''GEICAM/2003-10:''' Martín M, Ruiz Simón A, Ruiz Borrego M, Ribelles N, Rodríguez-Lescure A, Muñoz-Mateu M, González S, Margelí Vila M, Barnadas A, Ramos M, Del Barco Berron S, Jara C, Calvo L, Martínez-Jáñez N, Mendiola Fernández C, Rodríguez CA, Martínez de Dueñas E, Andrés R, Plazaola A, de la Haba-Rodríguez J, López-Vega JM, Adrover E, Ballesteros AI, Santaballa A, Sánchez-Rovira P, Baena-Cañada JM, Casas M, del Carmen Cámara M, Carrasco EM, Lluch A. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. J Clin Oncol. 2015 Nov 10;33(32):3788-95. Epub 2015 Sep 28. [http://ascopubs.org/doi/full/10.1200/JCO.2015.61.9510 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26416999 PubMed]
# '''tAnGo:''' Earl HM, Hiller L, Howard HC, Dunn JA, Young J, Bowden SJ, McDermaid M, Waterhouse AK, Wilson G, Agrawal R, O'Reilly S, Bowman A, Ritchie DM, Goodman A, Hickish T, McAdam K, Cameron D, Dodwell D, Rea DW, Caldas C, Provenzano E, Abraham JE, Canney P, Crown JP, Kennedy MJ, Coleman R, Leonard RC, Carmichael JA, Wardley AM, Poole CJ; tAnGo trial collaborators. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Jun;18(6):755-769. Epub 2017 May 4. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30319-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28479233 PubMed]
# '''APHINITY:''' von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. Epub 2017 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1703643 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1703643/suppl_file/nejmoa1703643_protocol.pdf link to supplementary protocol] '''contains verified protocol in supplementary protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28581356 PubMed]
# '''DBCG 07-READ:''' Ejlertsen B, Tuxen MK, Jakobsen EH, Jensen MB, Knoop AS, Højris I, Ewertz M, Balslev E, Danø H, Vestlev PM, Kenholm J, Nielsen DL, Bechmann T, Andersson M, Cold S, Nielsen HM, Maae E, Carlsen D, Mouridsen HT. Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2A-normal breast cancer: DBCG 07-READ, an open-label, phase III, randomized trial. J Clin Oncol. 2017 Aug 10;35(23):2639-2646. Epub 2017 Jun 29. [http://ascopubs.org/doi/full/10.1200/JCO.2017.72.3494 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28661759 PubMed]

==EP {{#subobject:332a92|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EP: '''<u>E</u>'''pirubicin & '''<u>P</u>'''aclitaxel
===Regimen {{#subobject:4824ee|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/19/5/853/167304 Fountzilas et al. 2007 (HE 10/00)]
| style="background-color:#1a9851" |Phase III (C)
|ddE, then ddP
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Epirubicin (Ellence)]] 83 mg/m<sup>2</sup> IV once on day 1
*[[Paclitaxel (Taxol)]] 187 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*ddCMF x 3

===References===
# '''HE 10/00:''' Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E, Pectasides D, Samantas E, Bafaloukos D, Stathopoulos GP, Karina M, Papadimitriou C, Skarlos D, Pisanidis N, Papakostas P, Markopoulos C, Tzorakoeleftherakis E, Dimitrakakis K, Makrantonakis P, Xiros N, Polichronis A, Varthalitis I, Karanikiotis C, Dimopoulos AM; Hellenic Cooperative Oncology Group. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol. 2008 May;19(5):853-60. Epub 2007 Nov 27. [https://academic.oup.com/annonc/article/19/5/853/167304 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18042835 PubMed]
## '''Update:''' Gogas H, Dafni U, Karina M, Papadimitriou C, Batistatou A, Bobos M, Kalofonos HP, Eleftheraki AG, Timotheadou E, Bafaloukos D, Christodoulou C, Markopoulos C, Briasoulis E, Papakostas P, Samantas E, Kosmidis P, Stathopoulos GP, Karanikiotis C, Pectasides D, Dimopoulos MA, Fountzilas G. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Res Treat. 2012 Apr;132(2):609-19. Epub 2011 Dec 21. [https://link.springer.com/article/10.1007%2Fs10549-011-1913-4 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22187126 PubMed]

==iddEPC {{#subobject:28ad40|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
iddEPC: '''<u>i</u>'''ntense '''<u>d</u>'''ose-'''<u>d</u>'''ense '''<u>E</u>'''pirubicin, '''<u>P</u>'''aclitaxel, '''<u>C</u>'''yclophosphamide
===Regimen {{#subobject:ca391d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2009.24.7643 Möbus et al. 2010]
|style="background-color:#1a9851" |Phase III (E)
|EC, then Paclitaxel
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://academic.oup.com/annonc/article/28/8/1803/3778272 Möbus et al. 2017 (GAIN)]
|style="background-color:#1a9851" |Phase III (C)
|ddEC, then PwX
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: this dosing of cyclophosphamide was after a mid-protocol amendment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy, part 1====
*[[Epirubicin (Ellence)]] 150 mg/m<sup>2</sup> IV once on day 1 
====Supportive medications====
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2 or 4

'''14-day cycle for 3 cycles, then:'''
====Chemotherapy, part 2====
*[[Paclitaxel (Taxol)]] 225 mg/m<sup>2</sup> IV once on day 1 
====Supportive medications====
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2 or 4

'''14-day cycle for 3 cycles, then:'''
====Chemotherapy, part 3====
*[[Cyclophosphamide (Cytoxan)]] 2000 mg/m<sup>2</sup> IV once on day 1
====Supportive medications====
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2 or 4

'''14-day cycle for 3 cycles'''
===References===
# Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Kreienberg R, Konecny GE, Untch M. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol. 2010 Jun 10;28(17):2874-80. Epub 2010 May 10. [http://ascopubs.org/doi/full/10.1200/JCO.2009.24.7643 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20458045 PubMed]
# '''GAIN:''' Möbus V, von Minckwitz G, Jackisch C, Lück HJ, Schneeweiss A, Tesch H, Elling D, Harbeck N, Conrad B, Fehm T, Huober J, Müller V, Bauerfeind I, du Bois A, Loibl S, Nekljudova V, Untch M, Thomssen C; German Breast Group (GBG), the AGO Breast Study Group (AGO-B) and NOGGO Study Groups. German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients. Ann Oncol. 2017 Aug 1;28(8):1803-1810. [https://academic.oup.com/annonc/article/28/8/1803/3778272 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28459941 PubMed]

==Epirubicin monotherapy {{#subobject:fda4d3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
E: '''<u>E</u>'''pirubicin
===Variant #1, 50 mg/m<sup>2</sup> {{#subobject:91512f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.32.7254 Coombes et al. 2011 (DEVA)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#DEVA|See link]]
|[[Complex_multipart_regimens#DEVA|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycle for 3 cycles'''
====Subsequent treatment====
*[[#Docetaxel_monotherapy_2|Docetaxel]] x 3

===Variant #2, 75 mg/m<sup>2</sup> {{#subobject:b83fae|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1990.8.8.1310 Boccardo et al. 1990 (GROCTA-1)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#GROCTA-1|See link]]
|[[Complex_multipart_regimens#GROCTA-1|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]], then [[#CMF|CMF]] x 6
====Chemotherapy====
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Breast_cancer,_ER/PR-positive#Tamoxifen_monotherapy|Tamoxifen]] x 5 y versus no further treatment

===Variant #3, 90 mg/m<sup>2</sup> {{#subobject:237268|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584474/ Mavroudis et al. 2017]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#Mavroudis_et_al._2017|See link]]
|[[Complex_multipart_regimens#Mavroudis_et_al._2017|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Epirubicin (Ellence)]] 90 mg/m<sup>2</sup> IV over 5 to 15 minutes once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Docetaxel_monotherapy_2|Docetaxel]]

===Variant #4, 100 mg/m<sup>2</sup> {{#subobject:f04a3c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa052084 Poole et al. 2006 (NEAT/BR9601)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#BR9601|See link]]
|[[Complex_multipart_regimens#BR9601|See link]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687939/ Ellis et al. 2009 (TACT)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[Complex_multipart_regimens#TACT|See link]]
|style="background-color:#ffffbf"|[[Complex_multipart_regimens#TACT|See link]]
|-
|[https://www.karger.com/Article/Abstract/315735 Boccardo et al. 2010]
| style="background-color:#1a9851" |Phase III (C)
|T-EV
|style="background-color:#ffffbf"|Seems not superior
|-
|[https://link.springer.com/article/10.1007%2Fs10549-010-1257-5 Amadori et al. 2010]
| style="background-color:#1a9851" |Phase III (E)
|See note
|style="background-color:#ffffbf"|See note
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489700/ Cameron et al. 2017 (TACT2)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#TACT2|See link]]
|[[Complex_multipart_regimens#TACT2|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. Amadori et al. 2010 was a sequencing trial comparing E -> CMF with CMF -> E; there were no statistically significant differences in outcome.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Epirubicin (Ellence)]] 100 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*NEAT, TACT, BR9601, Boccardo et al. 2010: [[#CMF|CMF]]
*TACT2: [[#Capecitabine_monotherapy|capecitabine]] versus [[#CMF|CMF]]

===References===
# '''GROCTA-1:''' Boccardo F, Rubagotti A, Bruzzi P, Cappellini M, Isola G, Nenci I, Piffanelli A, Scanni A, Sismondi P, Santi L, Genta F, Saccani F, Sassi M, Malacarne P, Donati D, Farris A, Castagnetta L, Di Carlo A, Traina A, Galletto L, Smerieri F, Buzzi F; Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. J Clin Oncol. 1990 Aug;8(8):1310-20. [http://ascopubs.org/doi/abs/10.1200/JCO.1990.8.8.1310 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2199618 PubMed]
## '''Update:''' Boccardo F, Guglielmini P, Parodi A, Rubagotti A. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients: very late results of the 'gruppo di ricerca per la chemio-ormonoterapia adiuvante (GROCTA)' 01-Trial in early breast cancer. Breast Cancer Res Treat. 2011 Apr;126(3):653-61. Epub 2011 Feb 24. [https://link.springer.com/article/10.1007%2Fs10549-011-1405-6 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21347647 PubMed]
<!-- no pre-pub disclosed -->
# Poole CJ, Earl HM, Hiller L, Dunn JA, Bathers S, Grieve RJ, Spooner DA, Agrawal RK, Fernando IN, Brunt AM, O'Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, Harvey P, McAdam K, Foster L, Leonard RC, Twelves CJ; NEAT Investigators and the SCTBG. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. N Engl J Med. 2006 Nov 2;355(18):1851-62. [https://www.nejm.org/doi/full/10.1056/NEJMoa052084 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17079759 PubMed]
## '''Update:''' Earl HM, Hiller L, Dunn JA, Vallier AL, Bowden SJ, Jordan SD, Blows F, Munro A, Bathers S, Grieve R, Spooner DA, Agrawal R, Fernando I, Brunt AM, O'Reilly SM, Crawford SM, Rea DW, Simmonds P, Mansi JL, Stanley A, McAdam K, Foster L, Leonard RC, Twelves CJ, Cameron D, Bartlett JM, Pharoah P, Provenzano E, Caldas C, Poole CJ; NEAT Investigators and the SCTBG. Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. Br J Cancer. 2012 Oct 9;107(8):1257-67. Epub 2012 Sep 11. [https://www.nature.com/articles/bjc2012370 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494422/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23047592 PubMed]
# '''TACT:''' Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C, Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JM, Ellis I, Peckitt C, Hall E, Bliss JM; TACT Trial Management Group; TACT Trialists. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet. 2009 May 16;373(9676):1681-92. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60740-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687939/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19447249 PubMed]
# Boccardo F, Amadori D, Guglielmini P, Sismondi P, Farris A, Agostara B, Gambi A, Catalano G, Faedi M, Rubagotti A. Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil versus paclitaxel followed by epirubicin and vinorelbine in patients with high-risk operable breast cancer. Oncology. 2010;78(3-4):274-81. Epub 2010 Jun 8. [https://www.karger.com/Article/Abstract/315735 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20530973 PubMed]
# Amadori D, Silvestrini R, De Lena M, Boccardo F, Rocca A, Scarpi E, Schittulli F, Brandi M, Maltoni R, Serra P, Ponzone R, Biglia N, Gianni L, Tienghi A, Valerio MR, Bonginelli P, Amaducci L, Faedi M, Baldini E, Paradiso A. Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer. Breast Cancer Res Treat. 2011 Feb;125(3):775-84. Epub 2010 Dec 4. [https://link.springer.com/article/10.1007%2Fs10549-010-1257-5 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21132360 PubMed]
<!-- Presented at the 46th Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL. -->
# Coombes RC, Bliss JM, Espie M, Erdkamp F, Wals J, Tres A, Marty M, Coleman RE, Tubiana-Mathieu N, den Boer MO, Wardley A, Kilburn LS, Cooper D, Thomas MW, Reise JA, Wilkinson K, Hupperets P. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with  node-positive breast cancer. J Clin Oncol. 2011 Aug 20;29(24):3247-54. Epub 2011 Jul 18. [http://ascopubs.org/doi/full/10.1200/JCO.2010.32.7254 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21768453 PubMed]
# Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, Agrawal R, Banerji J, Bertelli G, Bloomfield D, Brunt AM, Earl H, Ellis P, Gaunt C, Gillman A, Hearfield N, Laing R, Murray N, Couper N, Stein RC, Verrill M, Wardley A, Barrett-Lee P, Bliss JM; TACT2 Investigators. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2017 Jul;18(7):929-945. Epub 2017 Jun 7. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30404-7/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489700/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28600210 PubMed]
# Mavroudis D, Saloustros E, Boukovinas I, Papakotoulas P, Kakolyris S, Ziras N, Christophylakis C, Kentepozidis N, Fountzilas G, Rigas G, Varthalitis I, Kalbakis K, Agelaki S, Hatzidaki D, Georgoulias V. Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group. Br J Cancer. 2017 Jul 11;117(2):164-170. Epub 2017 Jun 22. [https://www.nature.com/bjc/journal/v117/n2/full/bjc2017158a.html link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584474/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28641315 PubMed]

==FAC {{#subobject:1e6621|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FAC: '''<u>F</u>'''luorouracil, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide
<br>CAF: '''<u>C</u>'''yclophosphamide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>F</u>'''luorouracil
===Variant #1, 500/50/500 x 4 {{#subobject:04f8a6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/31/20/2593.long Martín et al. 2013 (GEICAM/2003-02)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#GEICAM.2F2003-02|See link]]
|style="background-color:#91cf60" |[[Complex_multipart_regimens#GEICAM.2F2003-02|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#Paclitaxel_monotherapy.2C_weekly_2|wP]] x 8

===Variant #2, 500/50/500 x 6 {{#subobject:63e780|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/14/6/833/155778 Martin et al. 2003 (GEICAM 8701)]
| style="background-color:#1a9851" |Phase III (E)
|[[#CMF|CMF]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa043681 Martin et al. 2005 (BCIRG 001)]
| style="background-color:#1a9851" |Phase III (C)
|[[#TAC_.28Taxotere.29_2|TAC]]
| style="background-color:#d73027" |Inferior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa0910320 Martín et al. 2010 (GEICAM 9805)]
| style="background-color:#1a9851" |Phase III (C)
|[[#TAC_.28Taxotere.29_2|TAC]]
| style="background-color:#d73027" |Inferior DFS
|-
|[http://jco.ascopubs.org/content/31/20/2593.long Martín et al. 2013 (GEICAM/2003-02)]
| style="background-color:#1a9851" |Phase III (C)
|FAC-[[#Paclitaxel_monotherapy.2C_weekly_2|wP]]
| style="background-color:#fc8d59" |Seems to have inferior DFS
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
''Infusion times per Martin et al. 2005 (BCIRG 001).''
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV over 15 minutes once on day 1, '''given second'''
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV over 15 minutes once on day 1, '''given first'''
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV over 1 to 5 minutes once on day 1, '''given third'''
**A HemOnc.org user reached out to us and said their institutional practice is to infuse cyclophosphamide over 20 to 30 minutes to decrease the likelihood of head and sinus pain.

====Supportive medications====
*If patients had febrile neutropenia or infection: [[Ciprofloxacin (Cipro)]] 500 mg PO twice per day on days 5 to 14 of every cycle
*G-CSF not originally routinely administered unless patients had febrile neutropenia:
**[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 4 to 11
**OR [[Lenograstim (Granocyte)]] 150 mcg/m<sup>2</sup> SC once per day on days 4 to 11

'''21-day cycle for 6 cycles'''

===Variant #3, 800/40/400 x 6 {{#subobject:23cb8b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJM199405053301801 Wood et al. 1994 (CALGB 8541)]
|rowspan=2 style="background-color:#1a9851" |Phase III (C)
|1. FAC 600/30/300 x 4
| style="background-color:#1a9850" |Superior OS
|-
|2. FAC 1200/60/600 x 4
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Doxorubicin (Adriamycin)]] 40 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 400 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for 6 cycles'''

===Variant #4, 800/40/400 until max doxorubicin {{#subobject:53e7a0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19840201)53:3%3C384::AID-CNCR2820530303%3E3.0.CO;2-G/abstract Buzdar et al. 1984]
| style="background-color:#1a9851" |Phase III (C)
|FAC + BCG
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Doxorubicin (Adriamycin)]] 40 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 400 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles until cumulative doxorubicin dose of 300 mg/m<sup>2</sup> reached.'''
====Subsequent treatment====
*After reaching cumulative maximum doxorubicin, patients would go on to receive maintenance CMF. This is now obsolete.

===Variant #5, 1000/50/500 x 8 {{#subobject:a3523e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://academic.oup.com/jnci/article/92/3/225/2965047 Hortobagyi et al. 2000]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 4
*[[Doxorubicin (Adriamycin)]] 16.7 mg/m<sup>2</sup>/day IV continuous infusion over 72 hours, started on day 1 (total dose per cycle: 50 mg/m<sup>2</sup>)
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 8 cycles'''
====Subsequent treatment====
*CEP with auto HSCT versus no further treatment

===Variant #6, 1000/60/1400 x 6 {{#subobject:f18a6a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa030684 Tallman et al. 2003 (INT-0121)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.05.551 Davidson et al. 2005 (ECOG E5188)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://jco.ascopubs.org/content/23/33/8313.long Hutchins et al. 2005 (INT-0102)]
| style="background-color:#1a9851" |Phase III (E)
|[[#CMF|CMF]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140679/ Albain et al. 2009 (SWOG-8814)]
| style="background-color:#1a9851" |Phase III (*)
|[[Complex_multipart_regimens#SWOG-8814|See link]]
| style="background-color:#d9ef8b" |[[Complex_multipart_regimens#SWOG-8814|See link]]
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Doxorubicin (Adriamycin)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Cyclophosphamide (Cytoxan)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 14

'''28-day cycle for 6 cycles'''
====Subsequent treatment====
*INT-0121: Cyclophosphamide & thiotepa with auto HSCT versus no further chemotherapy
*ECOG E5188: Goserelin x 5 y versus [[Breast_cancer,_ER/PR-positive#Goserelin_.26_Tamoxifen|Goserelin & Tamoxifen]] x 5 y versus [[Breast_cancer,_ER/PR-positive#Observation|no further treatment]]
*SWOG-8814: [[Breast_cancer,_ER/PR-positive#Tamoxifen_monotherapy|Tamoxifen]] x 5 y

===Variant #7, 1200/60/600 x 4 {{#subobject:7953f3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.nejm.org/doi/full/10.1056/NEJM199405053301801 Wood et al. 1994 (CALGB 8541)]
|rowspan=2 style="background-color:#1a9851" |Phase III (C)
|1. FAC 600/30/300 x 4
| style="background-color:#1a9850" |Superior OS
|-
|2. FAC 800/40/400 x 6
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for 4 cycles'''

===Variant #8, with range x 3 {{#subobject:67eda7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ von Minckwitz et al. 2017 (APHINITY)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. Patients had HER2-positive breast cancer. Note that ranges for FAC are given in the protocol, replicated here.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 to 600 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 to 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Breast_cancer,_HER2-positive#TH_.28Taxol.29_2|TH (Taxol)]] versus [[Breast_cancer,_HER2-positive#THP_.28Taxol.29_2|THP (Taxol)]] or [[Breast_cancer,_HER2-positive#TH_.28Taxotere.29_2|TH (Taxotere)]] versus [[Breast_cancer,_HER2-positive#THP_.28Taxotere.29_2|THP (Taxotere)]]

===References===
# Buzdar AU, Blumenschein GR, Smith TL, Powell KC, Hortobagyi GN, Yap HY, Schell FC, Barnes BC, Ames FC, Martin RG, Hersh EM. Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guérin and with or without irradiation in operable breast cancer: a prospective randomized trial. Cancer. 1984 Feb 1;53(3):384-9. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19840201)53:3%3C384::AID-CNCR2820530303%3E3.0.CO;2-G/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/6362814 PubMed]
## '''Update:''' Buzdar AU, Kau SW, Smith TL, Hortobagyi GN. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol. 1989 Apr;12(2):123-8. [https://www.ncbi.nlm.nih.gov/pubmed/2705401 PubMed]
# '''CALGB 8541:''' Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR, Ballow AC, Frei E, Henderson IC. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994 May 5;330(18):1253-9. Erratum in: N Engl J Med 1994 Jul 14;331(2):139. [https://www.nejm.org/doi/full/10.1056/NEJM199405053301801 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8080512 PubMed]
## '''Subgroup analysis:''' Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994 May 5;330(18):1260-6. Erratum in: N Engl J Med 1994 Jul 21;331(3):211. [https://www.nejm.org/doi/10.1056/NEJM199405053301802 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7908410 PubMed]
# Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, Holmes FA, Giralt S, Khouri I, Andersson B, Gajewski JL, Rondon G, Smith TL, Singletary SE, Ames FC, Sneige N, Strom EA, McNeese MD, Deisseroth AB, Champlin RE. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000 Feb 2;92(3):225-33. [https://academic.oup.com/jnci/article/92/3/225/2965047 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10655439 PubMed]
# '''GEICAM 8701:''' Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, Albanell J, Aranda J, Munarriz B, Campbell J, Diaz-Rubio E; GEICAM Group (Spanish Breast Cancer Research Group), Spain. Doxorubicin in combination with fluorouracil and cyclophosphamide (iv FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (iv CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol. 2003 Jun;14(6):833-42. [https://academic.oup.com/annonc/article/14/6/833/155778 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12796019 PubMed]
# Assikis V, Buzdar A, Yang Y, Smith T, Theriault R, Booser D, Valero V, Walters R, Singletary E, Ames F, Hortobagyi G. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer. 2003 Jun 1;97(11):2716-23. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.11396/full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12767083 PubMed]
# '''INT-0121:''' Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, Gradishar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003 Jul 3;349(1):17-26. [https://www.nejm.org/doi/full/10.1056/NEJMoa030684 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12840088 PubMed]
<!-- no pre-pub disclosed -->
# '''BCIRG 001:''' Martín M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005 Jun 2;352(22):2302-13. [https://www.nejm.org/doi/full/10.1056/NEJMoa043681 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15930421 PubMed]
## '''Update:''' Mackey JR, Martín M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C; TRIO/BCIRG 001 investigators. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013 Jan;14(1):72-80. Epub 2012 Dec 12. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70525-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23246022 PubMed]
# '''ECOG E5188:''' Davidson NE, O'Neill AM, Vukov AM, Osborne CK, Martino S, White DR, Abeloff MD. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 2005 Sep 1;23(25):5973-82. Epub 2005 Aug 8. [http://ascopubs.org/doi/full/10.1200/JCO.2005.05.551 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16087950 PubMed]
# '''INT-0102:''' Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE, Osborne CK. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol. 2005 Nov 20;23(33):8313-21. [http://jco.ascopubs.org/content/23/33/8313.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16293862 PubMed]
# '''SWOG-8814:''' Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne CK; Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Dec 19;374(9707):2055-2063. Epub 2009 Dec 10. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61523-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140679/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20004966 PubMed]
<!-- no pre-pub disclosed -->
# '''GEICAM 9805:''' Martín M, Seguí MA, Antón A, Ruiz A, Ramos M, Adrover E, Aranda I, Rodríguez-Lescure A, Grosse R, Calvo L, Barnadas A, Isla D, Martinez del Prado P, Ruiz Borrego M, Zaluski J, Arcusa A, Muñoz M, López Vega JM, Mel JR, Munarriz B, Llorca C, Jara C, Alba E, Florián J, Li J, López García-Asenjo JA, Sáez A, Rios MJ, Almenar S, Peiró G, Lluch A; GEICAM 9805 Investigators. Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med. 2010 Dec 2;363(23):2200-10. [https://www.nejm.org/doi/full/10.1056/NEJMoa0910320 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21121833 PubMed]
<!-- Presented in part at the 48th Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2012, Chicago, IL. -->
# '''GEICAM/2003-02:''' Martín M, Ruiz A, Ruiz Borrego M, Barnadas A, González S, Calvo L, Margelí Vila M, Antón A, Rodríguez-Lescure A, Seguí-Palmer MA, Muñoz-Mateu M, Dorca Ribugent J, López-Vega JM, Jara C, Espinosa E, Mendiola Fernández C, Andrés R, Ribelles N, Plazaola A, Sánchez-Rovira P, Salvador Bofill J, Crespo C, Carabantes FJ, Servitja S, Chacón JI, Rodríguez CA, Hernando B, Álvarez I, Carrasco E, Lluch A. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study. J Clin Oncol. 2013 Jul 10;31(20):2593-9. Epub 2013 Jun 3. [http://jco.ascopubs.org/content/31/20/2593.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23733779 PubMed]
# '''APHINITY:''' von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. Epub 2017 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1703643 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1703643/suppl_file/nejmoa1703643_protocol.pdf link to supplementary protocol] '''contains verified protocol in supplementary protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28581356 PubMed]

==FEC {{#subobject:3613b7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FEC: '''<u>F</u>'''luorouracil, '''<u>E</u>'''pirubicin, '''<u>C</u>'''yclophosphamide
<br>CEF: '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''pirubicin, '''<u>F</u>'''luorouracil
===Variant #1, 500/50/500 x 6 ("FEC 50") {{#subobject:24ca82|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1988.6.4.679 Hurteloup 1988 (FESG)]
| style="background-color:#1a9851" |Phase III (E)
|[[#FAC_2|FAC]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2001.19.3.602 Bonneterre 2001 (FASG 05)]
| style="background-color:#1a9851" |Phase III (C)
|FEC 100 x 6
| style="background-color:#d73027" |Inferior OS
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2003.04.148 Fumoleau et al. 2003 (FASG 01)]
|rowspan=2 style="background-color:#1a9851" |Phase III (E)
|1. FEC 50 x 3
| style="background-color:#d9ef8b" |Might have superior OS
|-
|2. FEC 75 x 3
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.tandfonline.com/doi/full/10.1080/02841860510029987 Arriagada et al. 2005]
| style="background-color:#1a9851" |Phase III (E)
|[[Breast_cancer_-_historical#Observation|Observation]]
| style="background-color:#1a9850" |Superior DFS
|-
|[http://www.jle.com/fr/revues/bdc/e-docs/epirubicin_based_chemotherapy_as_adjuvant_treatment_for_poor_prognosis_node_negative_breast_cancer_10_year_follow_up_results__272048/article.phtml Héry et al. 2006 (FASG 03)]
| style="background-color:#1a9851" |Phase III (E)
|[[Breast_cancer_-_historical#Observation|Observation]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://academic.oup.com/annonc/article/17/8/1221/174554 Roché et al. 2006 (FASG 06)]
| style="background-color:#1a9851" |Phase III (C)
|[[Breast_cancer,_ER/PR-positive#Goserelin_.26_Tamoxifen_2|Goserelin & Tamoxifen]] x 3y
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 cycles'''

===Variant #2, 500/60/500 x 4 {{#subobject:ea8219|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.redjournal.org/article/S0360-3016(05)02813-0/fulltext Rouëssé et al. 2006]
| style="background-color:#1a9851" |Phase III (C)
|FNC & RT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''

===Variant #3, 500/100/500 x 3 {{#subobject:99d167|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/24/36/5664.long Roché et al. 2006 (FNCLCC PACS 01)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#FNCLCC_PACS_01|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#FNCLCC_PACS_01|See link]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61847-3/fulltext Baselga et al. 2012 (NeoALTTO)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://jamanetwork.com/journals/jama/fullarticle/2579866 Foukakis et al. 2016 (PANTHER)]
| style="background-color:#1a9851" |Phase III (C)
|Dose-dense tailored chemotherapy
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. Patients in NeoALTTO all had HER2-positive disease.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 100 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*FNCLCC PACS 01 & PANTHER: [[#Docetaxel_monotherapy_2|Docetaxel]] x 3
*NeoALTTO: Lapatinib or [[Breast_cancer,_HER2-positive#Lapatinib_.26_Trastuzumab_2|Lapatinib & Trastuzumab]] or [[Breast_cancer,_HER2-positive#Trastuzumab_monotherapy_2|Trastuzumab]], according to initial randomization

===Variant #4, 500/100/500 x 4 {{#subobject:9cee26|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.36.2079 Kelly et al. 2012]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ejcancer.com/article/S0959-8049(17)30822-5/fulltext Kerbrat et al. 2017 (UCBG-0106)]
| style="background-color:#1a9851" |Phase III (E)
|FEC 100 x 6
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: this is an experimental arm that did not meet its primary endpoint; included here because it represents a de-escalation strategy.''
====Preceding treatment====
*Kelly et al. 2012: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#Paclitaxel_monotherapy.2C_weekly_2|weekly paclitaxel]] x 12 versus XT
*UCBG-0106: [[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 100 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''

===Variant #5, 500/100/500 x 6 ("FEC 100") {{#subobject:8382ec|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2001.19.3.602 Bonneterre 2001 (FASG 05)]
| style="background-color:#1a9851" |Phase III (E)
|FEC 50 x 6
| style="background-color:#1a9850" |Superior OS
|-
|[http://jco.ascopubs.org/content/24/36/5664.long Roché et al. 2006 (FNCLCC PACS 01)]
| style="background-color:#1a9851" |Phase III (C)
|FEC-[[#Docetaxel_monotherapy_2|D]]
| style="background-color:#d73027" |Inferior OS (*)
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359910/ Kerbrat et al. 2007 (FASG 09)]
| style="background-color:#1a9851" |Phase III (C)
|Epirubicin & Vinorelbine
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://link.springer.com/article/10.1007%2Fs12032-013-0457-3 Sakr et al. 2013]
| style="background-color:#1a9851" |Phase III (C)
|FEC 100 x 3, then [[#Docetaxel_monotherapy_2|D]] x 3
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://www.ejcancer.com/article/S0959-8049(13)00898-8/fulltext Delbaldo et al. 2013 (Trial B2000)]
| style="background-color:#1a9851" |Phase III (C)
|FEC 100 x 4, then Taxol x 4
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://academic.oup.com/annonc/article/25/8/1551/273198 Nitz et al. 2014 (WSG-AGO EC-Doc)]
| style="background-color:#1a9851" |Phase III (C)
|[[#EC_2|EC]]-[[#Docetaxel_monotherapy_2|Doc]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://www.ejcancer.com/article/S0959-8049(17)30822-5/fulltext Kerbrat et al. 2017 (UCBG-0106)]
| style="background-color:#1a9851" |Phase III (C)
|FEC 100 x 4
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: efficacy for FNCLCC PACS 01 is based on the 2012 update.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 100 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 cycles'''

===Variant #6, 600/50/600 x 8 {{#subobject:85d304|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1996.14.1.35 Coombes et al. 1996]
| style="background-color:#1a9851" |Phase III (E)
|[[#CMF|CMF]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ejcancer.com/article/S0959-8049(16)00156-8/fulltext Coombes et al. 2016 (HMFEC)]
| style="background-color:#1a9851" |Phase III (C)
|FEC<sub>75</sub>
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: this is an experimental arm that did not meet its primary endpoint; included here because other variants of this regimen have demonstrated comparative superiority.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 8 cycles'''

===Variant #7, 600/60/600 x 3 {{#subobject:e6b54b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa053028 Joensuu et al. 2006 (FinHer)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*HER2-negative: [[#Docetaxel_monotherapy_2|Docetaxel]] x 3 versus [[#Vinorelbine_monotherapy|Vinorelbine]] x 3
*HER2-positive: [[#Docetaxel_monotherapy_2|Docetaxel]] x 3 versus [[Breast_cancer,_HER2-positive#TH_.28Taxotere.29_2|TH]] x 3 versus [[#Vinorelbine_monotherapy|Vinorelbine]] x 3 versus [[Breast_cancer,_HER2-positive#VH|VH]] x 3
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 3 cycles'''

===Variant #8, 600/60/600 x 4 {{#subobject:32aa4a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2001.19.22.4224 van der Hage et al. 2001 (EORTC 10902)]
| style="background-color:#1a9851" |Phase III (C)
|[[#FEC|Neoadjuvant FEC]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687939/ Ellis et al. 2009 (TACT)]
|style="background-color:#1a9851"|Randomized Phase II (E)
|[[Complex_multipart_regimens#TACT|See link]]
|style="background-color:#ffffbf"|[[Complex_multipart_regimens#TACT|See link]]
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*TACT: [[#Docetaxel_monotherapy_2|D]] x 4

===Variant #9, 600/60/600 x 6 {{#subobject:d13a49|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/jnci/article/97/23/1724/2521486 Venturini et al. 2005]
| style="background-color:#1a9851" |Phase III (C)
|ddFEC
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://academic.oup.com/annonc/article/21/8/1623/153229 Sirohi et al. 2010 (TRAFIC)]
| style="background-color:#1a9851" |Phase III (C)
|ECisF
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://link.springer.com/article/10.1007%2Fs10549-015-3655-1 del Mastro et al. 2016 (GONO-MIG5)]
| style="background-color:#1a9851" |Phase III (C)
|EP x 4
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 cycles'''

===Variant #10, 600/60/600 x 8 {{#subobject:695f44|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687939/ Ellis et al. 2009 (TACT)]
|style="background-color:#1a9851"|Randomized Phase II (C)
|[[Complex_multipart_regimens#TACT|See link]]
|style="background-color:#ffffbf"|[[Complex_multipart_regimens#TACT|See link]]
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 8 cycles'''

===Variant #11, 600/60/600 x 9 {{#subobject:cfbcd1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ejcancer.com/article/S0959-8049(07)00014-7/fulltext Ejlertsen et al. 2007 (DBCG 89D)]
|style="background-color:#1a9851"|Phase III (E)
|[[#CMF|CMF]]
| style="background-color:#1a9850" |Superior OS
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 9 cycles'''

===Variant #12, 600/75/600 x 3 {{#subobject:b0f889|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70307-9/fulltext Joensuu et al. 2009 (FinXX)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#FinXX|See link]]
|[[Complex_multipart_regimens#FinXX|See link]]
|-
|[https://jamanetwork.com/journals/jamaoncology/fullarticle/2682589 Joensuu et al. 2018 (SOLD)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. Patients in SOLD had HER2+ breast cancer.''
====Preceding treatment====
*FinXX: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#Docetaxel_monotherapy_2|T (Taxotere)]] x 3
*SOLD: [[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer,_HER2-positive#TH_.28Taxotere.29_2|TH (Taxotere)]] x 3
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*SOLD: [[Breast_cancer,_HER2-positive#Trastuzumab_monotherapy_2|Trastuzumab maintenance]] for a total of 1 year versus no further treatment

===Variant #13, 600/90/600 x 4 {{#subobject:9794f0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jnci.oxfordjournals.org/content/100/11/805.long Martín et al. 2008 (GEICAM 9906)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#GEICAM_9906|See link]]
|[[Complex_multipart_regimens#GEICAM_9906|See link]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62048-1/fulltext Del Mastro et al. 2015 (GIM2)]
|style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#GIM2|See link]]
|[[Complex_multipart_regimens#GIM2|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 90 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 4 cycles'''
====Subsequent treatment====
*GEICAM 9906: [[#Paclitaxel_monotherapy.2C_weekly_2|Weekly Paclitaxel]]
*GIM2: [[#Paclitaxel monotherapy.2C_q3wk|Paclitaxel, q3wk dosing]]

===Variant #14, 600/90/600 x 6 {{#subobject:916209|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jnci.oxfordjournals.org/content/100/11/805.long Martín et al. 2008 (GEICAM 9906)]
| style="background-color:#1a9851" |Phase III (C)
|FEC x 4, then [[#Paclitaxel_monotherapy.2C_weekly_2|wP]]
| style="background-color:#d73027" |Inferior DFS
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 90 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 cycles'''

===Variant #15, 700/75/700 x 6 {{#subobject:31e320|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://link.springer.com/article/10.1007%2Fs10549-009-0468-0 Polyzos et al. 2009]
| style="background-color:#1a9851" |Phase III (C)
|[[#Docetaxel_monotherapy_2|D]], then [[#EC_2|EC]]
| style="background-color:#fc8d59" |Seems to have inferior DFS
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 700 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 700 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 cycles'''

===Variant #16, 1000/50/500 x 6 {{#subobject:caf441|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2001.19.19.3929 Paradiso et al. 2001]
| style="background-color:#1a9851" |Phase III (E)
|[[Breast_cancer_-_historical#Observation|Observation]]
| style="background-color:#91cf60" |Seems to have superior DFS
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

===Variant #17, 1000/50/500 until max anthracycline {{#subobject:caf441|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1988.6.6.976 Ambrosini et al. 1988]
| style="background-color:#1a9851" |Phase III (E)
|[[#FAC_2|FAC]]
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#1a9850" |Less toxic
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 14 cycles (maximum of 700 mg/m<sup>2</sup> epirubicin)'''

===Variant #18, 1000/120/1050 x 6 ("FEC 120") {{#subobject:978850|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/16/8/2651.long Levine et al. 1998 (NCIC CTG MA.5)]
| style="background-color:#1a9851" |Phase III (E)
|[[#CMF|CMF]]
| style="background-color:#1a9850" |Superior RFS
|-
|[http://annonc.oxfordjournals.org/content/16/5/726.long Coombes et al. 2005 (ICCG HDT trial)]
| style="background-color:#1a9851" |Phase III (C)
|FEC x 3, then HDT
| style="background-color:#ffffbf" |Seems not superior
|-
|rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799234/ Burnell et al. 2009 (NCIC CTG MA.21)]
|rowspan = 2 style="background-color:#1a9851" |Phase III (C)
|[[#AC_2|1. AC]] x 4, then [[Breast_cancer_-_historical#Paclitaxel_monotherapy.2C_q3wk|T (Taxol)]] x 4
| style="background-color:#1a9850" |Superior RFS
|-
|[[#ddEC|2. ddEC]] x 6, then [[Breast_cancer_-_historical#Paclitaxel_monotherapy.2C_q3wk|T (Taxol)]] x 4
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984804/ Janni et al. 2016 (ADEBAR)]
| style="background-color:#1a9851" |Phase III (C)
|EC x 3, then Docetaxel
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Cyclophosphamide (Cytoxan)]] 75 mg/m<sup>2</sup> PO once per day on days 1 to 14

'''28-day cycle for 6 cycles'''

===Variant #19, 1200/50/1200 x 6 {{#subobject:d46835|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1996.14.1.35 Coombes et al. 1996]
| style="background-color:#1a9851" |Phase III (E)
|[[#CMF|CMF]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: this is an experimental arm that did not meet its primary endpoint; however, based on a subgroup analysis, it became a preferred regimen.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycle for 6 cycles'''

===Variant #20, with range x 3 {{#subobject:a1c683|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ von Minckwitz et al. 2017 (APHINITY)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. Patients had HER2-positive breast cancer. Note that ranges for FEC are given in the protocol, replicated here.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 to 600 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 90 to 120 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 to 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Breast_cancer,_HER2-positive#TH_.28Taxol.29_2|TH (Taxol)]] versus [[Breast_cancer,_HER2-positive#THP_.28Taxol.29_2|THP (Taxol)]] or [[Breast_cancer,_HER2-positive#TH_.28Taxotere.29_2|TH (Taxotere)]] versus [[Breast_cancer,_HER2-positive#THP_.28Taxotere.29_2|THP (Taxotere)]]

===References===
# '''FESG:''' Hurteloup P; French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol. 1988 Apr;6(4):679-88. [http://ascopubs.org/doi/abs/10.1200/JCO.1988.6.4.679 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2895801 PubMed]
# Ambrosini G, Balli M, Garusi G, Demicheli R, Jirillo A, Bonciarelli G, Bruscagnin G, Fila G, Bumma C, Lacroix F, Buzzi F, Di Costanzo F, Padalino D, Brugia M, Calabresi F, Natali M, Cartei G, Chiesa G, Blasina B, Ciambellotti E, Moro G, D'Aquino S, Altavilla G, Adamo V, De Maria D, Falchi AM, Bertoncelli P, Farris A, Fiorentino M, Fornasiero A, Fosser V, Daniele O, Foggi CM, Speranza GB, Sartori S, Camilluzzi E, Gallo L, Poggio R, Secondo V, Gambi A, Grignani F, Capodicasa E, Lopez M, Papaldo P, Di Lauro L, Vici P, Marenco G, Folco U, Bonanni F, Marsilio P, Palazzotto G, Di Carlo A, Cusimano MP, Pastorino G, Puccetti C, Giusto M, Rausa L, Gebbia N, Palmeri S, D'Alessandro N, Saccani F, Becchi G, Schieppati G, Spinelli I, Tagliagambe A, Tonato M, Minotti V, Ardia A, Viaro D, De Micheli P, Zingali G, Sacchetti G, Intini C; Italian Multicentre Breast Study with Epirubicin. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J Clin Oncol. 1988 Jun;6(6):976-82. [http://ascopubs.org/doi/abs/10.1200/JCO.1988.6.6.976 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2897433 PubMed]
# Coombes RC, Bliss JM, Wils J, Morvan F, Espié M, Amadori D, Gambrosier P, Richards M, Aapro M, Villar-Grimalt A, McArdle C, Pérez-López FR, Vassilopoulos P, Ferreira EP, Chilvers CE, Coombes G, Woods EM, Marty M; The International Collaborative Cancer Group. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. J Clin Oncol. 1996 Jan;14(1):35-45. [http://ascopubs.org/doi/full/10.1200/JCO.1996.14.1.35 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8558217 PubMed]
# '''NCIC CTG MA.5:''' Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D; National Cancer Institute of Canada Clinical Trials Group. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol. 1998 Aug;16(8):2651-8. [http://jco.ascopubs.org/content/16/8/2651.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9704715 PubMed]
## '''Update:''' Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N; National Cancer Institute of Canada Clinical Trials Group. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol. 2005 Aug 1;23(22):5166-70. [http://ascopubs.org/doi/full/10.1200/JCO.2005.09.423 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16051958 PubMed]
## '''Subgroup analysis:''' Pritchard KI, Shepherd LE, O'Malley FP, Andrulis IL, Tu D, Bramwell VH, Levine MN; National Cancer Institute of Canada Clinical Trials Group. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med. 2006 May 18;354(20):2103-11. [https://www.nejm.org/doi/10.1056/NEJMoa054504 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16707747 PubMed]
# '''FASG 05:''' Bonneterre J; French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol. 2001 Feb 1;19(3):602-11. [http://ascopubs.org/doi/full/10.1200/JCO.2001.19.3.602 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11157009 PubMed]
## '''Update:''' Bonneterre J, Roché H, Kerbrat P, Brémond A, Fumoleau P, Namer M, Goudier MJ, Schraub S, Fargeot P, Chapelle-Marcillac I. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol. 2005 Apr 20;23(12):2686-93. [http://ascopubs.org/doi/full/10.1200/JCO.2005.05.059 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15837983 PubMed]
# Paradiso A, Schittulli F, Cellamare G, Mangia A, Marzullo F, Lorusso V, De Lena M. Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer. J Clin Oncol. 2001 Oct 1;19(19):3929-37. [http://ascopubs.org/doi/full/10.1200/JCO.2001.19.19.3929 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11579113 PubMed]
# '''EORTC 10902:''' van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001 Nov 15;19(22):4224-37. [http://ascopubs.org/doi/full/10.1200/JCO.2001.19.22.4224 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11709566 PubMed] 
## '''Update:''' van Nes JG, Putter H, Julien JP, Tubiana-Hulin M, van de Vijver M, Bogaerts J, de Vos M, van de Velde CJ; Cooperating Investigators of the EORTC. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. Breast Cancer Res Treat. 2009 May;115(1):101-13. Epub 2008 May 18. [https://link.springer.com/article/10.1007%2Fs10549-008-0050-1 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18484198 PubMed]
# '''FASG 01:''' Fumoleau P, Kerbrat P, Romestaing P, Fargeot P, Brémond A, Namer M, Schraub S, Goudier MJ, Mihura J, Monnier A, Clavère P, Serin D, Seffert P, Pourny C, Facchini T, Jacquin JP, Sztermer JF, Datchary J, Ramos R, Luporsi E. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol. 2003 Jan 15;21(2):298-305. [http://ascopubs.org/doi/full/10.1200/JCO.2003.04.148 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12525522 PubMed]
# Arriagada R, Spielmann M, Koscielny S, Le Chevalier T, Delozier T, Rémé-Saumon M, Ducourtieux M, Tursz T, Hill C. Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1146 patients with early breast cancer. Acta Oncol. 2005;44(5):458-66. [https://www.tandfonline.com/doi/full/10.1080/02841860510029987 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16118079 PubMed]
# Coombes RC, Howell A, Emson M, Peckitt C, Gallagher C, Bengala C, Tres A, Welch R, Lawton P, Rubens R, Woods E, Haviland J, Vigushin D, Kanfer E, Bliss JM. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. Ann Oncol. 2005 May;16(5):726-34. Epub 2005 Apr 7. [http://annonc.oxfordjournals.org/content/16/5/726.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15817602 PubMed]
# Venturini M, Del Mastro L, Aitini E, Baldini E, Caroti C, Contu A, Testore F, Brema F, Pronzato P, Cavazzini G, Sertoli MR, Canavese G, Rosso R, Bruzzi P. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst. 2005 Dec 7;97(23):1724-33. [https://academic.oup.com/jnci/article/97/23/1724/2521486 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16333028 PubMed]
<!-- no pre-pub disclosed -->
# '''FinHer:''' Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006 Feb 23;354(8):809-20. [https://www.nejm.org/doi/full/10.1056/NEJMoa053028 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16495393 PubMed]
## '''Update:''' Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009 Dec 1;27(34):5685-92. [http://ascopubs.org/doi/full/10.1200/JCO.2008.21.4577 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19884557 PubMed]
# '''FASG 06:''' Roché H, Kerbrat P, Bonneterre J, Fargeot P, Fumoleau P, Monnier A, Clavère P, Goudier MJ, Chollet P, Guastalla JP, Serin D. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. Ann Oncol. 2006 Aug;17(8):1221-7. Epub 2006 May 26. [https://academic.oup.com/annonc/article/17/8/1221/174554 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16731539 PubMed]
# '''FASG 03:''' Héry M, Bonneterre J, Roché H, Luporsi E, Kerbrat P, Namer M, Fumoleau P, Monnier A, Fargeot P. Epirubicin-based chemotherapy as adjuvant treatment for poor prognosis, node-negative breast cancer: 10-year follow-up results of the French Adjuvant Study Group 03 trial. Bull Cancer. 2006 Oct;93(10):E109-14. [http://www.jle.com/fr/revues/bdc/e-docs/epirubicin_based_chemotherapy_as_adjuvant_treatment_for_poor_prognosis_node_negative_breast_cancer_10_year_follow_up_results__272048/article.phtml link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17074656 PubMed]
# Rouëssé J, de la Lande B, Bertheault-Cvitkovic F, Serin D, Graïc Y, Combe M, Leduc B, Lucas V, Demange L, Nguyen TD, Castèra D, Krzisch C, Villet R, Mouret-Fourme E, Garbay JR, Noguès C; Centre René Huguenin Breast Cancer Group. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results. Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1072-80. [https://www.redjournal.org/article/S0360-3016(05)02813-0/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16504757 PubMed]
<!-- Presented in oral format at the 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2004. -->
# '''FNCLCC PACS 01:''' Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, Symann M, Kerbrat P, Soulié P, Eichler F, Viens P, Monnier A, Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero JM, Martin AL, Genève J, Asselain B. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006 Dec 20;24(36):5664-71. Epub 2006 Nov 20. [http://jco.ascopubs.org/content/24/36/5664.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17116941 PubMed]
## '''Update:''' Coudert B, Asselain B, Campone M, Spielmann M, Machiels JP, Pénault-Llorca F, Serin D, Lévy C, Romieu G, Canon JL, Orfeuvre H, Piot G, Petit T, Jerusalem G, Audhuy B, Veyret C, Beauduin M, Eymard JC, Martin AL, Roché H; UNICANCER Breast Group. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. Oncologist. 2012;17(7):900-9. Epub 2012 May 18. [http://theoncologist.alphamedpress.org/content/17/7/900.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399644/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22610153 PubMed]
# '''DBCG 89D:''' Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Cold S, Edlund P, Ewertz M, Jensen BB, Kamby C, Nordenskjold B, Bergh J. Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Eur J Cancer. 2007 Mar;43(5):877-84. Epub 2007 Feb 16. [https://www.ejcancer.com/article/S0959-8049(07)00014-7/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17306974 PubMed]
# '''FASG 09:''' Kerbrat P, Roché H, Bonneterre J, Veyret C, Lortholary A, Monnier A, Fumoleau P, Fargeot P, Namer M, Chollet P, Goudier MJ, Audhuy B, Simon H, Montcuquet P, Eymard JC, Walter S, Clavère P, Guastalla JP; French adjuvant Study Group. Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial. Br J Cancer. 2007 Jun 4;96(11):1633-8. Epub 2007 May 15. [https://www.nature.com/articles/6603773 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359910/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/17505516 PubMed]
# '''GEICAM 9906:''' Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. Epub 2008 May 27. [http://jnci.oxfordjournals.org/content/100/11/805.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18505968 PubMed]
# '''TACT:''' Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C, Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JM, Ellis I, Peckitt C, Hall E, Bliss JM; TACT Trial Management Group; TACT Trialists. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet. 2009 May 16;373(9676):1681-92. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60740-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687939/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19447249 PubMed]
# Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, Kakolyris S, Syrigos K, Papakotoulas P, Kouroussis C, Karvounis N, Vamvakas L, Christophyllakis C, Athanasiadis A, Varthalitis I, Georgoulias V, Mavroudis D. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Res Treat. 2010 Jan;119(1):95-104. Epub 2009 Jul 28. [https://link.springer.com/article/10.1007%2Fs10549-009-0468-0 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19636702 PubMed]
# '''NCIC CTG MA.21:''' Burnell M, Levine MN, Chapman JA, Bramwell V, Gelmon K, Walley B, Vandenberg T, Chalchal H, Albain KS, Perez EA, Rugo H, Pritchard K, O'Brien P, Shepherd LE. Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol. 2010 Jan 1;28(1):77-82. Epub 2009 Nov 9. [http://ascopubs.org/doi/full/10.1200/JCO.2009.22.1077 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2799234/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19901117 PubMed]
# '''FinXX:''' Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Asola R, Kokko R, Ahlgren J, Auvinen P, Hemminki A, Paija O, Helle L, Nuortio L, Villman K, Nilsson G, Lahtela SL, Lehtiö K, Pajunen M, Poikonen P, Nyandoto P, Kataja V, Bono P, Leinonen M, Lindman H; FinXX Study Investigators. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncol. 2009 Dec;10(12):1145-51. Epub 2009 Nov 10. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70307-9/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19906561 PubMed]
## '''Update:''' Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Paija O, Helle L, Villman K, Nyandoto P, Nilsson G, Pajunen M, Asola R, Poikonen P, Leinonen M, Kataja V, Bono P, Lindman H. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol. 2012 Jan 1;30(1):11-8. Epub 2011 Nov 21. [http://ascopubs.org/doi/full/10.1200/JCO.2011.35.4639 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22105826 PubMed]
# '''TRAFIC:''' Sirohi B, A'Hern R, Coombes G, Bliss JM, Hickish T, Perren T, Crawford M, O'Brien M, Iveson T, Ebbs S, Skene A, Laing R, Smith IE. A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial. Ann Oncol. 2010 Aug;21(8):1623-9. Epub 2010 Jan 21. [https://academic.oup.com/annonc/article/21/8/1623/153229 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20093351 PubMed]
# '''NeoALTTO:''' Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012 Feb 18;379(9816):633-40. Epub 2012 Jan 17. Erratum in: Lancet. 2012 Feb 18;379(9816):616. Dosage error in published abstract; MEDLINE/PubMed abstract corrected. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61847-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705192/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22257673 PubMed]
## '''Update:''' de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA Jr, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber RD, Eidtmann H, Baselga J. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014 Sep;15(10):1137-46. Epub 2014 Aug 14. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70320-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25130998 PubMed]
<!-- Presented at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30-June 3, 2008. -->
# Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012 Mar 20;30(9):930-5. Epub 2012 Feb 13. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.2079 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22331946 PubMed]
# Sakr H, Hamed RH, Anter AH, Yossef T. Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University). Med Oncol. 2013 Mar;30(1):457. Epub 2013 Jan 16. [https://link.springer.com/article/10.1007%2Fs12032-013-0457-3 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23322524 PubMed]
# '''Trial B2000:''' Delbaldo C, Serin D, Mousseau M, Greget S, Audhuy B, Priou F, Berdah JF, Teissier E, Laplaige P, Zelek L, Quinaux E, Buyse M, Piedbois P; Association Européenne de Recherche en Oncologie (AERO). A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000). Eur J Cancer. 2014 Jan;50(1):23-30. Epub 2013 Oct 29. [https://www.ejcancer.com/article/S0959-8049(13)00898-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24183460 PubMed]
# '''WSG-AGO EC-Doc:''' Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W. Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression. Ann Oncol. 2014 Aug;25(8):1551-7. Epub 2014 May 14. Erratum in: Ann Oncol. 2017 Nov 1;28(11):2899. [https://academic.oup.com/annonc/article/25/8/1551/273198 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24827128 PubMed]
# '''GIM2:''' Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet. 2015 May 9;385(9980):1863-72. Epub 2015 Mar 2. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62048-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25740286 PubMed]
# '''GONO-MIG5:''' Del Mastro L, Levaggi A, Michelotti A, Cavazzini G, Adami F, Scotto T, Piras M, Danese S, Garrone O, Durando A, Accortanzo V, Bighin C, Miglietta L, Pastorino S, Pronzato P, Castiglione F, Landucci E, Conte P, Bruzzi P. 5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial. Breast Cancer Res Treat. 2016 Jan;155(1):117-26. [http://link.springer.com/article/10.1007%2Fs10549-015-3655-1 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26661403 PubMed]
# '''ADEBAR:''' Janni W, Harbeck N, Rack B, Augustin D, Jueckstock J, Wischnik A, Annecke K, Scholz C, Huober J, Zwingers T, Friedl TW, Kiechle M. Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study. Br J Cancer. 2016 Apr 12;114(8):863-71. Epub 2016 Mar 31. [https://www.nature.com/articles/bjc201682 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984804/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27031854 PubMed] 
# '''HMFEC:''' Coombes RC, Kilburn LS, Tubiana-Mathieu N, Olmos T, Van Bochove A, Perez-Lopez FR, Palmieri C, Stebbing J, Bliss JM. Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer. Eur J Cancer. 2016 Jun;60:146-53. Epub 2016 Apr 26. [https://www.ejcancer.com/article/S0959-8049(16)00156-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27125966 PubMed]
# '''PANTHER:''' Foukakis T, von Minckwitz G, Bengtsson NO, Brandberg Y, Wallberg B, Fornander T, Mlineritsch B, Schmatloch S, Singer CF, Steger G, Egle D, Karlsson E, Carlsson L, Loibl S, Untch M, Hellström M, Johansson H, Anderson H, Malmström P, Gnant M, Greil R, Möbus V, Bergh J; Swedish Breast Cancer Group (SweBCG); German Breast Group (GBG); Austrian Breast & Colorectal Cancer Study Group (ABCSG). Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer: a randomized clinical trial. JAMA. 2016 Nov 8;316(18):1888-1896. [https://jamanetwork.com/journals/jama/fullarticle/2579866 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27825007 PubMed]
# '''UCBG-0106:''' Kerbrat P, Desmoulins I, Roca L, Levy C, Lortholary A, Marre A, Delva R, Rios M, Viens P, Brain É, Serin D, Edel M, Debled M, Campone M, Mourret-Reynier MA, Bachelot T, Foucher-Goudier MJ, Asselain B, Lemonnier J, Martin AL, Roché H. Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106). Eur J Cancer. 2017 Jul;79:166-175. Epub 2017 May 11. [https://www.ejcancer.com/article/S0959-8049(17)30822-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28501763 PubMed]
# '''APHINITY:''' von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017 Jul 13;377(2):122-131. Epub 2017 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1703643 link to original article] [https://www.nejm.org/doi/suppl/10.1056/NEJMoa1703643/suppl_file/nejmoa1703643_protocol.pdf link to supplementary protocol] '''contains verified protocol in supplementary protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538020/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28581356 PubMed]
# '''SOLD:''' Joensuu H, Fraser J, Wildiers H, Huovinen R, Auvinen P, Utriainen M, Nyandoto P, Villman KK, Halonen P, Granstam-Björneklett H, Lundgren L, Sailas L, Turpeenniemi-Hujanen T, Tanner M, Yachnin J, Ritchie D, Johansson O, Huttunen T, Neven P, Canney P, Harvey VJ, Kellokumpu-Lehtinen PL, Lindman H. Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trial. JAMA Oncol. 2018 Sep 1;4(9):1199-1206. [https://jamanetwork.com/journals/jamaoncology/fullarticle/2682589 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29852043 PubMed]

==Paclitaxel monotherapy, weekly {{#subobject:5218a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
T: '''<u>T</u>'''axol (Paclitaxel)
<br>P: '''<u>P</u>'''aclitaxel
<br>pT: '''<u>p</u>'''acli'''<u>T</u>'''axel
<br>wP: '''<u>w</u>'''eekly '''<u>P</u>'''aclitaxel
<br>wT: '''<u>w</u>'''eekly '''<u>T</u>'''axol (Paclitaxel)
===Variant #1, 80 mg/m<sup>2</sup> x 12 {{#subobject:6b14dd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa052122 Romond et al. 2005 (NSABP B-31)]
| style="background-color:#1a9851" |Phase III (C)
|[[Breast_cancer,_HER2-positive#TH_.28Taxol.29_2|TH]]
| style="background-color:#d73027" |Inferior OS
| style="background-color:#fee08b" |Might have inferior DASI score
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa052122 Romond et al. 2005 (NCCTG N9831)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#NCCTG_N9831|See link]]
|[[Complex_multipart_regimens#NCCTG_N9831|See link]]
| style="background-color:#d3d3d3" |
|-
| rowspan="2" |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743943/ Sparano et al. 2008 (ECOG E1199)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[Breast_cancer_-_historical#Paclitaxel_monotherapy.2C_q3wk|Paclitaxel q3wk]]
| style="background-color:#1a9850" |Superior OS
| style="background-color:#d3d3d3" |
|-
|2. [[#Docetaxel_monotherapy_2|Docetaxel q3wk]]<br> 3. [[#Docetaxel_monotherapy_2|Docetaxel weekly]]
| style="background-color:#d3d3d3" |Not reported
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.36.2079 Kelly et al. 2012]
| style="background-color:#1a9851" |Phase III (C)
|XT
|style="background-color:#ffffbf"|Seems not superior
| style="background-color:#d3d3d3" |
|-
| rowspan="3" |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494835/ Shulman et al. 2012 (CALGB 40101)]
| rowspan="3" style="background-color:#1a9851" |Phase III (E)
|[[#AC_2|1. AC]] x 4
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#d3d3d3" |
|-
|2. AC x 6
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#d3d3d3" |
|-
|3. Weekly paclitaxel x 18
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268253/ Budd et al. 2014 (SWOG S0221)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Paclitaxel monotherapy.2C_dose-dense_.28q2wk.29_2|ddT]] x 6
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2018.79.2028 Miller et al. 2018 (ECOG E5103)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#ECOG_E5103|See link]]
| style="background-color:#ffffbf" |[[Complex_multipart_regimens#ECOG_E5103|See link]]
| style="background-color:#d3d3d3" |
|-
|}
''Note: Patients in '''NSABP B-31''' and '''NCCTG N9831''' were HER2-positive. This paclitaxel dosing schedule was an option after 2003 in '''NSABP B-31''', and was used for all patients in '''NCCTG N9831'''. In '''CALGB 40101''', this is the dosing before a mid-protocol amendment in 2003. This is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*NSABP B-31, NCCTG N9831, ECOG E1199: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#AC_2|AC]] x 4
*Kelly et al. 2012: [[Surgery#Breast_cancer_surgery|Surgery]]
*SWOG S0221: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#ddAC_2|ddAC]] x 6 versus continuous AC
*ECOG E5103: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#AC_2|AC]] x 4 or [[#ddAC_2|ddAC]] x 4

====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per week

'''12-week course'''
====Subsequent treatment====
*NCCTG N9831: [[Breast_cancer,_HER2-positive#Trastuzumab_monotherapy_2|H]] x 52 versus no further treatment
*Kelly et al. 2012: [[#FEC_2|FEC]] x 4

===Variant #2, 100 mg/m<sup>2</sup> x 8 {{#subobject:d9efe7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jnci.oxfordjournals.org/content/100/11/805.long Martín et al. 2008 (GEICAM 9906)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#GEICAM_9906|See link]]
| style="background-color:#1a9850" |[[Complex_multipart_regimens#GEICAM_9906|See link]]
|-
|[http://jco.ascopubs.org/content/31/20/2593.long Martín et al. 2013 (GEICAM/2003-02)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#GEICAM.2F2003-02|See link]]
|style="background-color:#91cf60" |[[Complex_multipart_regimens#GEICAM.2F2003-02|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*GEICAM 9906: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#FEC_2|FEC]] x 4
*GEICAM/2003-02: [[Surgery#Breast_cancer_surgery|Surgery]], then [[#FAC_2|FAC]] x 4
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 100 mg/m<sup>2</sup> IV once per week

'''8 week course'''

===References===
<!-- no pre-pub disclosed -->
# '''NCCTG N9831:''' Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1673-84. [https://www.nejm.org/doi/full/10.1056/NEJMoa052122 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16236738 PubMed]
## '''Update:''' Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011 Sep 1;29(25):3366-73. Epub 2011 Jul 18. [http://ascopubs.org/doi/full/10.1200/JCO.2011.35.0868 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164242/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21768458 PubMed]
## '''Update:''' Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011 Dec 1;29(34):4491-7. Epub 2011 Oct 31. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.7045 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236650/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22042958 PubMed]
## '''Update:''' Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014 Nov 20;32(33):3744-52. [http://ascopubs.org/doi/full/10.1200/JCO.2014.55.5730 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226805/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25332249 PubMed]
## '''Update and HRQoL analysis:''' Ganz PA, Romond EH, Cecchini RS, Rastogi P, Geyer CE Jr, Swain SM, Jeong JH, Fehrenbacher L, Gross HM, Brufsky AM, Flynn PJ, Wahl TA, Seay TE, Wade JL 3rd, Biggs DD, Atkins JN, Polikoff J, Zapas JL, Mamounas EP, Wolmark N. Long-term follow-up of cardiac function and quality of life for patients in NSABP protocol B-31/NRG Oncology: a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2. J Clin Oncol. 2017 Dec 10;35(35):3942-3948. Epub 2017 Oct 26. [http://ascopubs.org/doi/full/10.1200/JCO.2017.74.1165 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721228/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29072977 PubMed]
<!-- Presented in part at the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 8–11, 2007, and the American Society of Clinical Oncology meeting, Chicago, June 1–4, 2005. -->
# '''ECOG E1199:''' Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008 Apr 17;358(16):1663-71. [https://www.nejm.org/doi/full/10.1056/NEJMoa0707056 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743943/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/18420499 PubMed]
## '''Update:''' Sparano JA, Zhao F, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE. Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer. J Clin Oncol. 2015 Jul 20;33(21):2353-60. Epub 2015 Jun 15. [http://jco.ascopubs.org/content/33/21/2353.full link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500829/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26077235 PubMed]
# '''GEICAM 9906:''' Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM; GEICAM 9906 Study Investigators. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. Epub 2008 May 27. [http://jnci.oxfordjournals.org/content/100/11/805.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18505968 PubMed]
<!-- Presented at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30-June 3, 2008. -->
# Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012 Mar 20;30(9):930-5. Epub 2012 Feb 13. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.2079 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22331946 PubMed]
# '''CALGB 40101:''' Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol. 2012 Nov 20;30(33):4071-6. Epub 2012 Jul 23. [http://jco.ascopubs.org/content/30/33/4071.long link to original article] '''contains verified protocol''' [http://jco.ascopubs.org/content/suppl/2012/07/23/JCO.2011.40.6405.DC1/Protocol.pdf link to study protocol PDF] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494835/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22826271 PubMed]
## '''Update:''' Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014 Aug 1;32(22):2311-7. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105484/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24934787 PubMed]
# '''GEICAM/2003-02:''' Martín M, Ruiz A, Ruiz Borrego M, Barnadas A, González S, Calvo L, Margelí Vila M, Antón A, Rodríguez-Lescure A, Seguí-Palmer MA, Muñoz-Mateu M, Dorca Ribugent J, López-Vega JM, Jara C, Espinosa E, Mendiola Fernández C, Andrés R, Ribelles N, Plazaola A, Sánchez-Rovira P, Salvador Bofill J, Crespo C, Carabantes FJ, Servitja S, Chacón JI, Rodríguez CA, Hernando B, Álvarez I, Carrasco E, Lluch A. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study. J Clin Oncol. 2013 Jul 10;31(20):2593-9. Epub 2013 Jun 3. [http://jco.ascopubs.org/content/31/20/2593.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23733779 PubMed]
# '''SWOG S0221:''' Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew DL, Gralow JR, Hortobagyi GN. SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol. 2015 Jan 1;33(1):58-64. Epub 2014 Nov 24. [http://ascopubs.org/doi/full/10.1200/JCO.2014.56.3296 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268253/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25422488 PubMed]
# '''ECOG E5103:''' Miller KD, O'Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA, Bloom S, Brufsky AM, Tevaarwerk AJ, Sparano JA, Le-Lindqwister NA, Hendricks CB, Northfelt DW, Dang CT, Sledge GW Jr. Double-blind phase III trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node-positive and high-risk lymph node-negative breast cancer (E5103). J Clin Oncol. 2018 Sep 1;36(25):2621-2629. Epub 2018 Jul 24. [http://ascopubs.org/doi/full/10.1200/JCO.2018.79.2028 link to original article] '''refers to ECOG E1199 protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30040523 PubMed]

==Paclitaxel monotherapy, dose-dense (q2wk) {{#subobject:8acb30|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ddT: '''<u>d</u>'''ose-'''<u>d</u>'''ense '''<u>T</u>'''axol (Paclitaxel)
<br>ddP: '''<u>d</u>'''ose-'''<u>d</u>'''ense '''<u>P</u>'''aclitaxel
===Variant #1, 175 mg/m<sup>2</sup> x 4 {{#subobject:d853ac|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/21/8/1431.long Citron et al. 2003 (CALGB 9741)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#CALGB_9741|See link]]
|[[Complex_multipart_regimens#CALGB_9741|See link]]
|-
|[http://jco.ascopubs.org/content/23/33/8340.long Burstein et al. 2005]
| style="background-color:#91cf61" |Non-randomized
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
| rowspan="3" |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494835/ Shulman et al. 2012 (CALGB 40101)]
| rowspan="3" style="background-color:#1a9851" |Phase III (E)
|[[#ddAC_2|1. ddAC]] x 4
| style="background-color:#ffffbf" |Seems not superior
|-
|2. ddAC x 6
| style="background-color:#ffffbf" |Seems not superior
|-
|3. ddT x 6
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757290/ Swain et al. 2013 (NSABP B-38)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#NSABP_B-38|See link]]
|[[Complex_multipart_regimens#NSABP_B-38|See link]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62048-1/fulltext Del Mastro et al. 2015 (GIM2)]
|style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#GIM2|See link]]
|[[Complex_multipart_regimens#GIM2|See link]]
|-
|}
''Note: in '''CALGB 40101''', this is the dosing after a mid-protocol amendment in 2003.''
====Preceding treatment====
*CALGB 9741: [[#ddA|ddA]] x 4 or [[#ddAC_2|ddAC]] x 4
*Burstein et al. 2005: [[#ddAC|Neoadjuvant ddAC]], then [[Surgery#Breast_cancer_surgery|surgery]] or [[Surgery#Breast_cancer_surgery|surgery]], then [[#ddAC_2|adjuvant ddAC]]
*CALGB 40101: [[Surgery#Breast_cancer_surgery|Surgery]], within 90 days
*NSABP B-38: [[#ddAC_2|ddAC]] x 4
*GIM2: [[#ddEC|ddEC]] x 4 versus [[#ddFEC|ddFEC]] x 4

====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1

====Supportive medications====
*[[Diphenhydramine (Benadryl)]] 12.5 to 50 mg IV 30 to 60 minutes prior to paclitaxel
*One of the following H2 blockers:
**[[Ranitidine (Zantac)]] 50 mg IV 30 to 60 minutes prior to paclitaxel
**[[Cimetidine (Tagamet)]] 300 mg IV 30 to 60 minutes prior to paclitaxel
**[[Famotidine (Pepcid)]] 20 mg IV 30 to 60 minutes prior to paclitaxel
*One of the following dexamethasone choices:
**[[Dexamethasone (Decadron)]] 10 mg IV less than 60 minutes prior to paclitaxel
**[[Dexamethasone (Decadron)]] 10 mg PO greater than 60 minutes prior to paclitaxel
**[[Dexamethasone (Decadron)]] 20 mg PO 6 hours and 12 hour prior to paclitaxel
*Recommended growth factor support with one of the following:
**[[Filgrastim (Neupogen)]] 5 mcg/kg (rounded to 300 mcg or 480 mcg, whichever is closer) SC once per day on days 3 to 10; may be discontinued before day 10 if ANC has recovered to an "acceptable range, as determined by the treating physician" 
**[[Sargramostim (Leukine)]] 250 to 500 mcg/m<sup>2</sup> SC once per day on days 3 to 10; may be discontinued before day 10 if ANC has recovered to an "acceptable range, as determined by the treating physician" 
**[[Pegfilgrastim (Neulasta)]] 6 mg SC, administered once 24 to 36 hours after chemotherapy
***GIM2: a mid-protocol amendment suggested giving the pegilgrastim at least 72 h after chemotherapy

'''14-day cycle for 4 cycles'''

====Subsequent treatment====
*CALGB 9741: [[#ddC|ddC]] x 4 (if preceded by ddA)
===Variant #2, 175 mg/m<sup>2</sup> x 6 {{#subobject:33516a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268253/ Budd et al. 2014 (SWOG S0221)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel_monotherapy.2C_weekly_2|Weekly paclitaxel]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#ddAC_2|ddAC]] x 6 versus continuous AC
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1
====Supportive medications====
*[[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2

'''14-day cycle for 6 cycles'''

===Variant #3, 200 mg/m<sup>2</sup> x 4 {{#subobject:6a0bb6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.karger.com/Article/Abstract/86987 Kahan et al. 2005]
| style="background-color:#91cf61" |Phase II
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#ddA|ddA]] x 4
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours day 1

====Supportive medications====
*[[Filgrastim (Neupogen)]]

'''14-day cycle for 4 cycles'''
====Subsequent treatment====
*[[#ddC|ddC]]

===References===
# '''CALGB 9741:''' Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003 Apr 15;21(8):1431-9. Epub 2003 Feb 13. [http://jco.ascopubs.org/content/21/8/1431.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12668651 PubMed]
# Kahan Z, Uhercsak G, Hajnal-Papp R, Boda K, Thurzo L. Dose-dense sequential adriamycin-paclitaxel-cyclophosphamide chemotherapy is well tolerated and safe in high-risk early breast cancer. Oncology. 2005;68(4-6):446-53. Epub 2005 Jul 13. [http://www.karger.com/Article/Abstract/86987 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16020975 PubMed]
## '''Update:''' Kelemen G, Uhercsák G, Ormándi K, Eller J, Thurzó L, Kahán Z. Long-term efficiency and toxicity of adjuvant dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy in high-risk breast cancer. Oncology. 2010;78(3-4):271-3. Epub 2010 Jun 7. [http://content.karger.com/produktedb/produkte.asp?DOI=000315734&typ=pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20523088 PubMed]
# Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20;23(33):8340-7. [http://jco.ascopubs.org/content/23/33/8340.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16293865 PubMed]
# '''CALGB 40101:''' Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol. 2012 Nov 20;30(33):4071-6. Epub 2012 Jul 23. [http://jco.ascopubs.org/content/30/33/4071.long link to original article] '''contains verified protocol''' [http://jco.ascopubs.org/content/suppl/2012/07/23/JCO.2011.40.6405.DC1/Protocol.pdf link to study protocol PDF] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494835/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22826271 PubMed]
## '''Update:''' Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014 Aug 1;32(22):2311-7. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105484/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24934787 PubMed]
# '''NSABP B-38:''' Swain SM, Tang G, Geyer CE Jr, Rastogi P, Atkins JN, Donnellan PP, Fehrenbacher L, Azar CA, Robidoux A, Polikoff JA, Brufsky AM, Biggs DD, Levine EA, Zapas JL, Provencher L, Northfelt DW, Paik S, Costantino JP, Mamounas EP, Wolmark N. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol. 2013 Sep 10;31(26):3197-204. Epub 2013 Aug 12. [http://ascopubs.org/doi/full/10.1200/JCO.2012.48.1275 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757290/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23940225 PubMed]
# '''SWOG S0221:''' Budd GT, Barlow WE, Moore HC, Hobday TJ, Stewart JA, Isaacs C, Salim M, Cho JK, Rinn KJ, Albain KS, Chew HK, Burton GV, Moore TD, Srkalovic G, McGregor BA, Flaherty LE, Livingston RB, Lew DL, Gralow JR, Hortobagyi GN. SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol. 2015 Jan 1;33(1):58-64. Epub 2014 Nov 24. [http://ascopubs.org/doi/full/10.1200/JCO.2014.56.3296 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268253/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25422488 PubMed]
# '''GIM2:''' Del Mastro L, De Placido S, Bruzzi P, De Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò C, Valle E, Garrone O, Puglisi F, Montemurro F, Barni S, Ardizzoni A, Gamucci T, Colantuoni G, Giuliano M, Gravina A, Papaldo P, Bighin C, Bisagni G, Forestieri V, Cognetti F; Gruppo Italiano Mammella (GIM) investigators. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet. 2015 May 9;385(9980):1863-72. Epub 2015 Mar 2. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)62048-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25740286 PubMed]

==TAC (Taxotere) {{#subobject:ed77a6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TAC: '''<u>T</u>'''axotere (Docetaxel), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide
<br>ACT: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, '''<u>T</u>'''axotere (Docetaxel)
===Variant #1, 4 cycles {{#subobject:36e78d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935316/ Swain et al. 2010 (NSABP B-30)]
| style="background-color:#1a9851" |Phase III (C)
|[[Complex_multipart_regimens#NSABP_B-30|See link]]
| style="background-color:#fee08b" |[[Complex_multipart_regimens#NSABP_B-30|See link]]
|-
|}
''Note: this was a mid-protocol dosing amendment.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV over 15 minutes once on day 1
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV over 1 to 5 minutes once on day 1

'''21-day cycle for 4 cycles'''

===Variant #2, 6 cycles {{#subobject:9660e9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa043681 Martin et al. 2005 (BCIRG 001)]
| style="background-color:#1a9851" |Phase III (E)
|[[#FAC_2|FAC]]
| style="background-color:#1a9850" |Superior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa0910320 Martín et al. 2010 (GEICAM 9805)]
| style="background-color:#1a9851" |Phase III (E)
|[[#FAC_2|FAC]]
| style="background-color:#1a9850" |Superior DFS
|-
|[http://jco.ascopubs.org/content/29/29/3877.long Eiermann et al. 2011 (BCIRG-005)]
| style="background-color:#1a9851" |Phase III (C)
|[[#AC_2|AC]], then [[#Docetaxel_monotherapy_2|T]]
| style="background-color:#ffffbf" |Seems not superior
|-
| rowspan="2" |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757290/ Swain et al. 2013 (NSABP B-38)]
| rowspan="2" style="background-color:#1a9851" |Phase III (C)
|[[#ddAC_2|1. ddAC]], then [[#Paclitaxel monotherapy.2C_dose-dense_.28q2wk.29_2|ddP]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[[#ddAC_2|2. ddAC]], then ddPG
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549453/ Blum et al. 2017 (USOR 06-090; NSABP-46-I/USOR 07132; NSABP B-49)]
| style="background-color:#1a9851" |Phase III (C)
|[[#DC|TC]]
| style="background-color:#91cf60" |Seems to have superior IDFS
|-
|}
''Note: Blum et al. 2017 is a pooled analysis of three RCTs, some of which had arms other than TAC and TC. Refer to the paper for further details.''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1, '''given third, one hour after cyclophosphamide'''
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV over 15 minutes once on day 1, '''given first'''
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV over 1 to 5 minutes once on day 1, '''given second'''

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg PO every 12 hours x 6 total doses, starting the day before treatment
*[[Ciprofloxacin (Cipro)]] 500 mg PO twice per day on days 5 to 14 of every cycle (prophylaxis)
*G-CSF not originally routinely administered unless patients had febrile neutropenia, but some guidelines recommend one of the following:
**[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 4 to 11
**[[Lenograstim (Granocyte)]] 150 mcg/m<sup>2</sup> SC once per day on days 4 to 11

'''21-day cycle for 6 cycles'''

===References===
<!-- no pre-pub disclosed -->
# '''BCIRG 001:''' Martín M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornander T, Hainsworth J, Coleman R, Vinholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005 Jun 2;352(22):2302-13. [https://www.nejm.org/doi/full/10.1056/NEJMoa043681 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15930421 PubMed]
## '''Update:''' Mackey JR, Martín M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C; TRIO/BCIRG 001 investigators. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013 Jan;14(1):72-80. Epub 2012 Dec 12. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70525-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23246022 PubMed]
# '''NSABP B-30:''' Swain SM, Jeong JH, Geyer CE Jr, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land SR, Ganz PA, Wolmark N. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010 Jun 3;362(22):2053-65. [https://www.nejm.org/doi/10.1056/NEJMoa0909638 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935316/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20519679 PubMed]
<!-- no pre-pub disclosed -->
# '''GEICAM 9805:''' Martín M, Seguí MA, Antón A, Ruiz A, Ramos M, Adrover E, Aranda I, Rodríguez-Lescure A, Grosse R, Calvo L, Barnadas A, Isla D, Martinez del Prado P, Ruiz Borrego M, Zaluski J, Arcusa A, Muñoz M, López Vega JM, Mel JR, Munarriz B, Llorca C, Jara C, Alba E, Florián J, Li J, López García-Asenjo JA, Sáez A, Rios MJ, Almenar S, Peiró G, Lluch A; GEICAM 9805 Investigators. Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med. 2010 Dec 2;363(23):2200-10. [https://www.nejm.org/doi/full/10.1056/NEJMoa0910320 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21121833 PubMed]
<!-- Presented in part at the 28th Annual San Antonio Breast Cancer Symposia, December 8-11, 2005, San Antonio, TX, and at the 31st Annual San Antonio Breast Cancer Symposia, December 10-14, 2008, San Antonio, TX. -->
# '''BCIRG-005:''' Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martín M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press M, Sauter G, Lindsay MA, Riva A, Buyse M, Drevot P, Taupin H, Mackey JR. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol. 2011 Oct 10;29(29):3877-84. Epub 2011 Sep 12. [http://jco.ascopubs.org/content/29/29/3877.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21911726 PubMed]
## '''Update:''' Mackey JR, Pieńkowski T, Crown J, Sadeghi S, Martín M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press MF, Sauter G, Lindsay M, Houé V, Buyse M, Drevot P, Hitier S, Bensfia S, Eiermann W; Translational Research In Oncology (TRIO)/ Breast Cancer International Research Group (BCIRG)-005 investigators. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial. Ann Oncol. 2016 Jun;27(6):1041-7. Epub 2016 Mar 2. [https://academic.oup.com/annonc/article/27/6/1041/2240122 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26940688 PubMed]
# '''NSABP B-38:''' Swain SM, Tang G, Geyer CE Jr, Rastogi P, Atkins JN, Donnellan PP, Fehrenbacher L, Azar CA, Robidoux A, Polikoff JA, Brufsky AM, Biggs DD, Levine EA, Zapas JL, Provencher L, Northfelt DW, Paik S, Costantino JP, Mamounas EP, Wolmark N. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol. 2013 Sep 10;31(26):3197-204. Epub 2013 Aug 12. [http://ascopubs.org/doi/full/10.1200/JCO.2012.48.1275 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757290/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23940225 PubMed]
# '''USOR 06-090; NSABP-46-I/USOR 07132; NSABP B-49:''' Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, Robert NJ, Hopkins JO, O'Shaughnessy JA, Dang CT, Gómez HL, Fehrenbacher L, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Jeong JH, Colangelo LH, Swain SM, Mamounas EP, Jones SE, Wolmark N. Anthracyclines in early breast cancer: The ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017 Aug 10;35(23):2647-2655. Epub 2017 Apr 11. [http://ascopubs.org/doi/full/10.1200/JCO.2016.71.4147 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549453/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28398846 PubMed]

==Vinorelbine monotherapy {{#subobject:84c1e0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
V: '''<u>V</u>'''inorelbine
===Regimen {{#subobject:712969|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[https://www.nejm.org/doi/full/10.1056/NEJMoa053028 Joensuu et al. 2006 (FinHer)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[#Docetaxel_monotherapy_2|Docetaxel]]
| style="background-color:#d73027" |Inferior DDFS
|-
|2. [[Breast_cancer,_HER2-positive#TH_.28Taxotere.29_2|TH (Taxotere)]]<br> 3. [[Breast_cancer,_HER2-positive#VH|VH]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Patients without HER2/neu amplification were only randomized to this arm verus the  [[#Docetaxel_monotherapy_2|docetaxel arm]].''
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] as follows:
**Cycles 1 & 2: 25 mg/m<sup>2</sup> IV over 5 to 10 minutes once per day on days 1, 8, 15
**Cycle 3: 25 mg/m<sup>2</sup> IV over 5 to 10 minutes once per day on days 1 & 8

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[#FEC_2|FEC]]

===References===
<!-- no pre-pub disclosed -->
# '''FinHer:''' Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johansson K, Jääskeläinen AS, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, Isola J; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006 Feb 23;354(8):809-20. [https://www.nejm.org/doi/full/10.1056/NEJMoa053028 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16495393 PubMed]
## '''Update:''' Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009 Dec 1;27(34):5685-92. [http://ascopubs.org/doi/full/10.1200/JCO.2008.21.4577 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19884557 PubMed]

=Metastatic disease, first-line chemotherapy=
'''''Note: in many of these regimens, patients were allowed to have received (neo)adjuvant chemotherapy and hormonal therapy (when applicable). These are first-line regimens in the metastatic setting, with a few being specifically for the locally advanced but unresectable setting.''
==AC {{#subobject:843320|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
AC: '''<u>A</u>'''driamycin (Doxorubicin) & '''<u>C</u>'''yclophosphamide
===Variant #1, 40/500 {{#subobject:2e4988|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://academic.oup.com/annonc/article/20/7/1210/344738 Katsumata et al. 2009 (JCOG9802)]
|rowspan=2 style="background-color:#1a9851" |Phase III (C)
|1. AC-D
| style="background-color:#ffffbf" |Seems not superior
|-
|[[#Docetaxel_monotherapy_3|2. Docetaxel]]
| style="background-color:#fee08b" |Might have inferior OS
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 40 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 cycles'''

===Variant #2, 40/800 (PO) {{#subobject:136e1b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197507)36:1%3C90::AID-CNCR2820360104%3E3.0.CO;2-H/abstract Jones et al. 1975]
| style="background-color:#91cf61" |Non-randomized
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19820301)49:5%3C835::AID-CNCR2820490502%3E3.0.CO;2-Z Tranum et al. 1982]
| style="background-color:#1a9851" |Randomized (E)
|1. [[#FAC_3|FAC]]<br> 2. A, then COMFP
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 40 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 200 mg/m<sup>2</sup>/day PO in divided doses on days 3 to 6

'''21- to 28-day cycles'''

===Variant #3, 50/750 {{#subobject:2e4755|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1986.4.2.186 Forbes 1986]
| style="background-color:#1a9851" |Randomized (C)
|AC-TAM
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 750 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 9 cycles'''

===Variant #4, 60/600 {{#subobject:2e4988|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM200103153441101 Slamon et al. 2001]
| style="background-color:#1a9851" |Phase III (C)
|[[#ACH|ACH]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[http://ascopubs.org/doi/10.1200/JCO.2002.11.005 Biganzoli et al. 2002 (EORTC 10961)]
| style="background-color:#1a9851" |Phase III (C)
|[[#AT_.28Taxol.29_2|AT (Taxol)]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://jco.ascopubs.org/content/21/6/968.long Nabholtz et al. 2003 (TAX 306)]
| style="background-color:#1a9851" |Phase III (C)
|[[#AT_.28Taxotere.29|AT (Taxotere)]]
| style="background-color:#fc8d59" |Seems to have inferior TTP
|-
|}
''Note: patients in Slamon et al. 2001 had not previously received adjuvant (postoperative) therapy with an anthracycline.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles (see note)'''

===Variant #5, with range {{#subobject:900e58|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 Robert et al. 2011 (RIBBON-1)]
| style="background-color:#1a9851" |Phase III (C)
|[[#AC_.26_Bevacizumab|AC & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 50 to 60 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 500 to 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 8 cycles'''
===References===
# Jones SE, Durie BG, Salmon SE. Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer. 1975 Jul;36(1):90-7. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197507)36:1%3C90::AID-CNCR2820360104%3E3.0.CO;2-H/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1203853 PubMed]
# Tranum BL, McDonald B, Thigpen T, Vaughn C, Wilson H, Maloney T, Costanzi J, Bickers J, el Mawli NG, Palmer R, Hoogstraten B, Heilburn L, Rasmusen S. Adriamycin combinations in advanced breast cancer: a Southwest Oncology Group Study. Cancer. 1982 Mar 1;49(5):835-9. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19820301)49:5%3C835::AID-CNCR2820490502%3E3.0.CO;2-Z link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7037152 PubMed]
# Forbes JF; The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J Clin Oncol. 1986 Feb;4(2):186-93. [http://ascopubs.org/doi/abs/10.1200/JCO.1986.4.2.186 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2868074 PubMed]
# Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. [https://www.nejm.org/doi/full/10.1056/NEJM200103153441101 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11248153 PubMed]
# '''EORTC 10961:''' Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol. 2002 Jul 15;20(14):3114-21. [http://ascopubs.org/doi/10.1200/JCO.2002.11.005 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12118025 PubMed]
# '''TAX 306:''' Nabholtz JM, Falkson C, Campos D, Szanto J, Martín M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P; TAX 306 Study Group. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003 Mar 15;21(6):968-75. [http://jco.ascopubs.org/content/21/6/968.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12637459 PubMed]
# '''JCOG9802:''' Katsumata N, Watanabe T, Minami H, Aogi K, Tabei T, Sano M, Masuda N, Andoh J, Ikeda T, Shibata T, Takashima S. Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802). Ann Oncol. 2009 Jul;20(7):1210-5. Epub 2009 Mar 2. [https://academic.oup.com/annonc/article/20/7/1210/344738 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19254942 PubMed]
<!-- Presented in part at the 45th Annual Meeting of the American Society for Clinical Oncology, May 29-June 2, 2009, Orlando, FL, and at the 15th Congress of the European Cancer Organisation and 34th Congress of the European Society for Medical Oncology Multidisciplinary Congress, September 20-24, 2009, Berlin, Germany. -->
# '''RIBBON-1:''' Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 1;29(10):1252-60. Epub 2011 Mar 7. [http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21383283 PubMed]

==AC & Bevacizumab {{#subobject:843320|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
AC & Bevacizumab: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, Bevacizumab
===Variant #1, with range {{#subobject:900e58|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 Robert et al. 2011 (RIBBON-1)]
| style="background-color:#1a9851" |Phase III (E)
|[[#AC_3|AC]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 50 to 60 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 500 to 600 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycle for up to 8 cycles'''
====Subsequent treatment====
*[[#Bevacizumab_monotherapy_2|Bevacizumab]] maintenance, if no PD

===References===
<!-- Presented in part at the 45th Annual Meeting of the American Society for Clinical Oncology, May 29-June 2, 2009, Orlando, FL, and at the 15th Congress of the European Cancer Organisation and 34th Congress of the European Society for Medical Oncology Multidisciplinary Congress, September 20-24, 2009, Berlin, Germany. -->
# '''RIBBON-1:''' Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 1;29(10):1252-60. Epub 2011 Mar 7. [http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21383283 PubMed]

==AT (Taxol) {{#subobject:86ac2d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
AT: '''<u>A</u>'''driamycin (Doxorubicin) & '''<u>T</u>'''axol (Paclitaxel)
===Variant #1, 50/150 {{#subobject:bf9bd0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2003.08.013 Sledge et al. 2003 (ECOG E1193)]
| style="background-color:#1a9851" |Phase III (E)
|1. [[ #Doxorubicin_monotherapy_2|Doxorubicin]]<br> 2. [[#Paclitaxel_monotherapy.2C_q3wk|Paclitaxel]]
| style="background-color:#1a9850" |Superior TTF
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] as follows, '''given first''':
**Cycles 1 to 8: 50 mg/m<sup>2</sup> IV once on day 1
*[[Paclitaxel (Taxol)]] 150 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1, '''given second, 3 hours after doxorubicin'''

'''21-day cycles'''

===Variant #2, 50/220 {{#subobject:adad22|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.2001.19.6.1707 Jassem et al. 2001]
| style="background-color:#1a9851" |Phase III (E)
|[[#FAC_3|FAC]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Paclitaxel (Taxol)]] 220 mg/m<sup>2</sup> IV over 3 hours once on day 2

'''21-day cycle for up to 8 cycles'''

===Variant #3, 60/200 {{#subobject:91549a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.06.072 Schmid et al. 2005]
| style="background-color:#1a9851" |Phase III (C)
|Tandem auto HSCT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV over 15 minutes once on day 1
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1

'''21-day cycle for up to 6 cycles'''

===Variant #4, with range {{#subobject:1f6e13|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/13/11/2688.long Gianni et al. 1995]
| style="background-color:#91cf61" |Non-randomized
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Paclitaxel (Taxol)]] 125 to 200 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===References===
# Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C, Stefanelli M, Valagussa P, Bonadonna G. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol. 1995 Nov;13(11):2688-99. [http://jco.ascopubs.org/content/13/11/2688.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7595726 PubMed]
# Jassem J, Pieńkowski T, Płuzańska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, Berzins J, Nagykalnai T, Wigler N, Renard J, Munier S, Weil C; Central & Eastern Europe and Israel Pacitaxel Breast Cancer Study Group. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol. 2001 Mar 15;19(6):1707-15. [http://ascopubs.org/doi/10.1200/JCO.2001.19.6.1707 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11251000 PubMed]
# '''ECOG E1193:''' Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003 Feb 15;21(4):588-92. [http://ascopubs.org/doi/full/10.1200/JCO.2003.08.013 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12586793 PubMed]
# Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W, Hausmaninger H, Wischnewsky M, Possinger K. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol. 2005 Jan 20;23(3):432-40. [http://ascopubs.org/doi/full/10.1200/JCO.2005.06.072 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15659490 PubMed]

==AT (Taxotere) {{#subobject:145802|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
AT: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>T</u>'''axotere (Docetaxel)
===Regimen {{#subobject:9c6b82|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/21/6/968.long Nabholtz et al. 2003 (TAX 306)]
| style="background-color:#1a9851" |Phase III (E)
|[[#AC_3|AC]]
| style="background-color:#91cf60" |Seems to have superior TTP
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2004.08.125 Alba et al. 2004 (GEICAM-9903)]
| style="background-color:#1a9851" |Phase III (C)
|A, then T (Taxotere)
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/10.1200/JCO.2005.06.236 Bontenbal et al. 2005]
| style="background-color:#1a9851" |Phase III (E)
|[[#FAC_3|FAC]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://www.karger.com/Article/Abstract/320625 Stemmler et al. 2010 (D4)]
| style="background-color:#1a9851" |Phase III (C)
|AT (Taxotere), weekly docetaxel
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 cycles (GEICAM-9903 & Bontenbal et al. 2005) or 8 cycles (TAX 306 & D4)'''

===References===
# '''TAX 306:''' Nabholtz JM, Falkson C, Campos D, Szanto J, Martín M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski M, Vorobiof D, Leonard R, Kennedy I, Azli N, Murawsky M, Riva A, Pouillart P; TAX 306 Study Group. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003 Mar 15;21(6):968-75. [http://jco.ascopubs.org/content/21/6/968.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12637459 PubMed]
# '''GEICAM-9903:''' Alba E, Martín M, Ramos M, Adrover E, Balil A, Jara C, Barnadas A, Fernández-Aramburo A, Sánchez-Rovira P, Amenedo M, Casado A; Spanish Breast Cancer Research Group. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol. 2004 Jul 1;22(13):2587-93. [http://ascopubs.org/doi/full/10.1200/JCO.2004.08.125 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15226326 PubMed]
# Bontenbal M, Creemers GJ, Braun HJ, de Boer AC, Janssen JT, Leys RB, Ruit JB, Goey SH, van der Velden PC, Kerkhofs LG, Schothorst KL, Schmitz PI, Bokma HJ, Verweij J, Seynaeve C; Dutch Community Setting Trial for the Clinical Trial Group. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol. 2005 Oct 1;23(28):7081-8. [http://ascopubs.org/doi/10.1200/JCO.2005.06.236 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16192591 PubMed]
# '''D4:''' Stemmler HJ, Harbeck N, Gröll de Rivera I, Vehling Kaiser U, Rauthe G, Abenhardt W, Artmann A, Sommer H, Meerpohl HG, Kiechle M, Heinemann V. Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancer. Oncology. 2010;79(3-4):204-10. Epub 2011 Mar 1. [https://www.karger.com/Article/Abstract/320625 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21358208 PubMed]

==Capecitabine monotherapy {{#subobject:842c42|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 650 mg/m<sup>2</sup> PO twice per day, continuous {{#subobject:45bb7c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[http://jco.ascopubs.org/content/29/34/4498.long Stockler et al. 2011 (ANZ 0001)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|[[#CMF_2|1. CMF]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|2. Intermittent Capecitabine
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 650 mg/m<sup>2</sup> PO twice per day

'''21-day cycles'''

===Variant #2, 1000 mg/m<sup>2</sup> PO twice per day {{#subobject:674c2d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/10/2155.long Bajetta et al. 2005]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 Robert et al. 2011 (RIBBON-1)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Capecitabine_.26_Bevacizumab|Capecitabine & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
| rowspan="2" |[http://jco.ascopubs.org/content/29/34/4498.long Stockler et al. 2011 (ANZ 0001)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|[[#CMF_2|1. CMF]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|2. Continuous Capecitabine
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433520/ Smorenburg et al. 2014 (OMEGA)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Doxorubicin_pegylated_liposomal_monotherapy|PLD]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14

'''21-day cycle for 8 cycles (OMEGA) or indefinitely'''

===Variant #3, 1250 mg/m<sup>2</sup> PO twice per day {{#subobject:fb2810|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/10/2155.long Bajetta et al. 2005]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5222915/ Harbeck et al. 2016 (PELICAN)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Doxorubicin_pegylated_liposomal_monotherapy|Pegylated liposomal doxorubicin]]
| style="background-color:#ffffbf" |Inconclusive whether non-inferior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1706450 Robson et al. 2017 (OlympiAD)]
| style="background-color:#1a9851" |Phase III (C)
|[[Breast_cancer,_BRCA-mutated#Olaparib_monotherapy|Olaparib]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Patients in '''GBG 26/BIG 3-05''' had HER2-positive disease. Patients in '''OlympiAD''' had confirmed deleterious or suspected deleterious germline BRCA mutation.''
====Preceding treatment====
*JO21095: [[#Docetaxel_monotherapy_4|Docetaxel, with PD]]
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1250 mg/m<sup>2</sup> PO twice per day on days 1 to 14

'''21-day cycles'''

===References===
# Bajetta E, Procopio G, Celio L, Gattinoni L, Della Torre S, Mariani L, Catena L, Ricotta R, Longarini R, Zilembo N, Buzzoni R. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol. 2005 Apr 1;23(10):2155-61. Epub 2005 Feb 14. [http://jco.ascopubs.org/content/23/10/2155.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15710946 PubMed]
<!-- Presented in part at the 45th Annual Meeting of the American Society for Clinical Oncology, May 29-June 2, 2009, Orlando, FL, and at the 15th Congress of the European Cancer Organisation and 34th Congress of the European Society for Medical Oncology Multidisciplinary Congress, September 20-24, 2009, Berlin, Germany. -->
# '''RIBBON-1:''' Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 1;29(10):1252-60. Epub 2011 Mar 7. [http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21383283 PubMed]
<!-- Presented in part at the 29th Annual San Antonio Breast Cancer Symposium, December 14-17, 2006, San Antonio, TX, and 43rd Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL. -->
# '''ANZ 0001:''' Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, Van Hazel G, Wilcken NR, Grimison PS, Nowak AK, Gainford MC, Fong A, Paksec L, Sourjina T, Zannino D, Gebski V, Simes RJ, Forbes JF, Coates AS. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol. 2011 Dec 1;29(34):4498-504. Epub 2011 Oct 24. [http://jco.ascopubs.org/content/29/34/4498.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22025143 PubMed]
# '''OMEGA:''' Smorenburg CH, de Groot SM, van Leeuwen-Stok AE, Hamaker ME, Wymenga AN, de Graaf H, de Jongh FE, Braun JJ, Los M, Maartense E, van Tinteren H, Nortier JW, Seynaeve C. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG. Ann Oncol. 2014 Mar;25(3):599-605. Epub 2014 Feb 6. [https://academic.oup.com/annonc/article/25/3/599/149516 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433520/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24504445 PubMed]
# '''PELICAN:''' Harbeck N, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller L, Otremba BJ, Waldenmaier D, Dorn J, Warm M, Scholz M, Untch M, de Wit M, Barinoff J, Lück HJ, Harter P, Augustin D, Harnett P, Beckmann MW, Al-Batran SE; PELICAN Investigators. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. Breast Cancer Res Treat. 2017 Jan;161(1):63-72. Epub 2016 Oct 31. [https://link.springer.com/article/10.1007%2Fs10549-016-4033-3 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5222915/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27798749 PubMed]
# '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1706450 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28578601 PubMed]

==Capecitabine & Bevacizumab {{#subobject:14a8f1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:b1de3e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 Robert et al. 2011 (RIBBON-1)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Capecitabine_monotherapy_2|Capecitabine]]
| style="background-color:#1a9850" |Superior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70566-1/fulltext Lang et al. 2013 (TURANDOT)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel_.26_Bevacizumab|Paclitaxel & Bevacizumab]]
| style="background-color:#eeee01" |Non-inferior OS (*)
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788680/ Welt et al. 2016 (CARIN)]
| style="background-color:#1a9851" |Phase III (C)
|Capecitabine, Vinorelbine, Bevacizumab
| style="background-color:#fee08b" |Might have inferior PFS
|-
|}
''Note: efficacy for TURANDOT is based on the 2016 update.''
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''

===References===
<!-- Presented in part at the 45th Annual Meeting of the American Society for Clinical Oncology, May 29-June 2, 2009, Orlando, FL, and at the 15th Congress of the European Cancer Organisation and 34th Congress of the European Society for Medical Oncology Multidisciplinary Congress, September 20-24, 2009, Berlin, Germany. -->
# '''RIBBON-1:''' Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 1;29(10):1252-60. Epub 2011 Mar 7. [http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21383283 PubMed]
# '''TURANDOT:''' Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C; Central European Cooperative Oncology Group. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol. 2013 Feb;14(2):125-33. Epub 2013 Jan 10. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70566-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23312888 PubMed]
## '''Update:''' Zielinski C, Láng I, Inbar M, Kahán Z, Greil R, Beslija S, Stemmer SM, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Petruzelka L, Eniu A, Nisenbaum B, Dank M, Anghel R, Messinger D, Brodowicz T; TURANDOT investigators. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncol. 2016 Sep;17(9):1230-9. Epub 2016 Aug 5. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30154-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27501767 PubMed]
# '''CARIN:''' Welt A, Marschner N, Lerchenmueller C, Decker T, Steffens CC, Koehler A, Depenbusch R, Busies S, Hegewisch-Becker S. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial. Breast Cancer Res Treat. 2016 Feb;156(1):97-107. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788680/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26927446 PubMed]

==Capecitabine & Docetaxel {{#subobject:9d5b30|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CD: '''<u>C</u>'''apecitabine & '''<u>D</u>'''ocetaxel
<br>TX: '''<u>T</u>'''axotere (Docetaxel) & '''<u>X</u>'''eloda (Capecitabine)
===Regimen {{#subobject:acd1c7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/22/5/1094/178774 Seidman et al. 2010]
| style="background-color:#1a9851" |Phase III (C)
|[[#Docetaxel_.26_Gemcitabine|GD]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.29492 Wang et al. 2015]
| style="background-color:#1a9851" |Phase III (C)
|NX
| style="background-color:#ffffbf" |Inconclusive whether non-inferior
|-
|}
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 8 cycles (Wang et al. 2015) or indefinitely'''

====Subsequent treatment====
*Seidman et al. 2010, upon progression: [[#Gemcitabine_monotherapy_2|Gemcitabine]]
*Wang et al. 2015: Capecitabine maintenance

===References===
# Seidman AD, Brufsky A, Ansari RH, Hart LL, Stein RS, Schwartzberg LS, Stewart JF, Russell CA, Chen SC, Fein LE, De La Cruz Vargas JA, Kim SB, Cavalheiro J, Zhao L, Gill JF, Obasaju CK, Orlando M, Tai DF. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Ann Oncol. 2011 May;22(5):1094-101. Epub 2010 Nov 17. [https://academic.oup.com/annonc/article/22/5/1094/178774 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21084429 PubMed]
# Wang J, Xu B, Yuan P, Ma F, Li Q, Zhang P, Cai R, Fan Y, Luo Y, Li Q. Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: phase 3 randomized trial. Cancer. 2015 Oct 1;121(19):3412-21. Epub 2015 Jun 19. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.29492 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26096296 PubMed]

==Capecitabine & Paclitaxel {{#subobject:bd0f63|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TX: '''<u>T</u>'''axol (Paclitaxel), '''<u>X</u>'''eloda (Capecitabine)
===Regimen {{#subobject:74e9d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/24/27/4384.long Blum et al. 2006]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 825 mg/m<sup>2</sup> (rounded to nearest 500 mg) PO twice per day on days 1 to 14
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycles'''

===References===
# Blum JL, Dees EC, Chacko A, Doane L, Ethirajan S, Hopkins J, McMahon R, Merten S, Negron A, Neubauer M, Ilegbodu D, Boehm KA, Asmar L, O'Shaughnessy JA. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2006 Sep 20;24(27):4384-90. Epub 2006 Aug 22. [http://jco.ascopubs.org/content/24/27/4384.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16926223 PubMed]

==Capecitabine & Paclitaxel, nanoparticle albumin-bound {{#subobject:821a8e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e2b0d2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.clinical-breast-cancer.com/article/S1526-8209(11)00206-0/fulltext Schwartzberg et al. 2011]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 825 mg/m<sup>2</sup> (rounded to nearest 500 mg) PO twice per day on days 1 to 15
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 125 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycles'''

===References===
# Schwartzberg LS, Arena FP, Mintzer DM, Epperson AL, Walker MS. Phase II multicenter trial of albumin-bound paclitaxel and capecitabine in first-line treatment of patients with metastatic breast cancer. Clin Breast Cancer. 2012 Apr;12(2):87-93. Epub 2011 Dec 6. [http://www.clinical-breast-cancer.com/article/S1526-8209(11)00206-0/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22154117 PubMed]

==CMF {{#subobject:9c9c1d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CMF: '''<u>C</u>'''yclophosphamide, '''<u>M</u>'''ethotrexate, '''<u>F</u>'''luorouracil
===Variant #1, 600/40/600 {{#subobject:4a66d3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1988.6.9.1377 Tannock et al. 1988]
| style="background-color:#1a9851" |Phase III (C)
|Lower-dose CMF
| style="background-color:#d9ef8b" |Might have superior OS
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19940501)73:9%3C2337::AID-CNCR2820730916%3E3.0.CO;2-Q Ingle et al. 1994]
| style="background-color:#1a9851" |Randomized (C)
|DES-CEF
| style="background-color:#fee08b" |Might have inferior ORR
|-
|}
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Methotrexate (MTX)]] 40 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #2, 1400/80/1000 {{#subobject:d3cef4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1987.5.10.1523 Aisner et al. 1987]
| style="background-color:#1a9851" |Phase III (C)
|1. [[#FAC_3|CAF]]<br> 2. CAFVP
| style="background-color:#d73027" |Inferior ORR
|-
|}
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 14
*[[Methotrexate (MTX)]] 40 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycles'''

===Variant #3, 1400/80/1200 {{#subobject:4a77d3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1639498/ Brambilla et al. 1976]
| style="background-color:#1a9851" |Phase III (C)
|AV
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197805)41:5%3C1649::AID-CNCR2820410501%3E3.0.CO;2-J/abstract Bull et al. 1978]
| style="background-color:#1a9851" |Phase III (C)
|[[#FAC_3|CAF]]
| style="background-color:#fee08b" |Might have inferior ORR
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19851215)56:12%3C2745::AID-CNCR2820561204%3E3.0.CO;2-G Viladiu et al. 1985]
|style="background-color:#1a9851" |Phase III (C)
|1. [[#CMFT_2|CMFT]]<br> 2. CMF & MPA
| style="background-color:#fc8d59" |Seems to have inferior ORR
|-
|[https://academic.oup.com/annonc/article-abstract/1/1/36/164180 Cocconi et al. 1990]
| style="background-color:#1a9851" |Phase III (C)
|CMF x 6, then intensification
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ejcancer.com/article/0277-5379(91)90259-G/fulltext Engelsman et al. 1991 (EORTC 10808)]
| style="background-color:#1a9851" |Phase III (C)
|CMF 600/40/600 (IV)
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1991.9.4.664 Cocconi et al. 1991]
| style="background-color:#1a9851" |Phase III (C)
|PE
| style="background-color:#fee08b" |Might have inferior ORR
|-
|[https://www.ejcancer.com/article/S0959-8049(05)80296-5/pdf Yosef et al. 1993]
| style="background-color:#1a9851" |Phase III (C)
|SMF
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM200004133421501 Stadtmauer et al. 2000 (Philadelphia Bone Marrow Transplant Group)]
| style="background-color:#1a9851" |Phase III (C)
|CMF x 4-6, then [[#CTCb.2C_then_auto_HSCT_2|HDT]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://jco.ascopubs.org/content/19/4/943.long Ackland et al. 2001 (HEPI 013)]
| style="background-color:#1a9851" |Phase III (C)
|[[#FEC_3|CEF]]
| style="background-color:#d73027" |Inferior TTP
|-
|[https://insights.ovid.com/pubmed?pmid=16096436 von Minckwitz et al. 2005]
| style="background-color:#1a9851" |Phase III (C)
|BMF
| style="background-color:#d73027" |Inferior TTP
|-
|[http://jco.ascopubs.org/content/29/34/4498.long Stockler et al. 2011 (ANZ 0001)]
| style="background-color:#1a9851" |Phase III (C)
|1. [[#Capecitabine_monotherapy_2|Continuous Capecitabine]]<br> 2. [[#Capecitabine_monotherapy_2|Intermittent Capecitabine]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|}
====Chemotherapy====
*[[Cyclophosphamide (Cytoxan)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 14
*[[Methotrexate (MTX)]] 40 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycles'''

===References===
# Brambilla C, De Lena M, Rossi A, Valagussa P, Bonadonna G. Response and survival in advanced breast cancer after two non-cross-resistant combinations. Br Med J. 1976 Apr 3;1(6013):801-4. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1639498/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/1260337 PubMed]
# Bull JM, Tormey DC, Li SH, Carbone PP, Falkson G, Blom J, Perlin E, Simon R. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer. 1978 May;41(5):1649-57. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197805)41:5%3C1649::AID-CNCR2820410501%3E3.0.CO;2-J/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/348293 PubMed]
# Viladiu P, Alonso MC, Avella A, Beltrán M, Borrás J, Ojeda B, Bosch FX. Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients: a randomized trial. Cancer. 1985 Dec 15;56(12):2745-50. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19851215)56:12%3C2745::AID-CNCR2820561204%3E3.0.CO;2-G link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/3902200 PubMed]
# Aisner J, Weinberg V, Perloff M, Weiss R, Perry M, Korzun A, Ginsberg S, Holland JF; Cancer and Leukemia Group B. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. J Clin Oncol. 1987 Oct;5(10):1523-33. [http://ascopubs.org/doi/abs/10.1200/JCO.1987.5.10.1523 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/3655855 PubMed]
# Tannock IF, Boyd NF, DeBoer G, Erlichman C, Fine S, Larocque G, Mayers C, Perrault D, Sutherland H. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol. 1988 Sep;6(9):1377-87. [http://ascopubs.org/doi/abs/10.1200/JCO.1988.6.9.1377 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2458438 PubMed]
# Cocconi G, Bisagni G, Bacchi M, Buzzi F, Canaletti R, Carpi A, Ceci G, Colozza A, De Lisi V, Lottici R, et al. A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol. 1990;1(1):36-44. [https://academic.oup.com/annonc/article-abstract/1/1/36/164180 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2078484 PubMed]
# '''EORTC 10808:''' Engelsman E, Klijn JC, Rubens RD, Wildiers J, Beex LV, Nooij MA, Rotmensz N, Sylvester R. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer: an EORTC Breast Cancer Co-operative Group Phase III Trial (10808). Eur J Cancer. 1991;27(8):966-70. [https://www.ejcancer.com/article/0277-5379(91)90259-G/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1832904 PubMed]
# Cocconi G, Bisagni G, Bacchi M, Boni C, Bartolucci R, Ceci G, Colozza MA, De Lisi V, Lottici R, Mosconi AM, Passalacqua R, Tonato M. Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol. 1991 Apr;9(4):664-9. [http://ascopubs.org/doi/abs/10.1200/JCO.1991.9.4.664 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2066763 PubMed]
# Yosef H, Slater A, Keen CW, Bunting JS, Hope-Stone H, Parmar H, Roberts JT, Termander B, Nilsson B. Prednimustine (Sterecyt) versus cyclophosphamide both in combination with methotrexate and 5-fluorouracil in the treatment of advanced breast cancer. Eur J Cancer. 1993;29A(8):1100-5. [https://www.ejcancer.com/article/S0959-8049(05)80296-5/pdf link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8518020 PubMed]
# Ingle JN, Foley JF, Mailliard JA, Krook JE, Hartmann LC, Jung SH, Veeder MH, Gesme DH Jr, Hatfield AK, Goldberg RM. Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer. Cancer. 1994 May 1;73(9):2337-43. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19940501)73:9%3C2337::AID-CNCR2820730916%3E3.0.CO;2-Q link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8168039 PubMed]
# '''Philadelphia Bone Marrow Transplant Group:''' Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH; Philadelphia Bone Marrow Transplant Group. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med. 2000 Apr 13;342(15):1069-76. [https://www.nejm.org/doi/full/10.1056/NEJM200004133421501 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10760307 PubMed]
# '''HEPI 013:''' Ackland SP, Anton A, Breitbach GP, Colajori E, Tursi JM, Delfino C, Efremidis A, Ezzat A, Fittipaldo A, Kolaric K, Lopez M, Viaro D; HEPI 013 study group. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study. J Clin Oncol. 2001 Feb 15;19(4):943-53. [http://jco.ascopubs.org/content/19/4/943.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11181656 PubMed]
# von Minckwitz G, Chernozemsky I, Sirakova L, Chilingirov P, Souchon R, Marschner N, Kleeberg U, Tsekov C, Fritze D, Thomssen C, Stuart N, Vermorken JB, Loibl S, Merkle Kh, Kaufmann M. Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs. 2005 Sep;16(8):871-7. [https://insights.ovid.com/pubmed?pmid=16096436 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16096436 PubMed]
<!-- Presented in part at the 29th Annual San Antonio Breast Cancer Symposium, December 14-17, 2006, San Antonio, TX, and 43rd Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL. -->
# '''ANZ 0001:''' Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, Van Hazel G, Wilcken NR, Grimison PS, Nowak AK, Gainford MC, Fong A, Paksec L, Sourjina T, Zannino D, Gebski V, Simes RJ, Forbes JF, Coates AS. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol. 2011 Dec 1;29(34):4498-504. Epub 2011 Oct 24. [http://jco.ascopubs.org/content/29/34/4498.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22025143 PubMed]

==CMFT {{#subobject:9c9c1d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CMFT: '''<u>C</u>'''yclophosphamide, '''<u>M</u>'''ethotrexate, '''<u>F</u>'''luorouracil, '''<u>T</u>'''amoxifen
===Regimen {{#subobject:ab14d5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19830215)51:4%3C581::AID-CNCR2820510404%3E3.0.CO;2-G Cocconi et al. 1983]
| style="background-color:#1a9851" |Randomized (E)
|[[#CMF_2|CMF]]
| style="background-color:#d9ef8b" |Might have superior TTF
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19851215)56:12%3C2745::AID-CNCR2820561204%3E3.0.CO;2-G Viladiu et al. 1985]
|style="background-color:#1a9851" |Phase III (E)
|1. [[#CMF_2|CMF]]<br> 2. CMF & MPA
| style="background-color:#91cf60" |Seems to have superior ORR
|-
|}
====Chemohormonotherapy====
*[[Cyclophosphamide (Cytoxan)]]
*[[Methotrexate (MTX)]]
*[[Fluorouracil (5-FU)]]
*[[Tamoxifen (Nolvadex)]]
===References===
# Cocconi G, De Lisi V, Boni C, Mori P, Malacarne P, Amadori D, Giovanelli E. Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer: a prospective randomized study. Cancer. 1983 Feb 15;51(4):581-8. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19830215)51:4%3C581::AID-CNCR2820510404%3E3.0.CO;2-G link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/6336981 PubMed]
# Viladiu P, Alonso MC, Avella A, Beltrán M, Borrás J, Ojeda B, Bosch FX. Chemotherapy versus chemotherapy plus hormonotherapy in postmenopausal advanced breast cancer patients: a randomized trial. Cancer. 1985 Dec 15;56(12):2745-50. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19851215)56:12%3C2745::AID-CNCR2820561204%3E3.0.CO;2-G link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/3902200 PubMed]

==DE {{#subobject:8039af|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DE: '''<u>D</u>'''ocetaxel & '''<u>E</u>'''pirubicin
<br>ED: '''<u>E</u>'''pirubicin & '''<u>D</u>'''ocetaxel
<br>ET: '''<u>E</u>'''pirubicin & '''<u>T</u>'''axotere (Docetaxel)
===Regimen {{#subobject:ab14d5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409942/ Bonneterre et al. 2004]
| style="background-color:#1a9851" |Randomized Phase II (E)
|[[#FEC_3|FEC]]
| style="background-color:#1a9850" |Superior ORR
|-
|[https://academic.oup.com/annonc/article/21/1/48/146142 Mavroudis et al. 2009]
| style="background-color:#1a9851" |Phase III (C)
|Capecitabine & Docetaxel
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 8 cycles (Bonneterre et al. 2004) or indefinitely (Mavroudis et al. 2009)'''

===References===
# Bonneterre J, Dieras V, Tubiana-Hulin M, Bougnoux P, Bonneterre ME, Delozier T, Mayer F, Culine S, Dohoulou N, Bendahmane B. Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer. 2004 Oct 18;91(8):1466-71. [https://www.nature.com/articles/6602179 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409942/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15381937 PubMed]
# Mavroudis D, Papakotoulas P, Ardavanis A, Syrigos K, Kakolyris S, Ziras N, Kouroussis C, Malamos N, Polyzos A, Christophyllakis C, Kentepozidis N, Georgoulias V; Breast Cancer Investigators of the Hellenic Oncology Research Group. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. Ann Oncol. 2010 Jan;21(1):48-54. Epub 2009 Nov 11. [https://academic.oup.com/annonc/article/21/1/48/146142 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19906761 PubMed]

==Docetaxel monotherapy {{#subobject:47db8e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
D: '''<u>D</u>'''ocetaxel
<br>T: '''<u>T</u>'''axotere (Docetaxel)
===Variant #1, 40 mg/m<sup>2</sup> 3 weeks out of 4 {{#subobject:09eecd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.23321 Rivera et al. 2008]
| style="background-color:#1a9851" |Phase III (E)
|Docetaxel q3wk 
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#1a9850" |Superior toxicity
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] as follows:
**Cycle 1: 35 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15
**Cycle 2 onwards: 40 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15

'''28-day cycles'''

===Variant #2, 40 mg/m<sup>2</sup> 6 weeks out of 8 {{#subobject:6ed28b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/18/6/1212.long Burstein et al. 2000]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 40 mg/m<sup>2</sup> IV once per week for weeks 1 to 6

'''8-week cycles'''

===Variant #3, 60 mg/m<sup>2</sup> q3wk {{#subobject:cf6000|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00411-8/fulltext Takashima et al. 2015 (SELECT BC)]
| style="background-color:#1a9851" |Phase III (C)
|[[#S-1_monotherapy|S-1]]
| style="background-color:#eeee01" |Seems to have non-inferior OS
| style="background-color:#d73027" |Inferior EQ-5D score
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #4, 60 mg/m<sup>2</sup> q4wk {{#subobject:c5cf8d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00411-8/fulltext Takashima et al. 2015 (SELECT BC)]
| style="background-color:#1a9851" |Phase III (C)
|[[#S-1_monotherapy|S-1]]
| style="background-color:#eeee01" |Seems to have non-inferior OS
| style="background-color:#d73027" |Inferior EQ-5D score
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV once on day 1

'''28-day cycles'''

===Variant #5, 75 mg/m<sup>2</sup> q3wk {{#subobject:32c5e5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2008.20.5013 Sparano et al. 2009 (DOXIL-BCA-3001)]
| style="background-color:#1a9851" |Phase III (C)
|Docetaxel & PLD
| style="background-color:#d73027" |Inferior TTP
| style="background-color:#1a9850" |Less toxic
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 Robert et al. 2011 (RIBBON-1)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Docetaxel_.26_Bevacizumab_2|Docetaxel & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2014.57.1513 Mackey et al. 2014 (ROSE/TRIO-12)]
| style="background-color:#1a9851" |Phase III (C)
|Docetaxel & Ramucirumab
| style="background-color:#fee08b" |Might have inferior PFS
|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00411-8/fulltext Takashima et al. 2015 (SELECT BC)]
| style="background-color:#1a9851" |Phase III (C)
|[[#S-1_monotherapy|S-1]]
| style="background-color:#eeee01" |Seems to have non-inferior OS
| style="background-color:#d73027" |Inferior EQ-5D score
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #6, 75 mg/m<sup>2</sup> q4wk {{#subobject:79ac92|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00411-8/fulltext Takashima et al. 2015 (SELECT BC)]
| style="background-color:#1a9851" |Phase III (C)
|[[#S-1_monotherapy|S-1]]
| style="background-color:#eeee01" |Seems to have non-inferior OS
| style="background-color:#d73027" |Inferior EQ-5D score
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1

'''28-day cycles'''

===Variant #7, 100 mg/m<sup>2</sup> {{#subobject:bf6578|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1996.14.2.422 Trudeau et al. 1996]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://jco.ascopubs.org/content/23/19/4265.long Marty et al. 2005 (M77001)]
| style="background-color:#1a9851" |Phase III (C)
|[[Breast_cancer,_HER2-positive#TH_.28Taxotere.29_3|Docetaxel & Trastuzumab]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.23321 Rivera et al. 2008]
| style="background-color:#1a9851" |Phase III (C)
|Weekly Docetaxel 
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#d73027" |Inferior toxicity
|-
| rowspan="3" |[http://jco.ascopubs.org/content/27/22/3611.long Gradishar et al. 2009]
| rowspan="3" style="background-color:#1a9851" |Phase III (C)
|[[#Paclitaxel.2C_nanoparticle_albumin-bound_monotherapy_2|1. Higher-dose weekly nanoparticle albumin-bound paclitaxel]]
| style="background-color:#d73027" |Inferior PFS
|
|-
|[[#Paclitaxel.2C_nanoparticle_albumin-bound_monotherapy_2|2. Lower-dose weekly nanoparticle albumin-bound paclitaxel]]
| style="background-color:#ffffbf" |Seems not superior
|
|-
|[[#Paclitaxel.2C_nanoparticle_albumin-bound_monotherapy_2|q3wk nanoparticle albumin-bound paclitaxel]]
| style="background-color:#ffffbf" |Seems not superior
|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860103/ Joensuu et al. 2009]
| style="background-color:#1a9851" |Phase III (C)
|D/G
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#d73027" |More toxic
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2008.21.6457 Miles et al. 2010 (AVADO)]
|rowspan=2 style="background-color:#1a9851" |Phase III (C)
|1. Docetaxel & Bevacizumab (7.5 mg/kg)
| style="background-color:#ffffbf" |Seems not superior
|
|-
|2. Docetaxel & Bevacizumab (15 mg/kg)
| style="background-color:#d73027" |Inferior PFS
|
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 Robert et al. 2011 (RIBBON-1)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Docetaxel_.26_Bevacizumab_2|Docetaxel & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.33.9507 Nielsen et al. 2011]
| style="background-color:#1a9851" |Phase III (C)
|[[#Docetaxel_.26_Gemcitabine|Docetaxel & Gemcitabine]]
| style="background-color:#fee08b" |Might have inferior TTP
|
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.35.7376 Bergh et al. 2012 (SUN 1064)]
| style="background-color:#1a9851" |Phase III (C)
|Docetaxel & Sunitinib
| style="background-color:#ffffbf" |Seems not superior
|
|-
|}
''Note: AVADO gave up to 9 cycles.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1
**Note: Rivera et al. 2008 gave 75 mg/m<sup>2</sup> in cycle 1, with escalation to 100 mg/m<sup>2</sup> depending on toxicity

'''21-day cycles (see note)'''

===References===
# Trudeau ME, Eisenhauer EA, Higgins BP, Letendre F, Lofters WS, Norris BD, Vandenberg TA, Delorme F, Muldal AM. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol. 1996 Feb;14(2):422-8. [http://ascopubs.org/doi/abs/10.1200/JCO.1996.14.2.422 link to original article] '''contains protocol'''  [https://www.ncbi.nlm.nih.gov/pubmed/8636752 PubMed]
# '''Review:''' Burris HA 3rd. Single-agent docetaxel (Taxotere) in randomized phase III trials. Semin Oncol. 1999 Jun;26(3 Suppl 9):1-6. [https://www.ncbi.nlm.nih.gov/pubmed/10426452 PubMed]
# Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000 Mar;18(6):1212-9. [http://jco.ascopubs.org/content/18/6/1212.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10715290 PubMed] content property of [http://hemonc.org HemOnc.org]
# '''M77001:''' Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005 Jul 1;23(19):4265-74. Epub 2005 May 23. [http://jco.ascopubs.org/content/23/19/4265.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15911866 PubMed]
# Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, Broglio KR, Yin G, Esmaeli B, Hortobagyi GN, Valero V. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer. 2008 Apr 1;112(7):1455-61. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.23321 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18300256 PubMed]
<!-- Presented in part at the 29th Annual San Antonio Breast Cancer Symposium, December 14-17, 2006, San Antonio, TX; the 43rd Annual Meeting of the American Society for Clinical Oncology, June 1-5, 2007, Chicago, IL; the 14th European Cancer Conference, September 23-27, 2007, Barcelona, Spain; and the 6th European Breast Cancer Conference, April 15-19, 2008, Berlin, Germany. -->
# Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009 Aug 1;27(22):3611-9. Epub 2009 May 26. Erratum in: J Clin Oncol. 2011 Jul 1;29(19):2739. [http://jco.ascopubs.org/content/27/22/3611.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19470941 PubMed]
# '''DOXIL-BCA-3001:''' Sparano JA, Makhson AN, Semiglazov VF, Tjulandin SA, Balashova OI, Bondarenko IN, Bogdanova NV, Manikhas GM, Oliynychenko GP, Chatikhine VA, Zhuang SH, Xiu L, Yuan Z, Rackoff WR. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol. 2009 Sep 20;27(27):4522-9. Epub 2009 Aug 17. [http://ascopubs.org/doi/full/10.1200/JCO.2008.20.5013 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19687336 PubMed]
# Joensuu H, Sailas L, Alanko T, Sunela K, Huuhtanen R, Utriainen M, Kokko R, Bono P, Wigren T, Pyrhönen S, Turpeenniemi-Hujanen T, Asola R, Leinonen M, Hahka-Kemppinen M, Kellokumpu-Lehtinen P. Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial. Ann Oncol. 2010 May;21(5):968-73. Epub 2009 Oct 9. [https://academic.oup.com/annonc/article/21/5/968/235484 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860103/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19819914 PubMed]
# '''AVADO:''' Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010 Jul 10;28(20):3239-47. Epub 2010 May 24. [http://ascopubs.org/doi/full/10.1200/JCO.2008.21.6457 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20498403 PubMed]
<!-- Presented in part at the 45th Annual Meeting of the American Society for Clinical Oncology, May 29-June 2, 2009, Orlando, FL, and at the 15th Congress of the European Cancer Organisation and 34th Congress of the European Society for Medical Oncology Multidisciplinary Congress, September 20-24, 2009, Berlin, Germany. -->
# '''RIBBON-1:''' Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 1;29(10):1252-60. Epub 2011 Mar 7. [http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21383283 PubMed]
# Nielsen DL, Bjerre KD, Jakobsen EH, Cold S, Stenbygaard L, Sørensen PG, Kamby C, Møller S, Jørgensen CL, Andersson M. Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2011 Dec 20;29(36):4748-54. Epub 2011 Nov 14. [http://ascopubs.org/doi/full/10.1200/JCO.2010.33.9507 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22084374 PubMed]
<!-- Presented, in part, at the 46th Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL. -->
# '''SUN 1064:''' Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, Makhson AN, Cortes J, Lortholary A, Bischoff J, Chan A, Delaloge S, Huang X, Kern KA, Giorgetti C. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol. 2012 Mar 20;30(9):921-9. Epub 2012 Feb 13. [http://ascopubs.org/doi/full/10.1200/JCO.2011.35.7376 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22331954 PubMed]
# '''ROSE/TRIO-12:''' Mackey JR, Ramos-Vazquez M, Lipatov O, McCarthy N, Krasnozhon D, Semiglazov V, Manikhas A, Gelmon KA, Konecny GE, Webster M, Hegg R, Verma S, Gorbunova V, Abi Gerges D, Thireau F, Fung H, Simms L, Buyse M, Ibrahim A, Martín M. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. J Clin Oncol. 2015 Jan 10;33(2):141-8. Epub 2014 Sep 2. [http://ascopubs.org/doi/full/10.1200/JCO.2014.57.1513 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25185099 PubMed]
# '''SELECT BC:''' Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y; SELECT BC Study Group. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2016 Jan;17(1):90-8. Epub 2015 Nov 27. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00411-8/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26617202 PubMed]
## '''HRQoL analysis:''' Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Doihara H, Akabane H, Kashiwaba M, Watanabe T, Ohashi Y, Mukai H. Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial. Qual Life Res. 2017 Feb;26(2):445-453. Epub 2016 Aug 12. [https://link.springer.com/article/10.1007%2Fs11136-016-1388-1 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288429/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27517267 PubMed]

==Docetaxel & Bevacizumab {{#subobject:65222f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, docetaxel 75 mg/m<sup>2</sup> {{#subobject:4040c4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 Robert et al. 2011 (RIBBON-1)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Docetaxel_monotherapy_3|Docetaxel]]
| style="background-color:#1a9850" |Superior PFS
|-
|[https://link.springer.com/article/10.1007%2Fs10549-014-3217-y Lück et al. 2014 (TABEA)]
| style="background-color:#1a9851" |Phase III (C)
|TBX
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''

===Variant #2, docetaxel 100 mg/m<sup>2</sup> {{#subobject:48a438|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2008.21.6457 Miles et al. 2010 (AVADO)]
|rowspan=2 style="background-color:#1a9851" |Phase III (C)
|[[#Docetaxel_monotherapy_3|1. Docetaxel]]
| style="background-color:#1a9850" |Superior PFS
|-
|2. Docetaxel & Bevacizumab (7.5 mg/kg)
| style="background-color:#d3d3d3" |Not reported
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 Robert et al. 2011 (RIBBON-1)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Docetaxel_monotherapy_3|Docetaxel]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycle for up to 9 cycles (AVADO) or indefinitely (RIBBON-1)'''
====Subsequent treatment====
*AVADO: [[#Bevacizumab_monotherapy_2|Bevacizumab maintenance]]

===References===
# '''AVADO:''' Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010 Jul 10;28(20):3239-47. Epub 2010 May 24. [http://ascopubs.org/doi/full/10.1200/JCO.2008.21.6457 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20498403 PubMed]
<!-- Presented in part at the 45th Annual Meeting of the American Society for Clinical Oncology, May 29-June 2, 2009, Orlando, FL, and at the 15th Congress of the European Cancer Organisation and 34th Congress of the European Society for Medical Oncology Multidisciplinary Congress, September 20-24, 2009, Berlin, Germany. -->
# '''RIBBON-1:''' Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 1;29(10):1252-60. Epub 2011 Mar 7. [http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21383283 PubMed]
# '''TABEA:''' Lück HJ, Lübbe K, Reinisch M, Maass N, Feisel-Schwickardi G, Tomé O, Janni W, Aydogdu M, Neunhöffer T, Ober A, Aktas B, Park-Simon TW, Schumacher C, Höffkes HG, Illmer T, Wagner H, Mehta K, von Minckwitz G, Nekljudova V, Loibl S. Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer. Breast Cancer Res Treat. 2015 Jan;149(1):141-9. Epub 2014 Dec 18. [https://link.springer.com/article/10.1007%2Fs10549-014-3217-y link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25519041 PubMed]

==Docetaxel & Gemcitabine {{#subobject:031a92|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
GD: '''<u>G</u>'''emcitabine & '''<u>D</u>'''ocetaxel
===Regimen {{#subobject:c95bcd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/22/5/1094/178774 Seidman et al. 2010]
| style="background-color:#1a9851" |Phase III (C)
|[[#Capecitabine_.26_Docetaxel|CD]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.33.9507 Nielsen et al. 2011]
| style="background-color:#1a9851" |Phase III (E)
|[[#Docetaxel_monotherapy_3|Docetaxel]]
| style="background-color:#d9ef8b" |Might have superior TTP
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
**Nielsen et al. 2011 gave docetaxel on day 8
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8

'''21-day cycles'''

====Subsequent treatment====
*Seidman et al. 2010, upon progression: [[#Capecitabine_monotherapy_3|Capecitabine]]

===References===
# Fountzilas G, Dafni U, Dimopoulos MA, Koutras A, Skarlos D, Papakostas P, Gogas H, Bafaloukos D, Kalogera-Fountzila A, Samantas E, Briasoulis E, Pectasides D, Maniadakis N, Matsiakou F, Aravantinos G, Papadimitriou C, Karina M, Christodoulou C, Kosmidis P, Kalofonos HP. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat. 2009 May;115(1):87-99. Epub 2008 May 16. [https://link.springer.com/article/10.1007%2Fs10549-008-0047-9 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18483853 PubMed]
# Seidman AD, Brufsky A, Ansari RH, Hart LL, Stein RS, Schwartzberg LS, Stewart JF, Russell CA, Chen SC, Fein LE, De La Cruz Vargas JA, Kim SB, Cavalheiro J, Zhao L, Gill JF, Obasaju CK, Orlando M, Tai DF. Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Ann Oncol. 2011 May;22(5):1094-101. Epub 2010 Nov 17. [https://academic.oup.com/annonc/article/22/5/1094/178774 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21084429 PubMed]
# Nielsen DL, Bjerre KD, Jakobsen EH, Cold S, Stenbygaard L, Sørensen PG, Kamby C, Møller S, Jørgensen CL, Andersson M. Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2011 Dec 20;29(36):4748-54. Epub 2011 Nov 14. [http://ascopubs.org/doi/full/10.1200/JCO.2010.33.9507 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22084374 PubMed]

==Doxorubicin monotherapy {{#subobject:8a2b88|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 20 mg/m<sup>2</sup> weekly {{#subobject:96cac2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://www.sciencedirect.com/science/article/pii/0277537986900751 Gundersen et al. 1986]
| style="background-color:#1a9851" |Phase III (E)
|[[Breast_cancer_-_historical#VAC_.28Adriamycin.29|VAC]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.sciencedirect.com/science/article/pii/027753799090255R Gundersen et al. 1990]
| style="background-color:#1a9851" |Phase III (C)
|[[#Epirubicin_monotherapy_2|Epirubicin]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.sciencedirect.com/science/article/pii/095980499400213O Gundersen et al. 1994]
| style="background-color:#1a9851" |Randomized (C)
|Doxorubicin & MPA
| style="background-color:#fee08b" |Might have inferior ORR
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 20 mg/m<sup>2</sup> IV once per week

'''Duration not specified'''

===Variant #2, 60 mg/m<sup>2</sup> q3wk {{#subobject:cf8189|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(197402)33:2%3C519::AID-CNCR2820330229%3E3.0.CO;2-X Gottlieb et al. 1974]
| style="background-color:#1a9851" |Phase III (E)
|1. Lomustine<br> 2. Semustine
| style="background-color:#1a9850" |Superior OS
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/mpo.2950160505 Vaughn et al. 1988 (SWOG S8020)]
| style="background-color:#1a9851" |Phase III (C)
|Doxorubicin & Etoposide
| style="background-color:#fc8d59" |Seems to have inferior TTP
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1991.9.12.2148 Perez et al. 1991]
| style="background-color:#1a9851" |Phase III (C)
|[[#Epirubicin_monotherapy_2|Epirubicin]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.12.2385 Norris et al. 2000 (NCIC CTG MA.8)]
| style="background-color:#1a9851" |Phase III (C)
|Doxorubicin & Vinorelbine
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://annonc.oxfordjournals.org/content/15/3/440.long O'Brien et al. 2004 (CAELYX Breast Cancer Study Group)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Doxorubicin_pegylated_liposomal_monotherapy|Pegylated liposomal doxorubicin]]
| style="background-color:#eeee01" |Seems to have non-inferior PFS
|-
|}
''Note: in NCIC CTG MA.8, this dose was after a mid-protocol amendment. Treatment in NCIC CTG MA.8 was given until a cumulative dose of 450 mg/m<sup>2</sup>.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles (see note)'''

===Variant #3, 75 mg/m<sup>2</sup> q3wk {{#subobject:1982c0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.2000.18.4.724 Paridaens et al. 2000 (EORTC 10923)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Paclitaxel_monotherapy.2C_q3wk|Paclitaxel]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 7 cycles'''

===References===
# Gottlieb JA, Rivkin SE, Spigel SC, Hoogstraten B, O'Bryan RM, Delaney FC, Singhakowinta A. Proceedings: Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma: a Southwest Cancer Chemotherapy study Group study. Cancer. 1974 Feb;33(2):519-26. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(197402)33:2%3C519::AID-CNCR2820330229%3E3.0.CO;2-X link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/4812769 PubMed]
# Gundersen S, Kvinnsland S, Klepp O, Kvaløy S, Lund E, Høst H. Weekly adriamycin versus VAC in advanced breast cancer: a randomized trial. Eur J Cancer Clin Oncol. 1986 Dec;22(12):1431-4. [http://www.sciencedirect.com/science/article/pii/0277537986900751 link to SD article] [https://www.ncbi.nlm.nih.gov/pubmed/3595668 PubMed]
# '''SWOG S8020:''' Vaughn CB, Green SJ, O'Bryan R, Reed M, Grozea PN, Fletcher WS, Green JB, Metch B, Oishi N. VP-16 + adriamycin vs adriamycin alone in advanced adenocarcinoma of the breast, phase II, a randomized trial: a Southwest Oncology Group Study. Med Pediatr Oncol. 1988;16(5):312-9. [https://onlinelibrary.wiley.com/doi/abs/10.1002/mpo.2950160505 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/3054453 PubMed]
# Gundersen S, Kvinnsland S, Klepp O, Lund E, Høst H; The Norwegian Breast Cancer Group. Weekly Adriamycin vs 4-epidoxorubicin every second week in advanced breast cancer: a randomized trial. Eur J Cancer. 1990 Jan;26(1):45-8. [https://www.sciencedirect.com/science/article/pii/027753799090255R link to SD article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2138477 PubMed]
# Perez DJ, Harvey VJ, Robinson BA, Atkinson CH, Dady PJ, Kirk AR, Evans BD, Chapman PJ. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol. 1991 Dec;9(12):2148-52. [http://ascopubs.org/doi/abs/10.1200/JCO.1991.9.12.2148 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1960557 PubMed]
# Gundersen S, Hannisdal E, Lundgren S, Wist E; The Norwegian Breast Cancer Group. Weekly doxorubicin with or without high-dose medroxyprogesterone acetate in hormone-resistant advanced breast cancer: a randomised study. Eur J Cancer. 1994;30A(12):1775-8. [https://www.sciencedirect.com/science/article/pii/095980499400213O link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7880604 PubMed]
# '''EORTC 10923:''' Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol. 2000 Feb;18(4):724-33. [http://ascopubs.org/doi/10.1200/JCO.2000.18.4.724 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10673513 PubMed]
# '''NCIC CTG MA.8:''' Norris B, Pritchard KI, James K, Myles J, Bennett K, Marlin S, Skillings J, Findlay B, Vandenberg T, Goss P, Latreille J, Rudinskas L, Lofters W, Trudeau M, Osoba D, Rodgers A. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group study MA8. J Clin Oncol. 2000 Jun;18(12):2385-94. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.12.2385 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10856098 PubMed]
# '''CAELYX Breast Cancer Study Group:''' O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C; CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004 Mar;15(3):440-9. [http://annonc.oxfordjournals.org/content/15/3/440.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14998846 PubMed]

==Doxorubicin non-pegylated liposomal & Cyclophosphamide {{#subobject:7ac8f8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
MC: '''<u>M</u>'''yocet (non-pegylated liposomal doxorubicin) & '''<u>C</u>'''yclophosphamide
===Regimen {{#subobject:57bc79|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.spandidos-publications.com/ijo/45/5/2137 Lorusso et al. 2014]
| style="background-color:#1a9851" |Phase III (C)
|NPLD & Vinorelbine
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Non-pegylated liposomal doxorubicin (Myocet)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===References===
# Lorusso V, Giotta F, Bordonaro R, Maiello E, Del Prete S, Gebbia V, Filippelli G, Pisconti S, Cinieri S, Romito S, Riccardi F, Forcignanò R, Ciccarese M, Petrucelli L, Saracino V, Lupo LI, Gambino A, Leo S, Colucci G; Gruppo Oncologico Dell'Italia Meridionale. Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy:a multicenter phase III study. Int J Oncol. 2014 Nov;45(5):2137-42. Epub 2014 Aug 18. [https://www.spandidos-publications.com/ijo/45/5/2137 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25176223 PubMed]

==Doxorubicin pegylated liposomal monotherapy {{#subobject:2b08a6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 45 mg/m<sup>2</sup> {{#subobject:c2baf3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433520/ Smorenburg et al. 2014 (OMEGA)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Capecitabine_monotherapy_2|Capecitabine]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Pegylated liposomal doxorubicin (Doxil)]] 45 mg/m<sup>2</sup> IV once on day 1

'''28-day cycle for 6 cycles'''

===Variant #2, 50 mg/m<sup>2</sup> {{#subobject:6ebaf9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/15/3/440.long O'Brien et al. 2004 (CAELYX Breast Cancer Study Group)]
| style="background-color:#1a9851" |Phase III (E)
|[[ #Doxorubicin_monotherapy_2|Doxorubicin]]
| style="background-color:#eeee01" |Seems to have non-inferior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5222915/ Harbeck et al. 2016 (PELICAN)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Capecitabine_monotherapy_2|Capecitabine]]
| style="background-color:#ffffbf" |Inconclusive whether non-inferior
|-
|}
====Chemotherapy====
*[[Pegylated liposomal doxorubicin (Doxil)]] 50 mg/m<sup>2</sup> IV over up to 60 minutes once on day 1
**If infusion reactions occurred, infusion could be given over up to 90 minutes

'''28-day cycles'''

===References===
# '''CAELYX Breast Cancer Study Group:''' O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C; CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004 Mar;15(3):440-9. [http://annonc.oxfordjournals.org/content/15/3/440.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/14998846 PubMed]
# '''OMEGA:''' Smorenburg CH, de Groot SM, van Leeuwen-Stok AE, Hamaker ME, Wymenga AN, de Graaf H, de Jongh FE, Braun JJ, Los M, Maartense E, van Tinteren H, Nortier JW, Seynaeve C. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG. Ann Oncol. 2014 Mar;25(3):599-605. Epub 2014 Feb 6. [https://academic.oup.com/annonc/article/25/3/599/149516 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433520/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24504445 PubMed]
# '''PELICAN:''' Harbeck N, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller L, Otremba BJ, Waldenmaier D, Dorn J, Warm M, Scholz M, Untch M, de Wit M, Barinoff J, Lück HJ, Harter P, Augustin D, Harnett P, Beckmann MW, Al-Batran SE; PELICAN Investigators. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. Breast Cancer Res Treat. 2017 Jan;161(1):63-72. Epub 2016 Oct 31. [https://link.springer.com/article/10.1007%2Fs10549-016-4033-3 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5222915/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27798749 PubMed]

==EC {{#subobject:b81844|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EC: '''<u>E</u>'''pirubicin & '''<u>C</u>'''yclophosphamide

===Variant #1, 75/600 {{#subobject:8466d6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM200103153441101 Slamon et al. 2001]
| style="background-color:#1a9851" |Phase III (C)
|[[Breast_cancer,_HER2-positive#ECH_2|ECH]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://academic.oup.com/annonc/article/15/10/1527/170632 Chan et al. 2004]
| style="background-color:#1a9851" |Phase III (C)
|MC
| style="background-color:#fc8d59" |Seems to have inferior TTP
|-
|[http://jco.ascopubs.org/content/23/33/8322.long Langley et al. 2005 (UKNCRI AB01)]
| style="background-color:#1a9851" |Phase III (C)
|[[#EP_3|EP]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: patients in Slamon et al. 2001 had HER2+ disease.''
====Chemotherapy====
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 6 to 8 cycles'''

===Variant #2, 90/600 {{#subobject:6079b8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/21/7/1430/164927 Blohmer et al. 2010]
| style="background-color:#1a9851" |Phase III (C)
|[[#DE_2|ED]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Epirubicin (Ellence)]] 90 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 6 to 8 cycles'''

===Variant #3, with range {{#subobject:21d6fa|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 Robert et al. 2011 (RIBBON-1)]
| style="background-color:#1a9851" |Phase III (C)
|[[#EC_.26_Bevacizumab|EC & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
====Chemotherapy====
*[[Epirubicin (Ellence)]] 90 to 100 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 to 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 8 cycles'''
===References===
# Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. [https://www.nejm.org/doi/full/10.1056/NEJM200103153441101 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11248153 PubMed]
# Chan S, Davidson N, Juozaityte E, Erdkamp F, Pluzanska A, Azarnia N, Lee LW. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol. 2004 Oct;15(10):1527-34. [https://academic.oup.com/annonc/article/15/10/1527/170632 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15367414 PubMed]
<!-- Presented at the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001. -->
# '''UKNCRI AB01:''' Langley RE, Carmichael J, Jones AL, Cameron DA, Qian W, Uscinska B, Howell A, Parmar M. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. J Clin Oncol. 2005 Nov 20;23(33):8322-30. [http://jco.ascopubs.org/content/23/33/8322.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16293863 PubMed]
# Blohmer JU, Schmid P, Hilfrich J, Friese K, Kleine-Tebbe A, Koelbl H, Sommer H, Morack G, Wischnewsky MB, Lichtenegger W, Kuemmel S. Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial. Ann Oncol. 2010 Jul;21(7):1430-5. Epub 2010 Jan 20. [https://academic.oup.com/annonc/article/21/7/1430/164927 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20089562 PubMed]
<!-- Presented in part at the 45th Annual Meeting of the American Society for Clinical Oncology, May 29-June 2, 2009, Orlando, FL, and at the 15th Congress of the European Cancer Organisation and 34th Congress of the European Society for Medical Oncology Multidisciplinary Congress, September 20-24, 2009, Berlin, Germany. -->
# '''RIBBON-1:''' Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 1;29(10):1252-60. Epub 2011 Mar 7. [http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21383283 PubMed]

==EC & Bevacizumab {{#subobject:3e6b59|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EC & Bevacizumab: '''<u>E</u>'''pirubicin, '''<u>C</u>'''yclophosphamide, Bevacizumab
===Regimen {{#subobject:56e1be|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 Robert et al. 2011 (RIBBON-1)]
| style="background-color:#1a9851" |Phase III (E)
|[[#EC_3|EC]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Epirubicin (Ellence)]] 90 to 100 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 to 600 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycle for up to 8 cycles'''
====Subsequent treatment====
*[[#Bevacizumab_monotherapy_2|Bevacizumab]] maintenance, if no PD

===References===
<!-- Presented in part at the 45th Annual Meeting of the American Society for Clinical Oncology, May 29-June 2, 2009, Orlando, FL, and at the 15th Congress of the European Cancer Organisation and 34th Congress of the European Society for Medical Oncology Multidisciplinary Congress, September 20-24, 2009, Berlin, Germany. -->
# '''RIBBON-1:''' Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 1;29(10):1252-60. Epub 2011 Mar 7. [http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21383283 PubMed]

==EP {{#subobject:e10567|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EP: '''<u>E</u>'''pirubicin & '''<u>P</u>'''aclitaxel
<br>ET: '''<u>E</u>'''pirubicin & '''<u>T</u>'''axol (Paclitaxel)
===Variant #1, 60/175 {{#subobject:1a480a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://link.springer.com/article/10.1007%2Fs10549-013-2589-8 Lück et al. 2013]
| style="background-color:#1a9851" |Phase III (C)
|XP
| style="background-color:#ffffbf" |Inconclusive whether non-inferior
|-
|}
====Chemotherapy====
*[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 6 cycles'''

===Variant #2, 75/175 {{#subobject:d6aabd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://link.springer.com/article/10.1007%2Fs10549-011-1880-9 Hatschek et al. 2011]
| style="background-color:#1a9851" |Phase III (C)
|TEX
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: the doses of this regimen were individually adjusted after cycle 1; see paper for details.''
====Chemotherapy====
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #3, 75/200 {{#subobject:f9fb8b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/33/8322.long Langley et al. 2005 (UKNCRI AB01)]
| style="background-color:#1a9851" |Phase III (E)
|[[#EC_3|EC]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1 
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 6 cycles'''

===Variant #4, 80/175 {{#subobject:2bee43|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/15/10/1517/170681 Fountzilas et al. 2004]
| style="background-color:#1a9851" |Phase III (C)
|Carboplatin & Paclitaxel
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Epirubicin (Ellence)]] 80 mg/m<sup>2</sup> IV once on day 1, '''given second'''
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''

'''21-day cycle for up to 6 cycles'''

===Variant #5, 90/200 {{#subobject:cabbcf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.20400 Conte et al. 2004]
| style="background-color:#1a9851" |Phase III (C)
|E, then P
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Epirubicin (Ellence)]] 90 mg/m<sup>2</sup> IV once on day 1
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 8 cycles'''

===References===
# Conte PF, Guarneri V, Bruzzi P, Prochilo T, Salvadori B, Bolognesi A, Aldrighetti D, Venturini M, Rosso R, Mammoliti S, Carnino F, Giannessi P, Costantini M, Moyano A, Baldini E; Gruppo Oncologico Nord Ovest. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. Cancer. 2004 Aug 15;101(4):704-12. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.20400 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15305399 PubMed]
# Fountzilas G, Kalofonos HP, Dafni U, Papadimitriou C, Bafaloukos D, Papakostas P, Kalogera-Fountzila A, Gogas H, Aravantinos G, Moulopoulos LA, Economopoulos T, Pectasides D, Maniadakis N, Siafaka V, Briasoulis E, Christodoulou C, Tsavdaridis D, Makrantonakis P, Razis E, Kosmidis P, Skarlos D, Dimopoulos MA. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2004 Oct;15(10):1517-26. [https://academic.oup.com/annonc/article/15/10/1517/170681 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15367413 PubMed]
<!-- Presented at the 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001. -->
# '''UKNCRI AB01:''' Langley RE, Carmichael J, Jones AL, Cameron DA, Qian W, Uscinska B, Howell A, Parmar M. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. J Clin Oncol. 2005 Nov 20;23(33):8322-30. [http://jco.ascopubs.org/content/23/33/8322.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16293863 PubMed]
# Hatschek T, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B, Lindh B, Loman N, Malmberg M, Rotstein S, Söderberg M, Sundquist M, Walz TM, Hellström M, Svensson H, Aström G, Brandberg Y, Carstensen J, Fernö M, Bergh J. Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial. Breast Cancer Res Treat. 2012 Feb;131(3):939-47. Epub 2011 Nov 18. [https://link.springer.com/article/10.1007%2Fs10549-011-1880-9 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22094937 PubMed]
# Lück HJ, Du Bois A, Loibl S, Schrader I, Huober J, Heilmann V, Beckmann M, Stähler A, Jackisch C, Hubalek M, Richter B, Stickeler E, Eidtmann H, Thomssen C, Untch M, Wollschläger K, Schuster T, von Minckwitz G. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Breast Cancer Res Treat. 2013 Jun;139(3):779-87. Epub 2013 Jun 15. [https://link.springer.com/article/10.1007%2Fs10549-013-2589-8 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23771714 PubMed]

==Epirubicin monotherapy {{#subobject:e941f2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 35 mg/m<sup>2</sup>, 3 out of 4 weeks {{#subobject:e75cc8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/16/6/899/193851 Feher et al. 2005]
|style="background-color:#1a9851" |Phase III (C)
|Gemcitabine
| style="background-color:#1a9850" |Superior OS
|-
|}
====Chemotherapy====
*[[Epirubicin (Ellence)]] 35 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===Variant #2, 40 mg/m<sup>2</sup> {{#subobject:740b22|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="3" |[http://jco.ascopubs.org/content/14/4/1146.long Bastholt et al. 1996]
| rowspan="3" style="background-color:#1a9851" |Phase III (E)
|1. Epirubicin 60 mg/m<sup>2</sup>
| style="background-color:#ffffbf" |Seems not superior
|-
|2. Epirubicin 90 mg/m<sup>2</sup>
| style="background-color:#d73027" |Inferior TTP
|-
|3. Epirubicin 135 mg/m<sup>2</sup>
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Epirubicin (Ellence)]] 40 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #3, 60 mg/m<sup>2</sup> {{#subobject:5b43d9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/1/4/275/215098 Nielsen et al. 1990]
|style="background-color:#1a9851" |Phase III (C)
|Epirubicin & Vindesine
| style="background-color:#ffffbf" |Seems not superior
|-
| rowspan="3" |[http://jco.ascopubs.org/content/14/4/1146.long Bastholt et al. 1996]
| rowspan="3" style="background-color:#1a9851" |Phase III (E)
|1. Epirubicin 40 mg/m<sup>2</sup>
| style="background-color:#ffffbf" |Seems not superior
|-
|2. Epirubicin 90 mg/m<sup>2</sup>
| style="background-color:#ffffbf" |Seems not superior
|-
|3. Epirubicin 135 mg/m<sup>2</sup>
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #4, 70 mg/m<sup>2</sup>, 2 out of 4 weeks {{#subobject:03c8f3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://link.springer.com/article/10.1007%2Fs002800000178 Nielsen et al. 2000]
|style="background-color:#1a9851" |Phase III (C)
|Cisplatin & Epirubicin
| style="background-color:#fc8d59" |Seems to have inferior TTP
| style="background-color:#1a9850" |Superior toxicity
|-
|}
====Chemotherapy====
*[[Epirubicin (Ellence)]] 70 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycles until maximum dose of epirubicin reached (1000 mg/m<sup>2</sup>)'''

===Variant #5, 90 mg/m<sup>2</sup> {{#subobject:e56ea6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="3" |[http://jco.ascopubs.org/content/14/4/1146.long Bastholt et al. 1996]
| rowspan="3" style="background-color:#1a9851" |Phase III (C)
|1. Epirubicin 40 mg/m<sup>2</sup>
| style="background-color:#1a9850" |Superior TTP
|-
|2. Epirubicin 60 mg/m<sup>2</sup>
| style="background-color:#ffffbf" |Seems not superior
|-
|3. Epirubicin 135 mg/m<sup>2</sup>
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2004.11.503 Ejlertsen et al. 2004 (SBG 9403)]
|style="background-color:#1a9851" |Phase III (C)
|Epirubicin & Vinorelbine
| style="background-color:#fc8d59" |Seems to have inferior PFS
|-
|}
====Chemotherapy====
*[[Epirubicin (Ellence)]] 90 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #6, 120 mg/m<sup>2</sup>, split doses {{#subobject:45c4d9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1996.14.4.1165 Dogliotti et al. 1996]
|style="background-color:#1a9851" |Phase III (C)
|Epirubicin & Lonidamine
| style="background-color:#d73027" |Inferior ORR
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.08.012 Berruti et al. 2002]
|style="background-color:#1a9851" |Phase III (C)
|1. Cisplatin & Epirubicin<br> 2. Cisplatin, Epirubicin, Lonidamine<br> 3. Epirubicin & Lonidamine
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IV once per day on days 1 & 2

'''21-day cycles'''

===Variant #7, 135 mg/m<sup>2</sup> {{#subobject:e0a80d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="3" |[http://jco.ascopubs.org/content/14/4/1146.long Bastholt et al. 1996]
| rowspan="3" style="background-color:#1a9851" |Phase III (E)
|1. Epirubicin 40 mg/m<sup>2</sup>
| style="background-color:#ffffbf" |Seems not superior
|-
|2. Epirubicin 60 mg/m<sup>2</sup>
| style="background-color:#ffffbf" |Seems not superior
|-
|3. Epirubicin 90 mg/m<sup>2</sup>
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Epirubicin (Ellence)]] 135 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===References===
# Nielsen D, Dombernowsky P, Skovsgaard T, Jensen J, Andersen E, Engelholm SA, Hansen M. Epirubicin or epirubicin and vindesine in advanced breast cancer: a phase III study. Ann Oncol. 1990 Jul;1(4):275-80. [https://academic.oup.com/annonc/article/1/4/275/215098 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2265137 PubMed]
# Bonneterre J, Hurteloup P; The French Epirubicin Study Group. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol. 1991 Feb;9(2):305-12. [http://ascopubs.org/doi/abs/10.1200/JCO.1991.9.2.305 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1988577 PubMed]
# Bastholt L, Dalmark M, Gjedde SB, Pfeiffer P, Pedersen D, Sandberg E, Kjaer M, Mouridsen HT, Rose C, Nielsen OS, Jakobsen P, Bentzen SM. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol. 1996 Apr;14(4):1146-55. [http://jco.ascopubs.org/content/14/4/1146.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8648369 PubMed]
# Dogliotti L, Berruti A, Buniva T, Zola P, Baù MG, Farris A, Sarobba MG, Bottini A, Alquati P, Deltetto F, Gosso P, Monzeglio C, Moro G, Sussio M, Perroni D. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. J Clin Oncol. 1996 Apr;14(4):1165-72. [http://ascopubs.org/doi/abs/10.1200/JCO.1996.14.4.1165 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8648371 PubMed]
# Nielsen D, Dombernowsky P, Larsen SK, Hansen OP, Skovsgaard T. Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer: a phase III study. Cancer Chemother Pharmacol. 2000;46(6):459-66. [https://link.springer.com/article/10.1007%2Fs002800000178 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11138459 PubMed]
# Berruti A, Bitossi R, Gorzegno G, Bottini A, Alquati P, De Matteis A, Nuzzo F, Giardina G, Danese S, De Lena M, Lorusso V, Farris A, Sarobba MG, DeFabiani E, Bonazzi G, Castiglione F, Bumma C, Moro G, Bruzzi P, Dogliotti L; Epirubicin-Lonidamine Group Orbassano Torino Italy. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. J Clin Oncol. 2002 Oct 15;20(20):4150-9. [http://ascopubs.org/doi/full/10.1200/JCO.2002.08.012 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12377958 PubMed]
# '''SBG 9403:''' Ejlertsen B, Mouridsen HT, Langkjer ST, Andersen J, Sjöström J, Kjaer M; Scandinavian Breast Group. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). J Clin Oncol. 2004 Jun 15;22(12):2313-20. [http://ascopubs.org/doi/full/10.1200/JCO.2004.11.503 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15197192 PubMed]
# Feher O, Vodvarka P, Jassem J, Morack G, Advani SH, Khoo KS, Doval DC, Ermisch S, Roychowdhury D, Miller MA, von Minckwitz G. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol. 2005 Jun;16(6):899-908. Epub 2005 Apr 8. [https://academic.oup.com/annonc/article/16/6/899/193851 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15821120 PubMed]

==FAC {{#subobject:b0cb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FAC: '''<u>F</u>'''luorouracil, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide
<br>CAF: '''<u>C</u>'''yclophosphamide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>F</u>'''luorouracil
===Variant #1, 500/50/500 {{#subobject:c92289|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(197708)40:2%3C625::AID-CNCR2820400206%3E3.0.CO;2-M Smalley et al. 1977]
| style="background-color:#1a9851" |Phase III (E)
|CMFVP
| style="background-color:#d9ef8b" |Might have superior OS (*)
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM199111073251904 Muss et al. 1991]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1988.6.10.1611 Bennett et al. 1988]
| style="background-color:#1a9851" |Phase III (C)
|CNF
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/%28SICI%291097-0142%2819990301%2985%3A5%3C1091%3A%3AAID-CNCR12%3E3.0.CO%3B2-A Blajman et al. 1999]
| style="background-color:#1a9851" |Phase III (C)
|NA
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/10.1200/JCO.2001.19.6.1707 Jassem et al. 2001]
| style="background-color:#1a9851" |Phase III (C)
|[[#AT_.28Taxol.29_2|AT (Taxol)]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 Robert et al. 2011 (RIBBON-1)]
| style="background-color:#1a9851" |Phase III (C)
|[[#FAC_.26_Bevacizumab|FAC & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Note: reported efficacy for Smalley et al. 1977 is based on the 1983 update.''
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 6 to 8 cycles'''
====Subsequent treatment====
*Muss et al. 1991: [[#CMF_2|CMF]] versus observation, then CMF at progression

===Variant #2, 600/50/600 {{#subobject:dbd450|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://link.springer.com/article/10.1007/BF00666487 Alonso et al. 1995]
| style="background-color:#1a9851" |Phase III (C)
|CNF
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup>/day IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 10 cycles'''

===Variant #3, 1000/40/500 {{#subobject:d56b20|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.6.1443 Aisner et al. 1995 (CALGB 8281)]
| style="background-color:#1a9851" |Phase III (C)
|1. VATH<br> 2. VATH/CMFVP
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2003.05.119 Parnes et al. 2003 (CALGB 9140)]
| style="background-color:#1a9851" |Phase III (C)
|FAC & Leucovorin
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: Aisner et al. 1995 does not describe dosing; included here because it is a CALGB study.''
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup> IV once per day on days 1 to 5
*[[Doxorubicin (Adriamycin)]] 40 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #4, 1000/50/500 {{#subobject:ed75b0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197911)44:5%3C1955::AID-CNCR2820440559%3E3.0.CO;2-P/abstract Hortobagyi et al. 1979]
| style="background-color:#1a9851" |Phase III (C)
|FAC-BCG
| style="background-color:#d73027" |Inferior OS in responders
|-
|}
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8 or days 1 & 4
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #5, 1000/50/1400 {{#subobject:b25f0f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1987.5.10.1534 Perry et al. 1987 (CALGB 8081)]
| style="background-color:#1a9851" |Phase III (C)
|CAFT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Cyclophosphamide (Cytoxan)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 14

'''28-day cycle for up to 9 cycles'''

===Variant #6, 1000/60/1400 {{#subobject:b89f0f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197805)41:5%3C1649::AID-CNCR2820410501%3E3.0.CO;2-J/abstract Bull et al. 1978]
| style="background-color:#1a9851" |Phase III (E)
|[[#CMF_2|CMF]]
| style="background-color:#d9ef8b" |Might have superior ORR
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1987.5.6.881 Falkson et al. 1987 (ECOG E2177)]
| style="background-color:#1a9851" |Phase III (C)
|O+CAF
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ejcancer.com/article/0959-8049(94)90123-6/pdf Tominaga et al. 1994]
| style="background-color:#1a9851" |Phase III (C)
|CAF & MPA
| style="background-color:#fc8d59" |Seems to have inferior ORR
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.2.262 Sledge et al. 2000 (ECOG E3186)]
| style="background-color:#1a9851" |Phase III (C)
|CAFTH
| style="background-color:#fee08b" |Might have inferior TTF
|-
|[https://insights.ovid.com/pubmed?pmid=17414459 Pandya et al. 2007 (ECOG E3185)]
| style="background-color:#1a9851" |Phase III (C)
|CAF/TsAVbH
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: the dosing details of ECOG E3185 are not described in the abstract.''
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Doxorubicin (Adriamycin)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Cyclophosphamide (Cytoxan)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 14

'''28-day cycle for up to 6 cycles (ECOG E3186) or indefinitely (Bull et al. 1978)'''

===References===
# Smalley RV, Carpenter J, Bartolucci A, Vogel C, Krauss S. A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project. Cancer. 1977 Aug;40(2):625-32. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(197708)40:2%3C625::AID-CNCR2820400206%3E3.0.CO;2-M link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/329975 PubMed]
## '''Update:''' Smalley RV, Lefante J, Bartolucci A, Carpenter J, Vogel C, Krauss S. A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer. Breast Cancer Res Treat. 1983;3(2):209-20. [https://link.springer.com/article/10.1007/BF01803563 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/6688538 PubMed]
# Bull JM, Tormey DC, Li SH, Carbone PP, Falkson G, Blom J, Perlin E, Simon R. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer. 1978 May;41(5):1649-57. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197805)41:5%3C1649::AID-CNCR2820410501%3E3.0.CO;2-J/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/348293 PubMed]
# Hortobagyi GN, Gutterman JU, Blumenschein GR, Tashima CK, Burgess MA, Einhorn L, Buzdar AU, Richman SP, Hersh EM. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer. 1979 Nov;44(5):1955-62. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197911)44:5%3C1955::AID-CNCR2820440559%3E3.0.CO;2-P/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/387212 PubMed]
# '''ECOG E2177:''' Falkson G, Gelman RS, Tormey DC, Falkson CI, Wolter JM, Cummings FJ. Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1987 Jun;5(6):881-9. [http://ascopubs.org/doi/abs/10.1200/JCO.1987.5.6.881 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/3585444 PubMed]
## '''Update:''' Falkson G, Holcroft C, Gelman RS, Tormey DC, Wolter JM, Cummings FJ. Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1995 Jun;13(6):1453-8. [http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.6.1453 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7751892 PubMed]
# '''CALGB 8081:''' Perry MC, Kardinal CG, Korzun AH, Ginsberg SJ, Raich PC, Holland JF, Ellison RR, Kopel S, Schilling A, Aisner J, Schulman P, Weinberg V, Rice MA, Wood W. Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081. J Clin Oncol. 1987 Oct;5(10):1534-45. [http://ascopubs.org/doi/abs/10.1200/JCO.1987.5.10.1534 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/3655856 PubMed]
# Bennett JM, Muss HB, Doroshow JH, Wolff S, Krementz ET, Cartwright K, Dukart G, Reisman A, Schoch I. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol. 1988 Oct;6(10):1611-20. [http://ascopubs.org/doi/abs/10.1200/JCO.1988.6.10.1611 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/3049953 PubMed]
# Muss HB, Case LD, Richards F 2nd, White DR, Cooper MR, Cruz JM, Powell BL, Spurr CL, Capizzi RL; The Piedmont Oncology Association. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med. 1991 Nov 7;325(19):1342-8. [https://www.nejm.org/doi/full/10.1056/NEJM199111073251904 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1922236 PubMed]
# Tominaga T, Abe O, Ohshima A, Hayasaka H, Uchino J, Abe R, Enomoto K, Izuo M, Watanabe H, Takatani O, Yoshida M, Sakai K, Koyama H, Hattori T, Senoo T, Monden Y, Nomura Y. Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer. Eur J Cancer. 1994;30A(7):959-64. [https://www.ejcancer.com/article/0959-8049(94)90123-6/pdf link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7946592 PubMed]
# Alonso MC, Tabernero JM, Ojeda B, Llanos M, Solà C, Climent MA, Seguí MA, López JJ. A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Breast Cancer Res Treat. 1995 Apr;34(1):15-24. [https://link.springer.com/article/10.1007/BF00666487 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7749156 PubMed]
# '''CALGB 8281:''' Aisner J, Cirrincione C, Perloff M, Perry M, Budman D, Abrams J, Panasci L, Muss H, Citron M, Holland J, Wood W, Henderson IC. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281. J Clin Oncol. 1995 Jun;13(6):1443-52. [http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.6.1443 link to original article] '''does not contain protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7751891 PubMed]
# Blajman C, Balbiani L, Block J, Coppola F, Chacon R, Fein L, Bonicatto S, Alvarez A, Schmilovich A, Delgado FM. A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma. Cancer. 1999 Mar 1;85(5):1091-7. [https://onlinelibrary.wiley.com/doi/full/10.1002/%28SICI%291097-0142%2819990301%2985%3A5%3C1091%3A%3AAID-CNCR12%3E3.0.CO%3B2-A link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10091793 PubMed]
# '''ECOG E3186:''' Sledge GW Jr, Hu P, Falkson G, Tormey D, Abeloff M. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2000 Jan;18(2):262-6. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.2.262 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10637238 PubMed]
# Jassem J, Pieńkowski T, Płuzańska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, Berzins J, Nagykalnai T, Wigler N, Renard J, Munier S, Weil C; Central & Eastern Europe and Israel Pacitaxel Breast Cancer Study Group. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol. 2001 Mar 15;19(6):1707-15. [http://ascopubs.org/doi/10.1200/JCO.2001.19.6.1707 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11251000 PubMed]
# '''CALGB 9140:''' Parnes HL, Cirrincione C, Aisner J, Berry DA, Allen SL, Abrams J, Chuang E, Cooper MR, Perry MC, Duggan DB, Szatrowski TP, Henderson IC, Norton L; Cancer and Leukemia Group B. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140. J Clin Oncol. 2003 May 1;21(9):1819-24. [http://ascopubs.org/doi/full/10.1200/JCO.2003.05.119 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12721259 PubMed] 
# '''ECOG E3185:''' Pandya KJ, Hu P, Osborne CK, Falkson G, Tormey DC; Eastern Cooperative Oncology Group. Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185). Am J Clin Oncol. 2007 Apr;30(2):113-25. [https://insights.ovid.com/pubmed?pmid=17414459 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17414459 PubMed]
<!-- Presented in part at the 45th Annual Meeting of the American Society for Clinical Oncology, May 29-June 2, 2009, Orlando, FL, and at the 15th Congress of the European Cancer Organisation and 34th Congress of the European Society for Medical Oncology Multidisciplinary Congress, September 20-24, 2009, Berlin, Germany. -->
# '''RIBBON-1:''' Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 1;29(10):1252-60. Epub 2011 Mar 7. [http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21383283 PubMed]

==FAC & Bevacizumab {{#subobject:4e04d9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FAC & Bevacizumab: '''<u>F</u>'''luorouracil, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>C</u>'''yclophosphamide, Bevacizumab
===Regimen {{#subobject:961016|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 Robert et al. 2011 (RIBBON-1)]
| style="background-color:#1a9851" |Phase III (E)
|[[#FAC_3|FAC]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Doxorubicin (Adriamycin)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycle for up to 8 cycles'''
====Subsequent treatment====
*[[#Bevacizumab_monotherapy_2|Bevacizumab]] maintenance, if no PD
===References===
<!-- Presented in part at the 45th Annual Meeting of the American Society for Clinical Oncology, May 29-June 2, 2009, Orlando, FL, and at the 15th Congress of the European Cancer Organisation and 34th Congress of the European Society for Medical Oncology Multidisciplinary Congress, September 20-24, 2009, Berlin, Germany. -->
# '''RIBBON-1:''' Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 1;29(10):1252-60. Epub 2011 Mar 7. [http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21383283 PubMed]

==FEC {{#subobject:ed96e7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FEC: '''<u>F</u>'''luorouracil, '''<u>E</u>'''pirubicin, '''<u>C</u>'''yclophosphamide
<br>CEF: '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''pirubicin, '''<u>F</u>'''luorouracil
===Variant #1, 500/50/500 ("FEC 50") {{#subobject:d92480|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://ascopubs.org/doi/abs/10.1200/JCO.1991.9.2.305 Bonneterre & Hurteloup 1991]
|rowspan=2 style="background-color:#1a9851" |Phase III (E)
|[[#Epirubicin_monotherapy_2|Epirubicin]]
| style="background-color:#91cf60" |Seems to have superior ORR
|-
|FEC 75
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1993.11.7.1253 Focan et al. 1993]
| style="background-color:#1a9851" |Phase III (C)
|FEC 100
| style="background-color:#fc8d59" |Seems to have inferior TTP
|-
|[http://annonc.oxfordjournals.org/content/8/2/155.long Brufman et al. 1997 (HEPI 010)]
| style="background-color:#1a9851" |Phase III (C)
|FEC 100
| style="background-color:#d73027" |Inferior ORR
|-
|}
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 to 8 cycles'''

===Variant #2, 500/60/500 {{#subobject:eb63d8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1993.11.3.467 Blomqvist et al. 1993]
| style="background-color:#1a9851" |Phase III (C)
|Weekly FEC
| style="background-color:#1a9850" |Superior OS
|-
|}
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''28-day cycles'''

===Variant #3, 500/75/500 ("FEC 75") {{#subobject:0df196|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://ascopubs.org/doi/abs/10.1200/JCO.1991.9.2.305 Bonneterre & Hurteloup 1991]
|rowspan=2 style="background-color:#1a9851" |Phase III (E)
|[[#Epirubicin_monotherapy_2|Epirubicin]]
| style="background-color:#1a9850" |Superior ORR
|-
|FEC 50
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ejcancer.com/article/S0959-8049(00)00068-X/fulltext Pacini et al. 2000]
| style="background-color:#1a9851" |Phase III (C)
|EM +/- Lonidamine
| style="background-color:#d73027" |Inferior OS
|-
|}
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 75 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #4, 500/90/500 {{#subobject:8aa343|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.2005.12.106 Zielinksi et al. 2005 (CECOG BM1)]
| style="background-color:#1a9851" |Phase III (C)
|GET
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 Robert et al. 2011 (RIBBON-1)]
| style="background-color:#1a9851" |Phase III (C)
|[[#FEC_.26_Bevacizumab|FEC & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Note: this is the lower bound of the dosing range allowed in RIBBON-1.''
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 90 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 8 cycles'''

===Variant #5, 500/100/500 ("FEC 100") {{#subobject:33c356|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1993.11.7.1253 Focan et al. 1993]
| style="background-color:#1a9851" |Phase III (E)
|FEC 50
| style="background-color:#91cf60" |Seems to have superior TTP
|-
|[http://annonc.oxfordjournals.org/content/8/2/155.long Brufman et al. 1997 (HEPI 010)]
| style="background-color:#1a9851" |Phase III (E)
|FEC 50
| style="background-color:#1a9850" |Superior ORR
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 Robert et al. 2011 (RIBBON-1)]
| style="background-color:#1a9851" |Phase III (C)
|[[#FEC_.26_Bevacizumab|FEC & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Note: this is the upper bound of the dosing range allowed in RIBBON-1.''
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 100 mg/m<sup>2</sup> IV once on day 1 
**Note: in Focan et al. 1993, dose was split: 50 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 6 to 8 cycles'''

===Variant #6, 600/60/600 ("CEF21") {{#subobject:80e015|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1987.5.3.339 Conte et al. 1987]
| style="background-color:#1a9851" |Randomized (C)
|DES-CEF
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ejcancer.com/article/S0959-8049(05)80145-5/pdf Ejlertsen et al. 1993]
| style="background-color:#1a9851" |Phase III (C)
|CEF x 18 mo
| style="background-color:#d73027" |Inferior OS
|-
|[https://academic.oup.com/annonc/article/7/5/487/153037 Conte et al. 1996]
| style="background-color:#1a9851" |Phase III (C)
|DES-CEF
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2001.19.8.2213 Del Mastro et al. 2001]
| style="background-color:#1a9851" |Phase III (C)
|HD-CEF14
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: dosing information was not available in the abstract of Ejlertsen et al. 1993; this dosing has been used in other studies by this group.''
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 600 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 60 mg/m<sup>2</sup> IV once on day 1 
*[[Cyclophosphamide (Cytoxan)]] 600 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 8 to 12 cycles'''

===Variant #7, 1000/60/1400 {{#subobject:8505fe|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://link.springer.com/article/10.1023/A:1006387801960 Esteban et al. 1999]
| style="background-color:#1a9851" |Phase III (C)
|[[Breast_cancer_-_historical#FNC|CNF]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Epirubicin (Ellence)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8 
*[[Cyclophosphamide (Cytoxan)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 14

'''28-day cycles'''

===Variant #8, 1000/100/800 {{#subobject:830d7f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/19/4/943.long Ackland et al. 2001 (HEPI 013)]
| style="background-color:#1a9851" |Phase III (E)
|[[#CMF_2|CMF]]
| style="background-color:#1a9850" |Superior TTP
|-
|}
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once per day on days 1 & 8 
*[[Cyclophosphamide (Cytoxan)]] 400 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''28-day cycle for 6 to 8 cycles'''

===References===
# Conte PF, Pronzato P, Rubagotti A, Alama A, Amadori D, Demicheli R, Gardin G, Gentilini P, Jacomuzzi A, Lionetto R, Monzeglio C, Nicolin A, Rosso R, Sismondi P, Sussio M, Santi L. Conventional versus cytokinetic polychemotherapy with estrogenic recruitment in metastatic breast cancer: results of a randomized cooperative trial. J Clin Oncol. 1987 Mar;5(3):339-47. [http://ascopubs.org/doi/abs/10.1200/JCO.1987.5.3.339 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/3546611 PubMed]
# Bonneterre J, Hurteloup P; The French Epirubicin Study Group. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol. 1991 Feb;9(2):305-12. [http://ascopubs.org/doi/abs/10.1200/JCO.1991.9.2.305 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1988577 PubMed]
# Ejlertsen B, Pfeiffer P, Pedersen D, Mouridsen HT, Rose C, Overgaard M, Sandberg E, Kristensen B. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer. 1993;29A(4):527-31. [https://www.ejcancer.com/article/S0959-8049(05)80145-5/pdf link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8435205 PubMed]
# Blomqvist C, Elomaa I, Rissanen P, Hietanen P, Nevasaari K, Helle L. Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration. J Clin Oncol. 1993 Mar;11(3):467-73. [http://ascopubs.org/doi/abs/10.1200/JCO.1993.11.3.467 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8445422 PubMed]
# Focan C, Andrien JM, Closon MT, Dicato M, Driesschaert P, Focan-Henrard D, Lemaire M, Lobelle JP, Longree L, Ries F. Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial. J Clin Oncol. 1993 Jul;11(7):1253-63. [http://ascopubs.org/doi/abs/10.1200/JCO.1993.11.7.1253 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8315422 PubMed]
# Conte PF, Baldini E, Gardin G, Pronzato P, Amadori D, Carnino F, Monzeglio C, Gentilini P, Gallotti P, DeMicheli R, Venturini M, Rubagotti A, Rosso R. Chemotherapy with or without estrogenic recruitment in metastatic breast cancer: a randomized trial of the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol. 1996 Jul;7(5):487-90. [https://academic.oup.com/annonc/article/7/5/487/153037 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8839903 PubMed]
# '''HEPI 010:''' Brufman G, Colajori E, Ghilezan N, Lassus M, Martoni A, Perevodchikova N, Tosello C, Viaro D, Zielinski C; The Epirubicin High Dose (HEPI 010) Study Group. Doubling epirubicin dose intensity (100 mg/m<sup>2</sup> versus 50 mg/m<sup>2</sup>) in the FEC regimen significantly increases response rates: an international randomised phase III study in metastatic breast cancer. Ann Oncol. 1997 Feb;8(2):155-62. [http://annonc.oxfordjournals.org/content/8/2/155.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9093724 PubMed]
# Estaban E, Lacave AJ, Fernández JL, Corral N, Buesa JM, Estrada E, Palacio I, Vieitez JM, Muñiz I, Alvarez E. Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer. Breast Cancer Res Treat. 1999 Nov;58(2):141-50. [https://link.springer.com/article/10.1023/A:1006387801960 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10674879 PubMed]
# Pacini P, Rinaldini M, Algeri R, Guarneri A, Tucci E, Barsanti G, Neri B, Bastiani P, Marzano S, Fallai C. FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer, a multicentric randomised study: final results. Eur J Cancer. 2000 May;36(8):966-75. [https://www.ejcancer.com/article/S0959-8049(00)00068-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10885599 PubMed]
# '''HEPI 013:''' Ackland SP, Anton A, Breitbach GP, Colajori E, Tursi JM, Delfino C, Efremidis A, Ezzat A, Fittipaldo A, Kolaric K, Lopez M, Viaro D; HEPI 013 study group. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study. J Clin Oncol. 2001 Feb 15;19(4):943-53. [http://jco.ascopubs.org/content/19/4/943.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11181656 PubMed]
# Del Mastro L, Venturini M, Lionetto R, Carnino F, Guarneri D, Gallo L, Contu A, Pronzato P, Vesentini L, Bergaglio M, Comis S, Rosso R. Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group. J Clin Oncol. 2001 Apr 15;19(8):2213-21. [http://ascopubs.org/doi/full/10.1200/JCO.2001.19.8.2213 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11304774 PubMed]
# '''CECOG BM1:''' Zielinski C, Beslija S, Mrsic-Krmpotic Z, Welnicka-Jaskiewicz M, Wiltschke C, Kahan Z, Grgic M, Tzekova V, Inbar M, Cervek J, Chernozemsky I, Szanto J, Spanik S, Wagnerova M, Ghilezan N, Pawlega J, Vrbanec D, Khamtsov D, Soldatenkova V, Brodowicz T. Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. J Clin Oncol. 2005 Mar 1;23(7):1401-8. [http://ascopubs.org/doi/10.1200/JCO.2005.12.106 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15735116 PubMed]
<!-- Presented in part at the 45th Annual Meeting of the American Society for Clinical Oncology, May 29-June 2, 2009, Orlando, FL, and at the 15th Congress of the European Cancer Organisation and 34th Congress of the European Society for Medical Oncology Multidisciplinary Congress, September 20-24, 2009, Berlin, Germany. -->
# '''RIBBON-1:''' Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 1;29(10):1252-60. Epub 2011 Mar 7. [http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21383283 PubMed]

==FEC & Bevacizumab {{#subobject:72fe69|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FEC & Bevacizumab: '''<u>F</u>'''luorouracil, '''<u>E</u>'''pirubicin, '''<u>C</u>'''yclophosphamide, Bevacizumab
===Regimen {{#subobject:cb9b3a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 Robert et al. 2011 (RIBBON-1)]
| style="background-color:#1a9851" |Phase III (E)
|[[#FEC_3|FEC]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Epirubicin (Ellence)]] 90 to 100 mg/m<sup>2</sup> IV once on day 1
*[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycle for up to 8 cycles'''
====Subsequent treatment====
*[[#Bevacizumab_monotherapy_2|Bevacizumab]] maintenance, if no PD
===References===
<!-- Presented in part at the 45th Annual Meeting of the American Society for Clinical Oncology, May 29-June 2, 2009, Orlando, FL, and at the 15th Congress of the European Cancer Organisation and 34th Congress of the European Society for Medical Oncology Multidisciplinary Congress, September 20-24, 2009, Berlin, Germany. -->
# '''RIBBON-1:''' Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 1;29(10):1252-60. Epub 2011 Mar 7. [http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21383283 PubMed]

==Gemcitabine monotherapy {{#subobject:b240d6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:7ea6c2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/13/11/2731.long Carmichael et al. 1995]
| style="background-color:#ffffbe" |Phase II, <20 pts in this subgroup
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 800 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15

'''28-day cycles'''

===References===
# Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol. 1995 Nov;13(11):2731-6. [http://jco.ascopubs.org/content/13/11/2731.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7595731 PubMed]

==Gemcitabine & Paclitaxel {{#subobject:1285e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
GT: '''<u>G</u>'''emcitabine & '''<u>T</u>'''axol (Paclitaxel)
<br>PG: '''<u>P</u>'''aclitaxel & '''<u>G</u>'''emcitabine
===Variant #1, 6 cycles {{#subobject:5e5f66|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2012.45.2490 Park et al. 2013 (KCSG-BR07-02)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8, '''given second on day 1'''
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1, '''given first'''

'''21-day cycle for 6 cycles'''
====Subsequent treatment====
*[[#Gemcitabine_.26_Paclitaxel_2|Maintenance PG]] versus [[#Observation|Observation]]

===Variant #2, indefinite {{#subobject:7a28ec|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/26/24/3950.long Albain et al. 2008]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel_monotherapy.2C_q3wk|Paclitaxel]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV over 30 to 60 minutes once per day on days 1 & 8, '''given second on day 1'''
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''

'''21-day cycles'''
===References===
<!-- Presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3, 2003, and the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004. -->
# Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, Rolski J, Melemed AS, Reyes-Vidal JM, Sekhon JS, Simms L, O'Shaughnessy J. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008 Aug 20;26(24):3950-7. [http://jco.ascopubs.org/content/26/24/3950.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18711184 PubMed]
# '''KCSG-BR07-02:''' Park YH, Jung KH, Im SA, Sohn JH, Ro J, Ahn JH, Kim SB, Nam BH, Oh DY, Han SW, Lee S, Park IH, Lee KS, Kim JH, Kang SY, Lee MH, Park HS, Ahn JS, Im YH. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. J Clin Oncol. 2013 May 10;31(14):1732-9. Epub 2013 Apr 8. [http://ascopubs.org/doi/full/10.1200/JCO.2012.45.2490 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23569309 PubMed]

==Paclitaxel monotherapy, weekly {{#subobject:3e5448|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 80 mg/m<sup>2</sup> weekly {{#subobject:718d5b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/19/22/4216.long Perez et al. 2001]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://jco.ascopubs.org/content/26/10/1642.long Seidman et al. 2008 (CALGB 9840)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel_monotherapy.2C_q3wk|Paclitaxel q3wk]]
| style="background-color:#1a9850" |Superior OS
|-
|[https://link.springer.com/article/10.1007%2Fs10549-008-0047-9 Fountzilas et al. 2008]
| style="background-color:#1a9851" |Phase III (E)
|1. Carboplatin & Paclitaxel<br> 2. [[#Docetaxel_.26_Gemcitabine|Docetaxel & Gemcitabine]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://academic.oup.com/annonc/article-abstract/28/2/313/2676884 Martin et al. 2017 (BELLE-4)]
| style="background-color:#1a9851" |Phase III (C)
|Buparlisib & Paclitaxel
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per week

'''28-day cycles'''

===Variant #2, 80 mg/m<sup>2</sup> 3 weeks out of 4 {{#subobject:b70577|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.40.5241 Guan et al. 2013 (EGF104535)]
| style="background-color:#1a9851" |Phase III (C)
|[[Breast_cancer,_HER2-positive#TL_.28Taxol.29_2|TL (Taxol)]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00411-8/fulltext Takashima et al. 2015 (SELECT BC)]
| style="background-color:#1a9851" |Phase III (C)
|[[#S-1_monotherapy|S-1]]
| style="background-color:#eeee01" |Seems to have non-inferior OS
| style="background-color:#d73027" |Inferior EQ-5D score
|-
|}
''Note: this is the lower limit of dosing allowed in SELECT BC. Patients in EGF104535 had HER2+ disease.''
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===Variant #3, 90 mg/m<sup>2</sup> 3 weeks out of 4 {{#subobject:1a1adf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa072113 Miller et al. 2007 (ECOG E2100)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Paclitaxel_.26_Bevacizumab|Paclitaxel & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|[https://www.ejcancer.com/article/S0959-8049(16)32470-4/fulltext Miles et al. 2016 (MERiDiAN)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Paclitaxel_.26_Bevacizumab|Paclitaxel & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 90 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===Variant #4, 100 mg/m<sup>2</sup> weekly {{#subobject:f8eb25|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1998.16.10.3353 Seidman et al. 1998]
| style="background-color:#ffffbe" |Phase II, <20 pts in this subgroup
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 100 mg/m<sup>2</sup> IV over 60 minutes once per week

'''Continued indefinitely'''

===Variant #5, 100 mg/m<sup>2</sup> 3 weeks out of 4 {{#subobject:1a1adf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00411-8/fulltext Takashima et al. 2015 (SELECT BC)]
| style="background-color:#1a9851" |Phase III (C)
|[[#S-1_monotherapy|S-1]]
| style="background-color:#eeee01" |Seems to have non-inferior OS
| style="background-color:#d73027" |Inferior EQ-5D score
|-
|}
''Note: this is the upper limit of dosing allowed in SELECT BC.''
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 100 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===References===
# Seidman AD, Hudis CA, Albanell J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol. 1998 Oct;16(10):3353-61. Erratum in: J Clin Oncol. 2006 May 10;24(14):2220. Albanel, J [corrected to Albanell, J ]. [http://ascopubs.org/doi/abs/10.1200/JCO.1998.16.10.3353 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9779712 PubMed]
# Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2001 Nov 15;19(22):4216-23. [http://jco.ascopubs.org/content/19/22/4216.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11709565 PubMed]
# '''ECOG E2100:''' Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 Dec 27;357(26):2666-76. [https://www.nejm.org/doi/full/10.1056/NEJMoa072113 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18160686 PubMed]
<!-- Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004, New Orleans, LA. -->
# '''CALGB 9840:''' Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008 Apr 1;26(10):1642-9. [http://jco.ascopubs.org/content/26/10/1642.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18375893 PubMed]
# Fountzilas G, Dafni U, Dimopoulos MA, Koutras A, Skarlos D, Papakostas P, Gogas H, Bafaloukos D, Kalogera-Fountzila A, Samantas E, Briasoulis E, Pectasides D, Maniadakis N, Matsiakou F, Aravantinos G, Papadimitriou C, Karina M, Christodoulou C, Kosmidis P, Kalofonos HP. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat. 2009 May;115(1):87-99. Epub 2008 May 16. [https://link.springer.com/article/10.1007%2Fs10549-008-0047-9 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18483853 PubMed]
<!-- Presented in part at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010, and at the 36th Annual European Society of Medical Oncology Congress, Stockholm, Sweden, September 23-27, 2011. -->
# '''EGF104535:''' Guan Z, Xu B, DeSilvio ML, Shen Z, Arpornwirat W, Tong Z, Lorvidhaya V, Jiang Z, Yang J, Makhson A, Leung WL, Russo MW, Newstat B, Wang L, Chen G, Oliva C, Gomez H. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol. 2013 Jun 1;31(16):1947-53. Epub 2013 Mar 18. [http://ascopubs.org/doi/full/10.1200/JCO.2011.40.5241 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23509322 PubMed]
# '''SELECT BC:''' Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y; SELECT BC Study Group. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2016 Jan;17(1):90-8. Epub 2015 Nov 27. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00411-8/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26617202 PubMed]
## '''HRQoL analysis:''' Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Doihara H, Akabane H, Kashiwaba M, Watanabe T, Ohashi Y, Mukai H. Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial. Qual Life Res. 2017 Feb;26(2):445-453. Epub 2016 Aug 12. [https://link.springer.com/article/10.1007%2Fs11136-016-1388-1 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288429/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27517267 PubMed]
# '''MERiDiAN:''' Miles D, Cameron D, Bondarenko I, Manzyuk L, Alcedo JC, Lopez RI, Im SA, Canon JL, Shparyk Y, Yardley DA, Masuda N, Ro J, Denduluri N, Hubeaux S, Quah C, Bais C, O'Shaughnessy J. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. Eur J Cancer. 2017 Jan;70:146-155. Epub 2016 Nov 4. [https://www.ejcancer.com/article/S0959-8049(16)32470-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27817944 PubMed]
## '''Update:''' Miles D, Cameron D, Hilton M, Garcia J, O'Shaughnessy J. Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer. Eur J Cancer. 2018 Feb;90:153-155. Epub 2017 Nov 23. [https://www.sciencedirect.com/science/article/pii/S0959804917313588 link to SD article] [https://www.ncbi.nlm.nih.gov/pubmed/29174181 PubMed]
# '''BELLE-4:''' Martín M, Chan A, Dirix L, O'Shaughnessy J, Hegg R, Manikhas A, Shtivelband M, Krivorotko P, Batista López N, Campone M, Ruiz Borrego M, Khan QJ, Beck JT, Ramos Vázquez M, Urban P, Goteti S, Di Tomaso E, Massacesi C, Delaloge S. A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4). Ann Oncol. 2017 Feb 1;28(2):313-320. [https://academic.oup.com/annonc/article-abstract/28/2/313/2676884 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27803006 PubMed]

==Paclitaxel monotherapy, q3wk {{#subobject:3e5448|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 175 mg/m<sup>2</sup> q3wk {{#subobject:72389a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[http://jco.ascopubs.org/content/13/10/2575.long Seidman et al. 1995]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM200103153441101 Slamon et al. 2001]
| style="background-color:#1a9851" |Phase III (C)
|[[Breast_cancer,_HER2-positive#TH_.28Taxol.29_2|TH]]
| style="background-color:#fc8d59" |Seems to have inferior OS
| style="background-color:#d3d3d3" |
|-
|rowspan=2|[http://ascopubs.org/doi/10.1200/JCO.2004.08.048 Winer et al. 2004 (CALGB 9342)]
|rowspan=2 style="background-color:#1a9851" |Phase III (C)
|1. Paclitaxel 210 mg/m<sup>2</sup> q3wk
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#d3d3d3" |
|-
|2. Paclitaxel 250 mg/m<sup>2</sup> q3wk
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#d3d3d3" |
|-
|[http://jco.ascopubs.org/content/23/31/7794.long Gradishar et al. 2005]
| style="background-color:#1a9851" |Phase III (C)
|[[#Paclitaxel.2C_nanoparticle_albumin-bound_monotherapy_2|Nanoparticle albumin-bound paclitaxel]]
| style="background-color:#d73027" |Inferior TTP
| style="background-color:#d3d3d3" |
|-
|[http://jco.ascopubs.org/content/26/10/1642.long Seidman et al. 2008 (CALGB 9840)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Paclitaxel_monotherapy.2C_weekly_3|Weekly paclitaxel]]
| style="background-color:#d73027" |Inferior OS
| style="background-color:#d3d3d3" |
|-
|[http://jco.ascopubs.org/content/26/24/3950.long Albain et al. 2008]
| style="background-color:#1a9851" |Phase III (C)
|[[#Gemcitabine_.26_Paclitaxel_3|GT]]
| style="background-color:#fc8d59" |Seems to have inferior OS
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651098/ Di Leo et al. 2008 (EGF30001)]
| style="background-color:#1a9851" |Phase III (C)
|Lapatinib & Paclitaxel
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#1a9850" |Less toxic
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00411-8/fulltext Takashima et al. 2015 (SELECT BC)]
| style="background-color:#1a9851" |Phase III (C)
|[[#S-1_monotherapy|S-1]]
| style="background-color:#eeee01" |Seems to have non-inferior OS
| style="background-color:#d73027" |Inferior EQ-5D score
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512366/ Park et al. 2016]
| style="background-color:#1a9851" |Phase III (C)
|Genexol-PM
| style="background-color:#eeee01" |Seems to have non-inferior ORR
| style="background-color:#d3d3d3" |
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1

'''21-day cycles'''

===Variant #2, 175 mg/m<sup>2</sup> q4wk {{#subobject:42c791|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00411-8/fulltext Takashima et al. 2015 (SELECT BC)]
| style="background-color:#1a9851" |Phase III (C)
|[[#S-1_monotherapy|S-1]]
| style="background-color:#eeee01" |Seems to have non-inferior OS
| style="background-color:#d73027" |Inferior EQ-5D score
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1

'''28-day cycles'''

===Variant #3, 200 mg/m<sup>2</sup> {{#subobject:2e25d1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.1999.17.8.2355 Bishop et al. 1999]
| style="background-color:#1a9851" |Phase III (E)
|CMFP
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[http://ascopubs.org/doi/10.1200/JCO.2000.18.4.724 Paridaens et al. 2000 (EORTC 10923)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Doxorubicin_monotherapy_2|Doxorubicin]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1

'''21-day cycle for 7 or 8 cycles'''

===Variant #4, 250 mg/m<sup>2</sup> {{#subobject:e60257|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/jnci/article-abstract/83/24/1797/898058 Holmes et al. 1991]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1999.17.11.3403 Smith et al. 1996 (NSABP B-26)]
| style="background-color:#1a9851" |Phase III (C)
|Paclitaxel 250 mg/m<sup>2</sup> over 3 hours
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: Holmes et al. 1991 is of historic interest, being the first phase II trial of a taxane in breast cancer.''
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 250 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on day 1

'''21-day cycles'''

===References===
# Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991 Dec 18;83(24):1797-805. [https://academic.oup.com/jnci/article-abstract/83/24/1797/898058 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1683908 PubMed]
# Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, Lepore J, Gilewski T, Currie V, Crown J, Hakes T, Baselga J, Sklarin N, Moynihan ME, Tong W, Egorin M, Kearns C, Spriggs D, Norton L. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol. 1995 Oct;13(10):2575-81. [http://jco.ascopubs.org/content/13/10/2575.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7595709 PubMed]
# Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MH, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J, Canetta R. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol. 1999 Aug;17(8):2355-64. [http://ascopubs.org/doi/10.1200/JCO.1999.17.8.2355 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10561297 PubMed]
# '''NSABP B-26:''' Smith RE, Brown AM, Mamounas EP, Anderson SJ, Lembersky BC, Atkins JH, Shibata HR, Baez L, DeFusco PA, Davila E, Tipping SJ, Bearden JD, Thirlwell MP. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol. 1999 Nov;17(11):3403-11. [http://ascopubs.org/doi/full/10.1200/JCO.1999.17.11.3403 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10550134 PubMed]
# '''EORTC 10923:''' Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol. 2000 Feb;18(4):724-33. [http://ascopubs.org/doi/10.1200/JCO.2000.18.4.724 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10673513 PubMed]
# Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. [https://www.nejm.org/doi/full/10.1056/NEJM200103153441101 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11248153 PubMed]
# '''CALGB 9342:''' Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342. J Clin Oncol. 2004 Jun 1;22(11):2061-8. [http://ascopubs.org/doi/10.1200/JCO.2004.08.048 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15169793 PubMed]
<!-- Presented in part at the 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 3-6, 2003. -->
# Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005 Nov 1;23(31):7794-803. Epub 2005 Sep 19. [http://jco.ascopubs.org/content/23/31/7794.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16172456 PubMed]
<!-- Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004, New Orleans, LA. -->
# '''CALGB 9840:''' Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008 Apr 1;26(10):1642-9. [http://jco.ascopubs.org/content/26/10/1642.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18375893 PubMed]
<!-- Presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3, 2003, and the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004. -->
# Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, Rolski J, Melemed AS, Reyes-Vidal JM, Sekhon JS, Simms L, O'Shaughnessy J. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008 Aug 20;26(24):3950-7. [http://jco.ascopubs.org/content/26/24/3950.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18711184 PubMed]
# '''EGF30001:''' Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH, Williams LS, Dering J, Finn RS, Press MF. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008 Dec 1;26(34):5544-52. Epub 2008 Oct 27. Erratum in: J Clin Oncol. 2009 Apr 10;27(11):1923. [http://ascopubs.org/doi/full/10.1200/JCO.2008.16.2578 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2651098/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18955454 PubMed]
# '''SELECT BC:''' Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y; SELECT BC Study Group. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2016 Jan;17(1):90-8. Epub 2015 Nov 27. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00411-8/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26617202 PubMed]
## '''HRQoL analysis:''' Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Doihara H, Akabane H, Kashiwaba M, Watanabe T, Ohashi Y, Mukai H. Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial. Qual Life Res. 2017 Feb;26(2):445-453. Epub 2016 Aug 12. [https://link.springer.com/article/10.1007%2Fs11136-016-1388-1 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288429/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27517267 PubMed]
# Park IH, Sohn JH, Kim SB, Lee KS, Chung JS, Lee SH, Kim TY, Jung KH, Cho EK, Kim YS, Song HS, Seo JH, Ryoo HM, Lee SA, Yoon SY, Kim CS, Kim YT, Kim SY, Jin MR, Ro J. An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer. Cancer Res Treat. 2017 Jul;49(3):569-577. Epub 2016 Sep 12. [https://www.e-crt.org/journal/view.php?doi=10.4143/crt.2016.289 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512366/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27618821 PubMed]

==Paclitaxel & Bevacizumab {{#subobject:ab5252|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:1c2f5c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa072113 Miller et al. 2007 (ECOG E2100)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel_monotherapy.2C_weekly_3|Paclitaxel]]
| style="background-color:#1a9850" |Superior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4617186/ Robert et al. 2011 (SUN 1094)]
| style="background-color:#1a9851" |Phase III (C)
|Paclitaxel & Sunitinib
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70566-1/fulltext Lang et al. 2013 (TURANDOT)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Capecitabine_.26_Bevacizumab|Capecitabine & Bevacizumab]]
| style="background-color:#eeee01" |Non-inferior OS (*)
|-
|rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500830/ Rugo et al. 2015 (CALGB 40502/NCCTG N063H)]
| rowspan=2 style="background-color:#1a9851" |Phase III (C)
|1. Ixabepilone & Bevacizumab
| style="background-color:#1a9850" |Superior PFS
|-
|[[#Paclitaxel.2C_nanoparticle_albumin-bound_.26_Bevacizumab|2. nab-Paclitaxel & Bevacizumab]]
| style="background-color:#d9ef8b" |Might have superior PFS
|-
|[https://www.ejcancer.com/article/S0959-8049(16)32470-4/fulltext Miles et al. 2016 (MERiDiAN)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel_monotherapy.2C_weekly_3|Paclitaxel]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
''Note: efficacy for TURANDOT is based on the 2016 update.''
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 90 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15
*[[Bevacizumab (Avastin)]] 10 mg/kg IV once per day on days 1 & 15

'''28-day cycles'''

===References===
# '''ECOG E2100:''' Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 Dec 27;357(26):2666-76. [https://www.nejm.org/doi/full/10.1056/NEJMoa072113 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18160686 PubMed]
# '''SUN 1094:''' Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, Copur MS, Brufsky AM, Minton SE, Giguere JK, Smith JW 2nd, Richards PD, Gernhardt D, Huang X, Liau KF, Kern KA, Davis J. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer. 2011 Apr;11(2):82-92. Epub 2011 Apr 11. Erratum in: Clin Breast Cancer. 2011 Aug;11(4):273. [https://www.clinical-breast-cancer.com/article/S1526-8209(11)00006-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4617186/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21569994 PubMed]
# '''TURANDOT:''' Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Messinger D, Zielinski C; Central European Cooperative Oncology Group. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol. 2013 Feb;14(2):125-33. Epub 2013 Jan 10. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70566-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23312888 PubMed]
## '''Update:''' Zielinski C, Láng I, Inbar M, Kahán Z, Greil R, Beslija S, Stemmer SM, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Petruzelka L, Eniu A, Nisenbaum B, Dank M, Anghel R, Messinger D, Brodowicz T; TURANDOT investigators. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. Lancet Oncol. 2016 Sep;17(9):1230-9. Epub 2016 Aug 5. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30154-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27501767 PubMed]
# '''CALGB 40502/NCCTG N063H:''' Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, Mayer EL, Naughton M, Toppmeyer D, Carey LA, Perez EA, Hudis C, Winer EP. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol. 2015 Jul 20;33(21):2361-9. Epub 2015 Jun 8. [http://ascopubs.org/doi/full/10.1200/JCO.2014.59.5298 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500830/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26056183 PubMed]
# '''MERiDiAN:''' Miles D, Cameron D, Bondarenko I, Manzyuk L, Alcedo JC, Lopez RI, Im SA, Canon JL, Shparyk Y, Yardley DA, Masuda N, Ro J, Denduluri N, Hubeaux S, Quah C, Bais C, O'Shaughnessy J. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. Eur J Cancer. 2017 Jan;70:146-155. Epub 2016 Nov 4. [https://www.ejcancer.com/article/S0959-8049(16)32470-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27817944 PubMed]
## '''Update:''' Miles D, Cameron D, Hilton M, Garcia J, O'Shaughnessy J. Overall survival in MERiDiAN, a double-blind placebo-controlled randomised phase III trial evaluating first-line bevacizumab plus paclitaxel for HER2-negative metastatic breast cancer. Eur J Cancer. 2018 Feb;90:153-155. Epub 2017 Nov 23. [https://www.sciencedirect.com/science/article/pii/S0959804917313588 link to SD article] [https://www.ncbi.nlm.nih.gov/pubmed/29174181 PubMed]

==Paclitaxel, nanoparticle albumin-bound monotherapy {{#subobject:5dc417|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Paclitaxel, nanoparticle albumin-bound (Abraxane) in breast cancer]]

===Variant #1, 100 mg/m<sup>2</sup>, 3 weeks out of 4 {{#subobject:f0096c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="3" |[http://jco.ascopubs.org/content/27/22/3611.long Gradishar et al. 2009]
| rowspan="3" style="background-color:#1a9851" |Randomized Phase II (E)
|[[#Docetaxel_monotherapy_3|1. Docetaxel]]
| style="background-color:#ffffbf" |Seems not superior
|-
|2. Weekly nab-paclitaxel (150 mg/m<sup>2</sup>)
| style="background-color:#d3d3d3" |Not reported
|-
|3. q3wk nab-paclitaxel
| style="background-color:#d3d3d3" |Not reported
|-
|}
====Chemotherapy====
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 100 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===Variant #2, 150 mg/m<sup>2</sup> weekly, 3 weeks out of 4 {{#subobject:f0096c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="3" |[http://jco.ascopubs.org/content/27/22/3611.long Gradishar et al. 2009]
| rowspan="3" style="background-color:#1a9851" |Randomized Phase II (E)
|[[#Docetaxel_monotherapy_3|1. Docetaxel]]
| style="background-color:#1a9850" |Superior PFS
|-
|2. Weekly nab-paclitaxel (100 mg/m<sup>2</sup>)
| style="background-color:#d3d3d3" |Not reported
|-
|3. q3wk nab-paclitaxel
| style="background-color:#d3d3d3" |Not reported
|-
|}
====Chemotherapy====
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 150 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===Variant #3, 260 mg/m<sup>2</sup> q3wk {{#subobject:bf6371|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/31/7794.long Gradishar et al. 2005]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel_monotherapy.2C_q3wk|Paclitaxel]]
| style="background-color:#1a9850" |Superior TTP
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 Robert et al. 2011 (RIBBON-1)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Paclitaxel.2C_nanoparticle_albumin-bound_.26_Bevacizumab|nab-Paclitaxel & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
====Chemotherapy====
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 260 mg/m<sup>2</sup> IV over 30 minutes once on day 1

====Supportive medications====
*Gradishar et al. 2005: No corticosteroid or antihistamine premedication

'''21-day cycles'''

===Variant #4, 300 mg/m<sup>2</sup> q3wk {{#subobject:11b87e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="3" |[http://jco.ascopubs.org/content/27/22/3611.long Gradishar et al. 2009]
| rowspan="3" style="background-color:#1a9851" |Randomized Phase II (E)
|[[#Docetaxel_monotherapy_3|1. Docetaxel]]
| style="background-color:#ffffbf" |Seems not superior
|-
|2. Weekly nab-paclitaxel (100 mg/m<sup>2</sup>)
| style="background-color:#d3d3d3" |Not reported
|-
|3. Weekly nab-paclitaxel (150 mg/m<sup>2</sup>)
| style="background-color:#d3d3d3" |Not reported
|-
|}
====Chemotherapy====
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 300 mg/m<sup>2</sup> IV over 30 minutes once on day 1

'''21-day cycles'''

===References===
<!-- Presented in part at the 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 3-6, 2003. -->
# Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005 Nov 1;23(31):7794-803. Epub 2005 Sep 19. [http://jco.ascopubs.org/content/23/31/7794.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16172456 PubMed]
<!-- Presented in part at the 29th Annual San Antonio Breast Cancer Symposium, December 14-17, 2006, San Antonio, TX; the 43rd Annual Meeting of the American Society for Clinical Oncology, June 1-5, 2007, Chicago, IL; the 14th European Cancer Conference, September 23-27, 2007, Barcelona, Spain; and the 6th European Breast Cancer Conference, April 15-19, 2008, Berlin, Germany. -->
# Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009 Aug 1;27(22):3611-9. Epub 2009 May 26. Erratum in: J Clin Oncol. 2011 Jul 1;29(19):2739. [http://jco.ascopubs.org/content/27/22/3611.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19470941 PubMed]
<!-- Presented in part at the 45th Annual Meeting of the American Society for Clinical Oncology, May 29-June 2, 2009, Orlando, FL, and at the 15th Congress of the European Cancer Organisation and 34th Congress of the European Society for Medical Oncology Multidisciplinary Congress, September 20-24, 2009, Berlin, Germany. -->
# '''RIBBON-1:''' Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 1;29(10):1252-60. Epub 2011 Mar 7. [http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21383283 PubMed]

==Paclitaxel, nanoparticle albumin-bound & Bevacizumab {{#subobject:17e71f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Paclitaxel, nanoparticle albumin-bound & Bevacizumab in breast cancer]]

===Variant #1, 150 mg/m<sup>2</sup>, 3 weeks out of 4 {{#subobject:1fce34|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500830/ Rugo et al. 2015 (CALGB 40502/NCCTG N063H)]
| rowspan=2 style="background-color:#1a9851" |Phase III (E)
|1. Ixabepilone & Bevacizumab
| style="background-color:#d3d3d3" |Not reported
|-
|[[#Paclitaxel_.26_Bevacizumab|2. Paclitaxel & Bevacizumab]]
| style="background-color:#fee08b" |Might have inferior PFS
|-
|}
====Chemotherapy====
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 150 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
*[[Bevacizumab (Avastin)]] 10 mg/kg IV once per day on days 1 & 15

'''28-day cycles'''

===Variant #2, 260 mg/m<sup>2</sup> q3wk {{#subobject:8ded2a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 Robert et al. 2011 (RIBBON-1)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel.2C_nanoparticle_albumin-bound_monotherapy_2|nab-Paclitaxel]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 260 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''

===References===
<!-- # '''Abstract:''' M. A. Danso, J. L. Blum, N. J. Robert, L. Krekow, R. Rotche, D. A. Smith, P. Richards, T. Anderson, D. A. Richards and J. O'Shaughnessy. Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer. 2008 ASCO Annual Meeting abstract 1075. [http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/1075 link to abstract] -->
<!-- Presented in part at the 45th Annual Meeting of the American Society for Clinical Oncology, May 29-June 2, 2009, Orlando, FL, and at the 15th Congress of the European Cancer Organisation and 34th Congress of the European Society for Medical Oncology Multidisciplinary Congress, September 20-24, 2009, Berlin, Germany. -->
# '''RIBBON-1:''' Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 1;29(10):1252-60. Epub 2011 Mar 7. [http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21383283 PubMed]
# '''CALGB 40502/NCCTG N063H:''' Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Leung E, Mayer EL, Naughton M, Toppmeyer D, Carey LA, Perez EA, Hudis C, Winer EP. Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol. 2015 Jul 20;33(21):2361-9. Epub 2015 Jun 8. [http://ascopubs.org/doi/full/10.1200/JCO.2014.59.5298 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500830/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26056183 PubMed]

==Pemetrexed monotherapy {{#subobject:93e4ed|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 500 mg/m<sup>2</sup> {{#subobject:b49e6b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://clincancerres.aacrjournals.org/content/12/3/832.long Gomez et al. 2006]
| style="background-color:#91cf61" |Phase II
|-
|}

''Patients in the study were "chemotherapy-naïve, with advanced (T4 and N0-N2, M0, M1) breast cancer."''
====Chemotherapy====
*[[Pemetrexed (Alimta)]] 500 mg/m<sup>2</sup> IV over 10 minutes once on day 1

====Supportive medications====
*[[Dexamethasone (Decadron)]] 4 mg PO twice per day the day before, day of, and day after chemotherapy 
*Folic acid 350 to 1000 mcg PO once per day, to start 5 to 7 days prior to start of pemetrexed therapy, to continue throughout therapy with pemetrexed
*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM every 9 weeks, the first dose given before the study's pretreatment biopsy, to continue throughout therapy with pemetrexed

'''21-day cycle for up to 3 cycles'''

===Variant #2, 600 mg/m<sup>2</sup> {{#subobject:a2f6d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.springerlink.com/content/b1354n1r36631118 Robert et al. 2011]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Pemetrexed (Alimta)]] 600 mg/m<sup>2</sup> IV once on day 1

====Supportive medications====
*[[Dexamethasone (Decadron)]] 4 mg PO twice per day the day before, day of, and day after chemotherapy 
*Folic acid 350 to 1000 mcg PO once per day, to start at least 5 days prior to start of pemetrexed therapy, to continue throughout therapy with pemetrexed, and until 3 weeks after the last dose of pemetrexed
*[[Cyanocobalamin (Vitamin B12)]] 1000 mcg IM every 8 to 10 weeks, the first dose given at least 1 week prior to start of pemetrexed therapy, to continue throughout therapy with pemetrexed, and until 3 weeks after the last dose of pemetrexed

'''14-day cycles'''
===References===
# Gomez HL, Santillana SL, Vallejos CS, Velarde R, Sanchez J, Wang X, Bauer NL, Hockett RD, Chen VJ, Niyikiza C, Hanauske AR. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):832-8. [http://clincancerres.aacrjournals.org/content/12/3/832.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16467096 PubMed]
# Robert NJ, Conkling PR, O'Rourke MA, Kuefler PR, McIntyre KJ, Zhan F, Asmar L, Wang Y, Shonukan OO, O'Shaughnessy JA. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer. Breast Cancer Res Treat. 2011 Feb;126(1):101-8. Epub 2010 Dec 25. [http://www.springerlink.com/content/b1354n1r36631118 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21188632 PubMed]

==S-1 monotherapy {{#subobject:7702f2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:48e547|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00411-8/fulltext Takashima et al. 2015 (SELECT BC)]
| style="background-color:#1a9851" |Phase III (E)
|1. [[#Docetaxel_monotherapy_3|Docetaxel]]<br> 2. [[#Paclitaxel_monotherapy.2C_weekly_3|Paclitaxel]]
| style="background-color:#eeee01" |Seems to have non-inferior OS
| style="background-color:#1a9850" |Superior EQ-5D score
|-
|}
====Chemotherapy====
*[[Tegafur, gimeracil, oteracil (S-1)]] as follows:
**BSA less than 1.25 m<sup>2</sup>: 40 mg PO twice per day on days 1 to 28
**BSA at least 1.25 m<sup>2</sup> and less than 1.5 m<sup>2</sup>: 50 mg PO twice per day on days 1 to 28
**BSA 1.5 m<sup>2</sup> or more: 60 mg PO twice per day on days 1 to 28

'''42-day cycles'''

===References===
# '''SELECT BC:''' Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y; SELECT BC Study Group. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2016 Jan;17(1):90-8. Epub 2015 Nov 27. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00411-8/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26617202 PubMed]
## '''HRQoL analysis:''' Shiroiwa T, Fukuda T, Shimozuma K, Mouri M, Hagiwara Y, Doihara H, Akabane H, Kashiwaba M, Watanabe T, Ohashi Y, Mukai H. Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial. Qual Life Res. 2017 Feb;26(2):445-453. Epub 2016 Aug 12. [https://link.springer.com/article/10.1007%2Fs11136-016-1388-1 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288429/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27517267 PubMed]

=Metastatic disease, maintenance after first-line therapy=
==Bevacizumab monotherapy {{#subobject:0e6349|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:f64795|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2008.21.6457 Miles et al. 2010 (AVADO)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 Robert et al. 2011 (RIBBON-1)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
====Preceding treatment====
*AVADO: [[#Docetaxel_.26_Bevacizumab_2|Docetaxel & Bev]] x 9
*RIBBON-1: [[#AC_.26_Bevacizumab_2|AC & Bev]] x 8 or [[#EC_.26_Bevacizumab|EC & Bev]] x 8 or [[#FAC_.26_Bevacizumab|FAC & Bev]] x 8 or [[#FEC_.26_Bevacizumab|FEC & Bev]] x 8
====Chemotherapy====
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''
===References===
# '''AVADO:''' Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010 Jul 10;28(20):3239-47. Epub 2010 May 24. [http://ascopubs.org/doi/full/10.1200/JCO.2008.21.6457 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20498403 PubMed]
<!-- Presented in part at the 45th Annual Meeting of the American Society for Clinical Oncology, May 29-June 2, 2009, Orlando, FL, and at the 15th Congress of the European Cancer Organisation and 34th Congress of the European Society for Medical Oncology Multidisciplinary Congress, September 20-24, 2009, Berlin, Germany. -->
# '''RIBBON-1:''' Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 1;29(10):1252-60. Epub 2011 Mar 7. [http://ascopubs.org/doi/full/10.1200/JCO.2010.28.0982 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21383283 PubMed]

==Gemcitabine & Paclitaxel {{#subobject:a86e9e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
GT: '''<u>G</u>'''emcitabine & '''<u>T</u>'''axol (Paclitaxel)
<br>PG: '''<u>P</u>'''aclitaxel & '''<u>G</u>'''emcitabine
===Regimen {{#subobject:19fc21|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2012.45.2490 Park et al. 2013 (KCSG-BR07-02)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Observation|Observation]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
====Preceding treatment====
*[[#Gemcitabine_.26_Paclitaxel|PG]] x 6
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV once per day on days 1 & 8, '''given second on day 1'''
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1, '''given first'''

'''21-day cycles'''

===References===
# '''KCSG-BR07-02:''' Park YH, Jung KH, Im SA, Sohn JH, Ro J, Ahn JH, Kim SB, Nam BH, Oh DY, Han SW, Lee S, Park IH, Lee KS, Kim JH, Kang SY, Lee MH, Park HS, Ahn JS, Im YH. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. J Clin Oncol. 2013 May 10;31(14):1732-9. Epub 2013 Apr 8. [http://ascopubs.org/doi/full/10.1200/JCO.2012.45.2490 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23569309 PubMed]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1998.16.5.1669 Falkson et al. 1998 (INT-0077)]
| style="background-color:#1a9851" |Phase III (C)
|CMF(P)TH
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2004.08.054 Sparano et al. 2004 (ECOG E2196)]
| style="background-color:#1a9851" |Phase III (C)
|Marimastat
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://link.springer.com/article/10.1007%2Fs10549-010-0860-9 Alba et al. 2010 (GEICAM 2001-01)]
| style="background-color:#1a9851" |Phase III (C)
|PLD x 6
| style="background-color:#d73027" |Inferior TTP
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2012.45.2490 Park et al. 2013 (KCSG-BR07-02)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Gemcitabine_.26_Paclitaxel|PG]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|}
''No further treatment.''
====Preceding treatment====
*ECOG E2196: Doxorubicin- and/or taxane-containing chemotherapy x 6-8
*GEICAM 2001-01: A x 3, then D x 3
*KCSG-BR07-02: [[#Gemcitabine_.26_Paclitaxel|PG]] x 6

===References===
# '''INT-0077:''' Falkson G, Gelman RS, Pandya KJ, Osborne CK, Tormey D, Cummings FJ, Sledge GW, Abeloff MD. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol. 1998 May;16(5):1669-76. [http://ascopubs.org/doi/abs/10.1200/JCO.1998.16.5.1669 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9586877 PubMed]
# '''ECOG E2196:''' Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol. 2004 Dec 1;22(23):4683-90. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248. [http://ascopubs.org/doi/full/10.1200/JCO.2004.08.054 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15570070 PubMed]
# '''GEICAM 2001-01:''' Alba E, Ruiz-Borrego M, Margelí M, Rodríguez-Lescure A, Sánchez-Rovira P, Ruiz A, Mel-Lorenzo JR, Ramos-Vázquez M, Ribelles N, Calvo E, Casado A, Márquez A, Vicente D, García-Sáenz JA, Martín M. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res Treat. 2010 Jul;122(1):169-76. Epub 2010 Apr 2. [https://link.springer.com/article/10.1007%2Fs10549-010-0860-9 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20361253 PubMed]
# '''KCSG-BR07-02:''' Park YH, Jung KH, Im SA, Sohn JH, Ro J, Ahn JH, Kim SB, Nam BH, Oh DY, Han SW, Lee S, Park IH, Lee KS, Kim JH, Kang SY, Lee MH, Park HS, Ahn JS, Im YH. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. J Clin Oncol. 2013 May 10;31(14):1732-9. Epub 2013 Apr 8. [http://ascopubs.org/doi/full/10.1200/JCO.2012.45.2490 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23569309 PubMed]

=Metastatic disease, subsequent lines of chemotherapy=
==Abemaciclib monotherapy {{#subobject:dcf11a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:9f24c0|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581697/ Dickler et al. 2017 (MONARCH 1)]
| style="background-color:#91cf61" |Phase II
| style="background-color:#88419d; color:white |20% (95% CI 13-27.5)
|-
|}
====Chemotherapy====
*[[Abemaciclib (Verzenio)]] 200 mg PO twice per day

'''Continued indefinitely'''

===References===
# '''MONARCH 1:''' Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 Inhibitor, as a single agent, in patients with refractory HR(+)/HER2(-) metastatic breast cancer. Clin Cancer Res. 2017 Sep 1;23(17):5218-5224. Epub 2017 May 22. [http://clincancerres.aacrjournals.org/content/23/17/5218.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581697/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28533223 PubMed]

==Capecitabine monotherapy {{#subobject:bd9beb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 1000 mg/m<sup>2</sup> PO twice per day {{#subobject:4eb6c8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855860/ Barrios et al. 2010 (SUN 1107)]
| style="background-color:#1a9851" |Phase III (C)
|Sunitinib
| style="background-color:#1a9850" |Superior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 Brufsky et al. 2011 (RIBBON-2)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Capecitabine_.26_Bevacizumab_2|Capecitabine & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Capecitabine_.26_Bevacizumab_2|Capecitabine & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|[https://www.clinical-breast-cancer.com/article/S1526-8209(17)30005-8/fulltext Baselga et al. 2017 (RESILIENCE)]
| style="background-color:#1a9851" |Phase III (C)
|Capecitabine & Sorafenib
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: in SUN 1107, this dosage was used for patients older than 65 years.''
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14

'''21-day cycles'''

===Variant #2, 1250 mg/m<sup>2</sup> PO twice per day {{#subobject:f3e92c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1999.17.2.485 Blum et al. 1999]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://academic.oup.com/annonc/article/14/8/1227/170782 Reichardt et al. 2003]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.05.098 Miller et al. 2005]
| style="background-color:#1a9851" |Phase III (C)
|[[#Capecitabine_.26_Bevacizumab_2|Capecitabine & Bevacizumab]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa064320 Geyer et al. 2006 (EGF100151)]
| style="background-color:#1a9851" |Phase III (C)
|[[Breast_cancer,_HER2-positive#Capecitabine_.26_Lapatinib|Capecitabine & Lapatinib]]
| style="background-color:#d73027" |Inferior TTP
|-
|[http://jco.ascopubs.org/content/25/33/5210.long Thomas et al. 2007 (CA163-046)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Capecitabine_.26_Ixabepilone|Capecitabine & Ixabepilone]]
| style="background-color:#d73027" |Inferior PFS
|-
|[http://jco.ascopubs.org/content/27/12/1999.long von Minckwitz et al. 2009 (GBG 26/BIG 3-05)]
| style="background-color:#1a9851" |Phase III (C)
|[[Breast_cancer,_HER2-positive#Capecitabine_.26_Trastuzumab_2|Capecitabine & Trastuzumab]]
| style="background-color:#fc8d59" |Seems to have inferior TTP
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855860/ Barrios et al. 2010 (SUN 1107)]
| style="background-color:#1a9851" |Phase III (C)
|Sunitinib
| style="background-color:#1a9850" |Superior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903325/ Sparano et al. 2010 (CA163-048)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Capecitabine_.26_Ixabepilone|Capecitabine & Ixabepilone]]
| style="background-color:#d73027" |Inferior PFS
|-
|[https://academic.oup.com/annonc/article/23/5/1164/193248 Pallis et al. 2011]
| style="background-color:#1a9851" |Phase III (C)
|Gemcitabine & Vinorelbine
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://jco.ascopubs.org/content/31/23/2870.long Crown et al. 2013 (A6181099)]
| style="background-color:#1a9851" |Phase III (C)
|Capecitabine & Sunitinib
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463422/ Kaufman et al. 2015 (E7389-G000-301)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Eribulin_monotherapy|Eribulin]]
| style="background-color:#fee08b" |Might have inferior OS
|-
|[https://link.springer.com/article/10.1007%2Fs10549-016-4075-6 Yamamoto et al. 2016 (JO21095)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30088-8/fulltext Zhang et al. 2017 (BG01-1323L)]
| style="background-color:#1a9851" |Phase III (C)
|Capecitabine & Utidelone
| style="background-color:#d73027" |Inferior PFS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1706450 Robson et al. 2017 (OlympiAD)]
| style="background-color:#1a9851" |Phase III (C)
|[[Breast_cancer,_BRCA-mutated#Olaparib_monotherapy|Olaparib]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Patients in EGF100151 & GBG 26/BIG 3-05 had HER2-positive disease. Patients in '''OlympiAD''' had confirmed deleterious or suspected deleterious germline BRCA mutation. To our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm in this context.''
====Preceding treatment====
*'''JO21095:''' [[#Docetaxel_monotherapy_4|Docetaxel, with PD]]
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1250 mg/m<sup>2</sup> PO twice per day on days 1 to 14

'''21-day cycles'''

===References===
# Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999 Feb;17(2):485-93. [http://ascopubs.org/doi/full/10.1200/JCO.1999.17.2.485 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10080589 PubMed]
# Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kölbl H, Jänicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S, Kaufmann M, Lück HJ. Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol. 2003 Aug;14(8):1227-33. [https://academic.oup.com/annonc/article/14/8/1227/170782 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12881384 PubMed]
# Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005 Feb 1;23(4):792-9. [http://ascopubs.org/doi/full/10.1200/JCO.2005.05.098 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15681523 PubMed]
# '''EGF100151:''' Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006 Dec 28;355(26):2733-43. [https://www.nejm.org/doi/full/10.1056/NEJMoa064320 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17192538 PubMed]
## '''Update:''' Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008 Dec;112(3):533-43. [http://link.springer.com/article/10.1007%2Fs10549-007-9885-0 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18188694 PubMed]
## '''Update:''' Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist. 2010;15(9):924-34. [http://theoncologist.alphamedpress.org/content/15/9/924.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228041/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20736298 PubMed]
<!-- Presented in part at the 43rd Annual Meeting of the American Society of Clinical Oncology, June 3, 2007, Chicago, IL. -->
# '''CA163-046:''' Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roché HH. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007 Nov 20;25(33):5210-7. [http://jco.ascopubs.org/content/25/33/5210.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17968020 PubMed]
## '''Update:''' Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roché HH. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat. 2010 Jul;122(2):409-18. Epub 2010 May 8. [https://link.springer.com/article/10.1007%2Fs10549-010-0901-4 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20454927 PubMed]
# '''GBG 26/BIG 03-05:''' von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol. 2009 Apr 20;27(12):1999-2006. Epub 2009 Mar 16. [http://jco.ascopubs.org/content/27/12/1999.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19289619 PubMed]
## '''Update:''' von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, Maartense E, de Jongh FE, Baumann KH, Bischoff J, Harbeck N, Lück HJ, Maass N, Zielinski C, Andersson M, Stein RC, Nekljudova V, Loibl S; GBG 26/BIG 03-05 study group and participating investigators. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011 Oct;47(15):2273-81. Epub 2011 Jul 7. [https://www.ejcancer.com/article/S0959-8049(11)00425-4/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21741829 PubMed]
# '''SUN 1107:''' Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Kern KA, Martin M. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat. 2010 May;121(1):121-31. Epub 2010 Mar 26. [https://link.springer.com/article/10.1007%2Fs10549-010-0788-0 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855860/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20339913 PubMed]
<!-- Presented in part at the American Society of Clinical Oncology Breast Cancer Symposium, September 5-7, 2008, Washington, DC (abstr 186). -->
# '''CA163-048:''' Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, Perez Manga G, Peck R, Poulart V, Conte P. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010 Jul 10;28(20):3256-63.[http://jco.ascopubs.org/content/28/20/3256.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903325/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20530276 PubMed]
# Pallis AG, Boukovinas I, Ardavanis A, Varthalitis I, Malamos N, Georgoulias V, Mavroudis D. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Ann Oncol. 2012 May;23(5):1164-9. Epub 2011 Sep 21. [https://academic.oup.com/annonc/article/23/5/1164/193248 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21937705 PubMed]
<!-- Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009, and at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010. -->
# '''RIBBON-2:''' Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10;29(32):4286-93. Epub 2011 Oct 11. [http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21990397 PubMed]
<!-- Presented in part at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010. -->
# '''A6181099:''' Crown JP, Diéras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, Wildiers H, Fasching PA, Capitain O, Ramos M, Greil R, Cognetti F, Fountzilas G, Blasinska-Morawiec M, Liedtke C, Kreienberg R, Miller WH Jr, Tassell V, Huang X, Paolini J, Kern KA, Romieu G. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol. 2013 Aug 10;31(23):2870-8. Epub 2013 Jul 15. [http://jco.ascopubs.org/content/31/23/2870.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23857972 PubMed]
# '''TANIA:''' von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1269-78. Epub 2014 Sep 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25273342 PubMed]
## '''Update:''' Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Ann Oncol. 2016 Nov;27(11):2046-2052. Epub 2016 Aug 8. [https://academic.oup.com/annonc/article/27/11/2046/2467135 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27502725 PubMed]
# '''E7389-G000-301:''' Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015 Feb 20;33(6):594-601. Epub 2015 Jan 20. [http://ascopubs.org/doi/full/10.1200/JCO.2013.52.4892 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463422/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25605862 PubMed]
# '''JO21095:''' Yamamoto D, Sato N, Rai Y, Yamamoto Y, Saito M, Iwata H, Masuda N, Oura S, Watanabe J, Hattori S, Matsuura Y, Kuroi K. Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial. Breast Cancer Res Treat. 2017 Feb;161(3):473-482. Epub 2016 Dec 22. [https://link.springer.com/article/10.1007%2Fs10549-016-4075-6 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28005247 PubMed]
# '''BG01-1323L:''' Zhang P, Sun T, Zhang Q, Yuan Z, Jiang Z, Wang XJ, Cui S, Teng Y, Hu XC, Yang J, Pan H, Tong Z, Li H, Yao Q, Wang Y, Yin Y, Sun P, Zheng H, Cheng J, Lu J, Zhang B, Geng C, Liu J, Peng R, Yan M, Zhang S, Huang J, Tang L, Qiu R, Xu B; BG01-1323L study group. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet Oncol. 2017 Mar;18(3):371-383. Epub 2017 Feb 11. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30088-8/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28209298 PubMed]
# '''RESILIENCE:''' Baselga J, Zamagni C, Gómez P, Bermejo B, Nagai SE, Melichar B, Chan A, Mángel L, Bergh J, Costa F, Gómez HL, Gradishar WJ, Hudis CA, Rapoport BL, Roché H, Maeda P, Huang L, Meinhardt G, Zhang J, Schwartzberg LS. RESILIENCE: phase III randomized, double-blind trial comparing sorafenib with capecitabine versus placebo with capecitabine in locally advanced or metastatic HER2-negative breast cancer. Clin Breast Cancer. 2017 Dec;17(8):585-594.e4. Epub 2017 May 22. [https://www.clinical-breast-cancer.com/article/S1526-8209(17)30005-8/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28830796 PubMed]
# '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1706450 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28578601 PubMed]

==Capecitabine & Bevacizumab {{#subobject:16ed34|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a7ad32|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 Brufsky et al. 2011 (RIBBON-2)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Capecitabine_monotherapy_3|Capecitabine]]
| style="background-color:#1a9850" |Superior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Capecitabine_monotherapy_3|Capecitabine]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
''Note: efficacy for TURANDOT is based on the 2016 update.''
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''

===References===
<!-- Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009, and at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010. -->
# '''RIBBON-2:''' Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10;29(32):4286-93. Epub 2011 Oct 11. [http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21990397 PubMed]
# '''TANIA:''' von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1269-78. Epub 2014 Sep 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25273342 PubMed]
## '''Update:''' Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Ann Oncol. 2016 Nov;27(11):2046-2052. Epub 2016 Aug 8. [https://academic.oup.com/annonc/article/27/11/2046/2467135 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27502725 PubMed]

==Capecitabine & Docetaxel {{#subobject:a11c57|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
TX: '''<u>T</u>'''axotere (Docetaxel) & '''<u>X</u>'''eloda (Capecitabine)
<br>XT: '''<u>X</u>'''eloda (Capecitabine) & '''<u>T</u>'''axotere (Docetaxel)
<br>DC: '''<u>D</u>'''ocetaxel & '''<u>C</u>'''apecitabine
===Variant #1, 825/60 {{#subobject:5bcf6a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://link.springer.com/article/10.1007%2Fs10549-016-4075-6 Yamamoto et al. 2016 (JO21095)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Docetaxel_monotherapy_4|Docetaxel]]
| style="background-color:#91cf60" |Seems to have superior PFS
|-
|}
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 825 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #2, 1250/75 {{#subobject:6c7dba|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/20/12/2812.long O'Shaughnessy et al. 2002]
| style="background-color:#1a9851" |Phase III (E)
|[[#Docetaxel_monotherapy_4|Docetaxel]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2007.15.8485 Chan et al. 2009]
| style="background-color:#1a9851" |Phase III (C)
|GD
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1250 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1

'''21-day cycles'''

===References===
# O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002 Jun 15;20(12):2812-23. [http://jco.ascopubs.org/content/20/12/2812.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12065558 PubMed]
# Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Schneeweiss A, Lluch A, Llombart A, du Bois A, Kreienberg R, Mayordomo JI, Antón A, Harrison M, Jones A, Carrasco E, Vaury AT, Frimodt-Moller B, Fumoleau P. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol. 2009 Apr 10;27(11):1753-60. Epub 2009 Mar 9. [http://ascopubs.org/doi/full/10.1200/JCO.2007.15.8485 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19273714 PubMed]
# '''JO21095:''' Yamamoto D, Sato N, Rai Y, Yamamoto Y, Saito M, Iwata H, Masuda N, Oura S, Watanabe J, Hattori S, Matsuura Y, Kuroi K. Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial. Breast Cancer Res Treat. 2017 Feb;161(3):473-482. Epub 2016 Dec 22. [https://link.springer.com/article/10.1007%2Fs10549-016-4075-6 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28005247 PubMed]

==Capecitabine & Ixabepilone {{#subobject:9ce286|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
XI: '''<u>X</u>'''eloda (Capecitabine) & '''<u>I</u>'''xabepilone
===Regimen {{#subobject:f5cae3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/25/33/5210.long Thomas et al. 2007 (CA163-046)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Capecitabine_monotherapy_3|Capecitabine]]
| style="background-color:#1a9850" |Superior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903325/ Sparano et al. 2010 (CA163-048)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Capecitabine_monotherapy_3|Capecitabine]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Ixabepilone (Ixempra)]] 40 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===References===
<!-- Presented in part at the 43rd Annual Meeting of the American Society of Clinical Oncology, June 3, 2007, Chicago, IL. -->
# '''CA163-046:''' Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roché HH. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007 Nov 20;25(33):5210-7. [http://jco.ascopubs.org/content/25/33/5210.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17968020 PubMed]
## '''Update:''' Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roché HH. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat. 2010 Jul;122(2):409-18. Epub 2010 May 8. [https://link.springer.com/article/10.1007%2Fs10549-010-0901-4 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20454927 PubMed]
<!-- Presented in part at the American Society of Clinical Oncology Breast Cancer Symposium, September 5-7, 2008, Washington, DC (abstr 186). -->
# '''CA163-048:''' Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, Da Costa SC, Ro J, Rubio G, Rondinon M, Perez Manga G, Peck R, Poulart V, Conte P. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010 Jul 10;28(20):3256-63. [http://jco.ascopubs.org/content/28/20/3256.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903325/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/20530276 PubMed]

==Carboplatin & Gemcitabine {{#subobject:83a5ee|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e571d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.clinical-breast-cancer.com/article/S1526-8209(11)70540-7/abstract Nagourney et al. 2008]
| style="background-color:#ffffbe" |Pilot, <20 pts
|-
|}
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 2 IV over 60 minutes once per day on days 1 & 8
*[[Gemcitabine (Gemzar)]] 800 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 & 8

'''21-day cycles until CR or indefinitely'''

===References===
# Nagourney RA, Flam M, Link J, Hager S, Blitzer J, Lyons W, Sommers BL, Evans S. Carboplatin plus gemcitabine repeating doublet therapy in recurrent breast cancer. Clin Breast Cancer. 2008 Oct;8(5):432-5. [http://www.clinical-breast-cancer.com/article/S1526-8209(11)70540-7/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18952557 PubMed]

==Cisplatin & Vinorelbine {{#subobject:c1c866|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:9caba1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/9428489 Ray-Coquard et al. 1998]
| style="background-color:#91cf61" |Phase II
|-
|[http://annonc.oxfordjournals.org/content/11/9/1155.long Vassilomanolakis et al. 2000]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*[[Vinorelbine (Navelbine)]] 25 mg/m<sup>2</sup> IV over 5 to 10 minutes once per day on days 1 & 8

====Supportive medications====
*Normal saline 200 mL bolus after [[Vinorelbine (Navelbine)]] to prevent phlebitis 
*Normal saline 2000 mL with KCl (unspecified amount of KCl) IV over 4 hours (infusion rate: 500 mL/H) once prior to [[Cisplatin (Platinol)]]
*[[Furosemide (Lasix)]] 40 mg IV once 20 minutes prior to [[Cisplatin (Platinol)]]
*Normal saline 1000 mL and D5W 1000 mL IV over 4 hours (overall infusion rate: 500 mL/H; paper did not say whether fluids were given sequentially or concurrently) once after [[Cisplatin (Platinol)]]
*[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonists]] used

'''21-day cycle for up to 6 cycles'''

===References===
# Ray-Coquard I, Biron P, Bachelot T, Guastalla JP, Catimel G, Merrouche Y, Droz JP, Chauvin F, Blay JY. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens. Cancer. 1998 Jan 1;82(1):134-40. [https://www.ncbi.nlm.nih.gov/pubmed/9428489 PubMed]
# Vassilomanolakis M, Koumakis G, Barbounis V, Demiri M, Pateras H, Efremidis AP. Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines. Ann Oncol. 2000 Sep;11(9):1155-60. [http://annonc.oxfordjournals.org/content/11/9/1155.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11061611 Pubmed]

==Docetaxel monotherapy {{#subobject:fb8c8d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
D: '''<u>D</u>'''ocetaxel
<br>T: '''<u>T</u>'''axotere (Docetaxel)
===Variant #1, 40 mg/m<sup>2</sup> 3 weeks out of 4 {{#subobject:f1b265|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.23321 Rivera et al. 2008]
| style="background-color:#91cf61" |Phase III (C), <20 pts in this subgroup
|Docetaxel q3wk 
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#1a9850" |Superior toxicity
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] as follows:
**Cycle 1: 35 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15
**Cycle 2 onwards: 40 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15

'''28-day cycles'''

===Variant #2, 40 mg/m<sup>2</sup> 6 weeks out of 8 {{#subobject:b23d7b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/18/6/1212.long Burstein et al. 2000]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 40 mg/m<sup>2</sup> IV once per week for weeks 1 to 6, then off for weeks 7 & 8

'''8-week cycles'''

===Variant #3, 60 mg/m<sup>2</sup> {{#subobject:f90ee9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074308/ Adachi et al. 1996]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
| rowspan="2" |[http://jco.ascopubs.org/content/24/31/4963.long Harvey et al. 2006]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. 75 mg/m<sup>2</sup> q3wk docetaxel
| style="background-color:#fee08b" |Might have inferior TTP
|-
|2. 100 mg/m<sup>2</sup> q3wk docetaxel
| style="background-color:#fee08b" |Might have inferior TTP
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Docetaxel_.26_Bevacizumab_3|Docetaxel & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Note: this is the dosage used for Japanese patients; Adachi et al. 1996 reported 21- to 28-day cycles''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #4, 70 mg/m<sup>2</sup> {{#subobject:a74e46|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://link.springer.com/article/10.1007%2Fs10549-016-4075-6 Yamamoto et al. 2016 (JO21095)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Capecitabine_.26_Docetaxel_2|Capecitabine & Docetaxel]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 70 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''
====Subsequent treatment====
*Upon progression: [[#Capecitabine_monotherapy_2|Capecitabine]]

===Variant #5, 75 mg/m<sup>2</sup> {{#subobject:81b82f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[http://jco.ascopubs.org/content/24/31/4963.long Harvey et al. 2006]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. 60 mg/m<sup>2</sup> q3wk docetaxel
| style="background-color:#d9ef8b" |Might have superior TTP
|-
|2. 100 mg/m<sup>2</sup> q3wk docetaxel
| style="background-color:#fee08b" |Might have inferior TTP
|-
|[https://www.ejcancer.com/article/S0959-8049(10)01207-4/fulltext Schröder et al. 2011]
| style="background-color:#1a9851" |Phase III (C)
|Weekly docetaxel
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 Brufsky et al. 2011 (RIBBON-2)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Docetaxel_.26_Bevacizumab_2|Docetaxel & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Docetaxel_.26_Bevacizumab_3|Docetaxel & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Note: Schröder et al. 2011 does not contain dosing information in the abstract. This is the lower end of the range of docetaxel dosing described in TANIA.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #6, 100 mg/m<sup>2</sup> {{#subobject:67c50d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://academic.oup.com/annonc/article/5/6/527/252068 ten Bokkel Huinink et al. 1994]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1999.17.5.1413 Nabholtz et al. 1999 (TAX 304)]
| style="background-color:#1a9851" |Phase III (E)
|MV
| style="background-color:#1a9850" |Superior OS
| style="background-color:#d3d3d3" |
|-
|[http://jco.ascopubs.org/content/17/8/2341.long Chan et al. 1999 (TAX 303)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Doxorubicin_monotherapy_3|Doxorubicin]]
| style="background-color:#1a9850" |Superior ORR
| style="background-color:#d3d3d3" |
|-
|[https://www.ejcancer.com/article/S0959-8049(99)00122-7/fulltext Sjöström et al. 1999]
| style="background-color:#1a9851" |Phase III (E)
|MF
| style="background-color:#1a9850" |Superior TTP
| style="background-color:#d3d3d3" |
|-
|[http://jco.ascopubs.org/content/20/12/2812.long O'Shaughnessy et al. 2002]
| style="background-color:#1a9851" |Phase III (C)
|[[#Capecitabine_.26_Docetaxel_2|Capecitabine & Docetaxel]]
| style="background-color:#fc8d59" |Seems to have inferior OS
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408916/  Bonneterre et al. 2002]
| style="background-color:#1a9851" |Phase III (E)
|5-FU & Vinorelbine
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#1a9850" |Less toxic 
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.02.027 Jones et al. 2005]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel_monotherapy.2C_q3wk|Paclitaxel]]
| style="background-color:#91cf60" |Seems to have superior OS
| style="background-color:#d3d3d3" |
|-
| rowspan="2" |[http://jco.ascopubs.org/content/24/31/4963.long Harvey et al. 2006]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. 60 mg/m<sup>2</sup> q3wk docetaxel
| style="background-color:#d9ef8b" |Might have superior TTP
| style="background-color:#d3d3d3" |
|-
|2. 75 mg/m<sup>2</sup> q3wk docetaxel
| style="background-color:#d9ef8b" |Might have superior TTP
| style="background-color:#d3d3d3" |
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.23321 Rivera et al. 2008]
| style="background-color:#91cf61" |Phase III (C), <20 pts in this subgroup
|Weekly Docetaxel 
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#d73027" |Inferior toxicity
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 Brufsky et al. 2011 (RIBBON-2)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Docetaxel_.26_Bevacizumab_2|Docetaxel & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.33.9507 Nielsen et al. 2011]
| style="background-color:#1a9851" |Phase III (C)
|Docetaxel & Gemcitabine
| style="background-color:#fee08b" |Might have inferior TTP
| style="background-color:#d3d3d3" |
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Docetaxel_.26_Bevacizumab_3|Docetaxel & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
| style="background-color:#d3d3d3" |
|-
|}
''Note: this is the upper end of the range of docetaxel dosing described in TANIA. TAX 304 stopped treatment after 10 cycles. TAX 303 stopped treatment after 7 cycles.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV once on day 1
**Note: Rivera et al. 2008 gave 75 mg/m<sup>2</sup> in cycle 1, with escalation to 100 mg/m<sup>2</sup> depending on toxicity

'''21-day cycles (see note)'''

===References===
# ten Bokkel Huinink WW, Prove AM, Piccart M, Steward W, Tursz T, Wanders J, Franklin H, Clavel M, Verweij J, Alakl M, Bayssas M, Kaye SB. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer: a study of the EORTC Early Clinical Trials Group. Ann Oncol. 1994 Jul;5(6):527-32. [https://academic.oup.com/annonc/article/5/6/527/252068 link to original article] '''contains protocol'''  [https://www.ncbi.nlm.nih.gov/pubmed/7918124 PubMed]
# Adachi I, Watanabe T, Takashima S, Narabayashi M, Horikoshi N, Aoyama H, Taguchi T. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer. 1996 Jan;73(2):210-6. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074308/ link to PMC article] '''contains protocol'''  [https://www.ncbi.nlm.nih.gov/pubmed/8546908 PubMed]
# '''TAX 304:''' Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschênes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M; 304 Study Group. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol. 1999 May;17(5):1413-24. [http://ascopubs.org/doi/full/10.1200/JCO.1999.17.5.1413 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10334526 PubMed]
# '''Review:''' Burris HA 3rd. Single-agent docetaxel (Taxotere) in randomized phase III trials. Semin Oncol. 1999 Jun;26(3 Suppl 9):1-6. [https://www.ncbi.nlm.nih.gov/pubmed/10426452 PubMed]
# '''TAX 303:''' Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, González Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J; 303 Study Group. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999 Aug;17(8):2341-54. [http://jco.ascopubs.org/content/17/8/2341.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10561296 PubMed]
# Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lönn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjövall M, Wist E, Valvere V, Anderson H, Bergh J. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer. 1999 Aug;35(8):1194-201. [https://www.ejcancer.com/article/S0959-8049(99)00122-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10615229 PubMed]
# O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002 Jun 15;20(12):2812-23. [http://jco.ascopubs.org/content/20/12/2812.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12065558 PubMed]
# Bonneterre J, Roché H, Monnier A, Guastalla JP, Namer M, Fargeot P, Assadourian S. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer. 2002 Nov 18;87(11):1210-5. [https://www.nature.com/articles/6600645 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408916/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/12439707 PubMed]
# Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005 Aug 20;23(24):5542-51. [http://ascopubs.org/doi/full/10.1200/JCO.2005.02.027 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16110015 PubMed]
# Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson BA, Groult V, Murawsky M, Cold S. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol. 2006 Nov 1;24(31):4963-70. Epub 2006 Oct 10. [http://jco.ascopubs.org/content/24/31/4963.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17033039 PubMed]
# Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, Broglio KR, Yin G, Esmaeli B, Hortobagyi GN, Valero V. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer. 2008 Apr 1;112(7):1455-61. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.23321 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18300256 PubMed]
# Schröder CP, de Munck L, Westermann AM, Smit WM, Creemers GJ, de Graaf H, Stouthard JM, van Deijk G, Erjavec Z, van Bochove A, Vader W, Willemse PH. Weekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxel. Eur J Cancer. 2011 Jun;47(9):1355-62. Epub 2011 Jan 19. [https://www.ejcancer.com/article/S0959-8049(10)01207-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21251813 PubMed]
<!-- Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009, and at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010. -->
# '''RIBBON-2:''' Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10;29(32):4286-93. Epub 2011 Oct 11. [http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21990397 PubMed]
# Nielsen DL, Bjerre KD, Jakobsen EH, Cold S, Stenbygaard L, Sørensen PG, Kamby C, Møller S, Jørgensen CL, Andersson M. Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2011 Dec 20;29(36):4748-54. Epub 2011 Nov 14. [http://ascopubs.org/doi/full/10.1200/JCO.2010.33.9507 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22084374 PubMed]
# '''TANIA:''' von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1269-78. Epub 2014 Sep 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25273342 PubMed]
## '''Update:''' Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Ann Oncol. 2016 Nov;27(11):2046-2052. Epub 2016 Aug 8. [https://academic.oup.com/annonc/article/27/11/2046/2467135 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27502725 PubMed]
# '''JO21095:''' Yamamoto D, Sato N, Rai Y, Yamamoto Y, Saito M, Iwata H, Masuda N, Oura S, Watanabe J, Hattori S, Matsuura Y, Kuroi K. Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial. Breast Cancer Res Treat. 2017 Feb;161(3):473-482. Epub 2016 Dec 22. [https://link.springer.com/article/10.1007%2Fs10549-016-4075-6 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28005247 PubMed]

==Docetaxel & Bevacizumab {{#subobject:481e73|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, docetaxel 60 mg/m<sup>2</sup> {{#subobject:f90ee9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Docetaxel_monotherapy_4|Docetaxel]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
''Note: this is the dosage used for Japanese patients.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''

===Variant #2, docetaxel 75 mg/m<sup>2</sup> {{#subobject:81b82f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 Brufsky et al. 2011 (RIBBON-2)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Docetaxel_monotherapy_4|Docetaxel]]
| style="background-color:#1a9850" |Superior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Docetaxel_monotherapy_4|Docetaxel]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
''Note: this is the lower end of the range of docetaxel dosing described in TANIA.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''

===Variant #3, docetaxel 100 mg/m<sup>2</sup> {{#subobject:67c50d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 Brufsky et al. 2011 (RIBBON-2)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Docetaxel_monotherapy_4|Docetaxel]]
| style="background-color:#1a9850" |Superior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Docetaxel_monotherapy_4|Docetaxel]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
''Note: this is the upper end of the range of docetaxel dosing described in TANIA.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''

===References===
<!-- Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009, and at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010. -->
# '''RIBBON-2:''' Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10;29(32):4286-93. Epub 2011 Oct 11. [http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21990397 PubMed]
# '''TANIA:''' von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1269-78. Epub 2014 Sep 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25273342 PubMed]
## '''Update:''' Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Ann Oncol. 2016 Nov;27(11):2046-2052. Epub 2016 Aug 8. [https://academic.oup.com/annonc/article/27/11/2046/2467135 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27502725 PubMed]

==Doxorubicin monotherapy {{#subobject:4f9e89|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 20 mg/m<sup>2</sup> weekly {{#subobject:39a14f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Doxorubicin_.26_Bevacizumab|Doxorubicin & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Note: this is the lower end of the range of weekly doxorubicin dosing described in TANIA.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 20 mg/m<sup>2</sup> IV once per week

'''Continued indefinitely'''

===Variant #2, 25 mg/m<sup>2</sup> weekly {{#subobject:903e76|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Doxorubicin_.26_Bevacizumab|Doxorubicin & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Note: this is the higher end of the range of weekly doxorubicin dosing described in TANIA.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per week

'''Continued indefinitely'''

===Variant #3, 60 mg/m<sup>2</sup> q3wk {{#subobject:fdff75|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/jnci/article-abstract/83/15/1077/882648 Cowan et al. 1991 (SWOG S8203)]
| style="background-color:#1a9851" |Phase III (E)
|1. Bisantrene<br> 2. Mitoxantrone
| style="background-color:#1a9850" |Superior ORR
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.12.2385 Norris et al. 2000 (NCIC CTG MA.8)]
| style="background-color:#1a9851" |Phase III (C)
|Doxorubicin & Vinorelbine
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2003.04.075 Reyno et al. 2004 (NCIC CT MA.19)]
| style="background-color:#1a9851" |Phase III (C)
|Doxorubicin & Tesmilifene
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Doxorubicin_.26_Bevacizumab|Doxorubicin & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Note: in NCIC CTG MA.8, this dose was after a mid-protocol amendment. Treatment in NCIC CTG MA.8 & MA.19 was given until a cumulative dose of 450 mg/m<sup>2</sup>. This is the lower end of the range of q3wk doxorubicin dosing described in TANIA.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles (see note)'''

===Variant #4, 75 mg/m<sup>2</sup> q3wk, limited duration {{#subobject:ccbd9e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/17/8/2341.long Chan et al. 1999 (TAX 303)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Docetaxel_monotherapy_4|Docetaxel]]
| style="background-color:#d73027" |Inferior ORR
|-
|}
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 7 cycles'''

===Variant #5, 75 mg/m<sup>2</sup> q3wk, indefinite {{#subobject:a3529b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150384/ Bontenbal et al. 1998]
| style="background-color:#1a9851" |Phase III (C)
|Epirubicin
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Doxorubicin_.26_Bevacizumab|Doxorubicin & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Note: this is the higher end of the range of q3wk doxorubicin dosing described in TANIA.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===References===
# '''SWOG S8203:''' Cowan JD, Neidhart J, McClure S, Coltman CA Jr, Gumbart C, Martino S, Hutchins LF, Stephens RL, Vaughan CB, Osborne CK. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst. 1991 Aug 7;83(15):1077-84. [https://academic.oup.com/jnci/article-abstract/83/15/1077/882648 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/1875415 PubMed]
# Bontenbal M, Andersson M, Wildiers J, Cocconi G, Jassem J, Paridaens R, Rotmensz N, Sylvester R, Mouridsen HT, Klijn JG, van Oosterom AT; EORTC Breast Cancer Cooperative Group. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. Br J Cancer. 1998 Jun;77(12):2257-63. [https://www.nature.com/articles/bjc1998375 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150384/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9649142 PubMed]
# '''TAX 303:''' Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, González Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J; 303 Study Group. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999 Aug;17(8):2341-54. [http://jco.ascopubs.org/content/17/8/2341.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10561296 PubMed]
# '''NCIC CTG MA.8:''' Norris B, Pritchard KI, James K, Myles J, Bennett K, Marlin S, Skillings J, Findlay B, Vandenberg T, Goss P, Latreille J, Rudinskas L, Lofters W, Trudeau M, Osoba D, Rodgers A. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group study MA8. J Clin Oncol. 2000 Jun;18(12):2385-94. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.12.2385 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10856098 PubMed]
# '''NCIC CT MA.19:''' Reyno L, Seymour L, Tu D, Dent S, Gelmon K, Walley B, Pluzanska A, Gorbunova V, Garin A, Jassem J, Pienkowski T, Dancey J, Pearce L, MacNeil M, Marlin S, Lebwohl D, Voi M, Pritchard K; National Cancer Institute of Canada Clinical Trials Group Study MA.19. Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. J Clin Oncol. 2004 Jan 15;22(2):269-76. [http://ascopubs.org/doi/full/10.1200/JCO.2003.04.075 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14722035 PubMed]
# '''TANIA:''' von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1269-78. Epub 2014 Sep 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25273342 PubMed]
## '''Update:''' Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Ann Oncol. 2016 Nov;27(11):2046-2052. Epub 2016 Aug 8. [https://academic.oup.com/annonc/article/27/11/2046/2467135 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27502725 PubMed]

==Doxorubicin & Bevacizumab {{#subobject:b345a5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, doxorubicin 20 mg/m<sup>2</sup> weekly {{#subobject:d9cf13|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (E)
|[[ #Doxorubicin_monotherapy_3|Doxorubicin]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
''Note: this is the lower end of the range of weekly doxorubicin dosing described in TANIA.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 20 mg/m<sup>2</sup> IV once per week
*[[Bevacizumab (Avastin)]] 10 mg/kg IV once per day on days 1 & 15

'''28-day cycles'''

===Variant #2, doxorubicin 25 mg/m<sup>2</sup> weekly {{#subobject:bb2f9f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (E)
|[[ #Doxorubicin_monotherapy_3|Doxorubicin]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
''Note: this is the higher end of the range of weekly doxorubicin dosing described in TANIA.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per week
*[[Bevacizumab (Avastin)]] 10 mg/kg IV once per day on days 1 & 15

'''28-day cycles'''

===Variant #3, doxorubicin 60 mg/m<sup>2</sup> q3wk {{#subobject:e69410|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (E)
|[[ #Doxorubicin_monotherapy_3|Doxorubicin]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
''Note: this is the lower end of the range of q3wk doxorubicin dosing described in TANIA.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''

===Variant #4, doxorubicin 75 mg/m<sup>2</sup> q3wk {{#subobject:1effcd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (E)
|[[ #Doxorubicin_monotherapy_3|Doxorubicin]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
''Note: this is the higher end of the range of q3wk doxorubicin dosing described in TANIA.''
====Chemotherapy====
*[[Doxorubicin (Adriamycin)]] 75 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''

===References===
# '''TANIA:''' von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1269-78. Epub 2014 Sep 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25273342 PubMed]
## '''Update:''' Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Ann Oncol. 2016 Nov;27(11):2046-2052. Epub 2016 Aug 8. [https://academic.oup.com/annonc/article/27/11/2046/2467135 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27502725 PubMed]

==Doxorubicin non-pegylated liposomal monotherapy {{#subobject:06760b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
NPLD: '''<u>N</u>'''on-'''<u>P</u>'''egylated '''<u>L</u>'''iposomal '''<u>D</u>'''oxorubicin
===Regimen {{#subobject:2ed37f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Doxorubicin_non-pegylated_liposomal_.26_Bevacizumab|NPLD & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
====Chemotherapy====
*[[Non-pegylated liposomal doxorubicin (Myocet)]] 60 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===References===
# '''TANIA:''' von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1269-78. Epub 2014 Sep 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25273342 PubMed]
## '''Update:''' Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Ann Oncol. 2016 Nov;27(11):2046-2052. Epub 2016 Aug 8. [https://academic.oup.com/annonc/article/27/11/2046/2467135 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27502725 PubMed]

==Doxorubicin non-pegylated liposomal & Bevacizumab {{#subobject:2e10a5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
NPLD/Bev: '''<u>N</u>'''on-'''<u>P</u>'''egylated '''<u>L</u>'''iposomal '''<u>D</u>'''oxorubicin & '''<u>Bev</u>'''acizumab
===Regimen {{#subobject:88281d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Doxorubicin_non-pegylated_liposomal_monotherapy|NPLD]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Non-pegylated liposomal doxorubicin (Myocet)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''

===References===
# '''TANIA:''' von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1269-78. Epub 2014 Sep 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25273342 PubMed]
## '''Update:''' Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Ann Oncol. 2016 Nov;27(11):2046-2052. Epub 2016 Aug 8. [https://academic.oup.com/annonc/article/27/11/2046/2467135 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27502725 PubMed]

==Doxorubicin pegylated liposomal monotherapy {{#subobject:06760b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PLD: '''<u>P</u>'''egylated '''<u>L</u>'''iposomal '''<u>D</u>'''oxorubicin
===Variant #1, 40 mg/m<sup>2</sup> {{#subobject:2ed37f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Doxorubicin_pegylated_liposomal_.26_Bevacizumab|PLD & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Note: this is the lower end of the range of pegylated liposomal doxorubicin dosing described in TANIA.''
====Chemotherapy====
*[[Pegylated liposomal doxorubicin (Doxil)]] 40 mg/m<sup>2</sup> IV once on day 1

'''28-day cycles'''

===Variant #2, 50 mg/m<sup>2</sup> {{#subobject:f033fb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2004.08.157 Keller et al. 2004]
| style="background-color:#1a9851" |Phase III (E)
|1. Mitomycin & Vinblastine<br> 2. [[#Vinorelbine_monotherapy_2|Vinorelbine]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Doxorubicin_pegylated_liposomal_.26_Bevacizumab|PLD & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Note: this is the higher end of the range of pegylated liposomal doxorubicin dosing described in TANIA.''
====Chemotherapy====
*[[Pegylated liposomal doxorubicin (Doxil)]] 50 mg/m<sup>2</sup> IV once on day 1

'''28-day cycles'''

===References===
# Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz G, Henderson IC, Mellars L, Alland L, Tendler C. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol. 2004 Oct 1;22(19):3893-901. [http://ascopubs.org/doi/full/10.1200/JCO.2004.08.157 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15459210 PubMed]
# '''TANIA:''' von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1269-78. Epub 2014 Sep 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25273342 PubMed]
## '''Update:''' Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Ann Oncol. 2016 Nov;27(11):2046-2052. Epub 2016 Aug 8. [https://academic.oup.com/annonc/article/27/11/2046/2467135 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27502725 PubMed]

==Doxorubicin pegylated liposomal & Bevacizumab {{#subobject:2e10a5|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
PLD/Bev: '''<u>P</u>'''egylated '''<u>L</u>'''iposomal '''<u>D</u>'''oxorubicin & '''<u>Bev</u>'''acizumab
===Variant #1, 40 mg/m<sup>2</sup> {{#subobject:88281d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Doxorubicin_pegylated_liposomal_monotherapy_2|PLD]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
''Note: this is the lower end of the range of pegylated liposomal doxorubicin dosing described in TANIA.''
====Chemotherapy====
*[[Pegylated liposomal doxorubicin (Doxil)]] 40 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 10 mg/kg IV once per day on days 1 & 15

'''28-day cycles'''

===Variant #2, 50 mg/m<sup>2</sup> {{#subobject:9feb98|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Doxorubicin_pegylated_liposomal_monotherapy_2|PLD]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
''Note: this is the higher end of the range of pegylated liposomal doxorubicin dosing described in TANIA.''
====Chemotherapy====
*[[Pegylated liposomal doxorubicin (Doxil)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 10 mg/kg IV once per day on days 1 & 15

'''28-day cycles'''

===References===
# '''TANIA:''' von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1269-78. Epub 2014 Sep 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25273342 PubMed]
## '''Update:''' Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Ann Oncol. 2016 Nov;27(11):2046-2052. Epub 2016 Aug 8. [https://academic.oup.com/annonc/article/27/11/2046/2467135 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27502725 PubMed]

==Eribulin monotherapy {{#subobject:ef2415|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:25ef0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2960070-6/fulltext Cortes et al. 2011 (EMBRACE)]
| style="background-color:#1a9851" |Phase III (E)
|Investigator's choice
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463422/ Kaufman et al. 2015 (E7389-G000-301)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Capecitabine_monotherapy_3|Capecitabine]]
| style="background-color:#d9ef8b" |Might have superior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1706450 Robson et al. 2017 (OlympiAD)]
| style="background-color:#1a9851" |Phase III (C)
|[[Breast_cancer,_BRCA-mutated#Olaparib_monotherapy|Olaparib]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Patients in '''OlympiAD''' had confirmed deleterious or suspected deleterious germline BRCA mutation.''
====Chemotherapy====
*[[Eribulin (Halaven)]] 1.4 mg/m<sup>2</sup> IV over 2 to 5 minutes once per day on days 1 & 8

'''21-day cycles'''

===References===
# '''EMBRACE:''' Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011 Mar 12;377(9769):914-23. Epub 2011 Mar 2. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2811%2960070-6/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21376385 PubMed]
# '''E7389-G000-301:''' Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2015 Feb 20;33(6):594-601. Epub 2015 Jan 20. [http://ascopubs.org/doi/full/10.1200/JCO.2013.52.4892 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463422/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25605862 PubMed]
# '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1706450 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28578601 PubMed]

==Gemcitabine monotherapy {{#subobject:af0915|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 800 mg/m<sup>2</sup> 3 weeks out of 4 {{#subobject:4db8d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/13/11/2731.long Carmichael et al. 1995]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 800 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15

'''28-day cycles'''

===Variant #2, 1000 mg/m<sup>2</sup> 3 weeks out of 4 {{#subobject:b0f55d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Gemcitabine_.26_Bevacizumab|Gemcitabine & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===Variant #3, 1200 mg/m<sup>2</sup> 3 weeks out of 4 {{#subobject:3bbee6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.karger.com/Article/Abstract/58524 Spielmann et al. 2001]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1200 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1, 8, 15

'''28-day cycles'''

===Variant #4, 1250 mg/m<sup>2</sup> 2 weeks out of 3 {{#subobject:11b425|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 Brufsky et al. 2011 (RIBBON-2)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Gemcitabine_.26_Bevacizumab|Gemcitabine & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Gemcitabine_.26_Bevacizumab|Gemcitabine & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8

'''21-day cycles'''

===References===
# Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol. 1995 Nov;13(11):2731-6. [http://jco.ascopubs.org/content/13/11/2731.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7595731 PubMed]
# Spielmann M, Llombart-Cussac A, Kalla S, Espié M, Namer M, Ferrero JM, Diéras V, Fumoleau P, Cuvier C, Perrocheau G, Ponzio A, Kayitalire L, Pouillart P. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology. 2001;60(4):303-7. [http://www.karger.com/Article/Abstract/58524 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11408796 PubMed]
<!-- Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009, and at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010. -->
# '''RIBBON-2:''' Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10;29(32):4286-93. Epub 2011 Oct 11. [http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21990397 PubMed]
# '''TANIA:''' von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1269-78. Epub 2014 Sep 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25273342 PubMed]
## '''Update:''' Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Ann Oncol. 2016 Nov;27(11):2046-2052. Epub 2016 Aug 8. [https://academic.oup.com/annonc/article/27/11/2046/2467135 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27502725 PubMed]

==Gemcitabine & Bevacizumab {{#subobject:134dbe|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 1000 mg/m<sup>2</sup>, 3 weeks out of 4 {{#subobject:ccfb9a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Gemcitabine_monotherapy_2|Gemcitabine]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1000 mg/m<sup>2</sup> IV once per day on days 1, 8, 15
*[[Bevacizumab (Avastin)]] 10 mg/kg IV once per day on days 1 & 15

'''28-day cycles'''

===Variant #2, 1250 mg/m<sup>2</sup>, 2 weeks out of 3 {{#subobject:15445c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 Brufsky et al. 2011 (RIBBON-2)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Gemcitabine_monotherapy_2|Gemcitabine]]
| style="background-color:#1a9850" |Superior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Gemcitabine_monotherapy_2|Gemcitabine]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Gemcitabine (Gemzar)]] 1250 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 & 8
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''
===References===
<!-- Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009, and at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010. -->
# '''RIBBON-2:''' Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10;29(32):4286-93. Epub 2011 Oct 11. [http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21990397 PubMed]
# '''TANIA:''' von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1269-78. Epub 2014 Sep 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25273342 PubMed]
## '''Update:''' Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Ann Oncol. 2016 Nov;27(11):2046-2052. Epub 2016 Aug 8. [https://academic.oup.com/annonc/article/27/11/2046/2467135 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27502725 PubMed]

==Paclitaxel monotherapy, weekly {{#subobject:b55e07|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 80 mg/m<sup>2</sup> weekly {{#subobject:686fc8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/19/22/4216.long Perez et al. 2001]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://jco.ascopubs.org/content/26/10/1642.long Seidman et al. 2008 (CALGB 9840)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel_monotherapy.2C_q3wk_2|Paclitaxel q3wk]]
| style="background-color:#1a9850" |Superior OS
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per week

'''28-day cycles'''

===Variant #2, 90 mg/m<sup>2</sup> 3 weeks out of 4 {{#subobject:55b062|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 Brufsky et al. 2011 (RIBBON-2)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Paclitaxel_.26_Bevacizumab_2|Paclitaxel & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 90 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===References===
# Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2001 Nov 15;19(22):4216-23. [http://jco.ascopubs.org/content/19/22/4216.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11709565 PubMed]
<!-- Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004, New Orleans, LA. -->
# '''CALGB 9840:''' Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008 Apr 1;26(10):1642-9. [http://jco.ascopubs.org/content/26/10/1642.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18375893 PubMed]
<!-- Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009, and at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010. -->
# '''RIBBON-2:''' Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10;29(32):4286-93. Epub 2011 Oct 11. [http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21990397 PubMed]

==Paclitaxel monotherapy, q3wk {{#subobject:b90e58|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 135 mg/m<sup>2</sup> {{#subobject:430acf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1996.14.6.1858 Nabholtz et al. 1996]
|style="background-color:#1a9851" |Phase III (E)
|Paclitaxel 175 mg/m<sup>2</sup> q3wk
| style="background-color:#ffffbf" |Seems not superior (*)
|-
|}
''Note: although Nabholtz et al. 1996 did not meet its primary endpoint, there seemed to be a TTP disadvantage in the lower-dose arm.''
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 135 mg/m<sup>2</sup> IV over 3 hours once on day 1

'''21-day cycles'''

===Variant #2, 175 mg/m<sup>2</sup> {{#subobject:f2e948|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/13/10/2575.long Seidman et al. 1995]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1996.14.6.1858 Nabholtz et al. 1996]
|style="background-color:#1a9851" |Phase III (E)
|Paclitaxel 135 mg/m<sup>2</sup> q3wk
| style="background-color:#ffffbf" |Seems not superior (*)
|-
|rowspan=2|[http://ascopubs.org/doi/10.1200/JCO.2004.08.048 Winer et al. 2004 (CALGB 9342)]
|rowspan=2 style="background-color:#1a9851" |Phase III (C)
|1. Paclitaxel 210 mg/m<sup>2</sup> q3wk
| style="background-color:#ffffbf" |Seems not superior
|-
|2. Paclitaxel 250 mg/m<sup>2</sup> q3wk
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361864/ Icli et al. 2005]
| style="background-color:#1a9851" |Phase III (C)
|EoP
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.02.027 Jones et al. 2005]
| style="background-color:#1a9851" |Phase III (E)
|[[#Docetaxel_monotherapy_4|Docetaxel]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[http://jco.ascopubs.org/content/23/31/7794.long Gradishar et al. 2005]
| style="background-color:#1a9851" |Phase III (C)
|[[#Paclitaxel.2C_nanoparticle_albumin-bound_monotherapy_3|Nanoparticle albumin-bound paclitaxel]]
| style="background-color:#d73027" |Inferior TTP
|-
|[http://jco.ascopubs.org/content/26/10/1642.long Seidman et al. 2008 (CALGB 9840)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Paclitaxel_monotherapy.2C_weekly_4|Weekly paclitaxel]]
| style="background-color:#d73027" |Inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 Brufsky et al. 2011 (RIBBON-2)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Paclitaxel_.26_Bevacizumab_2|Paclitaxel & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Note: although Nabholtz et al. 1996 did not meet its primary endpoint, there seemed to be a TTP advantage in the higher-dose arm, which subsequently led to its adoption as the standard-of-care.''
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV over 3 hours once on day 1

'''21-day cycles'''

===References===
# Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, Lepore J, Gilewski T, Currie V, Crown J, Hakes T, Baselga J, Sklarin N, Moynihan ME, Tong W, Egorin M, Kearns C, Spriggs D, Norton L. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol. 1995 Oct;13(10):2575-81. [http://jco.ascopubs.org/content/13/10/2575.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7595709 PubMed]
# Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 1996 Jun;14(6):1858-67. [http://ascopubs.org/doi/abs/10.1200/JCO.1996.14.6.1858 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8656254 PubMed]
# '''CALGB 9342:''' Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342. J Clin Oncol. 2004 Jun 1;22(11):2061-8. [http://ascopubs.org/doi/10.1200/JCO.2004.08.048 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15169793 PubMed]
# Icli F, Akbulut H, Uner A, Yalcin B, Baltali E, Altinbas M, Coşkun S, Komurcu S, Erkisi M, Demirkazik A, Senler FC, Sencan O, Büyükcelik A, Boruban C, Onur H, Zengin N, Sak SD. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. Br J Cancer. 2005 Feb 28;92(4):639-44. [https://www.nature.com/articles/6602388 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361864/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15726120 PubMed]
# Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005 Aug 20;23(24):5542-51. [http://ascopubs.org/doi/full/10.1200/JCO.2005.02.027 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16110015 PubMed]
<!-- Presented in part at the 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 3-6, 2003. -->
# Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005 Nov 1;23(31):7794-803. Epub 2005 Sep 19. [http://jco.ascopubs.org/content/23/31/7794.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16172456 PubMed]
<!-- Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004, New Orleans, LA. -->
# '''CALGB 9840:''' Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008 Apr 1;26(10):1642-9. [http://jco.ascopubs.org/content/26/10/1642.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18375893 PubMed]
<!-- Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009, and at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010. -->
# '''RIBBON-2:''' Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10;29(32):4286-93. Epub 2011 Oct 11. [http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21990397 PubMed]

==Paclitaxel & Bevacizumab {{#subobject:1d634b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 90 mg/m<sup>2</sup> 3 weeks out of 4 {{#subobject:ba68f9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 Brufsky et al. 2011 (RIBBON-2)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel_monotherapy.2C_weekly_4|Paclitaxel]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 90 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15
*[[Bevacizumab (Avastin)]] 10 mg/kg IV once per day on days 1 & 15

'''28-day cycles'''

===Variant #2, 175 mg/m<sup>2</sup> q3wk {{#subobject:8820d1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 Brufsky et al. 2011 (RIBBON-2)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel_monotherapy.2C_q3wk_2|Paclitaxel]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''

===References===
<!-- Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009, and at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010. -->
# '''RIBBON-2:''' Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10;29(32):4286-93. Epub 2011 Oct 11. [http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21990397 PubMed]

==Paclitaxel, nanoparticle albumin-bound monotherapy {{#subobject:7592da|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Paclitaxel, nanoparticle albumin-bound (Abraxane) in breast cancer]]

===Variant #1, 100 mg/m<sup>2</sup> weekly {{#subobject:4d1f30|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Paclitaxel.2C_nanoparticle_albumin-bound_.26_Bevacizumab_2|nab-Paclitaxel & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Note: the details of this regimen are minimal in the manuscript; it is unclear if this is truly given once per week or given in a 3 weeks on, 1 week off schedule.''
====Chemotherapy====
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 100 mg/m<sup>2</sup> IV once per week

'''28-day cycles'''

===Variant #2, 260 mg/m<sup>2</sup> q3wk {{#subobject:7d9620|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/31/7794.long Gradishar et al. 2005]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel_monotherapy.2C_q3wk_2|Paclitaxel]]
| style="background-color:#1a9850" |Superior TTP
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 Brufsky et al. 2011 (RIBBON-2)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Paclitaxel.2C_nanoparticle_albumin-bound_.26_Bevacizumab_2|nab-Paclitaxel & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Paclitaxel.2C_nanoparticle_albumin-bound_.26_Bevacizumab_2|nab-Paclitaxel & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
====Chemotherapy====
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 260 mg/m<sup>2</sup> IV over 30 minutes once on day 1

====Supportive medications====
*Gradishar et al. 2005: No corticosteroid or antihistamine premedication

'''21-day cycles'''

===References===
<!-- Presented in part at the 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 3-6, 2003. -->
# Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005 Nov 1;23(31):7794-803. Epub 2005 Sep 19. [http://jco.ascopubs.org/content/23/31/7794.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16172456 PubMed]
<!-- Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009, and at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010. -->
# '''RIBBON-2:''' Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10;29(32):4286-93. Epub 2011 Oct 11. [http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21990397 PubMed]
# '''TANIA:''' von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1269-78. Epub 2014 Sep 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25273342 PubMed]
## '''Update:''' Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Ann Oncol. 2016 Nov;27(11):2046-2052. Epub 2016 Aug 8. [https://academic.oup.com/annonc/article/27/11/2046/2467135 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27502725 PubMed]

==Paclitaxel, nanoparticle albumin-bound & Bevacizumab {{#subobject:645e02|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Paclitaxel, nanoparticle albumin-bound & Bevacizumab in breast cancer]]

===Variant #1, 100 mg/m<sup>2</sup> weekly {{#subobject:63e270|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel.2C_nanoparticle_albumin-bound_monotherapy_3|nab-Paclitaxel]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
''Note: the schedule of bevacizumab is inferred, as there was insufficient detail in the description in the manuscript.''
====Chemotherapy====
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 100 mg/m<sup>2</sup> IV once per week
*[[Bevacizumab (Avastin)]] 10 mg/kg IV once per day on days 1 & 15

'''28-day cycles'''

===Variant #2, 260 mg/m<sup>2</sup> q3wk {{#subobject:b2c00e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 Brufsky et al. 2011 (RIBBON-2)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel.2C_nanoparticle_albumin-bound_monotherapy_3|nab-Paclitaxel]]
| style="background-color:#1a9850" |Superior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext von Minckwitz et al. 2014 (TANIA)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel.2C_nanoparticle_albumin-bound_monotherapy_3|nab-Paclitaxel]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 260 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''

===References===
<!-- Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009, and at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010. -->
# '''RIBBON-2:''' Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10;29(32):4286-93. Epub 2011 Oct 11. [http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21990397 PubMed]
# '''TANIA:''' von Minckwitz G, Puglisi F, Cortes J, Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang I, Ciruelos E, De Laurentiis M, Veyret C, de Ducla S, Freudensprung U, Srock S, Gligorov J. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1269-78. Epub 2014 Sep 28. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70439-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25273342 PubMed]
## '''Update:''' Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer. Ann Oncol. 2016 Nov;27(11):2046-2052. Epub 2016 Aug 8. [https://academic.oup.com/annonc/article/27/11/2046/2467135 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27502725 PubMed]

==Vinorelbine monotherapy {{#subobject:5c104c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 25 mg/m<sup>2</sup> weekly {{#subobject:c0c952|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://jco.ascopubs.org/content/12/10/2094.long Gasparini et al. 1994]
| style="background-color:#91cf61" |Phase II
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/11745280 Zelek et al. 2001]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 25 mg/m<sup>2</sup> IV once per week

'''Continued indefinitely'''

===Variant #2, 30 mg/m<sup>2</sup> weekly {{#subobject:1b6c25|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.10.2567 Jones et al. 1995]
| style="background-color:#1a9851" |Phase III (E)
|Melphalan
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2004.08.157 Keller et al. 2004]
| style="background-color:#1a9851" |Phase III (C)
|[[#Doxorubicin_pegylated_liposomal_monotherapy_2|PLD]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once per week

'''Continued indefinitely'''

===Variant #3, 30 mg/m<sup>2</sup> q3wk {{#subobject:c63b68|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 Brufsky et al. 2011 (RIBBON-2)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Vinorelbine_.26_Bevacizumab|Vinorelbine & Bevacizumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #4, 30 mg/m<sup>2</sup> 2 out of 3 weeks {{#subobject:7321fd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(07)70041-4/fulltext Martín et al. 2007 (GEICAM 2000-04)]
| style="background-color:#1a9851" |Phase III (C)
|Gemcitabine & Vinorelbine
| style="background-color:#d73027" |Inferior PFS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1706450 Robson et al. 2017 (OlympiAD)]
| style="background-color:#1a9851" |Phase III (C)
|[[Breast_cancer,_BRCA-mutated#Olaparib_monotherapy|Olaparib]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Patients had confirmed deleterious or suspected deleterious germline BRCA mutation.''
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once per day on days 1 & 8

'''21-day cycles'''
===References===
# Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB, Ambrosini G. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol. 1994 Oct;12(10):2094-101. [http://jco.ascopubs.org/content/12/10/2094.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7931479 PubMed]
# Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M, Lembersky B, Budman D, Bigley J, Hohneker J. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol. 1995 Oct;13(10):2567-74. [http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.10.2567 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7595708 PubMed]
# Zelek L, Barthier S, Riofrio M, Fizazi K, Rixe O, Delord JP, Le Cesne A, Spielmann M. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer. 2001 Nov 1;92(9):2267-72. [https://www.ncbi.nlm.nih.gov/pubmed/11745280 PubMed]
# Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz G, Henderson IC, Mellars L, Alland L, Tendler C. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol. 2004 Oct 1;22(19):3893-901. [http://ascopubs.org/doi/full/10.1200/JCO.2004.08.157 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15459210 PubMed]
# '''GEICAM 2000-04:''' Martín M, Ruiz A, Muñoz M, Balil A, García-Mata J, Calvo L, Carrasco E, Mahillo E, Casado A, García-Saenz JA, Escudero MJ, Guillem V, Jara C, Ribelles N, Salas F, Soto C, Morales-Vasquez F, Rodríguez CA, Adrover E, Mel JR; Spanish Breast Cancer Research Group (GEICAM) trial. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol. 2007 Mar;8(3):219-25. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(07)70041-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17329192 PubMed]
<!-- Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009, and at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010. -->
# '''RIBBON-2:''' Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10;29(32):4286-93. Epub 2011 Oct 11. [http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21990397 PubMed]
# '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1706450 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28578601 PubMed]

==Vinorelbine & Bevacizumab {{#subobject:f3046|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Example orders===
*[[Example orders for Vinorelbine and Bevacizumab in breast cancer]]

===Variant #1, vinorelbine 25 mg/m<sup>2</sup> weekly {{#subobject:82cbe7|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://clincancerres.aacrjournals.org/content/14/23/7871.long Burstein et al. 2008]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 8
*[[Bevacizumab (Avastin)]] 10 mg/kg IV once on day 1

'''14-day cycles'''

===Variant #2, vinorelbine 30 mg/m<sup>2</sup> q3wk {{#subobject:2b0f5d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 Brufsky et al. 2011 (RIBBON-2)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Vinorelbine_monotherapy_2|Vinorelbine]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemotherapy====
*[[Vinorelbine (Navelbine)]] 30 mg/m<sup>2</sup> IV once on day 1
*[[Bevacizumab (Avastin)]] 15 mg/kg IV once on day 1

'''21-day cycles'''

===References===
# Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008 Dec 1;14(23):7871-7. [http://clincancerres.aacrjournals.org/content/14/23/7871.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19047116 PubMed]
<!-- Presented at the 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009, and at the 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010. -->
# '''RIBBON-2:''' Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011 Nov 10;29(32):4286-93. Epub 2011 Oct 11. [http://ascopubs.org/doi/full/10.1200/JCO.2010.34.1255 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21990397 PubMed]

=Additional resources=
*[http://www.cancer.gov/bcrisktool/ Gail model Breast Cancer Risk Assessment Tool]
**[[Gail model breast cancer risk factors]]
*[[Breast cancer BRCA1/BRCA2 genetic testing]]
*[http://www.adjuvantonline.com/index.jsp/ Adjuvant! Online (requires login)]
*[http://www.mycancergenome.org/content/disease/breast-cancer/ My Cancer Genome]
*[http://www.predict.nhs.uk/ PREDICT]

=Patient information=
*[http://www.lakeviewhealth.com/alcohol-increase-breast-cancer-risk-factors-infographic.php Alcohol and risk of breast cancer infographic]

[[Category:Breast cancer regimens]]
[[Category:Disease-specific pages]]
[[Category:Breast cancers]]
